0001171843-14-005281.txt : 20141106 0001171843-14-005281.hdr.sgml : 20141106 20141105201813 ACCESSION NUMBER: 0001171843-14-005281 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141106 DATE AS OF CHANGE: 20141105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 141198468 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 10-Q 1 gff10q_110314.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-21326

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Massachusetts	04-3145961
(State or Other Jurisdiction of	(I.R.S. Employer Identification No.)
Incorporation or Organization)

32 Wiggins Avenue, Bedford, Massachusetts	01730
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 457-9000

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report: N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

(Do not check if a smaller

reporting company)

Smaller reporting

company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes o No x

As of October 31, 2014 there were 14,504,014 outstanding shares of Common Stock, par value $.01 per share.

PART I:	FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(unaudited)

ASSETS	September 30, 2014			December 31, 2013
Current assets:
Cash and cash equivalents	$	71,772,194		$	63,333,160
Marketable securities		19,999,600			-
Accounts receivable, net of reserves of $546,455 and $593,023 at September 30, 2014 and December 31, 2013, respectively		20,170,095			18,736,845
Inventories		13,582,456			10,996,785
Prepaid income taxes		1,343,576			-
Current portion deferred income taxes		659,040			659,040
Prepaid expenses and other		1,128,693			865,957
Total current assets		128,655,654			94,591,787
Property and equipment, at cost		53,379,965			52,413,423
Less: accumulated depreciation		(21,343,322	)		(19,474,712	)
		32,036,643			32,938,711
Long-term deposits and other		69,054			69,080
Intangible assets, net		16,033,944			18,998,409
Goodwill		8,702,295			9,443,894
Total assets	$	185,497,590		$	156,041,881

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,167,545		$	2,793,911
Accrued expenses		5,253,693			5,537,881
Deferred revenue		12,885			180,433
Income taxes payable		-			770,276
Total current liabilities		6,434,123			9,282,501
Other long-term liabilities		948,858			1,133,544
Long-term deferred revenue		56,573			2,054,941
Deferred tax liability		8,353,531			7,936,864
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		-			-
Common stock, $.01 par value; 30,000,000 shares authorized, 14,800,453 and 14,289,308 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		148,004			142,893
Additional paid-in-capital		76,064,383			70,606,031
Accumulated other comprehensive loss		(3,595,487	)		(1,699,095	)
Retained earnings		97,087,605			66,584,202
Total stockholders’ equity		169,704,505			135,634,031
Total Liabilities and Stockholders’ Equity	$	185,497,590		$	156,041,881

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Income

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
Product revenue	$	21,975,312		$	17,023,346		$	57,593,873		$	51,585,242
Licensing, milestone and contract revenue		80,111			731,092			24,746,497			2,244,584
Total revenue		22,055,423			17,754,438			82,340,370			53,829,826

Operating expenses:
Cost of product revenue		5,724,800			5,377,568			15,418,732			16,530,070
Research & development		1,999,867			1,618,012			6,160,740			5,029,974
Selling, general & administrative		4,044,538			3,188,669			11,401,399			10,536,462
Restructuring credits		-			(196,084	)		-			(442,869	)
Total operating expenses		11,769,205			9,988,165			32,980,871			31,653,637
Income from operations		10,286,218			7,766,273			49,359,499			22,176,189
Interest income (expense), net		9,937			(32,816	)		16,339			(108,755	)
Income before income taxes		10,296,155			7,733,457			49,375,838			22,067,434
Provision for income taxes		4,125,355			2,776,199			18,872,435			8,147,282
Net income	$	6,170,800		$	4,957,258		$	30,503,403		$	13,920,152

Basic net income per share:
Net income	$	0.42		$	0.36		$	2.09		$	1.03
Basic weighted average common shares outstanding		14,758,781			13,682,449			14,626,933			13,534,334
Diluted net income per share:
Net income	$	0.40		$	0.33		$	1.97		$	0.95
Diluted weighted average common shares outstanding		15,434,875			14,958,965			15,469,237			14,673,879

Net income	$	6,170,800		$	4,957,258		$	30,503,403		$	13,920,152
Other comprehensive income (loss):
Unrealized gain on securities, net of tax		431			-			431			-
Foreign currency translation adjustment		(1,679,968	)		916,474			(1,896,823	)		507,119
Total other comprehensive income (loss)		(1,679,537	)		916,474			(1,896,392	)		507,119
Comprehensive income	$	4,491,263		$	5,873,732		$	28,607,011		$	14,427,271

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2014			2013
Cash flows from operating activities:
Net income	$	30,503,403		$	13,920,152
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		3,576,441			3,579,474
Stock-based compensation expense		1,196,361			1,156,929
Provision for doubtful accounts		-			24,098
Provision for inventory		220,207			165,803
Gain on sale of assets		-			(442,341	)
Tax benefit from exercise of stock options		(9,236,708	)		(764,181	)
Changes in operating assets and liabilities:
Accounts receivable		(1,840,407	)		4,667,839
Inventories		(2,923,628	)		(3,430,655	)
Prepaid expenses, other current and long-term assets		183,481			531,449
Long-term deposits and other		-			25,497
Accounts payable		(992,822	)		124,679
Accrued expenses		(989,291	)		(642,430	)
Deferred revenue		(2,078,543	)		(2,150,000	)
Income taxes		7,771,001			766,598
Other long-term liabilities		(167,123	)		(373,712	)
Net cash provided by operating activities		25,222,372			17,159,199

Cash flows from investing activities:
Purchase of marketable securities		(19,999,169	)		-
Proceeds from sale of assets		-			530,865
Purchase of property and equipment		(920,132	)		(235,803	)
Net cash provided by (used in) investing activities		(20,919,301	)		295,062

Cash flows from financing activities:
Proceeds from exercise of stock options		1,379,294			2,932,649
Tax benefit from exercise of stock options		9,236,708			764,181
Minimum tax withholding on share based awards		(6,348,900	)		-
Principal payments on debt		-			(1,200,000	)
Net cash provided by financing activities		4,267,102			2,496,830

Exchange rate impact on cash		(131,139	)		36,870

Increase in cash and cash equivalents		8,439,034			19,987,961
Cash and cash equivalents at beginning of period		63,333,160			44,067,477
Cash and cash equivalents at end of period	$	71,772,194		$	64,055,438

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANIKA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.	Nature of Business

Anika Therapeutics, Inc. (together with its subsidiaries, “Anika,” the “Company,” “we,” “us,” or “our”) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.

The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary information and technology, commercialization of existing and new products, and compliance with the U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business.

2.	Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S.”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. The year-end consolidated balance sheet is derived from our audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of September 30, 2014, the results of its operations for the three and nine-month periods ended September 30, 2014 and 2013, and cash flows for the nine-month periods ended September 30, 2014 and 2013.

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the three and nine-month periods ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.

A revision was made on the condensed consolidated statement of cash flows for the six months ended June 30, 2014 to correctly reflect the tax benefit from exercise of certain equity awards. This revision has an impact on the statement of cash flows as a reduction of cash provided by operating activities of $2.5 million with a corresponding increase to cash provided by financing activities related to the tax benefit from exercise of stock options for the six months ended June 30, 2014 of the same amount. This revision has no impact on the statement of operations or cash position. The revision to the condensed consolidated statement of cash flows represents amounts that are not deemed to be material, individually or in the aggregate, to the prior period condensed consolidated financial statements.

3.	Marketable Securities

	September 30, 2014
	Amortized Cost		Unrealized Gains, Net of Tax		Unrealized Losses, Net of Tax			Fair Value
United States Treasury securities	$	14,999,169	$	699	$	(268	)	$	14,999,600
Bank certificates of deposit		5,000,000		-		-			5,000,000
	$	19,999,169	$	699	$	(268	)	$	19,999,600

The Company considers securities with maturities of three months or less from the purchase date to be cash equivalents. Interest is recorded when earned. All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes.

4.	Fair Value Measurements

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements, a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value, was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. On a recurring basis, the Company records its marketable securities at fair value.

The Company’s investments are all classified within Level 1 and Level 2 of the fair value hierarchy. The Company’s investments classified within Level 1 of the fair value hierarchy are valued using quoted market prices. The Company’s investments classified within Level 2 of the fair value hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves, and credit risk.

The fair value hierarchy of the Company’s cash equivalents and marketable securities at fair value is as follows:

			Fair Value Measurements at Reporting Date Using
	September 30, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	49,285,168	$	-	$	49,285,168	$	-

Marketable securities:
United States Treasury securities		14,999,600		14,999,600		-		-
Bank certificates of deposit		5,000,000		-		5,000,000		-
Total marketable securities	$	19,999,600	$	14,999,600	$	5,000,000	$	-

Fair Value Measurements at Reporting
Date Using

December 31, 2013

Quoted Prices in
Active Markets
for Identical Assets
(Level 1)

Significant Other
Observable Inputs
(Level 2)

Significant

Unobservable

Inputs

(Level 3)

Money market funds

34,266,501

5.	Equity Incentive Plan

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. The fair value of each stock option award during the three and nine-month periods ended September 30, 2014 and 2013, respectively, was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

	Three Months Ended September 30,
	2014			2013
Risk free interest rate	1.30%	-	1.39%		-
Expected volatility		53.28%			-
Expected lives (years)		4			-
Expected dividend yield		0.00%			-

	Nine Months Ended September 30,
	2014			2013
Risk free interest rate	1.16%	-	1.39%	0.61%	-	0.70%
Expected volatility		53.28%			57.60%
Expected lives (years)		4			4
Expected dividend yield		0.00%			0.00%

The Company recorded $390,578 and $368,603 of share-based compensation expense for the three-month periods ended September 30, 2014 and 2013, respectively, for equity compensation awards. The Company recorded $1,196,361 and $1,156,929 of share-based compensation expense for the nine-month periods ended September 30, 2014 and 2013, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective recipients.

There were 7,000 and 139,240 stock options granted under the Plan during the three and nine-month periods ended September 30, 2014, respectively. There were no Restricted Stock Awards (“RSAs”) or Restricted Stock Units (“RSUs”) granted under the Plan during the three-month period ended September 30, 2014. There were 9,365 RSUs granted to members of the Company’s Board of Directors under the Plan during the nine-month period ended September 30, 2014. There were 30,700 RSAs granted to Company employees under the Plan during the nine-month period ended September 30, 2014. The stock options, RSAs and RSUs granted to employees and directors become exercisable or vest ratably over four years from the date of grant.

A portion of the stock options granted during the nine-month period ended September 30, 2014 contained certain performance features, as compared to established targets, in addition to time-based vesting conditions. The compensation costs associated with these grants was estimated using the Black-Scholes valuation method factored for the estimated probability of achieving the performance goals.

As of September 30, 2014, there was approximately $4.2 million of total unrecognized compensation cost related to non-vested stock options, stock appreciation rights (“SARs”), RSAs and RSUs granted under the Company’s incentive Plans. This cost is expected to be recognized over a weighted-average period of 3.0 years.

The total intrinsic value of stock options and SARs exercised during the nine-month periods ended September 30, 2014 and 2013 was $25,473,089 and $4,095,833, respectively. Cash received from the exercise of stock options during the three and nine-month periods ended September 30, 2014 and 2013 were $17,513 and $1,379,294, and $1,804,773 and $2,932,649, respectively. During the second quarter of 2014, the Company acquired and subsequently retired 133,774 common shares related to an employee SARs exercise, to meet minimum statutory tax withholding requirements.

There were 936,097 options and SARs outstanding under the Company’s incentive Plans as of September 30, 2014 with a weighted-average exercise price of $13.54 per share, an aggregate intrinsic value of approximately $21.8 million, and a weighted-average remaining contractual term of 6.8 years. None of the options or SARs outstanding at September 30, 2014 or 2013, respectively, had cash-settlement features.

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either authorized but unissued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards containing service conditions generally become exercisable ratably over one to four years, have a ten year contractual term and sometimes contain performance conditions.

6.	Earnings Per Share

The Company reports earnings per share in accordance with ASC 260, Earnings Per Share, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period.

Basic and diluted earnings per share for the three and nine-month periods ended September 30, 2014 and 2013 are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Shares used in the calculation of basic earnings per share		14,758,781		13,682,449		14,626,933		13,534,334
Effect of dilutive securities:
Stock options, SARs, and RSAs		676,094		1,276,516		842,304		1,139,545
Diluted shares used in the calculation of earnings per share		15,434,875		14,958,965		15,469,237		14,673,879

Equity awards of 122,967 and 118,725 shares were outstanding for the three and nine-month periods ended September 30, 2014, respectively, and were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive. There were no anti-dilutive equity awards for the three month period ended September 30, 2013. Equity awards of 88,278 shares were outstanding for the nine-month period ended September 30, 2013, and were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive.

7.	Inventories

Inventories consist of the following:

	September 30, 2014		December 31, 2013
Raw materials	$	6,843,441	$	5,926,030
Work-in-process		2,325,667		2,308,233
Finished goods		4,413,348		2,762,522
Total	$	13,582,456	$	10,996,785

Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead.

8.	Intangible Assets and Goodwill

In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”), the Company acquired various intangible assets and goodwill. The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets. The in-process research and development (“IPR&D”) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects. Until such determination is made, they are not amortized.

The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Intangible assets as of September 30, 2014 and December 31, 2013 consist of the following:

			September 30, 2014								December 31, 2013
	Gross Value		Currency Translation Adjustment			Accumulated Amortization			Net Book Value		Net Book Value		Useful Life
Developed technology	$	16,700,000	$	(1,828,214	)	$	(4,779,123	)	$	10,092,663	$	11,753,003		15
In-process research & development		5,502,686		(638,426	)		-			4,864,260		5,286,127		Indefinite
Distributor relationships		4,700,000		(440,953	)		(4,084,944	)		174,103		863,655		5
Patents		1,000,000		(107,910	)		(271,208	)		620,882		719,574		16
Elevess trade name		1,000,000		-			(717,964	)		282,036		376,050		9
Total	$	28,902,686	$	(3,015,503	)	$	(9,853,239	)	$	16,033,944	$	18,998,409

The aggregate amortization expense related to intangible assets was $518,699 and $521,387 for the three-month periods ended September 30, 2014 and 2013, respectively. The aggregate amortization expense related to intangible assets was $1,593,260 and $1,555,796 for the nine-month periods ended September 30, 2014 and 2013, respectively.

Changes in the carrying value of goodwill for the three and nine-month periods ended September 30, 2014 were as follows:

Goodwill	Three Months Ended September 30, 2014			Nine Months Ended September 30, 2014

Balance, beginning	$	9,360,884		$	9,443,894
Effect of foreign currency adjustments		(658,589	)		(741,599	)
Balance, ending	$	8,702,295		$	8,702,295

9.	Accrued Expenses

Accrued expenses consist of the following:

	September 30, 2014		December 31, 2013
Labor and related expenses	$	2,842,234	$	2,870,147
Clinical trial costs		962,031		882,651
Professional fees		382,423		383,231
Research grants		562,558		610,498
Restructuring costs		11,909		24,638
Other		492,538		766,716
Total	$	5,253,693	$	5,537,881

10.

Commitments and Contingencies

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any patent or intellectual property rights, trade secret or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure. Based on the Company’s historical activity in combination with its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no accrued warranties and has no history of claims paid.

On July 7, 2010, Genzyme Corporation filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The complaint alleged that the Company infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC® in the United States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company manufactured and sold MONOVISC in the United States. On March 7, 2014, Genzyme and the Company filed a joint motion to lift the stay in Genzyme’s lawsuit against the Company and to dismiss with prejudice all of Genzyme’s claims. On March 10, 2014, the District Court granted the motion to dismiss with prejudice all of Genzyme’s claims against the Company and the case was terminated.

The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations or cash flow.

11.

Mitek Monovisc Agreement

In December 2011, the Company entered into a fifteen-year licensing agreement (the “Mitek MONOVISC Agreement”) with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc., to exclusively market MONOVISC in the U.S. The Company received an upfront payment of $2,500,000 in December 2011. This non-refundable upfront payment did not have standalone value without Anika’s completion of development obligations which included obtaining regulatory approval of the product and resolving the patent litigation. As a result, we recognized the upfront payment over the development obligation period. During the first quarter of 2014, the Company received FDA approval of MONOVISC and resolved the patent lawsuit with Genzyme Corporation. As a result of the full delivery of its development obligations under this agreement, the Company recognized approximately $2,200,000 which represents the remaining balance of deferred revenue relating to the initial $2,500,000 payment in accordance with current generally accepted principles on revenue recognition. In the first quarter of 2014, the Company also received a milestone payment of $17,500,000 as a result of achieving FDA approval for MONOVISC and resolving the patent litigation with Genzyme. This milestone payment was fully recognized as revenue during the three months ended March 31, 2014. On April 15, 2014 the first U.S. commercial sale of MONOVISC was made by our commercial partner, DePuy Synthes Mitek Sports Medicine. Under the terms of the Mitek MONOVISC Agreement, the Company earned and collected a milestone payment of $5 million, which was fully recognized as revenue in the second quarter of 2014.

12.

Income Taxes

Provisions for income taxes were $4,125,355 and $18,872,435 for the three and nine-month periods ended September 30, 2014, respectively, based on effective tax rates of 40% and 38%. Provisions for income taxes were $2,776,199 and $8,147,282 for the three and nine-month periods ended September 30, 2013, respectively, based on effective tax rates of 36% and 37%, respectively. The increase in income taxes over the three-month period ended September 30, 2014 was primarily due to increased net income. The increase in income taxes over the nine-month period ended September 30, 2014 was primarily due to increased net income, which reflected $24,652,778 in milestone and contract revenue associated with our U.S. license agreement for MONOVISC. See the previous discussion under Note 11. The increase in the effective tax rate for each of the periods ended 2014, as compared to the same periods ended in 2013, was driven primarily by the unavailability of the federal R&D tax credit in 2014, due to its expiration on December 31, 2013, and a relative decrease to our estimated production activities deduction.

The Company files income tax returns in the U.S. on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. Our filings from 2011 through the present tax year remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. Our filings from 2009 through the present tax year remain subject to examination by the appropriate governmental authorities in Italy.

In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward. We have concluded that the positive evidence outweighs the negative evidence and, thus, those deferred tax assets are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance at September 30, 2014 or December 31, 2013.

13.

Segment and Geographic Information

The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements.

Product revenue by product group is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Orthobiologics	$	18,899,873	$	12,830,566	$	48,750,277	$	40,620,339
Dermal		401,355		267,766		938,966		1,066,409
Surgical		1,452,946		1,136,248		4,581,496		3,955,134
Ophthalmic		366,138		1,425,609		938,134		2,818,407
Veterinary		855,000		1,363,157		2,385,000		3,124,953
	$	21,975,312	$	17,023,346	$	57,593,873	$	51,585,242

Total revenue by geographic location and as a percentage of overall total revenue, for the three and nine-month periods ended September 30, 2014 and 2013 are as follows;

	Three Months Ended September 30,
	2014					2013
	Total Revenue		Percentage of Revenue			Total Revenue		Percentage of Revenue
Geographic Location:
United States	$	18,455,167		84	%	$	14,485,821		82	%
Europe		1,784,414		8	%		1,656,656		9	%
Other		1,815,842		8	%		1,611,961		9	%
Total	$	22,055,423		100	%	$	17,754,438		100	%

	Nine Months Ended September 30,
	2014					2013
	Total Revenue		Percentage of Revenue			Total Revenue		Percentage of Revenue
Geographic Location:
United States	$	72,935,722		89	%	$	42,251,336		78	%
Europe		5,274,071		6	%		5,226,619		10	%
Other		4,130,577		5	%		6,351,871		12	%
Total	$	82,340,370		100	%	$	53,829,826		100	%

14.

Restructuring Credits

In December 2012, the Company announced the closure of its tissue engineering facility in Abano Terme, Italy due to the Company’s inability to meet strict regulatory standards established by the European Medicines Agency (“EMA”) for Advanced Therapy Medicinal Products, which became effective on January 1, 2013. The restructuring plan involved a workforce reduction as well as associated asset abandonments. The Company recorded restructuring and impairment charges in the fourth quarter of 2012 of approximately $2.5 million. Of the total restructuring and impairment charges related to the tissue engineering operation, approximately $1.2 million was related to the non-cash termination and related impairment of an IPR&D project, $0.3 million was related to the disposal of property and equipment, and $0.1 million was related to the disposal of inventory. We completed the restructuring plan and related activities in 2013. Certain previously impaired and written-off equipment was sold, resulting in restructuring credits of $196,084 and $442,869 in the three and nine months ended September 30, 2013, respectively.

The following table summarizes restructuring accrual activity for the nine-period ended September 30, 2014:

	Restructuring Accrual
	Employee Severance and Related Benefits			Activity Termination and Facility Closure Costs			Total
December 31, 2013	$	21,709		$	2,929		$	24,638
Cash Proceeds (Disbursements)		(10,130	)		(1,425	)		(11,555	)
Foreign Exchange Impact		(1,050	)		(124	)		(1,174	)
September 30, 2014	$	10,529		$	1,380		$	11,909

15.

New Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. Thus, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The new guidance is effective for the Company beginning January 1, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 supersedes the revenue recognition requirements in "Topic 605, Revenue Recognition" and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective retrospectively for annual or interim reporting periods beginning after December 15, 2016, with early application not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In April 2014, the FASB issued ASU No. 2014-08, "Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 provides a narrower definition of discontinued operations than that provided under existing U.S. GAAP. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, which disposal represents a strategic shift that has, or will have, a major effect on the reporting entity's operations and financial results, should be reported in the financial statements as a discontinued operation. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations. ASU 2014-08 is effective prospectively for disposals (or classifications as held for disposal) of components of an entity that occur in annual or interim periods beginning after December 15, 2014. The Company does not expect the adoption of ASU 2014-08 to have a material impact on its consolidated financial statements.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding:

Our future sales and product revenue, including geographic expansions, possible retroactive price adjustments, and expectations of unit volumes or other offsets to price reductions;

Our manufacturing capacity, efficiency gains and work-in-process manufacturing operations;

The timing, scope and rate of patient enrollment for clinical trials;

The development of possible line extensions and new products;

Our ability to achieve and/or maintain compliance with laws and regulations;

The timing of and/or receipt of Food and Drug Administration (“FDA”), foreign or other regulatory approvals, clearances, and/or reimbursement approvals of current, new or potential products, and any limitations on such approvals;

Our intention to seek patent protection for our products and processes, and to protect our intellectual property;

Our ability to effectively compete against current and future competitors;

Negotiations with potential and existing partners, including our performance under any of our existing and future distribution, license or supply agreements, and our expectations with respect to sales and sales threshold milestones pursuant to such agreements;

The level of our revenue or sales in particular geographic areas and/or for particular products, and the market share for any of our products;

Our expectations of product revenue results in future quarters and for the full year 2014;

Our current strategy, including our corporate objectives, research and development activities and collaboration activities;

Our expectations regarding our orthobiologics products, including existing products and expectations regarding new products, expanded uses of existing products, new distribution partnerships and revenue growth;

Our intention to increase our market share for orthobiologics products in domestic and international markets or otherwise penetrate growing markets for osteoarthritis of the knee and other joints;

Our expectations regarding next generation orthobiologics product development, clinical trials, regulatory approvals and commercial launches;

Our and Bausch & Lomb’s performance under the non-exclusive, three-year contract for the supply of AMVISC^® and AMVISC^® Plus ophthalmic viscoelastic products, our expectations regarding revenue from ophthalmic products, and the impact that such agreement’s expiration will have on our results of operations going forward;

Our ability to commercialize ANIKAVISC® and ANIKAVISC® Plus and our expectations regarding such commercialization and the potential profits generated thereby;

Our ability to license our aesthetics product to new distribution partners domestically and outside the U.S., and our expectations regarding development of aesthetics product line extensions;

Our ability and the ability of our distribution partners, to market our aesthetics dermatology product; and our expectations regarding the distribution and sales of our ELEVESS® product and the timing thereof;

Our expectations regarding HYVISC^® sales;

Our expectations regarding product gross margin;

Our expectations regarding CINGAL^®, including the expense associated therewith, the timing of submission of our CE Mark application, and our ability to obtain regulatory approvals for this product;

Possible negotiations or re-negotiations with existing or new distribution or collaboration partners;

Our ability to continue streamlining operations and improving our manufacturing capabilities;

Our expectation for changes in operating expenses, including research and development, and selling, general and administrative expenses;

The rate at which we use cash, the amounts used and generated by operations, and our expectations regarding the adequacy and usage of such cash;

Our expectation for capital expenditures and future amounts of interest income and expense;

Our ability to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and other sources, to the extent our current sources of funds are insufficient;

Our ability to manage the operations of Anika S.r.l. as a company generating continued profits;

The strength of the economies in which the Company operates or will operate, as well as the political stability of any of those geographic areas;

Our ability to effectively prioritize the many research and development projects underway;

Our ability to expand the therapeutic applications of our existing products and create new applications for our HA technology;

Our ability to obtain U.S. approval for orthopedic and other product franchises of Anika S.r.l., including the timing and potential success of such efforts, and to expand sales of these products in the U.S., including the impact such efforts may have on our revenue; and

Our ability to successfully defend the Company against lawsuits and claims, and the uncertain financial impact such lawsuits and claims and related defense costs may have on the Company.

Furthermore, additional statements identified by words such as “will,” “likely,” “may,” “believe,” “expect,” “anticipate,” “intend,” “seek,” “designed,” “develop,” “would,” “future,” “can,” “could,” and other expressions that are predictions of or indicate future events and trends and which do not relate to historical matters, also identify forward-looking statements.

You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control, including those factors described in the section titled “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. These risks, uncertainties and other factors may cause our actual results, performance or achievement to be materially different from anticipated future results, performance or achievement, expressed or implied by the forward-looking statements. These forward-looking statements are based upon the current assumptions of our management and are only expectations of future results. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences, including those factors discussed herein and in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of this Quarterly Report on Form 10-Q, as well as the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2013 and in our press releases and other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors of new information, future events or other changes.

Management Overview

Anika Therapeutics, Inc. (together with its subsidiaries, “Anika,” the “Company,” “we,” “us,” or “our”) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.

Anika’s proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to intended therapeutic uses. Our patented technologies chemically modify the HA molecule to allow for longer residence time in the body. Anika Therapeutics, Inc.’s wholly-owned subsidiary, Anika Therapeutics S.r.l., has over 20 products currently commercialized. These products are also all made from HA, based on two technologies: “HYAFF,” which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by an extensive portfolio of owned and licensed patents. We offer therapeutic products from these aforementioned technologies in the following areas:

	Anika	Anika S.r.l.
Orthobiologics	X	X
Dermal Advanced wound care Aesthetic dermatology	X	X
Surgical Anti-adhesion Ear, nose and throat care (“ENT”)	X	X X
Ophthalmic	X
Veterinary	X

Please see Management’s Discussion and Analysis of Financial Condition and Results of Operations-Management Overview (Item 7) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, for a description of each of the above therapeutic areas, including the individual products.

Research and Development

Anika’s research and development efforts primarily consist of the development of new medical applications for our HA-based technologies, the management of clinical trials and studies for certain product candidates, the preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development, and process development and scale-up manufacturing activities related to our existing and new products. Our development focus includes products for tissue protection, healing and repair. Our investment in R&D varies considerably depending on the timing, number and size of clinical trials and studies underway. We anticipate that we will commit significant resources to research and development, including clinical trials, in the future.

During the first quarter of 2014, the Company received FDA approval of MONOVISC and resolved the patent lawsuit with Genzyme Corporation. The Company received a milestone payment of $17,500,000 under the Mitek MONOVISC Agreement related to FDA approval of MONOVISC and the successful resolution of the Genzyme patent litigation. As a result of the full delivery of our development obligations under this agreement, the Company also recognized the remaining balance of deferred revenue relating to the initial $2,500,000 non-refundable up-front payment. Both amounts were fully recognized as revenue during the three months ended March 31, 2014.

A key product currently under development is CINGAL, which is based on our HA material with an added active therapeutic molecule designed to provide broad pain relief for a longer period of time. We completed the formulation and biocompatibility studies of the product. During the second quarter of 2013, we commenced a multinational phase III clinical trial to obtain the clinical data necessary for a CE Mark submission and approval, and to support other product registrations including in the United States. Enrollment in the clinical trial was completed in February 2014, and the last patient follow-up was completed in September 2014. We expect to submit our CE Mark application by December 31, 2014, or shortly thereafter.

HYALOFAST™ is an innovative biodegradable matrix for human bone marrow mesenchymal stem cells used in connection with soft tissue regeneration. HYALOFAST received CE Mark approval in September 2009, and it is currently commercially available in Europe and certain international countries. During the second quarter of 2014, we submitted a proposed investigational device protocol to the FDA. Our current plan is to begin a phase III clinical trial in 2015.

The technologies obtained through our acquisition of Anika S.r.l. have enhanced our research and development capabilities, and our pipeline of product candidates. Anika S.r.l. has research and development programs for new products including HYALOFAST and HYALOSPINE™, an adhesion prevention gel for use after spinal surgery. Our research and development efforts may not be successful in (1) developing our existing product candidates, (2) expanding the therapeutic applications of our existing products, or (3) resulting in new applications for our HA technology. There is also a risk that we may choose not to pursue development of potential product candidates. We also may not be able to obtain regulatory approval for any new applications we develop.

Litigation and Other Legal Matters

On July 7, 2010, Genzyme Corporation filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The complaint alleged that the Company infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC in the United States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company manufactured and sold MONOVISC in the United States. On March 7, 2014 Genzyme and the Company filed a joint motion to lift the stay in Genzyme’s lawsuit against the Company and to dismiss with prejudice all of Genzyme’s claims. On March 10, 2014, the District Court granted the motion to dismiss with prejudice all of Genzyme’s claims against the Company and the case was terminated.

We are also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results of operations or cash flows.

Results of Operations

Three and Nine Months Ended September 30, 2014 Compared to the Three and Nine Months Ended September 30, 2013

	Three Months Ended September 30,									Nine Months Ended September 30,
	2014			2013			Inc/(Dec)			2014			2013			Inc/(Dec)
Product revenue	$	21,975,312		$	17,023,346			29	%	$	57,593,873		$	51,585,242			12	%
Licensing, milestone and contract revenue		80,111			731,092			(89	%)		24,746,497			2,244,584			1002	%
Total revenue		22,055,423			17,754,438			24	%		82,340,370			53,829,826			53	%

Operating expenses:
Cost of product revenue		5,724,800			5,377,568			6	%		15,418,732			16,530,070			(7	%)
Research & development		1,999,867			1,618,012			24	%		6,160,740			5,029,974			22	%
Selling, general & administrative		4,044,538			3,188,669			27	%		11,401,399			10,536,462			8	%
Restructuring credits		-			(196,084	)		(100	%)		-			(442,869	)		(100	%)
Total operating expenses		11,769,205			9,988,165			18	%		32,980,871			31,653,637			4	%
Income from operations		10,286,218			7,766,273			32	%		49,359,499			22,176,189			123	%
Interest income (expense), net		9,937			(32,816	)		(130	%)		16,339			(108,755	)		(115	%)
Income before income taxes		10,296,155			7,733,457			33	%		49,375,838			22,067,434			124	%
Provision for income taxes		4,125,355			2,776,199			49	%		18,872,435			8,147,282			132	%
Net income	$	6,170,800		$	4,957,258			24	%	$	30,503,403		$	13,920,152			119	%
Product gross profit	$	16,250,512		$	11,645,778			40	%	$	42,175,141		$	35,055,172			20	%
Product gross margin		74	%		68	%					73	%		68	%

Product Revenue

Product revenue for the quarter ended September 30, 2014 was $21,975,312, an increase of 29%, as compared to $17,023,346 for the quarter ended September 30, 2013. Product revenue for the nine-month period ended September 30, 2014 was $57,593,873, an increase of 12%, as compared to $51,585,242 for the nine-month period ended September 30, 2013. For the three months ended September 30, 2014, increases in product revenue from our Orthobiologics, Dermal and Surgical franchises were partially offset by timing related decreases in revenue from our Ophthalmic and Veterinary products. The increase in the nine-month period ended September 30, 2014 from the prior year period was primarily driven by MONOVISC product sales increases both domestically and internationally.

The following table presents product revenue by group for the three and nine-month periods ended September 30, 2014 and 2013:

	Three Months Ended September 30,				Increase (Decrease)
	2014		2013		$			%
Orthobiologics	$	18,899,873	$	12,830,566	$	6,069,307			47	%
Dermal		401,355		267,766		133,589			50	%
Surgical		1,452,946		1,136,248		316,698			28	%
Ophthalmic		366,138		1,425,609		(1,059,471	)		(74	%)
Veterinary		855,000		1,363,157		(508,157	)		(37	%)
	$	21,975,312	$	17,023,346	$	4,951,966			29	%

	Nine Months Ended September 30,				Increase (Decrease)
	2014		2013		$			%
Orthobiologics	$	48,750,277	$	40,620,339	$	8,129,938			20	%
Dermal		938,966		1,066,409		(127,443	)		(12	%)
Surgical		4,581,496		3,955,134		626,362			16	%
Ophthalmic		938,134		2,818,407		(1,880,273	)		(67	%)
Veterinary		2,385,000		3,124,953		(739,953	)		(24	%)
	$	57,593,873	$	51,585,242	$	6,008,631			12	%

Orthobiologics

Our orthobiologics franchise consists of our joint health and orthopedic products. Overall, sales increased 47% and 20% for the three and nine-month periods ended September 30, 2014, as compared to the same periods in 2013. The growth in the third quarter of 2014 reflected revenue from MONOVISC sales in the U.S. as a result of the product launch in April 2014. We expect orthobiologics product revenue to increase in 2014 as compared to 2013.

Dermal

Our dermal franchise consists of advanced wound care products and aesthetic dermal fillers. In July 2014, the Company entered into a new agreement with Medline Industries Inc. to commercialize HYALOMATRIX in the U.S. on an exclusive basis through 2019. For the three and nine month periods ended September 30, 2014, dermal product sales increased 50% and decreased 12%, respectively to $401,355 and $938,966, as compared to the same periods in 2013. The fluctuations primarily reflect order timing by our distribution partners. Anika’s advanced wound care products treat complex skin wounds ranging from burns to diabetic ulcers, with HYALOMATRIX® and HYALOFILL® as the lead products. We expect revenue from our dermal products to grow in the fourth quarter from the third quarter of 2014.

Surgical

Our surgical franchise consists of products used to prevent post-surgical adhesions in abdominal-pelvic, spinal, and ear, nose and throat (“ENT”) disorders. Sales of our surgical products increased 28% and 16% for the three and nine-month periods ended September 30, 2014 to $1,452,946 and $4,581,496 respectively, as compared to the same periods in 2013. The year-to-date increase of surgical product revenue was primarily due to strong demand for our HYALOBARRIER® product from our European and Asian partners. For the full year 2014, we expect revenue from our surgical products to increase as compared to 2013.

Ophthalmic

Our ophthalmic franchise consists of HA viscoelastic products used in ophthalmic surgery. Ophthalmic product sales decreased 74% and 67% to $366,138 and $938,134, respectively, for the three and nine-month periods ended September 30, 2014, as compared to the same periods in 2013. The decrease was primarily attributable to Bausch & Lomb (“B&L”) delaying its contractual minimum purchases until the fourth quarter of 2014. We expect the overall ophthalmic revenue to be lower in 2014, as compared to 2013, due to the terms of the current Bausch & Lomb supply agreement. B&L’s current contract expires at the end of this year and will not be renewed. Given that the ophthalmic franchise is not part of our core business, and that it has been steadily diminishing for the past few years, we do not expect this event to have a material impact on our results going forward.

Veterinary

Veterinary revenue from HYVISC decreased by 37% to $855,000 and 24% to $2,385,000 for the three and nine-month periods ended September 30, 2014, respectively, as compared to the same periods in 2013. We expect the overall veterinary revenue to be slightly lower in 2014, as compared to 2013 due to order timing and a slight downward trend in the number of performance horses in the U.S. We continue to look at other veterinary applications and opportunities to expand geographic territories.

Licensing, milestone and contract revenue

Licensing, milestone and contract revenue for the three and nine-month periods ended September 30, 2014 was $80,111 and $24,746,497, respectively, as compared to $731,092 and $2,244,584 for the same periods in 2013. Revenue for the quarter ended June 30, 2014 included a $5,000,000 milestone payment associated with our U.S. license agreement for MONOVISC. The year to date September 30, 2014 increase in licensing, milestone and contract revenue included a $17,500,000 milestone payment resulting from the resolution of the patent litigation with Genzyme and the FDA approval of MONOVISC, and the recognition of an approximately $2,200,000 remaining unamortized upfront payment previously received in December 2011. These payments are related to development obligations under the license agreement. The FDA’s approval of our MONOVISC product during the quarter ended March 31, 2014 completed the delivery of our development obligations under the license agreement, and resulted in the immediate recognition of the $17.5 million milestone payment, as well as the full recognition of prior deferred revenue in the first quarter of 2014. During the second quarter of 2014, a $5,000,000 milestone payment associated with the first commercial sale of MONOVISC in the U.S. was earned, received, and recognized as revenue.

Product gross profit and margin

Product gross profit and margin for the three and nine-month periods ended September 30, 2014 was $16,250,512 and $42,175,141, or 74% and 73%, respectively, of the product revenue. Product gross margin for the three and nine-month periods ended September 30, 2013 was $11,645,778 and $35,055,172, or 68% of the product revenue for each period, respectively. The increase in product gross margin for the three and nine-month periods ended September 30, 2014, as compared to the same periods in 2013, is attributable to a more favorable product mix, materials cost reduction, and continued efficiency gains at our Bedford, Massachusetts manufacturing facility. This quarter’s product gross margin may not be indicative of the rest of the year due to dynamics including the future mix of our product sales and other factors.

Research and development

Research and development expenses for the three and nine-month periods ended September 30, 2014 were $1,999,867 and $6,160,740, or 9% and 8% of total revenue, respectively. This primarily reflects the completion of patient follow-up activities of our phase III Cingal clinical trial during the first nine months of 2014, as compared to trial start-up activities in the same periods last year. Research and development spending is expected to increase in future quarters as we further develop new products based on our existing technology assets.

Selling, general and administrative

Selling, general and administrative (“SG&A”) expenses for the three and nine-month periods ended September 30, 2014 were $4,044,538 and $11,401,399, or, representing 19% and 14% of total revenue, respectively. SG&A expenses increased for both the three and nine-month periods ending September 30, 2014, as compared to the same periods in 2013, primarly as a result of increases in personnel related costs, external professional fees, and corporate goverance costs. Included in the first quarter of 2013 were certain non-recurring external professional fees and personnel costs. We expect general and administrative expenses to increase in 2014, as compared to 2013, reflective of the support required to grow our business both domestically and internationally.

Income taxes

Provisions for income taxes were $4,125,355 and $18,872,435 for the three and nine-month periods ended September 30, 2014, based on effective tax rates of 40% and 38%, respectively. Provisions for income taxes were $2,776,199 and $8,147,282 for the three and nine-month periods ended September 30, 2013, respectively, based on effective tax rates of 36% and 37%, respectively. The increase in income taxes over the three-month period ended September 30, 2014 was primarily due to increased net income. The increase in income taxes over the nine-month period ended September 30, 2014 was primarily due to increased net income, which reflected $24,652,778 in milestone and contract revenue associated with our U.S. license agreement for MONOVISC. The increase in the effective tax rate for each of the periods ended 2014, as compared to the same periods ended in 2013, was driven primarily by the unavailability of the federal R&D tax credit in 2014, due to its expiration on December 31, 2013, and a relative decrease to our estimated production activities deduction.

Liquidity and Capital Resources

We require cash to fund our operating expenses and capital expenditures. We expect that our requirements for cash to fund operations will increase as the scope of our operations expands. Historically, we have generated positive cash flow from operations, which together with our available cash and investments, have met our cash requirements. Cash, cash equivalents and investments totaled approximately $91.8 million and $63.3 million at September 30, 2014 and December 31, 2013, respectively. Working capital totaled approximately $122.2 million at September 30, 2014 and $85.3 million at December 31, 2013. The Company believes it has adequate financial resources to support its business for the next twelve months.

Cash provided by operating activities was $25,222,372 for the nine months ended September 30, 2014, as compared to cash provided by operating activities of $17,159,199 for the same period in the prior year. This increase in cash provided by operations was due primarily to a total of $22.5 million milestone payments received under the Mitek MONOVISC Agreement. This cash inflow is partially offset by an increase in inventory due to anticipated future sales demand.

Cash used in investing activities was $20,919,301 for the nine months ended September 30, 2014 as compared to cash provided by investing activities of $295,062 for the same period in 2013. The increase in cash used in investing activities is primarily the result of the purchase of approximately $20.0 million in marketable securities during the third quarter as well as higher capital expenditures in 2014 as compared to the same period in 2013, which included the proceeds received from the sale of property and equipment in the prior year period relating to our reorganization of Anika S.r.l. in the beginning of 2013.

Cash provided by financing activities was $4,267,102 for the nine months ended September 30, 2014, as compared to cash provided by financing activities of $2,496,830 for the same period in 2013. The increase in cash provided by financing activities in the current year’s period is attributable to the increased tax benefits received in regards to employees’ exercise of stock options during the first nine months of 2014, partially offset by minimum tax withholdings on share-based awards.

Critical Accounting Estimates

During the nine months ended September 30, 2014, the Company received FDA approval of MONOVISC and the patent litigation related to MONOVISC was also resolved. As a result, the Company shortened the estimate of the performance period related to the Mitek MONOVISC Agreement. There were no other significant changes in our critical accounting estimates during the nine months ended September 30, 2014, as compared to the estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Recent Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. Thus, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The new guidance is effective for the Company beginning January 1, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new standard on its financial statements.

In April 2014, the FASB issued ASU No. 2014-08, "Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 provides a narrower definition of discontinued operations than under existing U.S. GAAP. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity's operations and financial results should be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations. ASU 2014-08 is effective prospectively for disposals (or classifications as held for disposal) of components of an entity that occur in annual or interim periods beginning after December 15, 2014. The Company does not expect the adoption of ASU 2014-08 to have a material impact on the consolidated financial statements.

Contractual Obligations and Other Commercial Commitments

We have had no material changes outside the ordinary course to our contractual obligations disclosed in our Annual Report on Form 10-K for the period ended December 31, 2013.

To the extent that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.

Off-balance Sheet Arrangements

The Company does not use special purpose entities or other off-balance sheet financing techniques, except for operating leases, that we believe have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital resources.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risks since the date of our Annual Report on Form 10-K for the year ended December 31, 2013.

As of September 30, 2014, we did not utilize any derivative financial or commodity instruments for which fair value disclosure would be required under ASC 825, Financial Instruments, or ASC 815, Derivatives and Hedging. Our marketable securities investments consist of money market funds primarily invested in certificates of deposit, commercial paper, U.S. Treasury obligations and repurchase agreements secured by U.S. Treasury obligations that are carried on our books at fair market value.

Primary Market Risk Exposures

Our primary market risk exposure is in the area of currency rate risk. We have three supplier contracts denominated in foreign currencies. Unfavorable fluctuations in exchange rates would have a negative impact on our financial statements. The impact of changes in currency exchange rates for these supplier contracts on our financial statements was immaterial for the three months ended September 30, 2014. The impact of exchange rates related to the consolidation of the balance sheet amounts for our Anika S.r.l. subsidiary resulted in an unfavorable currency translation adjustment of $1,896,823 during the first nine months of 2014.

Our investment portfolio of cash equivalents and marketable securities is subject to interest rate fluctuations, changes in credit quality of the issuer or other factors.

ITEM 4.

CONTROLS AND PROCEDURES

	(a)	Evaluation of disclosure controls and procedures.

	As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

	(b)	Changes in internal controls over financial reporting.

	There were no changes in our internal control over financial reporting during the three-month period ended September 30, 2014 that have materially affected, or that are reasonably likely to materially affect, our internal controls over financial reporting.

PART II: OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

On July 7, 2010, Genzyme Corporation filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The complaint alleged that the Company infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC in the United States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company manufactured and sold MONOVISC in the United States. On March 7, 2014, Genzyme and the Company filed a joint motion to lift the stay in Genzyme’s lawsuit against the Company and to dismiss with prejudice all of Genzyme’s claims. On March 10, 2014, the District Court granted the motion to dismiss with prejudice all of Genzyme’s claims against the Company and the case was terminated.

ITEM 1A.

RISK FACTORS

To our knowledge there have been no material changes to the risk factors described in “Part I., Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013. In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 5.

OTHER INFORMATION

On November 5, 2014, our Board of Directors approved a form of indemnification agreement for our directors and authorized the Company to enter into such an agreement with each of our directors. Under the terms of the agreement, consistent with the provisions of our Articles of Incorporation, Bylaws and applicable law, the Company agrees to indemnify each director, to the maximum extent permitted by the laws of the Commonwealth of Massachusetts, from claims and losses arising from their service as a director. Subject to certain procedures outlined in the agreement, we are required to advance expenses incurred as a result of any such proceeding as to which a director could be indemnified. The agreement provides procedures for the determination of a person’s right to receive indemnification consistent with applicable laws. We anticipate that we will enter into substantially similar agreements with any new directors. The form of indemnification agreement is attached hereto as Exhibit 10.1 and incorporated by reference herein. The foregoing summary of the indemnification agreement is qualified in its entirety by the text of the Exhibit.

ITEM 6.

EXHIBITS

Exhibit No.	Description

*10.1	Form of Director Indemnification Agreement

(31)	Rule 13a-14(a)/15d-14(a) Certifications

*31.1	Certification of Charles H. Sherwood, Ph.D., pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*31.2	Certification of Sylvia Cheung pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

(32)	Section 1350 Certifications

**32.1	Certification of Charles H. Sherwood, Ph.D., and Sylvia Cheung, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(101)	XBRL

	The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, as filed with the SEC on November 5, 2014, formatted in XBRL (eXtensible Business Reporting Language), as follows:

	i.	Condensed Consolidated Balance Sheets as of September 30, 2014 (unaudited) and December 31, 2013

	ii.	Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2014 and September 30, 2013 (unaudited)

	iii.	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and September 30, 2013 (unaudited)

	iv.	Notes to Condensed Consolidated Financial Statements (unaudited)

*	Filed herewith
**	Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ANIKA THERAPEUTICS, INC.

Date: November 5, 2014	By:	/s/ SYLVIA CHEUNG
		Sylvia Cheung
		Chief Financial Officer
		(Authorized Officer and Principal Financial Officer)

EX-10.1 2 exh_101.htm EXHIBIT 10.1

Exhibit 10.1

DIRECTOR INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”) is made as of November 5, 2014 by and between Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and ____________ (“Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;

WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

WHEREAS, the Articles of Organization (as amended and in effect on the date hereof, the “Charter”) and the Bylaws (as amended and in effect on the date hereof, the “Bylaws” and, together with the Charter, the “Organizational Documents”) of the Company require indemnification of the directors, officers and employees of the Company, and Indemnitee may also be entitled to indemnification pursuant to the Massachusetts Business Corporation Act (the “MBCA”);

WHEREAS, the Bylaws and the MBCA expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that the increased difficulty in attracting and retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company’s shareholders;

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the Organizational Documents so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and

WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Organizational Documents and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

Section 1. Services to the Company. Indemnitee agrees to serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.

Section 2. Definitions.

As used in this Agreement:

(a) “Change in Control” shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the capital stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.

(b) “Corporate Status” describes the status of a person as a current or former director of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company.

(c) “Enforcement Expenses” shall include all reasonable attorneys’ fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee.

(d) “Enterprise” shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee.

(e) “Expenses” shall include all reasonable attorneys’ fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or compensatory, service or similar fees, salaries, wages or benefits owed to Indemnitee.

(f) “Special Legal Counsel” means a law firm, or a partner (or, if applicable, member or shareholder) of such a law firm, that is experienced in matters of Massachusetts corporation law and neither presently is, nor in the past has been, retained to represent: (i) the Company, any subsidiary of the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Special Legal Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Special Legal Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

(g) The term “Proceeding” shall include any threatened, pending or completed action, suit, alternate dispute resolution mechanism, or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, arbitrative or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of the fact that Indemnitee is or was a director of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on his or her part while acting as a director of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; provided, however, that the term “Proceeding” shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee’s rights under this Agreement as provided for in Section 12(a) of this Agreement.

Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee to the extent set forth in this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if (A) Indemnitee conducted himself or herself in good faith and in a manner he or she reasonably believed to be in the best interests of the Company, or at least not opposed to the best interests of the Company, and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful, or (B) Indemnitee engaged in conduct for which he or she shall not be liable under a provision of the Charter as authorized by Section 2.02(b)(4) of the MBCA (or any successor provision). The conduct of Indemnitee with respect to an employee benefit plan for a purpose Indemnitee reasonably believed to be in the best interests of the participants in, and the beneficiaries of, the plan is conduct that satisfies clause (A) of the preceding sentence.

Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee to the extent set forth in this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if (A) Indemnitee conducted himself in good faith and in a manner he or she reasonably believed to be in the best interests of the Company, or at least not opposed to the best interests of the Company, or (B) Indemnitee engaged in conduct for which he or she shall not be liable under a provision of the Charter as authorized by Section 2.02(b)(4) of the MBCA (or any successor provision). The conduct of Indemnitee with respect to an employee benefit plan for a purpose Indemnitee reasonably believed to be in the best interests of the participants in, and the beneficiaries of, the plan is conduct that satisfies clause (A) of the preceding sentence.

Section 5. Indemnification for Expenses of a Party Who is Successful. Notwithstanding any other provisions of this Agreement and except as provided in Section 7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is wholly successful, on the merits or otherwise, in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If in such Proceeding Indemnitee is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter to the extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

Section 6. Reimbursement for Expenses of a Witness or in Response to a Subpoena. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i) is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii) receives a subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

Section 7. Exclusions. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement:

(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise;

(b) to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law;

(c) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i) the Board has consented to the initiation of such Proceeding or part thereof and (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; provided, however, that this Section 7(c) shall not apply to (A) counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B) any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section 12; or

(d) to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement).

Section 8. Advancement of Expenses. Subject to Section 9(b), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Indemnitee shall qualify for advances upon the execution and delivery to the Company of an undertaking in the form attached hereto as Exhibit A. The right to advances under this Section 8 shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section 8 shall limit Indemnitee’s right to advancement pursuant to Section 12(e) of this Agreement.

Section 9. Procedure for Notification and Defense of Claim.

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company (a “Written Indemnification Request”).

(b) In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company’s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; provided that (i) Indemnitee shall have the right to employ separate counsel in any such Proceeding at Indemnitee’s expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, or (C) the Company shall not continue to retain such counsel to defend such Proceeding, then the reasonable fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder.

(c) In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b) above, then the Company will be entitled to participate in the Proceeding at its own expense.

(d) The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i) includes an admission of fault of Indemnitee, any non-monetary remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii) with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding.

Section 10. Procedure Upon Application for Indemnification.

(a) Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination, if such determination is required by applicable law, with respect to the permissibility thereof shall be made in the specific case: (i) if a Change in Control shall have occurred, by Special Legal Counsel in a written opinion to the Board, or (ii) if a Change in Control shall not have occurred, by the Company in accordance with applicable law. In the case that such determination is made by Special Legal Counsel, a copy of Special Legal Counsel’s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30) days after such determination. Indemnitee shall cooperate with the Special Legal Counsel or the Company, as applicable, in making such determination with respect to the permissibility of indemnification of Indemnitee, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any out-of-pocket costs or expenses (including reasonable attorneys’ fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Special Legal Counsel or the Company shall be borne by the Company (irrespective of the determination as to the permissibility of indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

(b) If the determination of permissibility of indemnification is to be made by Special Legal Counsel pursuant to Section 10(a), the Special Legal Counsel shall be selected by the Company in accordance with applicable law. The Indemnitee may, within ten (10) days after written notice of such selection, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Special Legal Counsel so selected does not meet the requirements of “Special Legal Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Special Legal Counsel. If such written objection is so made and substantiated, the Special Legal Counsel so selected may not serve as Special Legal Counsel unless and until such objection is withdrawn or the Massachusetts Court (as defined in Section 22) has determined that such objection is without merit. If, within twenty (20) days after the later of (i) submission by Indemnitee of a Written Indemnification Request, and (ii) the final disposition of the Proceeding, including any appeal therein, no Special Legal Counsel shall have been selected without objection, Indemnitee may petition the Massachusetts Court for resolution of any objection which shall have been made by Indemnitee to the selection of Special Legal Counsel and/or for the appointment as Special Legal Counsel of a person selected by the court or by such other person as the court shall designate. The person with respect to whom all objections are so resolved or the person so appointed shall act as Special Legal Counsel under Section 10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, Special Legal Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

Section 11. Presumptions and Effect of Certain Proceedings.

(a) To the extent permitted by applicable law, in making a determination with respect to the permissibility of indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a Written Indemnification Request in accordance with Section 9(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making of any determination contrary to that presumption. Neither (i) the failure of the Company or of Special Legal Counsel to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company or by Special Legal Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not meet the applicable standard of conduct for indemnification under this Agreement.

(c) The knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

Section 12. Remedies of Indemnitee.

(a) Subject to Section 12(f), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(a) of this Agreement within sixty (60) days after receipt by the Company of the Written Indemnification Request for which a determination of permissibility thereof is to be made other than by Special Legal Counsel, (iv) payment of indemnification or reimbursement of expenses is not made pursuant to Section 5 or 6 or the last sentence of Section 10(a) of this Agreement within thirty (30) days after receipt by the Company of a Written Indemnification Request therefor (which shall include any invoices received by Indemnitee but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice) or (v) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Massachusetts Court of his or her entitlement to such indemnification or advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

(b) In the event that a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be.

(c) If a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within thirty (30) days after receipt by the Company of a Written Indemnification Request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement or insurance recovery, as the case may be, in the suit for which indemnification or advancement is being sought. Such Written Indemnification Request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice.

(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.

Section 13. Non-exclusivity; Survival of Rights; Insurance; Subrogation.

(a) The rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Organizational Documents, any agreement, a vote of shareholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Massachusetts law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Organizational Documents and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(d) The Company’s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise.

Section 14. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director of the Company or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

Section 15. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

Section 16. Enforcement.

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve, or continue to serve, as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director of the Company.

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Organizational Documents and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

Section 17. Modification and Waiver. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment.

Section 18. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise.

Section 19. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third (3^rd) business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile or e-mail transmission, with receipt of oral confirmation that such transmission has been received:

(a) If to Indemnitee, at such address as Indemnitee shall provide to the Company.

(b) If to the Company to:

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, Massachusetts 01730

Attention: Chief Financial Officer
Fax: (781) 305-9720
E-Mail: scheung@anikatherapeutics.com

or to any other address as may have been furnished to Indemnitee by the Company.

Section 20. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transactions.

Section 21. Internal Revenue Code Section 409A. The Company intends for this Agreement to comply with the Indemnification exception under Section 1.409A-1(b)(10) of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the “Code”), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section 409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his capacity as a service provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent.

Section 22. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations between the parties shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Business Litigation Session of the Massachusetts Superior Court (the “Massachusetts Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Massachusetts Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 19 of this Agreement with the same legal force and validity as if served upon such party personally within the Commonwealth of Massachusetts, (iv) waive any objection to the laying of venue of any such action or proceeding in the Massachusetts Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Massachusetts Court has been brought in an improper or inconvenient forum.

Section 23. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

Section 24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.

	ANIKA THERAPEUTICS, INC.


	By:
		Name:
		Title:



		[Name of Indemnitee]

Exhibit A

Form of Undertaking

[Date]

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, Massachusetts 01730

Re: Request for Advancement of Expenses

Ladies and Gentlemen:

Reference is made to the Indemnification Agreement (the “Agreement”) by and between Anika Therapeutics, Inc. (the “Company”) and the undersigned, ________ (“Indemnitee”). Capitalized terms not defined herein shall have those meanings as set forth in the Agreement. Pursuant to Section 8 of the Agreement, Indemnitee hereby requests advancement of Expenses incurred as a result of Indemnitee being, or being threatened to be made, a party in the following Proceeding(s): _________________________________.

In accordance with Section 8 of the Agreement, Indemnitee hereby:

(1)

affirms [his/her] good faith belief that [he/she] has met the relevant standard of conduct described in Section 8.51 of the Massachusetts Business Corporation Act (“MBCA”) or the Proceeding involves conduct for which liability has been eliminated under a provision of the Company’s articles of organization as authorized by Section 2.02(b)(4) of the MBCA; and

(2)

undertakes to repay the advancement of Expenses if [he/she] is not entitled to mandatory indemnification under Section 8.52 of the MBCA and it is ultimately determined that [he/she] has not met the relevant standard of conduct described in Section 8.51 of the MBCA.

Very truly yours,

___________, Indemnitee

EX-31.1 3 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Charles H. Sherwood, certify that:

I have reviewed this report on Form 10-Q for the quarterly period ended September 30, 2014 of Anika Therapeutics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2014	/s/ CHARLES H. SHERWOOD
	Charles H. Sherwood, Ph.D.
	Chief Executive Officer
	Principal Executive Officer

EX-31.2 4 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Sylvia Cheung, certify that:

I have reviewed this report on Form 10-Q for the quarterly period ended September 30, 2014 of Anika Therapeutics, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2014	/s/ SYLVIA CHEUNG
	Sylvia Cheung
	Chief Financial Officer
	Principal Financial Officer

EX-32.1 5 exh_321.htm EXHIBIT 32.1

Exhibit 32.1

Section 906 Certification

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2014	/s/ CHARLES H. SHERWOOD
	Charles H. Sherwood, Ph.D.
	Chief Executive Officer
	Principal Executive Officer

Date: November 5, 2014	/s/ SYLVIA CHEUNG
	Sylvia Cheung
	Chief Financial Officer
	Principal Financial Officer

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Exchange Act.

EX-101.INS 6 anik-20140930.xml XBRL INSTANCE FILE 0000898437 2014-09-30 0000898437 2013-12-31 0000898437 2014-07-01 2014-09-30 0000898437 2013-07-01 2013-09-30 0000898437 2014-01-01 2014-09-30 0000898437 2013-01-01 2013-09-30 0000898437 2012-12-31 0000898437 2013-09-30 0000898437 2014-10-31 0000898437 anik:IncreaseToCashProvidedByFinancingActivitiesMember 2014-01-01 2014-06-30 0000898437 anik:DereaseToCashProvidedByOperatingActivitiesMember 2014-01-01 2014-06-30 0000898437 us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-09-30 0000898437 us-gaap:CertificatesOfDepositMember 2013-12-31 0000898437 us-gaap:MoneyMarketFundsMember 2014-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2014-09-30 0000898437 us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-09-30 0000898437 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member 2014-09-30 0000898437 us-gaap:CertificatesOfDepositMember 2014-09-30 0000898437 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2014-09-30 0000898437 us-gaap:FairValueInputsLevel1Member 2014-09-30 0000898437 us-gaap:FairValueInputsLevel2Member 2014-09-30 0000898437 us-gaap:MoneyMarketFundsMember 2013-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2013-12-31 0000898437 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2014-07-01 2014-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember anik:BoardOfDirectorsMember 2014-01-01 2014-09-30 0000898437 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-09-30 0000898437 us-gaap:StockAppreciationRightsSARSMember 2014-04-01 2014-06-30 0000898437 us-gaap:MinimumMember 2014-01-01 2014-09-30 0000898437 us-gaap:MaximumMember 2014-01-01 2014-09-30 0000898437 us-gaap:MinimumMember 2014-07-01 2014-09-30 0000898437 us-gaap:MaximumMember 2014-07-01 2014-09-30 0000898437 us-gaap:MinimumMember 2013-01-01 2013-09-30 0000898437 us-gaap:MaximumMember 2013-01-01 2013-09-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2014-09-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2014-01-01 2014-09-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2013-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2013-01-01 2013-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2014-09-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2014-01-01 2014-09-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2013-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2013-01-01 2013-12-31 0000898437 us-gaap:DistributionRightsMember 2014-09-30 0000898437 us-gaap:DistributionRightsMember 2014-01-01 2014-09-30 0000898437 us-gaap:DistributionRightsMember 2013-12-31 0000898437 us-gaap:DistributionRightsMember 2013-01-01 2013-12-31 0000898437 us-gaap:PatentsMember 2014-09-30 0000898437 us-gaap:PatentsMember 2014-01-01 2014-09-30 0000898437 us-gaap:PatentsMember 2013-12-31 0000898437 us-gaap:PatentsMember 2013-01-01 2013-12-31 0000898437 anik:ElevessTradeNameMember 2014-09-30 0000898437 anik:ElevessTradeNameMember 2013-12-31 0000898437 anik:ElevessTradeNameMember 2013-01-01 2013-12-31 0000898437 2014-06-30 0000898437 anik:MiltekMONOVISCAgreementMember 2011-12-01 2011-12-31 0000898437 anik:MiltekMONOVISCAgreementMember 2011-12-31 0000898437 anik:MiltekMONOVISCAgreementMember 2014-01-01 2014-03-31 0000898437 anik:MiltekMONOVISCAgreementMember 2014-04-01 2014-06-30 0000898437 anik:MilestoneAndContractRevenueMember 2014-01-01 2014-09-30 0000898437 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:EarliestTaxYearMember 2014-01-01 2014-09-30 0000898437 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember us-gaap:EarliestTaxYearMember 2014-01-01 2014-09-30 0000898437 anik:OrthobiologicsMember 2014-07-01 2014-09-30 0000898437 anik:OrthobiologicsMember 2013-07-01 2013-09-30 0000898437 anik:OrthobiologicsMember 2014-01-01 2014-09-30 0000898437 anik:OrthobiologicsMember 2013-01-01 2013-09-30 0000898437 anik:DermalMember 2014-07-01 2014-09-30 0000898437 anik:DermalMember 2013-07-01 2013-09-30 0000898437 anik:DermalMember 2014-01-01 2014-09-30 0000898437 anik:DermalMember 2013-01-01 2013-09-30 0000898437 anik:SurgicalMember 2014-07-01 2014-09-30 0000898437 anik:SurgicalMember 2013-07-01 2013-09-30 0000898437 anik:SurgicalMember 2014-01-01 2014-09-30 0000898437 anik:SurgicalMember 2013-01-01 2013-09-30 0000898437 anik:OphthalmicMember 2014-07-01 2014-09-30 0000898437 anik:OphthalmicMember 2013-07-01 2013-09-30 0000898437 anik:OphthalmicMember 2014-01-01 2014-09-30 0000898437 anik:OphthalmicMember 2013-01-01 2013-09-30 0000898437 anik:VeterinaryMember 2014-07-01 2014-09-30 0000898437 anik:VeterinaryMember 2013-07-01 2013-09-30 0000898437 anik:VeterinaryMember 2014-01-01 2014-09-30 0000898437 anik:VeterinaryMember 2013-01-01 2013-09-30 0000898437 anik:UnitedStatesMember 2014-07-01 2014-09-30 0000898437 anik:UnitedStatesMember 2013-07-01 2013-09-30 0000898437 anik:UnitedStatesMember 2014-01-01 2014-09-30 0000898437 anik:UnitedStatesMember 2013-01-01 2013-09-30 0000898437 us-gaap:EuropeMember 2014-07-01 2014-09-30 0000898437 us-gaap:EuropeMember 2013-07-01 2013-09-30 0000898437 us-gaap:EuropeMember 2014-01-01 2014-09-30 0000898437 us-gaap:EuropeMember 2013-01-01 2013-09-30 0000898437 anik:OtherLocationMember 2014-07-01 2014-09-30 0000898437 anik:OtherLocationMember 2013-07-01 2013-09-30 0000898437 anik:OtherLocationMember 2014-01-01 2014-09-30 0000898437 anik:OtherLocationMember 2013-01-01 2013-09-30 0000898437 2012-10-01 2012-12-31 0000898437 anik:NonCashTerminationAndImpairmentOfIPRDProjectMember 2012-10-01 2012-12-31 0000898437 anik:NoncashDisposalOfPropertyAndEquipmentMember 2012-10-01 2012-12-31 0000898437 anik:DisposalOfInventoryMember 2012-10-01 2012-12-31 0000898437 anik:EmployeeTerminationCostsMember 2013-12-31 0000898437 anik:ActivityTerminationAndFacilityClosureCostsMember 2013-12-31 0000898437 anik:EmployeeTerminationCostsMember 2014-01-01 2014-09-30 0000898437 anik:ActivityTerminationAndFacilityClosureCostsMember 2014-01-01 2014-09-30 0000898437 anik:EmployeeTerminationCostsMember 2014-09-30 0000898437 anik:ActivityTerminationAndFacilityClosureCostsMember 2014-09-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

71772194

63333160

19999600

20170095

18736845

13582456

10996785

1343576

659040

1128693

865957

128655654

94591787

53379965

52413423

21343322

19474712

32036643

32938711

69054 69080

16033944

18998409

8702295

9443894

185497590

156041881

1167545

2793911

5253693

5537881

12885

180433

770276

6434123

9282501

948858

1133544

56573

2054941

8353531

7936864

148004

142893

76064383

70606031

-3595487

-1699095

97087605

66584202

169704505

135634031

185497590

156041881

546455

593023

0.01

1250000

0.01

30000000

14800453

14289308

14800453

14289308

21975312

17023346

57593873

51585242

80111

731092

24746497

2244584

22055423

17754438

82340370

53829826

5724800

5377568

15418732

16530070

1999867

1618012

6160740

5029974

4044538

3188669

11401399

10536462

196084 442869

11769205

9988165

32980871

31653637

10286218

7766273

49359499

22176189

9937

-32816

16339

-108755

10296155

7733457

49375838

22067434

4125355

2776199

18872435

8147282

6170800

4957258

30503403

13920152

0.42

0.36

2.09

1.03

14758781

13682449

14626933

13534334

0.40

0.33

1.97

0.95

15434875

14958965

15469237

14673879

431

-1679968

916474

-1896823

507119

-1679537

916474

-1896392

507119

4491263

5873732

28607011

14427271

3576441

3579474

1196361

1156929

24098

220207

165803

442341

9236708

764181

1840407

-4667839

2923628

3430655

-183481

-531449

-25497

-992822

124679

-989291

-642430

-2078543

-2150000

7771001

766598

-167123

-373712

25222372

17159199

19999169

530865

920132

235803

-20919301

295062

1379294

2932649

9236708

764181

6348900

1200000

4267102

2496830

-131139

36870

8439034

19987961

44067477

64055438

Anika Therapeutics, Inc. 10-Q --12-31 14504014 false 0000898437 Yes No Accelerated Filer No 2014 Q3 2014-09-30

2500000

-2500000

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"> 3. </td> <td style="width: 94%"> Marketable Securities </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="15" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Amortized Cost </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Unrealized Gains, Net of Tax </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Unrealized Losses, Net of Tax </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Fair Value </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"> United States Treasury securities </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 14,999,169 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 699 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> (268 </td> <td style="width: 1%; text-align: left"> ) </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 14,999,600 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt"> Bank certificates of deposit </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 19,999,169 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 699 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> (268 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> ) </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 19,999,600 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table> The Company considers securities with maturities of three months or less from the purchase date to be cash equivalents. Interest is recorded when earned. All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes.

14999169

699

-268

14999600

5000000

19999169

699

-268

19999600

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"> 4. </td> <td style="width: 94%"> Fair Value Measurements </td> </tr> </table> Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements, a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value, was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. On a recurring basis, the Company records its marketable securities at fair value. The Company’s investments are all classified within Level 1 and Level 2 of the fair value hierarchy. The Company’s investments classified within Level 1 of the fair value hierarchy are valued using quoted market prices. The Company’s investments classified within Level 2 of the fair value hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves, and credit risk. The fair value hierarchy of the Company’s cash equivalents and marketable securities at fair value is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Fair Value Measurements at Reporting Date Using </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Other Observable Inputs (Level 2) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Unobservable Inputs (Level 3) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 2.75pt"> Money market funds </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 49,285,168 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 49,285,168 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Marketable securities: </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> United States Treasury securities </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 14,999,600 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 14,999,600 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Bank certificates of deposit </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.75pt"> Total marketable securities </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 19,999,600 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 14,999,600 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Fair Value Measurements at Reporting Date Using </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Quoted Prices in Active Markets  for Identical Assets   (Level 1) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Other Observable Inputs  (Level 2) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Unobservable Inputs (Level 3) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 2.75pt"> Money market funds </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 34,266,501 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 34,266,501 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> </tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Fair Value Measurements at Reporting Date Using </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Other Observable Inputs (Level 2) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Unobservable Inputs (Level 3) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 2.75pt"> Money market funds </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 49,285,168 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 49,285,168 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Marketable securities: </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> United States Treasury securities </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 14,999,600 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 14,999,600 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Bank certificates of deposit </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.75pt"> Total marketable securities </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 19,999,600 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 14,999,600 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 5,000,000 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Fair Value Measurements at Reporting Date Using </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Quoted Prices in Active Markets  for Identical Assets   (Level 1) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Other Observable Inputs  (Level 2) </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Significant Unobservable Inputs (Level 3) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 2.75pt"> Money market funds </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 34,266,501 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> 34,266,501 </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> <td style="width: 1%; padding-bottom: 2.75pt">   </td> <td style="width: 1%; border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="width: 8%; border-bottom: Black 2.75pt double; text-align: right"> - </td> <td style="border-bottom: Black 2.75pt double; text-align: left; width: 1%">   </td> </tr> </table>

49285168

14999600

5000000

14999600

5000000

34266501

390578

368603

1196361

1156929

7000

139240

9365

30700

P4Y

4200000

P3Y

25473089 4095833

17513

1804773

133774

936097 13.54 21800000 P6Y292D

P1Y

P4Y

P10Y

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="font-weight: bold">   </td> <td colspan="7" style="text-align: center"> Three Months Ended September 30, </td> </tr> <tr> <td style="padding-bottom: 1.1pt">   </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 71%"> Risk free interest rate </td> <td style="width: 3%; text-align: center"> 1.30% </td> <td style="width: 7%; text-align: center"> - </td> <td style="text-align: center; width: 3%"> 1.39% </td> <td style="text-align: right; width: 3%">   </td> <td style="width: 3%">   </td> <td style="width: 7%; text-align: center"> - </td> <td style="text-align: center; width: 3%"> </td> </tr> <tr style="background-color: White"> <td> Expected volatility </td> <td>   </td> <td style="text-align: center"> 53.28% </td> <td style="text-align: center"> </td> <td>   </td> <td>   </td> <td style="text-align: center"> - </td> <td style="text-align: center"> </td> </tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td> Expected lives (years) </td> <td>   </td> <td style="text-align: center"> 4 </td> <td style="text-align: center"> </td> <td style="text-align: right">   </td> <td>   </td> <td style="text-align: center"> - </td> <td style="text-align: center"> </td> </tr> <tr style="background-color: White"> <td> Expected dividend yield </td> <td>   </td> <td style="text-align: center"> 0.00% </td> <td style="text-align: center"> </td> <td>   </td> <td>   </td> <td style="text-align: center"> - </td> <td style="text-align: center"> </td> </tr> </table><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="font-weight: bold">   </td> <td colspan="7"> Nine Months Ended September 30, </td> </tr> <tr> <td style="padding-bottom: 1.1pt">   </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1.1pt">   </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 71%"> Risk free interest rate </td> <td style="width: 3%; text-align: center"> 1.16% </td> <td style="width: 7%; text-align: center"> - </td> <td style="text-align: center; width: 3%"> 1.39% </td> <td style="text-align: right; width: 3%">   </td> <td style="width: 3%; text-align: center"> 0.61% </td> <td style="width: 7%; text-align: center"> - </td> <td style="text-align: center; width: 3%"> 0.70% </td> </tr> <tr style="background-color: White"> <td> Expected volatility </td> <td>   </td> <td style="text-align: center"> 53.28% </td> <td style="text-align: center"> </td> <td>   </td> <td>   </td> <td style="text-align: center"> 57.60% </td> <td style="text-align: center"> </td> </tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td> Expected lives (years) </td> <td>   </td> <td style="text-align: center"> 4 </td> <td style="text-align: center"> </td> <td style="text-align: right">   </td> <td>   </td> <td style="text-align: center"> 4 </td> <td style="text-align: center"> </td> </tr> <tr style="background-color: White"> <td> Expected dividend yield </td> <td>   </td> <td style="text-align: center"> 0.00% </td> <td style="text-align: center"> </td> <td>   </td> <td>   </td> <td style="text-align: center"> 0.00% </td> <td style="text-align: center"> </td> </tr> </table>

0.0130

0.0139

0.0116

0.0139

0.0061

0.0070

0.5328

0.5760

P4Y

0.0000

122967

118725

88278

676094

1276516

842304

1139545

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"> 7. </td> <td style="width: 94%"> Inventories </td> </tr> </table> Inventories consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left"> Raw materials </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 6,843,441 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 5,926,030 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Work-in-process </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 2,325,667 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 2,308,233 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Finished goods </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 4,413,348 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 2,762,522 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 10pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 13,582,456 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 10,996,785 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table> Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead.

6843441

5926030

2325667

2308233

4413348

2762522

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"> 8.   </td> <td style="width: 94%; text-align: justify"> Intangible Assets and Goodwill </td> </tr> </table> In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”), the Company acquired various intangible assets and goodwill. The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets. The in-process research and development (“IPR&D”) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects. Until such determination is made, they are not amortized.  The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. Intangible assets as of September 30, 2014 and December 31, 2013 consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> </tr> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Gross Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Currency Translation Adjustment </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Accumulated Amortization </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Net Book Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Net Book Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Useful Life </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left"> Developed technology </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 16,700,000 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> (1,828,214 </td> <td style="width: 1%; text-align: left"> ) </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> (4,779,123 </td> <td style="width: 1%; text-align: left"> ) </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 10,092,663 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 11,753,003 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: center"> 15 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> In-process research & development </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,502,686 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (638,426 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 4,864,260 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,286,127 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> Indefinite </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Distributor relationships </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 4,700,000 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (440,953 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (4,084,944 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 174,103 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 863,655 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> 5 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> Patents </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,000,000 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (107,910 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (271,208 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 620,882 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 719,574 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> 16 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Elevess trade name </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (717,964 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 282,036 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 376,050 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="padding-bottom: 1.1pt; text-align: left">   </td> <td style="padding-bottom: 1.1pt; text-align: center"> 9 </td> <td style="padding-bottom: 1.1pt; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.75pt; padding-left: 10pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 28,902,686 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> (3,015,503 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> ) </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> (9,853,239 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> ) </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 16,033,944 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 18,998,409 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="padding-bottom: 2.75pt; text-align: left">   </td> <td style="padding-bottom: 2.75pt; text-align: right">   </td> <td style="padding-bottom: 2.75pt; text-align: left">   </td> </tr> </table> The aggregate amortization expense related to intangible assets was $518,699 and $521,387 for the three-month periods ended September 30, 2014 and 2013, respectively. The aggregate amortization expense related to intangible assets was $1,593,260 and $1,555,796 for the nine-month periods ended September 30, 2014 and 2013, respectively. Changes in the carrying value of goodwill for the three and nine-month periods ended September 30, 2014 were as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.1pt"> Goodwill </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Three Months Ended September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Nine Months Ended September 30, 2014 </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left"> Balance, beginning </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 9,360,884 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 9,443,894 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Effect of foreign currency adjustments </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (658,589 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (741,599 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.75pt"> Balance, ending </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 8,702,295 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 8,702,295 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table>

518699

521387

1593260

1555796

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> </tr> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Gross Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Currency Translation Adjustment </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Accumulated Amortization </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Net Book Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Net Book Value </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Useful Life </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left"> Developed technology </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 16,700,000 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> (1,828,214 </td> <td style="width: 1%; text-align: left"> ) </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> (4,779,123 </td> <td style="width: 1%; text-align: left"> ) </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 10,092,663 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 11,753,003 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: center"> 15 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> In-process research & development </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,502,686 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (638,426 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> - </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 4,864,260 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,286,127 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> Indefinite </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Distributor relationships </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 4,700,000 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (440,953 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (4,084,944 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 174,103 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 863,655 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> 5 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> Patents </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,000,000 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (107,910 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (271,208 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 620,882 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 719,574 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: center"> 16 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Elevess trade name </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,000,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> - </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (717,964 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 282,036 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 376,050 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="padding-bottom: 1.1pt; text-align: left">   </td> <td style="padding-bottom: 1.1pt; text-align: center"> 9 </td> <td style="padding-bottom: 1.1pt; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.75pt; padding-left: 10pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 28,902,686 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> (3,015,503 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> ) </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> (9,853,239 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> ) </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 16,033,944 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 18,998,409 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="padding-bottom: 2.75pt; text-align: left">   </td> <td style="padding-bottom: 2.75pt; text-align: right">   </td> <td style="padding-bottom: 2.75pt; text-align: left">   </td> </tr> </table> 16700000 -1828214 -4779123

10092663

11753003

P15Y

5502686 -638426

4864260

5286127

4700000 -440953 -4084944

174103

863655

P5Y

1000000 -107910 -271208

620882

719574

P16Y

1000000 -717964

282036

376050

P9Y

28902686 -3015503 -9853239

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.1pt"> Goodwill </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Three Months Ended September 30, 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Nine Months Ended September 30, 2014 </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left"> Balance, beginning </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 9,360,884 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 9,443,894 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Effect of foreign currency adjustments </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (658,589 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (741,599 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.75pt"> Balance, ending </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 8,702,295 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 8,702,295 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table>

9360884

-658589

-741599

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.1pt">   </td> <td style="padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="text-align: center; border-bottom: Black 1.1pt solid"> September 30, 2014 </td> <td style="padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="text-align: right; border-bottom: Black 1.1pt solid"> December 31, 2013 </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left"> Labor and related expenses </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 2,842,234 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 2,870,147 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Clinical trial costs </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 962,031 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 882,651 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Professional fees </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 382,423 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 383,231 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Research grants </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 562,558 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 610,498 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Restructuring costs </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 11,909 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 24,638 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt"> Other </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 492,538 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 766,716 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 10pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 5,253,693 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 5,537,881 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table>

2842234

2870147

962031 882651

382423

383231

562558 610498

11909

24638

492538

766716

P15Y

2500000

2200000

17500000

5000000

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"> 12. </td> <td style="width: 94%"> Income Taxes </td> </tr> </table> Provisions for income taxes were $4,125,355 and $18,872,435 for the three and nine-month periods ended September 30, 2014, respectively, based on effective tax rates of 40% and 38%. Provisions for income taxes were $2,776,199 and $8,147,282 for the three and nine-month periods ended September 30, 2013, respectively, based on effective tax rates of 36% and 37%, respectively. The increase in income taxes over the three-month period ended September 30, 2014 was primarily due to increased net income. The increase in income taxes over the nine-month period ended September 30, 2014 was primarily due to increased net income, which reflected $24,652,778 in milestone and contract revenue associated with our U.S. license agreement for MONOVISC. See the previous discussion under Note 11. The increase in the effective tax rate for each of the periods ended 2014, as compared to the same periods ended in 2013, was driven primarily by the unavailability of the federal R&D tax credit in 2014, due to its expiration on December 31, 2013, and a relative decrease to our estimated production activities deduction. The Company files income tax returns in the U.S. on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. Our filings from 2011 through the present tax year remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. Our filings from 2009 through the present tax year remain subject to examination by the appropriate governmental authorities in Italy. In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward. We have concluded that the positive evidence outweighs the negative evidence and, thus, those deferred tax assets are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance at September 30, 2014 or December 31, 2013.

0.40

0.38

0.36

0.37

24652778

2011

2009

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%">  13. </td> <td style="width: 94%">  Segment and Geographic Information </td> </tr> </table> The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements. Product revenue by product group is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Three Months Ended September 30, </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Nine Months Ended September 30, </td> </tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">   </td> <td style="width: 54%; text-align: left"> Orthobiologics </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 18,899,873 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 12,830,566 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 48,750,277 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 40,620,339 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">   </td> <td style="text-align: left"> Dermal </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 401,355 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 267,766 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 938,966 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,066,409 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">   </td> <td style="text-align: left"> Surgical </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,452,946 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,136,248 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 4,581,496 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 3,955,134 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">   </td> <td style="text-align: left"> Ophthalmic </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 366,138 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,425,609 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 938,134 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 2,818,407 </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.1pt; text-align: left">   </td> <td style="padding-bottom: 1.1pt; text-align: left"> Veterinary </td> <td style="padding-bottom: 1.1pt; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 855,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,363,157 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 2,385,000 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 3,124,953 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.75pt; text-align: left">   </td> <td style="padding-bottom: 2.75pt; text-align: right">   </td> <td style="padding-bottom: 2.75pt; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 21,975,312 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 17,023,346 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 57,593,873 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 51,585,242 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table> Total revenue by geographic location and as a percentage of overall total revenue, for the three and nine-month periods ended September 30, 2014 and 2013 are as follows; <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td colspan="15" style="font-weight: bold; text-align: center"> Three Months Ended September 30, </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> Geographic Location: </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt"> United States </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 18,455,167 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 84 </td> <td style="width: 1%; text-align: left"> % </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 14,485,821 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 82 </td> <td style="width: 1%; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt"> Europe </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,784,414 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 8 </td> <td style="text-align: left"> % </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,656,656 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 9 </td> <td style="text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"> Other </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,815,842 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 8 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,611,961 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 9 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 20pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 22,055,423 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 17,754,438 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td colspan="15" style="font-weight: bold; text-align: center"> Nine Months Ended September 30, </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> Geographic Location: </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt"> United States </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 72,935,722 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 89 </td> <td style="width: 1%; text-align: left"> % </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 42,251,336 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 78 </td> <td style="width: 1%; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt"> Europe </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,274,071 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 6 </td> <td style="text-align: left"> % </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,226,619 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 10 </td> <td style="text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"> Other </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 4,130,577 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 6,351,871 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 12 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 20pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 82,340,370 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 53,829,826 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> </tr> </table>

18899873

12830566

48750277

40620339

401355

267766

938966

1066409

1452946

1136248

4581496

3955134

366138

1425609

938134

2818407

855000

1363157

2385000

3124953

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td colspan="15" style="font-weight: bold; text-align: center"> Three Months Ended September 30, </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> Geographic Location: </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt"> United States </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 18,455,167 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 84 </td> <td style="width: 1%; text-align: left"> % </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 14,485,821 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 82 </td> <td style="width: 1%; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt"> Europe </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,784,414 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 8 </td> <td style="text-align: left"> % </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 1,656,656 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 9 </td> <td style="text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"> Other </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,815,842 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 8 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 1,611,961 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 9 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 20pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 22,055,423 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 17,754,438 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> </tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold">   </td> <td colspan="15" style="font-weight: bold; text-align: center"> Nine Months Ended September 30, </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2014 </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> 2013 </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total Revenue </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Percentage of Revenue </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> Geographic Location: </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> <td style="font-weight: bold">   </td> <td style="font-weight: bold; text-align: left">   </td> <td style="font-weight: bold; text-align: right">   </td> <td style="font-weight: bold; text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right">   </td> <td style="text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt"> United States </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 72,935,722 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 89 </td> <td style="width: 1%; text-align: left"> % </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 42,251,336 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 8%; text-align: right"> 78 </td> <td style="width: 1%; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt"> Europe </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,274,071 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 6 </td> <td style="text-align: left"> % </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 5,226,619 </td> <td style="text-align: left">   </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> 10 </td> <td style="text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"> Other </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 4,130,577 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 5 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 6,351,871 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> 12 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.75pt; padding-left: 20pt"> Total </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 82,340,370 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 53,829,826 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 100 </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> % </td> </tr> </table>

18455167

0.84

14485821

0.82

72935722

0.89

42251336

0.78

1784414

0.08

1656656

0.09

5274071

0.06

5226619

0.10

1815842

0.08

1611961

0.09

4130577

0.05

6351871

0.12 1.00 1.00 1.00 1.00

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; font: 10pt Times New Roman, Times, Serif"> 14. </td> <td style="width: 94%; font: 10pt Times New Roman, Times, Serif"> Restructuring Credits </td> </tr> </table> In December 2012, the Company announced the closure of its tissue engineering facility in Abano Terme, Italy due to the Company’s inability to meet strict regulatory standards established by the European Medicines Agency (“EMA”) for Advanced Therapy Medicinal Products, which became effective on January 1, 2013. The restructuring plan involved a workforce reduction as well as associated asset abandonments. The Company recorded restructuring and impairment charges in the fourth quarter of 2012 of approximately $2.5 million. Of the total restructuring and impairment charges related to the tissue engineering operation, approximately $1.2 million was related to the non-cash termination and related impairment of an IPR&D project, $0.3 million was related to the disposal of property and equipment, and $0.1 million was related to the disposal of inventory. We completed the restructuring plan and related activities in 2013. Certain previously impaired and written-off equipment was sold, resulting in restructuring credits of $196,084 and $442,869 in the three and nine months ended September 30, 2013, respectively. The following table summarizes restructuring accrual activity for the nine-period ended September 30, 2014: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Restructuring Accrual </td> </tr> <tr style="vertical-align: bottom"> <td>   </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Employee Severance and Related Benefits </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Activity Termination and Facility Closure Costs </td> <td style="font-weight: bold; padding-bottom: 1.1pt">   </td> <td colspan="3" nowrap="nowrap" style="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"> Total </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left"> December 31, 2013 </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 21,709 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 2,929 </td> <td style="width: 1%; text-align: left">   </td> <td style="width: 1%">   </td> <td style="width: 1%; text-align: left"> $ </td> <td style="width: 8%; text-align: right"> 24,638 </td> <td style="width: 1%; text-align: left">   </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Cash Proceeds (Disbursements) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (10,130 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (1,425 </td> <td style="text-align: left"> ) </td> <td>   </td> <td style="text-align: left">   </td> <td style="text-align: right"> (11,555 </td> <td style="text-align: left"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.1pt"> Foreign Exchange Impact </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (1,050 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (124 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> <td style="padding-bottom: 1.1pt">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: left">   </td> <td style="border-bottom: Black 1.1pt solid; text-align: right"> (1,174 </td> <td style="border-bottom: Black 1.1pt solid; text-align: left"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.75pt"> September 30, 2014 </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 10,529 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 1,380 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> <td style="padding-bottom: 2.75pt">   </td> <td style="border-bottom: Black 2.75pt double; text-align: left"> $ </td> <td style="border-bottom: Black 2.75pt double; text-align: right"> 11,909 </td> <td style="border-bottom: Black 2.75pt double; text-align: left">   </td> </tr> </table>

2500000

1200000

300000

100000

196084

21709

2929

24638

10130

1425

11555

-1050

-124

-1174

10529

1380

11909

EX-101.SCH 7 anik-20140930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Alternate 0 link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Note 1 - Nature of Business link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Note 2 - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Note 3 - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Note 4 - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Note 5 - Equity Incentive Plan link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note 6 - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Note 7 - Inventories link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Note 8 - Intangible Assets and Goodwill link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note 9 - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Note 10 - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Note 11 - Mitek Monovisc Agreement link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Note 12 - Income Taxes link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Note 13 - Segment and Geographic Information link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Note 14 - Restructuring Credits link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Note 15 - New Accounting Standards link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Note 3 - Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Note 5 - Equity Incentive Plan (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Note 6 - Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Note 7 - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Note 8 - Intangible Assets and Goodwill (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Note 9 - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Note 13 - Segment and Geographic Information (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Note 14 - Restructuring Credits (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Note 2 - Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Note 3 - Marketable Securities (Details) - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Note 5 - Equity Incentive Plan (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Note 6 - Earnings Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Note 6 - Earnings Per Share (Details) - Basic and Diluted Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Note 7 - Inventories (Details) - Inventories link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) - Changes in Carrying Value of Goodwill link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Note 9 - Accrued Expenses (Details) - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Note 10 - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Note 11 - Mitek Monovisc Agreement (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Note 12 - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Note 13 - Segment and Geographic Information (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Note 13 - Segment and Geographic Information (Details) - Product Revenue by Product Group link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Note 13 - Segment and Geographic Information (Details) - Product Revenue by Geographic Location link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Note 14 - Restructuring Credits (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 anik-20140930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 anik-20140930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 anik-20140930_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Marketable securities Accounts receivable, net of reserves of $546,455 and $593,023 at September 30, 2014 and December 31, 2013, respectively Accounts receivable, net of reserves (in Dollars) Inventories Total Prepaid income taxes Current portion deferred income taxes Prepaid expenses and other Total current assets Property and equipment, at cost Less: accumulated depreciation Long-term deposits and other Intangible assets, net Net Book Value Goodwill Balance, beginning Balance, ending Total assets Accounts payable Accrued expenses Total Deferred revenue Income taxes payable Total current liabilities Other long-term liabilities Long-term deferred revenue Deferred tax liability Commitments and contingencies (Note 10) Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, $.01 par value; 30,000,000 shares authorized, 14,800,453 and 14,289,308 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock,shares outstanding Additional paid-in-capital Accumulated other comprehensive loss Retained earnings Total stockholders’ equity Total Liabilities and Stockholders’ Equity Statement of Comprehensive Income [Abstract] Product revenue Product Revenue Licensing, milestone and contract revenue Total revenue Total Revenue Cost of product revenue Research & development Selling, general & administrative Restructuring credits Restructuring Credit Total operating expenses Income from operations Interest income (expense), net Income before income taxes Provision for income taxes Income Tax Expense (Benefit) Net income Net income Net income (in Dollars per share) Basic weighted average common shares outstanding (in Shares) Shares used in the calculation of basic earnings per share Net income (in Dollars per share) Diluted weighted average common shares outstanding (in Shares) Diluted shares used in the calculation of earnings per share Unrealized gain on securities, net of tax Foreign currency translation adjustment Total other comprehensive income (loss) Comprehensive income Statement of Stockholders' Equity [Abstract] Depreciation and amortization Stock-based compensation expense Provision for doubtful accounts Provision for inventory Gain on sale of assets Tax benefit from exercise of stock options Accounts receivable Inventories Prepaid expenses, other current and long-term assets Long-term deposits and other Accounts payable Accrued expenses Deferred revenue Income taxes Other long-term liabilities Net cash provided by operating activities Purchase of marketable securities Proceeds from sale of assets Purchase of property and equipment Net cash provided by (used in) investing activities Proceeds from exercise of stock options Proceeds from Stock Options Exercised Tax benefit from exercise of stock options Minimum tax withholding on share based awards Principal payments on debt Net cash provided by financing activities Exchange rate impact on cash Increase in cash and cash equivalents Disclosure Text Block [Abstract] Disclosure Text Block Supplement [Abstract] Marketable Securities [Abstract] Investment Type [Axis] US States and Political Subdivisions Debt Securities [Member] Amortized Cost Unrealized Gains Unrealized Losses Fair Value Marketable securities Certificates of Deposit [Member] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments [Abstract] Asset Class [Axis] Money Market Funds [Member] Money market funds Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards [Abstract] Risk free interest rate Expected volatility Expected lives (years) Expected dividend yield Range [Axis] Minimum [Member] Maximum [Member] Earnings Per Share [Abstract] Basic and Diluted Earnings Per Share [Abstract] Stock options, SARs, and RSAs Inventory Disclosure [Abstract] Inventories [Abstract] Raw materials Work-in-process Finished goods Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Developed Technology Rights [Member] Gross Value Currency Translation Adjustment Accumulated Amortization Useful Life In Process Research and Development [Member] Distribution Rights [Member] Patents [Member] Elevess Trade Name [Member] Changes in Carrying Value of Goodwill [Abstract] Effect of foreign currency adjustments Payables and Accruals [Abstract] Accrued Expenses [Abstract] Labor and related expenses Clinical trial costs Professional fees Research grants Restructuring costs Other Commitments and Contingencies Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Income Tax Disclosure [Abstract] Segment Reporting [Abstract] Product Revenue by Product Group [Abstract] Products and Services [Axis] Orthobiologics [Member] Dermal [Member] Surgical [Member] Ophthalmic [Member] Veterinary [Member] Product Revenue by Geographic Location [Abstract] Geographical [Axis] United States [Member] Percentage of Revenue Europe [Member] Other location [Member] Restructuring and Related Activities [Abstract] Restructuring Accrual Activity [Abstract] Balance Balance Cash Proceeds (Disbursements) Foreign Exchange Impact Restructuring Type [Axis] Employee termination costs [Member] Activity Termination and Facility Closure Costs [Member] Current assets: LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Stockholders’ equity: Operating expenses: Basic net income per share: Diluted net income per share: Other comprehensive income (loss): Cash flows from operating activities: Adjustments to reconcile net income to net cash provided by operating activities: Changes in operating assets and liabilities: Cash flows from investing activities: EX-101.PRE 11 anik-20140930_pre.xml XBRL PRESENTATION FILE XML 12 R39.htm IDEA: XBRL DOCUMENT

Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	$ 28,902,686
Currency Translation Adjustment	(3,015,503)
Accumulated Amortization	(9,853,239)
Net Book Value	16,033,944	18,998,409
Developed Technology Rights [Member]
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	16,700,000
Currency Translation Adjustment	(1,828,214)
Accumulated Amortization	(4,779,123)
Net Book Value	10,092,663	11,753,003
Useful Life		15 years
In Process Research and Development [Member]
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	5,502,686
Currency Translation Adjustment	(638,426)
Net Book Value	4,864,260	5,286,127
Useful Life
Distribution Rights [Member]
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	4,700,000
Currency Translation Adjustment	(440,953)
Accumulated Amortization	(4,084,944)
Net Book Value	174,103	863,655
Useful Life		5 years
Patents [Member]
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	1,000,000
Currency Translation Adjustment	(107,910)
Accumulated Amortization	(271,208)
Net Book Value	620,882	719,574
Useful Life		16 years
Elevess Trade Name [Member]
Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets [Line Items]
Gross Value	1,000,000
Accumulated Amortization	(717,964)
Net Book Value	$ 282,036	$ 376,050
Useful Life		9 years

XML 13 R48.htm IDEA: XBRL DOCUMENT

Note 14 - Restructuring Credits (Details) (USD $)	3 Months Ended			9 Months Ended
Note 14 - Restructuring Credits (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
Note 14 - Restructuring Credits (Details) [Line Items]
Restructuring Costs and Asset Impairment Charges			$ 2,500,000
Restructuring Credit	196,084	196,084		442,869
Non-Cash Termination And Impairment Of IPR&D [Member]
Note 14 - Restructuring Credits (Details) [Line Items]
Restructuring Costs and Asset Impairment Charges			1,200,000
Noncash Disposal of Property and Equipment [Member]
Note 14 - Restructuring Credits (Details) [Line Items]
Restructuring Costs and Asset Impairment Charges			300,000
Disposal of inventory [Member]
Note 14 - Restructuring Credits (Details) [Line Items]
Restructuring Costs and Asset Impairment Charges			$ 100,000

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!NR'4D#`(``#@>```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B M^6F:%I8SZ&?8!FBZ`$9ZM@1+)$$RJ;W[4G(2%('KP(B!WHD%2^2[1QR<@>[B M:COTQ3V%V#E;,5'.64&V=DUGUQ7[=?-M=LF*F(QM3.\L56Q'D5TMW[Y9W.P\ MQ2+OMK%B;4K^$^>Q;FDPL72>;'ZR;E$GYO6V>I

$LJ\I5-8UXHAF+:]13/_#%W/_2EY-8$:GZFD!O,LP/\/?L8 M1^[WKH/S,3>=@4X_A<F!SUI)&GO8AIH# MV7SJ?9=_````__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R M96QS+RYR96QS(*($`BB@``(````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````(R2ST[#,`S&[TB\ M0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50? M'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+ MBQJZE/PC8C0=3Q0+\>QRI9$P4P>J M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"\F4]KVT`4Q.^%?@>Q]WB][ZVTD!S$7@R2\^O&8G1E)=_>_CH?B1QCCON\JXQ9+4X1N MTS?[;E>9;T^?KVY,$5/=-?6A[T)E3B&:^_7'#W=?PJ%.^4^QW0^QR*MTL3)M M2L,G:^.F#<:YW@4KR^7*CG^O8=87:Q:/367& MQ\:I*9Y.0[[UVXOWV^U^$Q[ZS?=CZ-(_[F%_]N-S;$-(>=%ZW(54F>E4M.9V=C_X.1Y<'%N$(ZLR#BR0CAZ2\;16X0CCHPC#N&H)^.H1SA>R#A>(,XU M&^<:X939">?;Z"D;8L@+OGC.^=">?Z%BV".!$V'+!:K%L8W/0>,3MO$)-#[' M-CX'92QLXQ-H?,I6LD(I*WN7*]SF?E;CF]K5J_E-IUX*EU\B'_;EG#X\W1O@ ME`B'30-A')O&01QA5W6!55W855U@55=V8BE,+,].+(\3B^TZ#KJ.8T_'P>DH M.\\5YKEGY[F'>5[.FN>QK+8GN>@YSFVYSGH><(V&8$FHW3I0.TH>ULKW->> M_3SEX?.4L/-28%[Z65WO'>7&PR<&-@V$80MGTHV]^&BZ_@T``/__`P!02P,$ M%``&``@````A`**:F*DX!```>@\```\```!X;"]W;W)K8F]O:RYX;6R4EUU/ MXSH0AN]7VO\0Y7ZWS4=30)05+-VS7(#0@<->6B:9MA:)W6,[M/S[G;@0QM21 MZ%7KI'F9>>>9&7+Z8]O4T3-H(Y2*=A=(-MWC4 MRY%9:^"560'8IAZEXW$Q:KB0\4[A1']&0RT6HH1+5;8-2+L3T5!SB^&;E5B; M^.QT(6IXV&44\?7ZAC<8][:.HYH;.Z^$A6H63_"H-N!=T.WZHA4UWCW.QED\ M.NN3O-51!0O>UO8>TWM31[_2/$V+[I>=%0\"-N;]H>X8;?\(6:E-]U.T]J4_ M91C`QMWZ(RJ[POOC\;B_]AO$'&'GLF)S:85] M85=RY[Y06,+.]2O,+(DC?2+PB[ZJDBYPJO)3R0JD@8KA-Z-J47$TBUWPFLL2 MB$I*5-+#5#"`/IB,R#B_/Q',G<68&AI,3E3R3P;SJD*#0?-[9R8?96Z4!9:P M&VY;#4PMV$5KA`1C2#83+'"OX*"@Z3B%%+TTPG0"MQH,(NS(I2*T0--@&!F[ MYOH)+'^L@=U!V6IA!;;ENZ\36I^CH$C.?G&AV0.O6V#7P`WFU;64)T/KN< MG2+NSQB!TA^L*$A1DCU6W;-'^"R.N*7H##TW!JQA./'8/S2-*=79@]7I'+/S MLM0M=LQ\B^//^#7!0=K3D>QQZ@22,39>TPCK*N%BP$:TW8SL>V9R3'4&0$W8 M-8ZY)W:MI'H6IF3G2PU^UQ24UB2,:Y*B,Z5J@-WSK9=-03%-PIPF&=*Y[%+9 MN0EJJ?EZ)4J234%)3<*H)CG[%P>U;DML/H2$_=2`4YR26E!2DS"JR83=P*8K MD6H[3Y<,AP#N-4W#H;#BP/XP'UV1!MJ/W5,=2FP:)G:P`^E0*BB^:1C?@1[T M`Z+XIF%\0UV(A7_$S=G35U"*TS#%7BLZ`1\="G`:!GBP(ZDW4TKP;@OO#=S] MEMP/:$I93@]DV0N(PIP>!C,C)D\IS6F8YH%-PBZ)3D8-PL,A-%.=*>V*[$": MT9.>GHP:A(=00$,T>P'1]LK"-`_JT(IE7F9AG(-M<8GKER;F!11F>E#'"XCV M>Q:>RGY_=9&(VG3KCP9$^ST+,SW89%[):,-G8:8'A9#C]]K3ML_"4`\*89EZ MH9Q2C8<01(&VW_E$==#W?B'G8:H'%S*M64ZIQD,HH&1H(WM"M._S,-8?5C)[ M+3_-BS*=AYD>7,VT]#F%&@_!O(9V/"U]3J'&PT%"7NDIU7F8ZJ'_%ICG-*4Z M#U,]*.1Y1*G.'=4C1RJ^GY6\+O'%L?OHWKPF3S2,QA,MATTB)5(4Y7#-V'@&K6TL8'9V MWS[5-(:N8LS8N=EDS$?1?U=U]0_]\-.WPW[QM:B;LCJN/;;TO45QW%3;\OB\ M]O[^Z_-=Z"V:-C]N\WUU+-;>]Z+Q?GK\\8>'MZK^TKP41;N`",=F[;VT[>E^ MM6HV+\4A;Y;5J3C"E5U5'_(6_JR?5\VI+O)M=]-AO^*^'ZP.>7GT;(3[^IH8 MU6Y7;HJTVKP>BF-K@]3%/F]A_,U+>6K.T0Z;:$=\OK+Z^EN4QU.$.*IW)?M M]RZHMSAL[G]]/E9U_K0'W=^8S#?GV-T?D_"'GS8EJ#`3/NB+G9K[Q.[SX3OK1X?N@GZIRS>&N?_%\U+]?9S76Y_*X\%S#;D MR63@J:J^&/37K?D);EY-[O[<9>"/>K$M=OGKOOVS>ONE*)]?6DBW`D5&V/WV M>UHT&YA1"+/DRD3:5'L8`/R[.)2F-&!&\F_=?]_*;?NR]D2P5-H7#/#%4]&T MGTL3TEML7INV.OQK(=:'LD%X'P3NZ(,PON2A8BKX.,K*CJ@3F.9M_OA05V\+ MJ!IX9G/*30VR>XALE,%,]N,8M%Z2"AI-D$\FRMK3W@)N;R`_7Q^U>EA]A2G= M]$C\#A)@)#DC9@)-V/3\PQB6X5NR,V&R!XH&63!9KJSW$W4>O8'-Z,_/C>T/ M$'N0P_%SDRFA-4;2*4*"9%/""8+DB%OD&'CM0?!A]#K$8XLM$G:9XBS2"BH1 M(XF+,.US(23)5^HB2JM(A%K@*!E"F`H5E^.#D$2))9X+<3YSYB8B-<(CB"VB M.JFASQBIH,2]K@7SHW%\M@A=@$LM`QF15&<(X5*J4`ZC0")AA5U?E@;&XD)_ M"-N-+;:(%<>YKY3D)`.)BS"ME92"5$/J(B$7TA>:/"AS$25"'H5\K`8D,;A% MHH&AX3BE&I+\Q!:!&1ZJF726Y$,B_9#(Y@@D#WK<]1DT,,D@J:[8(C:#2G,9 M^F3J$T0(R&!`\^<23$D&RY`$D-(H(3O.RE&`HUG<3:$^?5G8"*0U%]L$2N0 M15$4!F3U)(@(&"Q2,OK4)0(6^%J22E3U=7XA*"A6$0D!:5N@1CTF"_19;0&`Z=(-:0H#*11JY#VKPPQ8#("+<78 M!;%.8Q.NUVE-A:LS(GT]-F]9T(*M3@FO2V(JTT4XE"OL,C25+@(M&/99,::J MSZ;+A$QJ'E[JL,8L7*_26@NDDG2$F%G&J@S`;4]=`$)D!%9!D9)/$2)\Y1LG MAVT&$DEF.F:N);EC@8XB:MP2Q$0L@+<+G*\4$7?0 M/P,PZ)C)$*-\S=A8_UBL<1&WB[7>`XDEPXR9ZT\ZL6K:<5WF?;$NT8F%`J5B M769.++_)!W4T?A.)2(>(>P:ZZL57D8^1]&,DFT501OE-/JBCL=F+R*X7]TS4 MK4U_Z;RMVTV%7!?D_A1=YTM_+$7;9M%U^&0Z%C,6!N5V>ZER"&0%K3DHB),4,V/$@$J.87JP=3_\LH82$37@H:"SX)@?$K7N! M?X=2C,AV$/?,;+G:,#-(^G&4;!;!(HTC<1K0_,LE-S3))BFWN&>&SY>3##KKN+YV6@'49[^#HNFZK-%]MJ3Y297'/]!6DP'F!RZ0B M7>?"P!O`+D&8E,:!UQO:H#/,R$##][QQ/%CP31:(7V&!>F;.`B'D?0N$D`L6 M"#'S%HC_+PO4W47JEFQC<<]5\LC@(K>6J!4)0Y ML>8@QQ4[WVX[&IP*3(>D$TO00CLKF+R-3)%"'R"@(^1]+N\ M.<\SW=$^B<''(,V=+RFV@NV!G3W/.A3UJ?\N?@]KY_+8[/8%SMXE+_4T(1K>S)H M_VBK4W>Z]E2U<*+7_>\+G.`6<*[E+P'>555[_L.<7@UGPH__`0``__\#`%!+ M`P04``8`"````"$`-ER#LL`"````!P``&0```'AL+W=O?WXO.?8A_7M4UVA1R85%TV,B>-AQ)I49+PI8OSKY_W- M$B.E:9/12C0LQL],X=O-QP_KDY`/JF1,(R`T*L:EUFWDNBHM64V5(UK6P#^Y MD#75,)2%JUK):-8MJBO7][RY6U/>8$N(Y'L8(L]YRA*1'FO6:`N1K*(:XE2Y3&^(]%^AMW-NLO/;\Y.ZN(=J5*< M/DF>?>4-@V1#F4P!#D(\&.F7S$S!8G>R^KXKP'>),I;38Z5_B--GQHM20[5# M,&1\1=ESPE0*"06,XX>&E(H*`H!?5'-S,B`A]*E[GGBFRQ@'`$!.3HP MI>^Y06*4'I46]1\K(F>4A?AG"*PX0XCO^,N0A/.W*:Z-J#.84$TW:RE."`X- M[*E::HX@B8#<.[-Q#%[_9Q4\&LB=H<1X@1&X4%">Q\W,GZ_=1\AI>M9LIYK% ME6372TP?I)UZX9$S=]PI3/K`T^()L7?KZ=Z7Z\(W8A-_ON[43P![\^.-] M=U/%8C&6)%/)%60_55Q`1G:"L1U3I@".\>NVS"+07;KPE^,@MU8SN]"$8\7N M347RIF+_FF+D$P)Y?]F,.,:0Q*%*,_^J"%NK679G,B3+^6IU96\D\$FPO"(D MEP(2K@)_[HT1T'E,''8/$H;A8O5RL*T[VUGLQ:N9+-B.595"J3B:KA%`=,/L MT-#N?',>K^:W)();,IU/H`%V\^ZP`!I02POVCM/&RWA2\/@_GD.B',A=#\PMVSX=FW^`@``__\#`%!+`P04``8` M"````"$`;TX$02<&``#='```&0```'AL+W=O^6Y:';5^;#V__G[ M\X?4][H^/^_R4W,NU_[/LO,_/OWZR^-;TW[KCF79>Q#AW*W]8]]?'H*@*XYE MG7>KYE*>X3_[IJWS'EZVAZ"[M&6^DQ?5IX"&81S4>77V,<)#.R=&L]]71?FI M*5[K\MQCD+8\Y3WH[X[5I;M&JXLYX>J\_?9Z^5`T]05"O%2GJO\I@_I>73Q\ M.9R;-G\YP;I_$)X7U]CRA16^KHJVZ9I]OX)P`0JUUYP%60"1GAYW%:Q`I-UK MR_W:?R8/6Q[ZP=.C3-"_5?G6C7[WNF/S]EM;[?ZHSB5D&^HD*O#2--\$^F4G M_@07!];5GV4%_FR]7;G/7T_]7\W;[V5U./90[@A6)!;VL/OYJ>P*R"B$6=%( M1"J:$PB`[UY=B:T!&F2*$Q%@9_7*/'L*`&N2Z;I4][G3X]M\^;!W@/E MW247.YD\0.1K?G`U0\;>2QAD2@1Y%E'6?N)[D(L.JOS]B=/T,?@.E2D4LT$& MO@\,T8FM37":#4P`B@?9D,JQ;'-.OU558J#%9&,SOZL9M-M70==")Z'X,@JM&/<2=(%B M;H\J?4<@3OGQ?+%;F""DVH2D-*7$V`9;QAO^AHAU,?3&.194WN,1#2-"4V&P:[E MCRZR%4D;];4Z6D'NY&!'NY!;CG6!BVR%NFSEMG3<@`J:%(AQW(BN3UC`:&C/ M:V2*Q@'3>3@7VT=_!;E%J$1B'#>BZUQD+M0V%_O\H""U$9W'!X7,T0?,.(_3 MC4(%K6]$^_B@(-7('(ZHD>E]"IFCSS"6._IFW#YH*V:. M0,-1[@A$!YB>-!0A%$@23D;G`K7_QD0:LSAZY_:.+O(12>OEI?:?6_D,C MF50XA>@9-'QDWIQA:`33 MRC==^TBP)`ZC=[H$G@8MZ&-)Z]FS^UA![JV%V7,@?'3NP/V'3YGP\4E=MH=R M6YY.G5_#D^WGJE\/C7\`QXN7?)#^35O#]6Y\T[E'BX-5PET M:8N/I_!%WUSDPYF7IH?'2O+7(SQ&+.'Q1;@">-\T_?6%>``V/)A\^A\``/__ M`P!02P,$%``&``@````A`*>Q=^+!`@``&@<``!D```!X;"]W;W)K&ULE)5=;YLP%(;O)^T_6+XO7^$S"JF:5-TJK=(T[>/:`0-6 M`2/;:=I_OV.<4"!=E-V0`*]?GO,>J%",MZFV+4ODR:W)KK%KB'C>=S<9;SJPV+&:J;?>%*,F6SZ6+1=D5T/=KZY/LI-W M?W)FW[!,<,D+98&=;4#/:T[LQ`:G]2IG4(&.'0E:I/C.76Y#;*]7?3Z_&3W( MT7\D*W[X(EC^C;44PH8VZ0;L.'_6TL=<7X+%]MGJA[X!WP7*:4'VM?K!#U\I M*RL%W0Z@(%W7,G^[IS*#0,'&\@+ME/$:`."(&J9W!@1"7OO?`\M5E>)%:`61 MLW!!CG94J@>F+3'*]E+QYH\1N4*;LB-Z"[A*<=64+R,=P#+7^JU2H49O<:9<41QC!<@GM>5G[_F)E MOT"FV5&S,1HX#IHHG$JVYQ)W4-@`/%!#%F/JC_MP@M-B#:?[HFDWYL*8Q!L> MTRNVEQ03$(AL#'**[S*07@0QCY+P?7]*L#$:?Z0)IHKM)<6$$4S&C)?9M#C% M4/_0)2^D3$25K):II`4L=*X)D MA!ENYD3QKA\0.ZY@*/5_*_@&47B''`O$!>?J=*+'Y_!56_\%``#__P,`4$L# M!!0`!@`(````(0""1MS]^0(``*$(```9````>&PO=V]R:W-H965TOWZ^SS9D?OO2-LXS%9+Q;H$"UT<.[0I>LFZ[0#]_/-QD MR)&*="5I>$<7Z)5*=+O\^&&^Y^))UI0J!Q(ZN4"U4OW,\V11TY9(E_>T@SL5 M%RU1<"FVGNP%)>4PJ&T\[/N)UQ+6(9,P$]=D\*IB!;WGQ:ZEG3(A@C9$@;^L M62^/:6UQ35Q+Q-.NOREXVT/$AC5,O0ZAR&F+V>.VXX)L&JC[)8A(<

+B[B M6U8(+GFE7(CSC.AES;F7>Y"TG)<,*M!M=P2M%N@NF*USY"WG0W]^,;J7H\^. MK/G^DV#E%]91:#8LDUZ`#>=/>L]5D]E`0V%&!?'.JG@#0C`7Z=E>F=`0\C+\'_/2E4O4)BX<>J' M`>#.ADKUP'0DSB+`[BY/\IGC$:"KPGBBSG M@N\=V#0PI^R)WH+!#))U92'TY^^504EZS)T>-`P%6L)J/"^C*)Y[S]#"XL"L M+AD\)=:71.B?$`_\3I)0^ECR;3D-0Q'(&(,@^N>'4FGEEF&QH*\XBC,-H:K^>$JD?1.F)F+A!@=>[:=AVL_MFF'AP MRQ,,&_@T\=#8]1C(,IS$9V!B!MO^>C,-VV;GBLV*&L:8A1F.<&B938$0C]0G M9LE[S#1LFV73B5>&,6;ZJ,86L!X#2>!'^1F8F*7O,=.P;99;9H8Q9D&0^];] M]?@^CI+P'U[Z)3=ZA+Q].C5L>67G4V_6TC#&*\IQ/)K8[+(QD"9)&ISWZ:1C M^7O,-&R98?ML&L:9A,B#M,LLT^`>A%3P5 M?#>%G2K,.\9<*-X/#]L-5_!N&#[6\%.`PI/8=P&N.%?'"_T6._VX6/X!``#_ M_P,`4$L#!!0`!@`(````(0"W4(1&H0(``-L&```9````>&PO=V]R:W-H965T MO5QP_+@Y"/JF9,(U#H5(YKK?N%[ZNB9BU5 MGNA9!T\J(5NJ82AWONHEHZ6=U#8^"8+4;RGOL%-8R$LT1%7Q@MV*8M^R3CL1 MR1JJP;^J>:]>U=KB$KF6RL=]?U6(M@>)+6^X?K&B&+7%XG[7"4FW#>1^#F-: MO&K;P9E\RPLIE*BT!W*^,WJ>>>[/?5!:+4L."4S9D615CF_"Q2;%_FIIZ_.3 MLX,:7"-5B\,GRE^:6S#9/YM]9Q?@JT0EJ^B^T=_$ MX3/CNUK#:B<0R.1:E"^W3!504)#Q2&*4"M&``?A%+3>=`06AS_;_P$M=YSA* MO6061"'@:,N4ON-&$J-BK[1H?SDH/$HY$7(4B<#]\3GQ2):$2?IO%=\YL@%O MJ::KI10'!$T#[U0]-2T8+D#9)(N@/G].!I',G!LSR4X%6L%J/*UB$B_])RAA M<636YPP9$YMS(@I.B`_^3B8A^M#D^^8,#"$P&IA+3KHVP-HQ\8"9$)OWB)$W M>-'EW@R<8]`^>2-D4I:U8S);UC2+HS@.Q^XW0R*9DS3X6]T@X.7>##SU%HW? MO'9,8KV1B"1I.AL3FS$19"1ZTQC5#1K_H613%V<3;D"`S MV#6#VH^\I?_CSZ!RQSN%&E9!/P7>#`)*=SJY@1:]W:9;H>%4L9&ULE);;CMHP$(;O*_4=HMPOP3D'`:N%L.U* MK515/5R;Q("U21S99ME]^XYC$N*DA>T-$//YS_PS$T_F]Z]E8;T0+BBK%C:: M3&V+5!G+:;5?V#]_/-[%MB4DKG)S38 M;D>$R=Q0&DYSRDX4&FW.-DM M[`_V45/"J1!Z6R ML"/;`A<"RO.R]%UW[KQ`3K,SLQHS46@BZQ91&52Z:;MPT47FEDU+J/*!I]*+X!VYV?@9CTFHL@,+1TC`Y'-F.B)&'8\TXXJDP=M M?-V6V@1F:0*\WX/28PB?5-(KU);*X1AD\(I%^V]_E4FQ8V)/-2+31( M]4HS0=.;R(^".(H'K;0V$"^,7=]/S%RD!N*';IAX@X1N#,0+/-_S_$[%\`J/ M6]_K]5HJV*REBP:W7FD&`NCR,*SE32*]26RN$8:_\'_\*7A8PTO>FM-@I1E= MPS`*I\D`6/?H8'V%9G"ZC]=3&-S-NM-M M@,%9XSWYBOF>5L(JR`YN-9U$T'=$,B,#>F$X!W MC,GV0DV'[IUK^0<``/__`P!02P,$%``&``@````A`'$`44J_`@``^`8``!D` M``!X;"]W;W)K&ULE)5=;YLP%(;O)^T_6+XO7X&0 MHI"J">E6J9.F:1_7#ABP"AC93M/^^QWCP`*L:W>3!.<]C\][SK%9WSS7%7JB M0C+>Q-BU'(QHD_*,-46,?WR_NUIA)!5I,E+QAL;XA4I\L_GX87WBXE&6E"H$ MA$;&N%2JC6Q;IB6MB;1X2QOX)^>B)@H>16'+5E"2=4%U97N.L[1KPAIL")%X M#X/G.4MIPM-C31ME(()61$'^LF2M[&EU^AY<3<3CL;U*>=T"XL`JIEXZ*$9U M&MT7#1?D4('O9]4O214IE!0P%A>H$DIKR`!^$0UTY,! M!2'/W?>)9:J,\6)I!:&S<$&.#E2J.Z:1&*5'J7C]RXC<,\I`O#,$(LX0U[.\ M5>`&R[+8<0N MLW>"<7);H_$O-!/%[DU%\J9B_R_%R!\DL;YL.BC$4<>B2[TWF M8VLT03>3KN==+R==VAF!WPDF(YN,@MU5Z$UJ!'>.SL#05RLO7`U5-N[,C6(. M7$U%07>TJB1*^5'?%@O8=%@=+K);3\_A9'WK1G`ZYNL)7'S=NCT$P,73DH)^ M(:)@C405S6$KQPJAG,)<7>9!\;8[_@>NX,KI?I;PAJ%P[AP+Q#GGJG_0IVMX M9VU^`P``__\#`%!+`P04``8`"````"$`>SY+@1H#```O"0``&0```'AL+W=O MKL&KJ:B,=M>Y/QN@6*-:N8>NE(,:JSV<.FX8*L M*XC[V1^1K.?N.B?T-Q`^<8#+VQ]$' M6,(]"[3_+V6T)X&V)P'ME^-PC2>=Q2E19#$7?(>@;&&E;(G^$_@S(.R]-4X, M;K]E-KBL2>XT2X)CC,!'"07RM`CC\=Q]@JQF>\SR%!,<(U8&`<^!Q4*DIXC0 M&TA<"&F("_)DQQ5"Y9VOF3X,O4B'H6M(Q[6T!U9FX%!B&$>#@FY1>@X3#Y@C ME5`'MLK1FY7=J]2+H(8/;`KCR@EQ%`5L6>H.9=(7D3^'G1Q9D=009G8.DAY"QU_V&?8[T@^/7Z]=@2__D MM0:-^P8SZO1'4UOZQ=FTGWWUYS5S1ZJCCZC68%NU/[AA5!N,47T31%9)K2Y/ MI_WTN[KAE+C>;0VV=5N'PM)@#JHE\JR$K(X@NEI.('"!Z9T,R_EJ,1>4.3UK M*C9T1:M*HHQO]>430+:'T>%>O`OT86*-+_T9G"SZRALFX+YJR89^)V+#&HDJ M6@"EY\10#<+<>*:C>-N=V6NNX*;J7DOX,*%P6'D.@`O.5=_1&PR?.HM_```` M__\#`%!+`P04``8`"````"$`)M(I.F0$``!7%```&0```'AL+W=OBY!OWC4OWR_:W3^N+J)_DF?/&@0BEW+CG MIJE6GB>3,R]B.1$5+^&;HZB+N('+^N3)JN9QJ@<5N1?X_MPKXJQT,<*J'A-# M'(]9PA]$\ESPLL$@-<_C!O3+=:\Z:"N M4R2K;Z=2U/$AAWF_LFFEM_0@TG:=9C`# ME7:GYL>-^Y6M]L'"];9KG:"_,WZ1G?>./(O+[W66?L]*#MD&GY0#!R&>%/HM M51_!8.]F]*-VX&?MI/P8/^?-+W'Y@V>G;#43Q4I"?X$#?Q=EV+BP.K!NXIJUBM0;:"R&IF MT_^<&4Q)C?FJ!NFA0$NPXV4;1N':>X$4)BVSNV4"D]C?$J%_13S0=Q4)4[]? MI!H$B7:=CLCI-;Z>R`Z9:8>9F<2>(@R-<*.NQOZE\9Y`!6]KWR/2K][0!DA7VSB3U2!+8V1E9X=,OP+42!&&1EAT]VM4@X8\ M1H;22!&&QKFID?98P5;^;(\1F:''TUZ/$>E7;VA;W*--P9:V:&ZN_!TR_7=& M;RG"T*;ZX-U%1@T:\A892B-%&!J7ID;:6P5;^;.]183T%I%^]88V!AW+3F`( MG]$B]2A+9;2P7&ZA?A%H,XF8.O]?-\%&`-7LHQI&=J5F")$Z*<34J:IZ9T$. MY!%[0+=:L\72SB-"Z/=TJ?KR/#*9/>LRX328SV<^NS*F0E7;.PI5R1[A.':$ MKM(PLE3L&-4V6LYLA1#I.(:9.J[T,.(X=POK, M\&[6HX9V&'7&?C?3RYFYE4E=[2.<)Q[`_TQ@X0ZA>!&YM$3)T0IJMSP'%% M6WFTZW>`#!K.^A^^6Z9_"J:^N_J+^KUNZUO83V8MU'_S-G^C&TQ@-9AQ!5R/ M&MS95!=I=5*(F4>KT0SXC(V!+.!P+J1RC3^D^_MTB_1G&N7AT1">G%3QB?^( MZU-62B?G1^AM_F0!3M1X,(07C:CT"X0"/P_&)/P'X*$3S?J&. MGJY'@MM_`0``__\#`%!+`P04``8`"````"$`O3/?D5P'``!8*@``&0```'AL M+W=OYWDS`@^G>C7>-\UY.9W6FWU^S.I)>L@;_5Z[0^5WFV;0L= M#].9HLRGQZPXC;F'9?6(CW*W*S:Y4V[>COFIX4ZJ_)`U4/]Z7YSKWMMQ\XB[ M8U9]>SM_V93',[AX*0Y%\[-U.AX=-\OP]516V[9@+NIKRBPS9;4VL*GIZ?M@6T@'7[J,IWJ_%7=9FJUGCZ_-1VT+]%_E[? M_![5^_+=KXIM4IQRZ&V($XO`2UE^8VBX928H/!V4]MH(_%F-MODN>SLT?Y7O M05Z\[AL(MP$M8@U;;G\Z>;V!'@4WDYG!/&W*`U0`/D?'@DD#>B3[T7Z_%]MF MOQIK\XEA*IH*^.@EKQNO8"['H\U;W93'_SBD=JZXDUGG1(/:=]=GD]G"4(WY M![SHG1?X[KT8'ZX*5+IM#WSW3CY1E7GGQ;QXF1D355<^TAP88;QGH>^ZJGRB M:]6^;]F/OD76A[M%A=#PVMS$R)HL#$.?+TPRTE.NFE:$3M9DST]5^3Z"D0UM MJ\\9FR?4);M'+S\NEHL@?Z5'$"+S\I6Y68VAMT%J-0RB[\^:I3Y-OX/P-QUC M#QES+B+K'F$R9WZ=WG#UB[RZ/=$7\;@!/B]5P;?Q^S)7!'D->J+W&M)>HR&" MO,9#`E0F1O#^!]`%C-`M8WT"[-UQO/$/!&1*F M*2+.$$%.W"&!G7@<@69>`HB<^"01D$1($A%)Q$-",Q6Q2Y(A@UJ3R@@APC`\ MA0BSL:K!@B./-"LE1!H;UMC@8(.+#1XWW,9(LU"[_`>8X!ZCB3T8/L!$#S#Q M/<80[Y7<8]`DE=YCK@-!B!BLA$+$Y)%BM!`I;%AC@X,-+C9XW,"7>S:E^M@0 M](;K>-,L7>R7L&?ZZ2+"AA@;$FQ(;PQ")\'B)7328[)FI4#^-[.$9BW$6MN< M@?M>9A(4[S5)."3ADH1'$CY)!"01DD1$$C%))"21R@@A\+!)^T3@6:G5&";- M2U`URT*!Y\RBVX@HAHF4L1:`^6*NH$G'N054U9IK<[28NR)AS*T9JH7'"8G\ M?)((2"(DB8@D8I)(2"*5$4+889<.HBO7Y[@V_^3>@9`H/1KQ:22@D9!&(AJ):22A MD52*B$)@Z8U/"(%G140AH%V\S5*JL&Y(A4`B3N>%SRHS0SATB4Z--(0",AC40T M$M-(0B.I%!&##QTC!/^Q'(_*BJ%-@8KVSG8'2;I^32,.C;@TXM&(3R,!C80T M$M%(W"'=^-$TTT323V@GJ1015<`R0[=3`%,!_1#(WH8.5("?`CM(J@)98JI[ MW<01WB'P(*98@PT!Z<2CJ^+32$`C(8U$-!+32$(CJ1015<`215@%[`TFL2#P M_)*P(5#Q,Z+*(:O-`*G:Q$!Z7G>`1"8.Y<.E?7@TXM-(0",AC40T$M-(0B.I M%!$EP-)&6`(/3`0\VR1*`*WGMLHAGON=J8N[#XFRM%4W$]!NW.Y6$C%Y-.+3 M2$`C(8U$-!+32$(CJ101A<#R2E@(#\P%/!TE"@$-=5N5Y:S:(*]IQ+F#Z"IZ M!'3O0`CQ:,2GD8!&0AJ):"2FD81&4BDB"H%EF+`0'L@:\<24*(1!NF"8O4+1 M6<,!+^)!TKF#Z.I@=T#Z\>[X0;7Q:22@D9!&(AJ):22A$7:`[M?]RX7`#\CQ MLTG'O'K-U_GA4(\VY1L[_,96](OU%L/]NFE`7"N[YR] MYFE6O1:G>G3(=]!T9<(FQ(J?#.1_FO+[RL3@'=E MV?1_V`TN9T*?_P<``/__`P!02P,$%``&``@````A`'5!@+BS`P``0`T``!D` M``!X;"]W;W)K&ULE%==CZ)*$'V_R?X'TN\#-(*( M43 M,6D`0RF69"]E-;Q9$0N35ZR$.UM>%[&$TWIGB:IF<=H$%;GEV/;4*N*L M)(IA7M_"P;?;+&$13PX%*Z4BJ5D>2\A?[+-*G-F*Y!:Z(JZ?#]5#PHL**#99 MGLFWAI0813+_NBMY'6]RT/U*W3@YW[\7&?IMZQDX#;4"2NPX?P9 MH5]3O`3!UE7T4U.!'[61LFU\R.5/?OS"LMU>0KD]4(3"YNE;Q$0"C@*-Z7C( ME/`<$H!OH\BP-<"1^+7Y/6:IW"_)9&IZOCVA`#6!S3F7G4FX[G8BE=C4U1+./5HN9'`WH/ M,A=5C)U,Y\",_KB@3*EI'7O/,'`*21Z194E\8D"X@"J_K%PZ6U@O4)GDA%DK M#'RW&'^J0\)K&JHCHC,":PX*6AE@;5?&O\M[SA;!F"V6&]-?JPO=U!S]N>$H M(KI&^'Y+HN4*A>SFBI;[[[;D.6<,@N;KN.?2H.57,A0&JM@Z[.F(]>&^%W0_ET[4 M1$)9;A>)X+Y(MR=282"9U@C7[AD1WH")AC&:AND]&A#X+"440TA-"RQ[FA]SH=7]L8-+:V M%69(Q2@B&D)H*@)=Q?#:1K!>`QKT7I]KA3FU##6=[M*#XT\/O8"P%T#UU7H= M$&D!4Y-VWAQPZ'YZN*PR32J%D:);L6&M#5H7.PDNKWG5<"?04*W&(=$@1)>` MF^+=34?55CJ\HYQ`@U(4SP`D&F31I>`NVI$R4@VUY^K;2J^3UC!=8G^VO3>9 MZ[4=E!^; M.;EW/<0!NAF!VQLPOU;QCGV/ZUU6"B-G6Z"T37P/U6H"5B>25\W\M^$2)M?F M<`__5!A,1+#]$F/+N3R?X+S5_O=9_0\``/__`P!02P,$%``&``@````A``*E MC_]P`@``QP4``!D```!X;"]W;W)K&ULC%1;;YLP M%'Z?M/]@^;T8"&G2**1*5W6KM$G3M,NS8PY@!6-D.TW[[W>,$R]=LRDO@.'S M=SD^A^7ML^K($Q@K=5_2+$DI@5[H2O9-27]\?[B:4V(=[RO>Z1Y*^@*6WJ[> MOUONM=G:%L`19.AM25OGA@5C5K2@N$WT`#U^J;51W.'2-,P.!G@U;E(=R]/T MFBDN>QH8%N82#EW74L"]%CL%O0LD!CKNT+]MY6"/;$I<0J>XV>Z&*Z'5@!0; MV4GW,I)2HL3BL>FUX9L.\_@6Q:AZ<]Q4`^UZ)ZN0UFYMJ23ZV0Z2R<9PLD&K'N0GI(2L;-.JU\!E'E3D20_ MD.#]0))-DR*?SN87L+#@:`QXSQU?+8W>$VP:U+0#]RV8+9#YF"SXB%G_%17M M>9*U9RGIC!),8?%XGE9%,5NR)ZRI.&#N`@:O$9-%!$,WT1+:.+5TOLA'90_V MRKY2WLI=>'$JDY^7F;R6\U5<[+?+-3WX;\V;R!LT`^:\9ABHT&\*3`,? MH.LL$7KGAR5#G_%MG.-U/HYB_(!S-/`&OG#3R-Z2#FK2!,$UUJ[X\+/>OP%KWX#``#__P,`4$L#!!0`!@`(```` M(0`8%G9R+`,```X*```9````>&PO=V]R:W-H965T M0B#'AW/.O?BRN7NI2O1,A62\CK!K.1C1.N49JP\1_OWKX6:%D52DSDC):QKA M5RKQW?;SI\V)BR=94*H0,-0RPH52S=JV95K0BDB+-[2&?W(N*J+@5!QLV0A* MLG915=J>XRSMBK`:&X:UN(:#YSE+:<+38T5K94@$+8D"_;)@C>S8JO0:NHJ( MIV-SD_*J`8H]*YEZ;4DQJM+UXZ'F@NQ+\/WB^B3MN-N3"_J*I8)+GBL+Z&PC M]-+SK7UK`]-VDS%PH&-'@N81OG?7R0K;VTV;SQ]&3W+P&\F"G[X(EGUC-86P MH4RZ`'O.GS3T,=.78+%]L?JA+<`/@3*:DV.I?O+35\H.A8)J!V!(^UIGKPF5 M*00*-)87:*:4ER``OE'%=&=`(.2E/9Y8IHH(+Y96$#H+%^!H3Z5Z8)H2H_0H M%:_^&I![IC(DWID$CF<2-[!\+PA7'V%9G%G@V+$`X942_/-B./:+K_5AFTS: MB!.BR'8C^`E!VX)KV1#]$+AK(-;9+J!")HD^[?^%#2EKDGO-$N$0(U@NH4&> MMW[@;.QGJ&IZQNP,!KX'&'>,B2]YPN48DG00W3'@H3<".0Z-O-TN%X48;C+($2_YS=> M#`:*V6.",2)^%Y',(48NX#8?=Z$709\-%/K!1./.8.91&$1@DH#!/TQBY$*_ M;;RQD\[WDEXT=7$[<6$PP^M`.SSM_@\8QPTYT.]$'%@M44ESH'2L M$!I&PO=V]R:W-H965TZWOS%."#9[=OJ27>`W?_R?,3"S_OQ65]8K[FA)FHV-G)EMX28G1=D< M-_:OG\^?%K9%6=84644:O+'?,;4_;__\8WTAW0L]8$4H.S`$Y5RQTZGGI+EU0VJZ+$ASPM%L=/FSL)[1* M46"[VW6?H']*?*&C_RUZ(IRM_WLI"W;:V'[HS*.9CP"W]IBRYY)+VE9^IHS4_PH(7:6$B'<5@8BK"/(< M;S%'\]"LXHH5]0:3C&7;=4-Q0G0'OQX\GUW4R**9"29(HI(.B5&(I(=7[;#R^3# M-M;;XD'`C5P$H9*_6##!B)G+-G9&(C$2J8Z0?,)"'B\;AS%(5HN90SD(P)M%A$7N`K(ND86:`@\A;WA4@&X1D;&WRL MD#Q(->K+BXP%$WF]TYD3R)=WRF5?>?02]?I"CD_5Z_?-+MD+I_8""-7O4QZD MVE/6'PL&TCS46BG!SD@D1B+5$9)/>-7]?AEYD.EY%(S.IY%(C$2J(R2?O(,9 M?1[T=>2P6D>E2K%@=/Z,1#(E@E#9S^F4N:]$/LJT9Z^0SJH92'CC(M%% MR%^2^WX1];Q"6I="1X,D'Z@$H?JR_0"ZKT;VR5N(D<\'JRH:#]FO\M6+D8`T M9G9F)#$CJ1:1W?(^XO?=BNX#?H=OQ[0/0KH6I=\`.S.2F)%4B\AN(?5CM_J7 M+\P_DW=2-.G!!:2MJ1%)KK<23947A'-HFR9;6"Z.>(>KBEHY M.?-1RH=&9C@[C'E/'F_2E?,Q6L'H,#V?\+&0GW>'`)C*VNR(_\ZZ8]E0J\(' MN-7,B:!'Z<1<)PX8:?O9:$\8S&/]OR>8OS$,)3,'X`,A[';`;S!,]-O_```` M__\#`%!+`P04``8`"````"$`*O#06QENICHVC:V@Y7MA8$STY^=K?[=S:]_=;V-GSWGQT?' MB340$6QG^F,<;ZYZO>WRT?'M[=MPXP3PS3J,?#N&C]%#;[N)''NUQ4:^US/Z M_;[N!GDBX\INU^[2*:.<]J8]D'1S'>Q\RX^WVC+*A:\3R;W4@IOK=1@00PR@"=FZ^AR$7P,+OX-@ M`//P9S?7VU^T+[8'1P8(;QEZ8:3%X&6PCQT);-])?C&W/7<1N?BSM>V[WG-R MV,`#+##2W_DNN`D/]A(-Y]6S0#2931.$P=DTQ"/4)A],LO%@O4WVSP=LXG2- MFG6=PA^GBUE1;Y6X*'%XBJ[<5T1/]+"8Z98%.630[R.MU&$=*9O.^Z#O M;,HN1V>S;&@-K;%4R[A8+/L-%0XMF50V*+3>C=^?C4[YRJJL2]/PN7H`=CBY M++K0=6OZ]]C"USGBY,P#6C<>8U*YI,^Z7I$;[UW?V6J?G*_:#Z%O!T@L'=38 MK[DQF0L\^>)SUS>*/JVTX,*L45<+EAA96V#1];R\,AR.L':"(S?74*3&3A18 M\$%+W]\_;Z!R"J">1OI[R>\:?OT0V<\#@]4/8@VVH>>N$,7#G-5KZ7@YO[RS MYG=,+T$FBJ)"J&7-QQT(O;N=SN4CG4^GLH4:%KPD"WTWPI=DH1;\-Y?&:9HQ M35D@N?9#&-@>O.UE+;*_-2UA^PAVBF9Z_.@N/X,R;G4BX291T96&/.N9.)LP MQV9_;(Z,RV3")DFU[ZSO9,D:5'V`S"+F!K-RP>HT2XS7%^S,0WTMIL=UH70)FQ=#SO M1QSX_[[.:PU8OKNY?EJ3$QO@;!/<^E^B&XA/7+C`<\&2@- M:G`!#>HZ/#(1P#)&A@"5).>"3E%& M;B76(20H,!6IA@!PE$`@CA@H&G\'%(.B$9A&@Z(AF$+@QN#Z+"&U3U!/<".D M(@R`1TFO*/+U@!LQSD@#@:`J0Y)H,%2E2(I!58XL7&&H2I$$@JH,23VA*D52 M#*IR)'&%JA1)(``C2C(D]82J%$DQJ,J1A2N&JE(D@:`J0Q)/##M.D3VZ;)HL MHI+UT_'PJ/53[6G=N)`ZJ)HT@=^SYLGL*9DY@B_87(I,I?%R,3M;.]4>P\C] M!2:9>-G8$A93G4C'RPQC=TF/?(WLS;WS!%/19'_K:5V]U@M(LO6-_6#D$59B M*O3#2K:NM5$NG9\3L)Q.1*/EN*[2N"Z_%QC\VG9C@#1B8`L+JD$@URD&Z2$@ MJ8M@SU5-$PR2RC%05\&`*98K+&`.DT]#-CNAM^(<2RJ6QHY#B#A#JI"J[;7R MC#-(94X>R([V-A$F7?FAK-@*$.EOP_WI)%\H\)W?8@O`C:F`XL-S2EK6$1VC M:V2*C.PT,S4P=7AL/YD_=H;-RR*0NO=4>/L+"2\K^CI`UQA]9+#@HH_#@CL6 MXE1E2\1==-RJSM(`MWUO.%Y!M)/Q`4!:' MK>*;%KO&^FGXN4ZWLLOFQK@OI(@:;!">L\\,4B@+R[8Z6?IZ?=UPZU0 M.A;,%$)5W%&)0@AE6K3!!0:]TLZ3$+3RP"\2GT>EK3JLP-`ZVZ6HJJ)*+/(Q M>#)?(ABZK.0..E$(5`,S77H+\:7GQL/;H@N6XTHZ"E21!PTMU+A1NL2-2'SS ME4:;R&JW)RN.FH_U+O%5TLJ-"*^&UGK4YZ/UN&`]"I^D/:B&%?6CH-$)3[;@ M\$K@I@6*)+00#D6R+'4FGENA_//S;AN[Z^>7NQ=1+J@TO/]9LGM]_-@'R;ZN MUCMEU#D^EW><=+JA4FH4GM!-,%-V7U*TE8+FH8$Z>EPN*@7!F"`ND&/3A"J)K6RLCF4$-FIQ7`R,;DU M`W]CAOS48PWO%@U/M^C_5KO0WBVQT,PW6W&K;;%S/;B1'"X5X6GA2RB=0O\V M.9B>R%LG*]^),'"F262!6]K*RLL7`R\5(+(@7MO*RJ-B"-8267#7BM:RX/*- MQ(%P(VA.%IRLV187-$EE\=R/!+DW#_F17?)$^`*317!1684?,2$066!R6UF% M'\%Q5!:8W%96X4=`2&29H*2MK,*/X`4J"\*MK:S="/?*SB M]0DBN*BLPH]\K`X%8Y7**OS(QRJ:W!97X4>02O@RX8NVL@H_\GG"%,P3U,;" MCSSW(T'N]S,J'_&&8,0G4@K?P3O"$=:.(APE4@JO\5$^%(SR1$KA+SZ^3<'X M3J04G@)YQ"(3OA"W*/?1D&?7%&3WUEYE693Q7BTZW8 M]3>X]48,PJLMA20].LO/VAQNIY0+XOL##J,B@NZ>-IX=V'$8/6MXS4TNCG?Z M2%#<'\,PYXB78,!'$4!_@F>!P6/&-.`E88B/8;S>HHV8O"_P].`%^&W$0.L$ M#1]_>+IB&S'0.A'#)U6LGT3$?`@VN]Q#?"[%H5M$Q$ZYE9&( MC%985%Q5"-7_ZJFX(1OC/<:GY;%;M>7S`2!JY:SMG1??YU_.].+]G]G=3B&8 MTE]][WX)8R9BIA?O/^)M9*$7P^P2TLW'+=R:%/YJN\B=Z?^YNQU/W]]9QL6D M?SNY,(?.Z&(ZNGU_,3+GM^_?6].^T9__%RC#1PM>P;/I3GAT'WO$(%Q7.#"O MMAX\X"]*C4W!_U@SF M]$42!_MAL-B76&`7,,[GQ3Z$]TWF2?;WC\BLJLZJ:K5LSYPY\!F(75F9D9%Q MC\BHK__EX]TP>Y]/IH/QZ'>/MC8V'V7YJ#?N#T8WOWOT]O+Y^N&C;#KKCOK= MX7B4_^[10SY]]"_?_.?_]/5T.LMX=S3]W:/;V>S^JR^_G/9N\[ON=&-\GX]X MW'5G_#FY^7)Z/\F[_>EMGL_NAE]N;V[N?WG7'8P>9;WQ?#1CW<-MUIF/ M!G^>YR?^T][FYJ-OOIX.OOEZ]LWIN#>_RT>S['C4SYZ-9H/90W8V\@6`^^LO M9]]\_:6&^O"C[.5X-+N=,K2?]].G%_G]1K:SVO>S,>;C4_+,`` M'0U@9'\ZOIK.)MW>[+^FTSY)?PB;.,]O!GJ%K;WJWN7IJ"?'H\&[;G9YFT^Z M]_E\-NA-.VR\MY$.+""[?+BOS[*UN?Z'](V3^60BC#X?3'O=8?;'O#L1NK+3 M[JP^P?KZUO;ZSE8Z1]C$R?CN;CS*+F;CWKM.=G';G>33[/5\9F0#':6O'7.4 M?3O.Y\-N[>F3Z^YP6@,A+@7($\`]XV`_9O^6/Z1S/]GD_PZ/#G=W#M)'<8JP M\?/\?CR9`1Z`=V?S:3K\R1_SVF]ABN_&P_EHUIT\@+TAK%-[]=4X_2F\:>.S M$W!\,Y[4@3_N]7(FY''?IVZ9YOM\.%Q_-QI_`.MY=PIC]K.SZ72>3](7"L)X MDT\&8U%M\Q$7XZKT\!RVJV^NB6W2U\-JS1/\82>%\F3,>8ZF[()_3P;[U5<+)=Z=3IOLJ M??>D.[W-Q-D]_2/_\WSPOCO,1[,:!EYV)^_R6?=JF&?3O#>?#&:#.JEPE))C MTVR2]W)F8G0G&^6S;'S-3]-\\AXFX=^/]W;W.[M[>[;RX[VCG<[F]D[6G7&P M][/\[BJ?%++*AK##\*L+J9V.IKO/>[/!^WQ8(ZFST7NV,)XT0/AFDM]W!_UL M@+B_R[-9]V-]%U%*&*O`X_W\.D=N+'\I3IQ_1!%,V::0.IXAQ%*47XYG,#,H M-%'DYY*.>3-!GTP0^)I%IW(OT=$1BGKCZ2P=_B*?3K_*NCT4QGQH5-3/[SF# M07?6H"E>C$?5"NP9+#^Z&>C8'5([SW3];\?C_H?!<)C^ M[EMMWF+$\G#0O1H,C9QJU%G0TWWW0<24SL_SR9R#B4A/GY_&DYOD4,2\]CY: MI:""K&6-Q>.J0)LN]EJ'G6$P!.0N&5H]@4!;+1`6.X!2LSACC>"EC`8SD8@? M90]+`"&/30,+9&NOQK,\V]JL"8XG/_WXTX_I-DRCW8Z'?63\__OWO_WW__.W M__'O1H*SA]KY0/0!_*GKP<<;FUL@;Y;[.MSO;>9@?ME$U=0W;GLUL8 M\R]Y'T(:QU\'$N-]I\)2A?YZ`B$HZQ8@,8N`L`W*K=W.(4]W]Q!0,"-_;A\> M=78V#_]1P!_W$?^P,4)#HFM],%KO=>\'")'TZ&"'0@"8Z$%8W"$';I%("$IH M,; MS"^,WQQC$4.J55,6\F29?EH;C++3\7#8G4QK'%,C^(+6L\IK&;+;J>/3$]3X M(D5G;>ZEEG#MC'[HZ:LB?(3S`J99O?+X3O'BNM.>K?9?^G> MW?\6`P+[:VS&24I6%YCKM@_4$$@?AC>Z_;O!R-P_V6[I2TP_FX`>[$N`[6%T M89VD@WRK,I`XRLJ>TG'A/*\GX[LLC,;0KH_"%&+9:!*N!11]T6CIA#FOZP[+A9LV@LS-FIPG@Z& ML<1DLT]SB9%^A;B['LPRPW?^,9_T!E-[Q4PH$"0>K$FADUO<+&QU,7DA MV'P1PU`T_;'G:SS58-6DX+\);F\4_QUW34LO%`U3>B[-FSNK.$OI_&+KE6@A M?3$E4!W`U*3Z$@)],T<#01`ZB+M5XA+01"_/^U,_E.G2,ZQ.#F5S&*D;GNZA M?)&'8%8I0G)5BTDT8J5I7RDNGGWD<&&& M3"'!;'!W+ZL'X$1?Z5AH$@T))<`W1G]F*GTBE&7(;AHHA_.*X/1(CI`90Q8_ M3!==^CY1WO8W7YDCGJT3]\;$,?I].L?:(WR3+G)*B!IEJU&7^<=9]G1(H'E) ML+V<\;7+#X1,]J?RU5ITOGRA#82&./Q//X+QC6QM-K[)S4H0`66*($WG5]-! M?]!5T*V3_>VO_\O>[OSMK_\[8Z!^D`KLCA[L)_[\D,=_S:?V+ZPD?A[/)[SS M1;0LF>NN.YI?0P.@(D8W[NXD5LTR0D65B8)HO<+HS#8SOT*_S10I'(\ZV:W, M*7$5IV0B<;*A1`,$Q"C9Y:P`QIT#H+G;!^(8D_$(\Z;;(VRX!H3_>BP`B<5E M(YUB=SA$[>%Y3V2S=K*KP5AJ"AVEH-G]>`B;3(!GSI*SV\EX?G.+%V-(N1KW M'S:RTSEQR+$AT7-!FN+^]@&;"C83I)J2+)/]'4228?E?C[/[8?=!6!&?H$.5 M4YF,61=^`+ZYA5)EU6NZ\7!\8W-&#YT:IGS7<%C!DRTZG%]-&&T6(S-, MQ]<`;1CU4_AA/"#PFS8&]-\?O$48T0O0EWL:9F-820)P1&XQF1 M..)MR/?9N!,I5<)0%I!FCT#)\(>DM#JA"2+2%OT>Y1^R8G%;$XDS?F^H!J$$ M91$BQ.[`Y2A[ES\HG#`=CT;YL%,])!TK^@D0+2LS*%.#CMMB>QU#1.28XD3S MC[AAD1D$4V0!/QL!C=4A,(S)M:^W&Q<;V7."O;;"Z61^DQU7_#G`%8,\/S4. ML3%RD^2(3/(;1:9E^MCOW7M6(TC(`V)`$_?067B:?>"H(TEZ9!BH<'R$6=)GD,YBX0B[^>3Z5Q2`I0*FQ,QVT\_^E3E$8E1>7I19'H,'85F MAK[O$`5R)M'9B3X'C.1 M\X424,"XW))O)NVG^<^D5Y"A6+.!7,8@.%UA* M@W0EAP"9#R$6ADBHEQ$E-S:8!_6>>[0.`S)?)T"!<83P)@<]S233^PV3&V>1 M7MX)8E?&:_#89<,P[<^9K"81+P-/_.HR9XHY,X3&'G7R`]LG'E=Y6P!-P(55)DM8(ZIB]A0"G7K[K]LU>T:9; M&+`X92''O+5%.I\./F;&,Y%9?C\G^!V+EGQ?;*0W`],D'K$446,L)T>V->K2 M"QB46)0C;UZM=HW\+39`,`$VK.Q>T[:!J[&\*F\AR!#;B^R995$P;?KQ]L:> MXOI#O6A651=DL2<,8$C'D>T.K4Y1HJ`Z;6`8AI51`2`92O'$LUZ*C(405$&$ MG\![H.0II5J!])K0MT`\-?15N`XZ]HVI\@`\&`661Q%)MEF&MYT)UHX3-6<3 MN&-VBS\< MM,!_+>3=),YJ7/-*$8`=#--*/4UI97V=U/0U!P$NYO=83^9OM!??G4`\'8JN M("%E64-5C^N8QK67FK6-;Z30'GL4MUY\J-Q2.KA,;:1/%&J==C+%CR`]0JKI M@!?D(!1D:!_Q'),@?>L[522D/RZ:F9=BO3E619ED25]XG/ZPMKU_F/Y62SP\ M[8[>X<,2X[Z6?L"$8V>A^"9]>3W]X1)9%"T42(\H"^Y@!407)!#UW(NR-+=; M(D&80M@8VR'X*=;$"?#X:1]81.(PA?&DA&2@E&`&6V+,ZKDPY^&@#]026*F` M3-UC;,\@':KJW0.>HD^X$0:LZ";)SO?=P5#%/.NHJ'6+Q?#$3QC2\HV04N%2"PH`SR8RR0IA*W0$:%O#2B@C7;44F+!<6%I5E1E;92R,<]V+3\ZL,*_F9V%QKW6S;"TN">957/@D*!TS$"?6' MQB,&@%E`G`=15\A0Z2&1B4M2_LEY?"B-/%7V<4B6WS!!'\/I6/8J,I0@M1H[ MR4X%=R@10F/&#(:L)"VM(Y/=;D/(G!:S5M4)MBU0+"`AS(&%1H>E`BNRR0ZT-$PW5)BG>58T:4 M.INM4PE)@*\<=XS'XX4=)"O*&XP;T]JHXKA![A+?`!>%L3!I.?]["2_=27;@0 M9JCM"6Y/E%!27N8`6]AN,($WD8%$@(,$HXJU3Q2Y$R"O$$6`/M!&9'"%WC&, M20K(ZNAD#X,<7QVJ("49X@U68Y--")@W'G$C"AN4?FH_V`FO0%>FB$JQM41Y M5A6;:--C`AQ@^LZIK)JW.MKTR1]LR\K4Z3MO*W(C?;9TE9W: M*B\QJAZB^"2#5,\-.]H2*5*K5O`:HT;*2"'\Z<TY^$KQ&9%@:#SIXPTV,%*;2A)/=,- MR?)VJ^^73KS$.EQI8Q5Y+IMB("^Y9J^PY<48@G2S_Z*,3KQQ@#BA7$O6B^0K MBCA[.NSVWJU?]"@V8%:)7\]#W8W[^9"<4FD]L80D%BPJT\3GQC(+EE*1T+C! MLIRMFP,CX5@$W*JZ8FIE8"[**W*,%?(N9EEU)QX8ROKX4`'B7QK,55`'T%;9(.>Q9CF^_'0\X6HZM61%4,&8(5XOZ*?M:K"8M1 M%IM1%L6T5KK>*T+LV;)-50G:C1WHZ?'.T69G[^#0U-/CG?W#SO[FCCC9:&5) MF5D1+3.Z^/S8_B(Y2*[)8D3<2.47(J0,3Y8^?PG[5F?K:+^SL[_ET//GWG[G M:/OHL^#_.=F$Q>M6'-O:NL6$3YAT94)TQB\4? MP_LX(!P^&<([7#?RZXIR+>"Q\#_ALA+S_!-OY?+*[K=$DOWG&VA)70@7HL868KB%\N.122;U(H0X;>0A*4J5`&,+*?. M8?R0(Y!^M947":;C2XN@4LR4:^NIN[S"P14A+<+MH:;/3"K.5G6$LN3YFW`U ME=`PXGQB220L:)6Y"[VF3\"HG7*-SBD94JTM&H@A&MY,VQ5%N#K6E?@)MXEB MVH64$[*.##(:^CJWJCIUDS56L60&]&!D#ZJ>`14%Y;V+,I56TLLAU( M6<8&,4M9/R^;22E].[''VWN=W0.N.!\>N=[>[6P>[74.=W92B6_9&O:=!%A; M*WNKX/TR<]45W^.M@\X>4$L6/=[J[!R@_8YV/4[`WX>;NYV#@_!XNW.TL]W9 MWSU*-W%:FM#$DF!1XBO$,!!6(%S7Z!?#4-V>!E3^#R/MW8V M]G:5V'>\Z*RR(GTI@STE^41^;&]M'$8!X@?=P&>4YY&3DQR3@-PS@UGR&]DKW5;C)^F5<-%!8=<:?HC>-&R;D5X'4UIL`=GG9V6JWJ.[U>\[NEVKE\"_RCI$-+/!7 MV$@;WF!D80V+(T83SDFEW(_'\N5;Z(0\>>VQEO`D;*U*ET$*NIF]:#UDPLCEF3IF@8OB\%\8O4)+7_4 M6NBKZ7VW1\NA>YA`_3(>?2,-%HX+F2CK#GUUWJ6!["#/KA2YMX]DT=+[75_TXKQWQ.:4Z2)KWJUJ?XZ>XD#L$X69C$UW\!T,K]I7T+7?6%["*K]X3 M>07_2*KJ9BTP`F5:T*!B@,6]OBW<[EE1KV$>,2("^YSX;`T70CS^E"%T491G7W6/B^:C1R%Z1W'1T%UCCHNY/A?"K-*ZW?+@)\C)/KAV1J^8.B<>7 M47?DVK#YZQA(%WYV?8W_(?.E(-`R&5H+JEY40T($^_$;W'Y2F"&=.K)G4/M"LLG%45';_HT!]FH&GBP/1Y2C2(35NC;75 MZG*8,N=Y]P.N`G(;153CW._'DW?K:!"3XO5;FL]QBZSRYH9+4;67+=69+E>% M7\)3+BGB($A]:G?<4[:H""+:Q7_P*^S'JUS&1BS\X-4RR9"R10LBL]PL[)? M\\:,7@Z-7HHV8L=>123MU-8V+/YN,)Z5'SI$EE[@H36K9?<(YP0DB3P\BEBU,4R+I6^$KR) M!*\M"[$L7NA#SJL9@^?_!!,UAD7GAT"J*N@L`I0M$X6):F!">#$D:T(W+Q1BL]HX:`;:%5(X55=&,@_@"FW`%45AP^$ M*2M- MTE#=*S:"R2HWQ2:WJ#6N`.K2;N1_U[!*D',!P\B"2PZ`.D(G!^12JENG MXV0DC7N_,>H,)=;SRY;QNQV[9R&(( M4K-'X;#5:X:25?A)4(0-*`XD=%R1@ICKP!1:5A\9542R8C'-`G4NSN$HM1X9 MR&<+HA&$0W)C&JB6H+(;RB:HE]7&61#C$TP2<-)%#Y!(G569>B%*CHK491[& M5%@*@A+X`M/JFD5"15S--D5U-K?0RD/A_,/=(S76*_8N5U64I>!*7XU3F5G9 MP#)C499%U(1W1Z9_!T/'Z7_O[6A=F+P74MDG3J?;$XUEEQ M#3M]?8V(^C969+T?\YKB[$>=K>V=])VSPA*!.E;MQ+6VOW/8V=W>KT\6Q5SZ M!`U+X)C[IG"'"6/$U_1V<%^S<-9V=S<[1WLU.-G!YN%NYVAW-YWZ#3P#IZ<_ MKVUM'G2.MC9KOV\?T$-RLW;%XMD0#$OB3G3O;-301GKM@&S&T7X-@#4R,5M[ MG;W-.M!'G<.]G<[VSE$*Q:6$2;P4%,6J2]Y8D5#1677]HL3=XSU\L_VCD`/: MVR:_UU#H[V"U!K+@WRY--W M6ZLQ_9JH.2EEOI!1B/-"\$73I0#BYT4MS$VK1"OJYTR94_KC2WF(+6W5%:Q( MQS_U^^''RU#;[X/'#BS_`*[<9MNNT7\G8,]LC:<8%TY`G52'9!`IG952R3 MRH-TS)O)^!IYA1QEQ#7%)NF`\RC.O3BAX7&U,6+3$HU5Q:]TREN;'#,FV4*/ MX!/(&K+P'L'IW`^)^5.GL>L@!IBVN5H=QF6H]_7*? M5*7<'NI7NHM<*?JERA4"!4T,]HI?N@C#3 MK$1`R<-KM.<\-:RIXPQ[T>0TZXEW%NP."GV1B+[*]ZGB/QZ+W[N5MW6G>T-@ MUPZM.(VNFEZ:IP$RY"QB4X<[?S*D+?1`A&-\;5E<%0S9X:JFDFXY5DLB=UN. M%[\-NP/RU7:_:T#=(!`'K`1B"50A,!BE5T*B6W^!IQNL.0PFQ8C#4O'P+7Y9 M5":/\IOA0'QEF&<.FV\<&J;8PA5D),ZX=5+2KG$8PO33XKJ5KLYQ/]6*J6@L M-5!?3[E`UHW(D8>,LJ9AEKYRSZ.RF%7ANXXB;HJTZ+IAA0Z@3C]V.1@\(]-JB&+&BDQ.JFP9G^7+Q"[)8S)')"91[76*$= M#2I^AM9>XDW!C#B;,S`\S?-W(N0Y3;!,A(C*NGN36YW4Z&QD>UUMG8IJ=G>51:R%&Z"XN7K5Z^_ M.[LX^>G_BB3JV]-^[,JND@K<#&P8HC/QVY<1@@0`ZKY*"#1ZK[-S1.'HWM9/ M/Q()J**X!`ZL:"@=D?H%D(T@FMAY:2V*_8RI-XIGK!FJT\=SME9FU-;;X:,3 MA@/U.N/8B#@8;X0)C'V&W0]3"K<;2<(6X.+@8"IN=S:ZG^0_T#T,:2#QQ?E7 M)W-2K<"\%3[1X_Q5D(U34RSZ$&@EM)^[6COD3(NX]CI#5?>$ED:IGKUD7$%E M4*G4%*'C\5!!(\@FAA!=8R`X7;TH"PJ-\4*0W8'"0JL?C,8):TLL*Z"-L81H M/!Z2TJ5CGIT&-`?=2SP;E6@PF-#E]OH*"D;J_J=5DO4'U]R[IWF/%#[GP6G, M%@58T59)-A[<*PSCL?#)&Z.)3R[(O*&.)682*%Y%R0-C,`(0*Q*HA!41WS(3 MRR@@"\7&0@U],A1E;8C?O3+#;@O#[B61PW>Z":%^T[WL.`K4]-B*3TF<*]A& M0`GJBBTFV_,S2]]:8KFM"M49S?;CUUVH_N+[+L)])"_.CT,458'A+MB[GG$_ M?-T*A=!_W"60U"IT2-&-+*P>I%F)$XO_6@C^-'\S?\@N'O#MH"@??X$&X(Q> MBD"@0.P&*^ZP/F>0@+_R>@))WG`&TW#5TAB"=KC;:(4_ET*9EC`DK0`ZE+ENW3" M(8YH&B*=HT_'2IF$1IJ*GOKWS"PD#9=C&BE!9+D%$VUP%XU%(L57@^ACRK-I MB&*VK=^N#ODA8IM7*OG6,80>?ZJNM``IWGM@U6C*F`PWOGJO%X248([J`S"^ M0+B/[TQ!WFNA$EAOI+NTZF`]:`8XQ.K59U/ZT!:U[-CRNM3B;.AFN+"=XE0E M['TO$&AU*T%!&)E%U5,Q+Q8V&!&DP#0;*#T#"8OF#97W%*"`@O07^4:AXU#_ MG19\$DUSFO)S++H^N/%6EGK&;G40OJQ>FA1INRXYS",V9'JD.N1/Z&]44&RD M8R@7PXTXMEFMAA-=2H>Q*V6#C/#N?_@6L3<@`K-^[+"A1AZ.A"(K78W?V.GNG/XFXWLTU!O MDPO9Y^+CD;WT^!#GY8!/,&W_(J!W/A?HG?T`],%O%E]U?PQLJQ915B?_&8FP M9YFJ&('.`2J#6^U&G94WP;V8$2JQ[6.J86#$):J?KUAU\5K(OCUB+\99:>U8 M;1LZ\<&\,+5+$D:$TUNURGA$B(#=M)1 M.E$1STUD4[=*)JO:`0>(")Y9:5A"X#O8QG7LZ+4Z5=K\%A^#.FUFJZJ-LM7O MK(`6CA7YQT8Y#0VS&ZE>"1#'LFV_PB`T]M7=U;H/A9-$GNH]NOV^MQY8=DFZ ML`!R0,=B"I4*QC/^`1PATX&(I(!M@*,R".$*-&5A'`85`'T+Z=)F0\PV6+"O M0)XH%."%ZC)*$\),"GP0K`H?!6%\:'!8$X:7;.$D1%+E02M*%"F>]6;S"=$K M0-96[4`U,3%OWYZJ,:=VNR_&:FV,JB5B2Q+>/>/K9A06:*D*G4B,L"*:5GI1 MH3+=&(H]O_./E*2'`!:8QNZ!DLPNUGOA+H:^6FGG370GQ(HI-+ZA!%!GKPAM M441F&]"KYFV`MMA6:`P62S#`+T4`KT%I_,UN8LJ780;K]VXSW6-8R.HI9OSD M#H3`L_,+.TGW='E79D:Z%\-@1+#.W;!I*U%CC*.9$W-I@'#SZ%>`L%(+0841 MXFXD_P5"KD)9'&GJE)XU%T>!+%C-HW&!*4O/V7:G1:`CX2@2(ZRHT+P9#2`- M"E)++PZN.XUG37R)T(T9.&3>"/2\D[]&[&QDCI(%T30@=CMS\AEGA`'T&2:C MV^LY)!Z+P`,(*OTOK&0CMU!VE0@Y6?4:6W9753S;$Y[`3FB38O[O<_?8B&); M#9Z\BY!#\*`![(SHZWN(>4[+-.Y%NOE.[-G9O7@..0A+N-A7@SOK+R29&O\0=S`-A'\\VO MF@1KC7FH>^9%?N/%2!#[M_F8P-@]G=:PSD0`1C8IH<4WBJY!2S*8];'54,D2 M^XS&Q#LU>?G3CW$^L>9JT$KP1;)6@%M.B]_]\0."U-DEHF#JB'!&<-?%[&R7 M5:I:DG:$R.`*F%#L(G?,\F!Z_V=UGJ]M$2M.V@(0W3]$_`:MPEWK\?Q>H7UV M$2\)I&=C(96K\'V*6F;T%-^A_JW+B_G$/F91F^O^%FX9\K&,],EW:I6&@JA_ M@MI;$E6`ORE)BL^NN!@R?2H'$=SK&G.7+]0@FJR0#-_=[QB'.;Q#AI#]LRQJ MD_BR(PB52@%&Q/TVW=*YXSO]^4T5PO1AA0!?A+W5RJ47E4=(>IESI]16Y>'&N%GA1 M7(7(XJBV%U41M9'40/1D*T($,)U$/.5OX:2LWO.WC<)/K1/.2@2YV$_78#C%!`> M7N\-@VHR/SF47PQY3@F5HE8>K&KVV4O_CH<"'L?]]Y+??9ED"-N'^`9Z/C`_ M"L:%SA7W.;"C2CL;=?)[ON&C=OWA\]UNV4T6Z()\EGRGD$;@%C*5]ZS)PG+5%56LPL6[ MZ];?+PVHE2V],;+<@8C"H$KW+E&\W=)R(H-F7*Q?7=03.-^UB] MF2AZM"D?[^YN=P[WCZ+.750#BUWN:_;03A)A2.4M+%CU4LPBX`*CG,R_0,"+ M$%K6G.,)B'G@30](6$R`X^+^:<H*88SA=8]E@9^;IJ?A8:ZJ1P7Z"MO'@! MK*GSDZ9*JA/UDT*L^;W- M-=3&E7*3)EJ^2&>@GISH]T?6%Y88:/O=W6OD@$@R>O`:* M7,T99A1VP58WE^'@RU MH@K8L&)H"[ M[>-ZKIHK78IM!=B_6,$;+P&9GECA>:87?HPR6X/8%D_&,OGAQ9`,!F-P"F M`0`7+ZJ$I9R,[D\:'DSH8EV\7._B)*7M;JHYU\6``%CXSLP((F.Z,NJ(3!:4 M\OJ@9"'6RB2\#59YO2&&V>P&IY;")9G[X5]+TX-$BC$F7H86MEHY>[MY5_W4 M39%?8WTMZEN5O'=4$T7`$+)R!=0B7:&X:V+3AL'I]N*%D1*O:*:P8)&CLY6D M#PN:-+BZ,Z_6]T74N13 MD2^(#0"XCN9AS+2C4?VI@F2S2-BE&P6 M&8!N]A.(2=0BJ^FG0D!002W1T".7*ON;I._BDN>>TQ4"'YF147`S;Y$^U_3^ MM6;+'C*GK\-T6-/LT*04.+IW?G==J-FB3VKU!ZQ1)V7,['-6E;( M:C;^LX^L^(R!%7U*'0"1J1"Z`YZ2\@Q*#M4J;&Q6^-A^U!>?F)<2"O_PJQ.6 M@E4U8(@Z<281LPOD2.B9>T0JW_$J#,WB=]2T&Q6[DE(!*RKR$$DYAZC77OSB MJ\O2PJT+N=-]'!MKZN,T[&%E(V/)HG\B.CZVC.\JE'QHE!P1P>ECXG!RH$54 M_YH]6C*_U!.0N'DDIV3#V53M& MO[[*9]CTNK.4IBL'EX%S5\/-6%]$I!51%`=8*((`:L/Z6P*_M#<]O4S#]5Q`GP<38WN)0+BR"]TS"VGZ21F'_&5 M(*I+C55EQ>YBY*&IK+!0@H!3RK)#R>ZTA#`JO%5U6_V6KUG\K9^;RM8N93+4 M6S!33L+W/\R":%:V M0@B$1>SSI4G=$TF-%=!3)8IO0P^%%5XSWFNZ8+?2SBRVPJ:J%^96Q"UY@U4R M9"N!$5-7YX795,FQX=A10AM2<9\&KHK':-3JS(*]@4EVYH4$S%IF*8A=':MR M856,;[6F'%;:\&*$B[_4A$_[O'RX-[&@B-&JL+1^@3I;.T6^#H8T>UA[>W&: M/:Z%E<[P2^@A@+&/L]'C=K/ZIO7T5@K=>5R64LE%\4//K MY&.#(%]XM@J1&`$KOF@)HQ&'D-D<`G%R-_[TTAI[-ZN!5?;^IQ=D0,AQT,>] M-LD;8A<3238%*%$`"RJ>&-,/>%ORE])M8+ZW;Z,DM56WL41Y%D?8\C7'MJ-] M>Z&`&^4N)K'>X*_.[#;6Q?RJ3_F-"IFF))>NE"I'[[EKUX;K$P+N?O&0^=!: MIS`J,9CE9_-+-K7LS([C%R`)5"W[Y&-FWWA,3Z[\)&3VPK[LEPXHK83TR:M/ M&AZ5PRJG$<("92-FSKAK.*$1H+R9%J[\U==9ALT23MTST.?@.EG\?E8DA^R_ M9;\J.:VR9HK\]G>V"S($3@03'Q!RTS)[3J5>NP!9<<;/I?U5IDTW]QE0&W$L ML3D+$FPA+E,]_MD;-S#C(:H8HB M;/K,>QVD*&H=?ZP+XS<6GS.;I]TU*)R";WD#08([Z3J,:XC6YF:-7VR=NMOU M*RS_S+M#5D79:UD-'DEI!2[[^T+EZ8WO/)L0\)'B_LFN=Q&O_;YEOZ<_QR0C M.M*3'6W(XSO!8]P4^\:!P8$47:`%,^A>A=Q5"++RX81_^(*=:.PH:A'@$.NE M@#S9:4:4(<#KV*I3[]*$<$AQ:0TB@BN-1W_B^RO;.]<\^4E"$V3D]&SDM M6\$4GA6U*_16-;\]A?)-3)]:->R"PYS%^6HX]F'X&N$#Q>[3G7,E3677X0)7 M9"?;#)KZ$_QDZ;?E&+$AGX61UV4[YE?SNROXZS\$C._#%S&.E5B_R2->,9U) M&0JB4V[.\(TM1:F]56G-SS`L_KUQM)Q4_B$@)*@ZCY\TB#D"B;`.G$I6H1K>JZ^1 M@K[*.TNJH0VT6G0PX@F88A10(8$6T[8ZI+V(TU9:)3)8+-ZR7/!#BW.H!0%3 M%'W^RMHV53,W`R7V0V2Q!9JM;?D^K4&97V?M903OL5FJ.B^5\!V&4'5K!(70 MX_QNSC"HNHK)&M*H]5%?Q.;.C64+Q,NB!6(4'FWNP9.MO69Y=X85+8."()A" MPYB`'/=P;&6&K3[':6QF6'%C6@%H6=^[I[0[K$^V@IY(<13[%(+Y?IZ] M4F%LZ]I'S7O_.?1Q4C;4.R'C:KU1S4R35"IBV"WTNMK+GV#CYL!WP;CUMG-M MHB,&PH/+QAD<7RF_VIO50H:&J4\W._MT\!5:L_L,WX,[O+@'[Y%7KW2LC6OQ M*QVP9K]E@I[$_0<@JI,"DSVLU-0WN7DQ05!RQ MCB+R.)+$L2A_]V^-),,:)G),I'?'J^?=?):??&\9UD(BY9+;BX$DL[5065OS M`)Y9L9_NB%;>.D?ZFQ-*T'_H(2#S3W7S)44O%@B=J'L_!&@'MA^H(]"B7!HF_1EQ&CWZ-RX_MH29"^:-BQ12D)U3!U$A\*9S/ M0PFN]M`(ID);R!WK,/:,8AD:NM%LY_J:S+4'\CV07-S9:!7S]-\X2N$M"4M: M+;H&!4;:YHH#I16MV"N=]Y55_*Z:#XS2N3:+N[BH#D\#AL(`NX)78\:?MR1F M9!2FD0S(N<6?B)QQB:Q%7<4$9&.*KM` M[0@=V0TC;.SB%A!<1;@)&2]1IGCT)\WSXM7BXD_K0:^.X_3>H=F1\&E(_'+% M;9G>785&/KG"LF,.W9G3DRG"VNC$XF1Z1@1M9U!LJ'J8PGUZ]R404WV>+Z?3 MV3?_7P````#__P,`4$L#!!0`!@`(````(0`Z"I%8]@(``#P)```8````>&PO M=V]R:W-H965T&ULE););MLP$(;O!?H.@N[1+GF!Y2!2D+9` M"Q1%ES,M4181211(.D[>OD/2=D)Z2>R#;9G__/IF.-1X>8NQ<,!AX+G; M"C'.?9]7+>X1]^B(!UAI*.N1@$NV]OG(,*I54-_Y41!D?H_(X&J'.?N(!VT: M4N%[6FUZ/`AMPG"'!/#SEHQ\[]97'['K$7OP6)&.B!=EZCI]-?^V M'BA#JP[R?@X35.V]U<61?4\J1CEMA`=VO@8]SGGFSWQP6BYJ`AG(LCL,-[E[ M%\[+,'#]Y4(5Z"_!6_[FN\-;NOW"2/V=#!BJ#?LD=V!%Z:.4?JOE3Q#L'T4_ MJ!WXR9P:-VC3B5]T^Q63=2M@NU/(2"8VKU_N,:^@HF#C1:ETJF@'`/#N]$2V M!E0$/:O/+:E%F[MQYJ63(`Y![JPP%P]$6KI.M>&"]O^T*-Q9:9-H9Q(#_6X] M\J)I&J;9^RZ^)E()WB.!E@M&MPYT#=R3CTCV8#@'9YE9)#W@'1LC<9HQA#T]7?\\H@W(7WE\9 MLX.]2J/0DJE*($VR)+62*`W!+`ZB^.!@`$+AK@>401;@Y&"O`;5DI@`#+PC- MY?+LL@&7F'"7JR;%%M34O&NA):F"@OX-X&4JRDL*`PT:[6W=+J-)L84V,V]< M:$FBZV6NE:?7#)SL&API-G$F5AT*+3F-VS>105QBDI% M=PML@<5B+\^*+<=";,N0E*;]^QUJ:(ND8E=*@,1.#H>'9X9S*/KAP_?#/OI6 M-FU5'UE,=GU?Q/W]_OM-QU';%<5/LZV.YBG^4;?SA\==?'M[J MYJ7=E647081CNXIW77>Z7R[;]:X\%.VB/I5'^,^V;@Y%!V^;YV5[:LIBTP\Z M[)>,$+4\%-4QQ@CWS908]79;K-H\/Z_LOSL6Z*ISVL^SL5Q?H&62'2\YG29+B'2X\.F@A48V:.FW*[BC_0^YS)>/C[T`OU;E6^M\SIJ M=_7;;TVU^:,ZEJ`VY,EDX*FN7PSTR\;\"08O1Z,_]QGXLXDVY;9XW7=_U6^_ ME]7SKH-T2UB16=C]YL>GLEV#HA!FP7H:ZWH/!.!G=*A,:8`BQ??^]UNUZ7:K MF*N%3`BG`(^>RK;[7)F0<;1^;;OZ\!^"J"%U"<)L$`[L[?_9U"!+)-2O[U/1 M%8\/3?T60='`E.VI,"5([R&P61@'>=Y?&)`Q8SZ:0?U00+>0C6^/+'U8?@,! MUQ:2O0/Q$?D8P_H90H0#D3XBOX7P MJ,$\TZD9\"J&V`,UYD^<(43WFB8T21A-A0_)78CB\$75%=U@A=/)&7!`COLS M9PB1/3F:PITY3N:V;`0?4$E^4#"%(3G3`;=2!3<15 M;,D!-RF5#+9+;@,A*!4RI8F^QC"PBMM9I=C>W6879BVS&)Q<C8,06@IT@1:L=\0 MA9C2XMIYUS4`W(?H`DTZTMU>IEELXRB1_O<9%#VF<6\ M7U66'?H-TD]@=SO'*Y_=+(]@9X]P2G[8;U8YUQ'`,`1U+-2REF608;6T;HIIG%X-R:2_@>YK:9Q3"V[E)XVE&#Z_G: M!98Q[2Z`C:U#!DTWLQAO>P2].[^-\8G.,@XV-@[G$&Z3?,L5K(ZW(#Z]P#B, MC@E4T>TC#!L;2+@/,HNYK2/&N8+QB)J+'G`8-IY$(M`1=;BI?0P!$-S5O>\F/'"3:=NF M'^6KJ(8)+%'7,NXX/#P*Y^',ZNAAJ$I3]\+#5W*6L?"QL:BP* M!'L_]S!*22T8&>+X!(U93+86;M"!@D$:,XNQ=:B`HI!CAAC(@KA47%Q/=N`O M$Y,]]AFG"=MD(P:O_NB5XS7<<9LU6]"5XS7>8N,M[ZEX+K\6S7-U;*-]N85. M1!:F%S5XAXUONOK4W^8^U1W&PO=&AE;64O M=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF998 M4Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5 MAT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX M3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV< M%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA M7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'# M'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LO MG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH- M<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W M%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)? M7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#. MM!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH; M!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK M-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'M MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5 MBF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U! M!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH M@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMS MX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[ MUQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[ MA28&80-1?F#R`Y+<&ULE%?;CMHP M$'VOU'^(\@Z)@(3C M<^;,#)-A\^FER*UGP@5EY=9&<]>V2!FSA):'K?WG]^-L95M"XC+!.2O)UGXE MPOZT^_AA.(.",%%G-6D1*^21DOL(1+?G!$Q0E. M]*$B=SS773@%IJ5M&-9\"@=+4QJ3!Q8?"U)*0\))CB7$+S):B3-;$4^A*S!_ M.E:SF!454.QI3N6K)K6M(EY_.Y2,XWT.OE]0@.,SM[X8T!"])D'A//#"Y6H"BV,BT@8?L,2[#6&PQJ$`Y$ MTX0$8;1#NISDL[("*V65=!7*O;G1EO$NR_A=&>4\&*WI64X=@NJU3`31HN$W M$1A,T,*\I:)C%"#3C2KPU@9W3?J":-E3-IB5+H`7+/Q5\WU'%UQ.UU7@KJ[O M^PVO<6PPH=:=(12&(X87MP@K<%^X;]A@&N%ET`36,0R-.=VP`G=UAXDV&*.+ M4.1&EW75_&_]N-[O9`7NZ[X5T"3:8":T5M15GM;=.V#;C+1& M.QR3[DVT]]L-F3'U_D"I076CNZ$WTNA(39Y6QE6_^=``5T(P\ZH;PIN":7E- M#:.Y-?A&IHMZ(O>#N#[1]:EK75^#I@1QTXQ#PR$W'#8UJ&[[:+0&-TTY-!QS M%[J^/>=F"):-D::_:="AX:3S_4'3GT>=6B9FR!N9[+#U=6I^I>',].HVW$#9 M@,Q3%/FK_J_-;(EFB2H(/Y#/),^%%;.CV@`1/`2;N\UV>N?I_;+Y`I;#"A_( M#\P/M!163E(XZLZ7T,'&PO M=V]R:W-H965TU,>-^>OG_8?0-"A+ZSPM<8TVYC.BYL?M^W?K"R8/](00,T"A MIAOSQ%BSLFV:G5"54@LWJ(9?#IA4*8-3GHJ%7M2J[1:Y*R<.Y^9#AJ@&)?5$6[+D5 M-8TJ6WTYUIBD^Q)\/[E^FEVUVY.)?%5D!%-\8!;(V2+0J>>EO;1!:;O."W#` MTVX0=-B8=^XJ<7W3WJ[;!/TNT(4.OAOTA"^?2)%_+6H$V88Z\0KL,7[@Z)>< M7X+!]F3T?5N![\3(T2$]E^P'OGQ&Q?'$H-P!..+&5OESC&@&&049RPNX4H9+ M"`".1E7PI0$929_:STN1L]/&G,VM8.',7,"-/:+LON"2II&=*PP9+O2_(^=#7Z_6^AL]A'OYUWDA<&$[C M]=.TD>VFQ&)D.)XB?AC*,LF4&UGX[8J,!!.TL;G+N1/ZY%@5#ZU1*PE$A4A^73AS?'V@K:C="NW@U16]4BL1Q(E(KOE M7<.;EZ\K>@WU2Z6#E&Z%C@*).Q6QA&>OK6#E/+)9WE(,S*I?+*YH0&23HQ=' MU$$*!SL]$NN11(G(+GD_,7!YVY/7%5T('%_ZA$D_U$%*MZININM;]M'UR%W!S@&NV_T/L*=KTB/ZEI)C45.C1`>0=*P% M-#1$[`K%"<--NR?:8P:[N?;K"7;O"#8CC@7P`6-V/>$3]/\/V/X%``#__P,` M4$L#!!0`!@`(````(0!37DP9D`0``&82```9````>&PO=V]R:W-H965TNAUIDZ9I+Y\)<1)4 MP!'0IOWW>XP)P68U5*K:`A77> MF7__]?PM,(VF3:MC6K"*[LP/VIC?]S__M+VQ^J6Y4-H:H%`U._/2MM>-9379 MA99ILV)76L&5$ZO+M(7#^FPUUYJFQ^ZFLK"P;7M6F>:5*10V]1(-=CKE&8U9 M]EK2JA4B-2W2%L;?7/)KW, M)[1)D&]:^VT7H']R>FM&_QO-A=U^J?/C;WE%(=J0)YZ!`V,O'/UQY*?@9FMR M]W.7@3]JXTA/Z6O1_LENO]+\?&DAW00<<6.;XT=,FPPB"C(K3+A2Q@H8`/PV MRIR7!D0D?>_^WO)C>]F9CK! M.WH1A%4UR#:@#)WYD!\Q#@&KY]9 M!8](*99SX13QO=D)+HC/()<-[Z?>.@JJLF= MX.D#2X,OB-;8U_]GZCY\#O/AWY\;BA.@/?C!RE"GA._+2#Q%%)%D2HQ$)#O. M5^QP&-(X&KV#B#RX4##NB%&(:):(9XE$1TC^8"#+T\7AG0G!&[+C!DIH0\$$ M72UB;!/B8D<.031&D.\3UW4"&8G'2(`=UW9\6T:2,4*<`*\#_"AKR2.TUW*/ M'%8]*@9"P?BX,ZDT1J2[&.LN)I]Q4H-1RIUY6AQ^KUM=P#B7+=?\Q&4NX0O)^7)Z^C56=*;X4]I"O/>22>1Q(M M(KOD;_;%)8K$.@#>-\/\,7WG]9#6I=#1(/&\2J)%9)=\";#S=$O':`(\QM:O+54%)02)JO#P+YN#8OF".4ZK[:@\.40"TE1A-(_$ M\TBB1627?%6P/(5B#0$1UK6C@+0N9Y&8[\,@H!J51(O(+OD"8;E+L9R0"U69 M]$,D(+$210$B@:L@D8QX"*V]1ZWUQ3I6<9%CD]%.H4,22<5S"`I&'2N[Y,N$ MY2[%HD)V.6E'`6G:404F[:@"RCN*;_!YHH='H$<8A3NQ?1>[VY+69QK1HFB, MC+WRK;D#2Y/A[/#9X`GS39]R/D0;V(I.S\?\,P,_;PTWP"[_FI[I[VE]SJO& M*.@)'F6O?"C*6GPG$`&ULE)A=CZLV$(;O*_4_(.Y/P(#YB)(<;8!MCW0J M554_K@EQ$K2`(R";W7_?,28$FQZ;WNQNV,>#WYD7,YG-UX^J--Y)TQ:TWIIH M99L&J7-Z+.KSUOSKS]!` MZ1M#OQW9)5ALS5:_]A7XO3&.Y)3=RNX/>O^5%.=+!^7&H(@)6Q\_$]+FD%$( MLW(PBY33$C8`/XVJ8-:`C&0?_>][<>PN6]/U5SBP702X<2!M]UJPD*:1W]J. M5O]P"`VA>!!G"`(KAB#(63DA1MC71['XCGJ!2=9ENTU#[P:X!N[97C/F0;2& MR$R9"_GA^QBU_D@J:&1!7EB4K1F8!BQOH3[O.R]P-]8[Y#0?F/V<"7P1B1\( MRR"+FSPN/.,B<4GZ(%CY0-*H"[(UU?7?E7ILG\%L^X_[[OD%B#WJ<<3[QG,B M"$0DF2-2D'1.3(((\YX$P:+1*PE$BV1J@A! M)VQD>=D8O#4AB6.5O$#:_9XS8>])!T4!AF=.$CA%4&`[KNM)QDRF"`YPY(:R MO5,!03C$CO>\D:`1'K/E&ADL:Y1VM^<,;&#,@Y2%6$LD6B)5$8(^7]2WS*ML MDI2GO.X-ZK*`RC:.:R6$"&&#;F1PJ_;&:"HCM.[;K1N-#(6AD'R)Z6*RF[=8"X73T;N5@B M8H%P_""8>54@X%2-9"(5"&3[OF?_P*J(M0*+O=K3LL1P?`CZYV0_0*HJZI%$ MCZ1*1"PDZQDF*ILAYU(?MO'(H)9%T#J<"XD88(_?9?(DJ(9__ M0R6C9><^GXG!N1Q2%"I&6B31(ZD2$56R!F)2RX7.Y6V'QKFJWJ1/2,R^KD'6 M%`E)]$BJ1$2UK(V8J-4XES<=&N=RB#O7]7WD2JZ,T91`GH/]R6'9YR$1$#AQ MIZ;LB50@G!"%GOU\B8L:61^Q7"/O.@2-H2V?N!Q2E"E&6B31(ZD2$56R9F*B M0NB\:VJ3QE\JT42I$52)2*J92W%1*W&M[P!$6HZ^PH&DQGVZ/'O8"'& MMBU5/18(.&]=A)^6&WP[#>*XX3P*FP`][P-?\[P(/V<07"2?\/`!2$6:,XE) M6;9&3F]L>N-"YSU>'2=++PZ;"TC7]V@-TXKY]81-HMAU:UP`@Z!K=B:_9XE;T*X$!J^"B)?^CHM1_''&@'(Z#^SPN,_`C,0>P5P"=*N\<'=H-Q MB+C[%P``__\#`%!+`P04``8`"````"$`S0#8,%H"``!+!0``&0```'AL+W=O M0H;$9K9QK)XQ9 M48'B-M(M-/BGT$9QATM3,ML:X'D7I&HVB.-'IKAL:&"8F'LX=%%(`4LMM@H: M%T@,U-RA?EO)UI[9E+B'3G&SV;8/0JL6*=:REN[8D5*BQ.2U;+3AZQI]'Y*4 MBS-WM[BA5U(8;77A(J1C0>BMYV?VS)!I-LTE.O!E)P:*C,Z3R2*E;#;MZO-+ MPMY>?1-;Z?UG(_.OL@$L-K;)-V"M]<9#7W._A<'L)GK5->";(3D4?%N[[WK_ M!619.>SV"`UY7Y/\N`0KL*!($PU&GDGH&@7@DRCI)P,+P@_=>R]S5V5T^!B- MQO$P03A9@W4KZ2DI$5OKM/H=0,F)*I`,3B3X/I$DHR@=C,9/=["PH*@SN.2. MSZ9&[PD.#>:T+?PLZ.B]_LLJ>O0D<\^2T3$EZ,)B>W:S=)Q,V0YK M*DZ81<#@L\=<$`S5]))0QK6D]XM\SNS!/K,ONI>R"!O7:0:]D+_2#/\GC0=C MUZ[$#^.+_)`Y8-(KS.C]S`BYWZ`'9Q1=]65+QQ='(7/`I%WA+ZJ"VS#4H><* M3`F?H*XM$7KK!S;!F'ZW/TOS07<<^A\XRRTOX8V;4C:6U%!@:!R-<7A-.`UA MX73;3=1:.YSB[K/"2PNP+W&$X$)K=U[X\]9?@[,_````__\#`%!+`P04``8` M"````"$`N7<&G<@#``"3#0``&````'AL+W=O:_X"XGX#)1YLH9-10=7>D'6FT.[-[[8"3H`)FL-.T_W[. MP03\T53DA@3R\OKQ\3GVR?K+:UEX+ZP1.:]BGTQ"WV-5RK.\.L3^SQ]/G^]] M3TA:9;3@%8O]-R;\+YM/?ZS/O'D61\:D!PZ5B/VCE/4J"$1Z9"45$UZS"G[9 M\Z:D$FZ;0R#JAM&L?:DL@B@,%T%)\\I7#JMFC`??[_.4/?+T5+)**I.&%50" MOSCFM;BXE>D8NY(VSZ?Z<\K+&BQV>9'+M];4]\IT]?50\8;N"ICW*YG1].+= MWCCV99XV7/"]G(!=H$#=.2^#90!.FW66PPPP[%[#]K'_0%8)6?C!9MT&Z+^< MG87VW1-'?OZSR;._\XI!M&&=)-W]RPJ62I;!ROD>KLB.\V=\]2L\"F$0T0IP M$/'K,LQ#A*,$_3#Z]\N03^VR?6^\C.WIJ9#_\/-?+#\<)8PTAS!@-%;9VR,3 M*2P#C#6)YNB:\@(LX.J5.>83A)&^*KH\D\?8GRXF\[MP2D#N[9B03SE:^EYZ M$I*7_RL1Z:R42=29P.=9_1Y%D_OY?+:XOQOO,NU(>MHIMDH! MUUY!3$5R4>#"`4,/`E,8#X)B!,%U0K*M>J"/&UGCNHIIKS!`(`HZ"";*%'+T MX\C@2Z#3YCWKW16A4LPTQ=Q4)!\I#$(PT0D_)D-Q[,/L^Q59F.-NE4(GNS,5 MB:L8V`TR2.+Q9"@VR>[-<;=*H9,M347B*JZ0+6XA0[%)1NQ$5Q(=C=B9[DJN ML$%!Z5$;EW'XDL5HI?Q6273&`:!-RD0IYFTID]D\G(5DR%MC9?'P'+U/H-AB M&XI-E8.2Z&S:R`K.E0SX!MOR%C846VR#K6)3$H/-JIG$E0PF!AN!K6-\X%JU M16<5X[;3&'A6X23O:*[QX7X\>F&)VKWUW818);GM-#I?9%5/\H[F&A_NV^/Y MU"ZO\T5666[QL(0,,/BLRDG>T5SCPUU[/)_:XPT^NS*(>PZX\7,UU_A@GC?P MH=K,OVC8$%1U$*59M)O&C"R)$SPE@&M_Y%R#N^F\P';-AAN,.SCW0(CLVNU\ MQO#==&I`S^OP.<7K'@J14[RN9IBFVEQ4RZL:N9(U!Y:PHA!>RD_8PA)8FOYI MWY-WS7+_`W2W-3VP;[0YY)7P"K:'5\,)-J*-ZH_5C>1UVR;NN(2^MOUZA#\_ M#-JN<`+B/>?R&PO=V]R:W-H965TK'LW$<8A''D6V.NW_?=0PI!-KF[H7$879V9G>S M6=R]R!(]>$&%9P24V@:E[!/[G2DEHXZBTQM>8T:X)D289A."&2 MB@I[AKGNPZ'R7#"^5FPO>64]B>8EM:#?%*(V)S;)^M!)JG?[>L"4K(%B(TIA M7QM2C"2;/VXKI>FF!-\OT8BR$W=SN**7@FEE5&X#H"->Z+7G&9D18%HN,@$. M7-F1YGF*[Z/Y:HK)1V2+%\208)V$<`1QMN+$/PE%BQ/;&*OG+@Z(CE2<9'DG@ M>B2)QL%H.$ZF/5B(5]087%-+EPNM#@B&!G*:FKH1C.;`[)S%4)_;SL"2B[EW M04THH`UTXWD93Y(%>882LB-F=0LS:S$$TK<:(.^YAG_G=N!N[FG+V^A;W<`D M88NYR!U?YN[GWP6E&++\\9]$+;_7X#&C,\RX15PH`,BY^WX*7!!TZHP]3H8M MOU?@,3T4P`R^78$+ZM8@[BCPF%DS(!2[H M?QWPF!X*W'?BS6^A"^K6H-L!C_$=&%RWP&\\OQ!JNN5?J=Z*RJ"2YS#:89!` M![7?=_Y@5=V\?!ME84\UMP5\ECALA3``<*Z4/1W<1FT_=,O?````__\#`%!+ M`P04``8`"````"$`KIK3M4P/```[2```&0```'AL+W=OA`D13/UNY>*[(+OS;[PW;W?'/I7/4N M+S;/Z]W=]OG+S>5_EM$?P\N+PW'U?+=ZW#UO;B[_V1PN__SX[W]]^+[;?ST\ M;#;'"U!X/MQK]U>+[A^6FV?+Z5"N/\9C=W]_7:]F>[6WYXVST@&)S]O'[?&?D^CEQ=,Z3+X\[_:KSX_0[[^=_FJ- MVJ?_,/FG[7J_.^SNCU<@=RT;ROL\NAY=@]+'#W=;Z(%X[!?[S?W-Y2-L1)1.#S;O=5F"9W`H'S-?.. M3A&H]A=WF_O5M\=CL_L>;[9?'HX0;A]Z)#H6WOTSW1S6\$1!YLKUA=)Z]P@- M@'\OGK9B:,`36?U]^OE]>W=\N+GT@BM_T/,<,+_XO#D]5U_,'Q+$_I*!7ZBRM70]_O!#5P>B/O#1J!TH"?[V_(0(G`SW M8F#*T+MO5VD'&?SR[OXX.,K$+TK%>7N,'1QOXI?W-P;'F_-+`T[,5/E\?V7( M.3A$JQH!UBK__KH!>Z' MZ[]@?5TKFS&W<4R+"5J(Q53(3FTPLT%D@[D-8ALD-DAML+!!9H/SYI6 M8VDC%O=V=OK6S&M-VC@R,F,D8F3.2,Q(PDC*R(*1C)&,Z_3,$3-OC;#ZF)&$ MD921!2,9([DD#C6Q:&WT)EK+5=D:81,K1FI&&D9N&5GJQ(@L'"E^/;)"Q(RL M)'ID&9DR,E,Z]-@B28+>:6/E]IR^%=2V')]8S$C"5-/61FS70-5:7!9M.:IF MC.1,M6AME*K5UK(M1]6*D9JI-JU-=UMOVW)47>K$B#5L4HU8=\Q6.*#C=!76 M9E`5&;83;](2&M5>;V#&:-H:80MGBHQ:H:BU(2''M\(RET:P5Q>/PAD.1Z/A MP+*)6R&L+&&5I:W-FZ+D# MZS%6K1!65K/*FM;F3&6W9F6]P.UYWLCLV;(5@LJ,,21R?/JIZ?P8$M;F&)+$ M==O03UI";?9Z0[,]T]8(.S]3Q&N%(F8SE\0;G`9,'^:Y;^W^8N:3,-V4V2P, M73<8#-C(8#XYTRV836GHCKSAR-:MF$_-=!MFS(A1SKP01 M::>(2'MA:CN02`[L"91QMQP1B1>(2+PTQ6'6LT!5W*M&1-H-(M*^-;7=H3/L MVZ_GI>%F#@.1=-$7>YDB>^.VWY&I&SC/843'B+1%@9`^.JP-\I2L4&N&2%L7 M%/)(?HYH='H50!*_U[/.!S&:D%?"M5-NM4`DM6%M\!S?>GEG:$/B.1,.M;A%)84I69RI'V7F5 MK#*32=:+<"QR36+;`B.J'2363G%"-KCT3#F:<11Q-.$3Z2`_/^S8",@D%HP`? MZUA\5BD"J4>-H:FR\OIR=699H!D9H'+$T9RCF*.$HY2CA4):PS.RZL[4Y&2` MK2PX*CFJ.*HY:@QDAD]DA/3P_6!VR022$2>)]'P>=%V$3D-31/IBZ[K60CHC M*WP,$4=S1/)^B7C9QHAT><_.""9DA?(I1PM$]*;+$.GRK/4Y6:%\P5&)B%I? M(=+E6>MKLD+YQD!F7$66!N,J;L>\;UJJ7(\^+2728CL1UP#L<"NDI]T].YEQRGB/1M#3ODS)25 MRI!`*@!R0H%U4(U("@,V1T05QH@HU9"@>B!/V-86.R4/?>A9M2_0BJK*$)WM M6XZURU2OT^\/_:%K90\*DL*^E8BHP@H1]:U&==4WZQ33D$=WWXQA(JX:O6&8 MG,S-W)I"/HP#;19;R:X).M+,FR*B$3Y3"'ZH[CL MAI6H;LBANQMF\$4N3%\CWO7&A@E`1(O]#)'X M*%!\S@9'=_O@'J$-NT5`&VI@B8BZ42$BJQJ1[`8;$ZJ!KW7#'!.PLOV&,2%4K#$A40"O M\W:=8!O:">3/3HXT!Z8*N;"_:QWYZP2MAJ=AXKH]N!GM6A_'1FA$-^OFO,*8 M6R6(5%+5SM:F6*ZWT7/82&&=R[H<6>=RM)*=-@)P-FP_=:?*%2K6M%>( M0C1!*T)3A5[/J9`!!4PJ@P^B.;>*.4HX2CE:*`3G793/R.J5G`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`G$X>5NE<#%HE#<>N$E\"< MALP#'#KLQVX(WZ?D.F.HH%._'WZ"ZTP=#OT0ON;%.9S>0K&EYR5PB`O%>:RK M)("2+A\XK(5B!\]]X,P6BN-75TD`)5T^D&*"DJYN0AHC%*D$K@:I`_#I*AE# M"\:=]4R@1!S*N!H.VZ$X@W$?.'5#J[O4X(`&)5T^<&,A M%!]C@J&4!)EP]^` M^\!-$VAUEQI<2H"2+I^Q'\)7%;E6Y(?P_4#."S^$+^5Q/@Y"^&(^-,M+ZLOFWRU_[)]/EP\;NYAH>N= M;GGOY1]_D?\YJAN7GW='^*,ML%6"Y`C\D9X-W,WI74$RZWZW.^)_1`7MG_WY M^'\```#__P,`4$L#!!0`!@`(````(0"7@K;1$`@``-0D```9````>&PO=V]R M:W-H965T2;@!%<#3F>_WO9\N6+$N+Z0DS_1*'SUO+EI:V+,E^^//'^=3ZGESS M-+L\MHU.K]U*+OOLD%[>'MO_^,OY8]1NY<7N;]`][])+NU*87+^BD;V^IOMDGNT_SLFEJ$2NR6E7T/WGQ_0]%VKG M_5?DSKOKMX_W/_;9^9TD7M)36OPL1=NM\W[BOUVRZ^[E1/7^8=B[O=`N?X#\ M.=U?LSQ[+3HDUZUN%.L\[HZ[I/3T<$BI!JS96]?D];'];$QB8]3N/CV4#?3/ M-/G,&_^W\F/VZ5[30Y!>$FIM\HDY\))EWUBH?V"("G>AM%,Z$%U;A^1U]W$J MXNS32]*W8T%V]ZE&K&*3P\]YDN^I14FF8_:9TCX[T0W0W]8Y95V#6F3WHSQ^ MIH?B^-@V1YVAT1M;0U)Y2?+"29EDN[7_R(OL_*\JR.!2E8C)1>C(1:Q!IS_L M609=\ZLB%A>AXPV17US=Y@7I**K0ZXSZ?7LP8G7X14DZ6U:>CKRD,?Y:R0$O M26ETYS7'O"0=[[RF09VC\DJVL_G%FAJB==D_]UY7-+!!M;ZSML90W#/]<^]U MJ7&K^GZYE;M5[RZ39;XK=D\/U^RS12,0]=_\? M4,(PE6`8@@-%;_# M$";SV*:_C:3IJPY,JQB#[J0.TD)F=4CM$I`%$`>("\0#X@-9`ED!"8"$0-9` M-D`B(%L@<9,HIM%@_3M,8S(T6-)E:D/,WD!SC0?]RK4ZI'8-R`*(`\0%X@'Q M@2R!K(`$0$(@:R`;(!&0+9"X2137:`:BN'9[^B8>0RRZ-$;7@YK+Y4;H4?\'3?"HM4;X<2LA]\9D#F0!1`'B`O$`^(#60)9`0F`A$#6 M0#9`(B!;('&3*`U/DPJEX=D,Q>QWR+L[YRA,2/6$$^I\C5P>U?Z7(!\8$L@:R`!$!"(&L@&R`1D"V0N$F4AJ?UTAT-SZ+5AN=$ M38*QE@1U4)T$0!9`'"`N$`^(#V0)9`4D`!("60/9`(F`;('$3:)XP5:B=YA1 MAJMN"-3(`T1S1`M$#B(7D8?(1[1$M$(4(`H1K1%M$$6(MHAB!:E>L.44+FT[ M;.NC.*;[;].,1GT*NC%2631=X`O;:E%&\SW1\Z<&1]56#UNGS@0:U%%SCBPE MKXR>FE<+&27D'40N(@^1CVB):,41;5F(*P8RJO$<-+3%>2BC1,$UH@VB"-$6 M4:P@U4BV#/O_C:P65(1MV^YZT,$,JQ@E1K MV6I-M]8]@?#4=:1CA8SA5(JGL"275?4[<&(].VM4?N$LNM!)+J@4!2/=34 M[8$Y&%M:UUICN8U`4CT22*IO-76K;]F6I76O6"FG.LY6>DW';XR^39M9N/:$ MK)!)F=JP6:O?S.!1LG_,!9*/U@5'EDQW!Z-<@:26)Y#4\E%KB5$K@:16()#4 M"E%KC5$;@:16))#4VJ)6K$2I]K`E<=.>:C_XWH.&7O1UQ?S0>:.I+$2355Z@>8%0H4'WO@[%IR7VF\I&S%D%2?8/J M$49M!1+W/AA:HZ'V-(E%4*FN6L^6]+KU1E^F_%_9.^7R?WT@\YT!Z>*4O>-B MV2P'HQFB.:(%(@>1B\A#Y"-:(EHA"A"%B-:(-H@B1%M$L8)4C]CJ7_?H?]H$ M8^_X]*&9(WIB-H9F;=";B8)V8]Y4%Q13O05&.8A<1!XB']$2T0I1@"A$M$:T M010AVB)B'S*4K5HV3N5<]6%"]:[UG%S?DEER.N6M??;!/CJ@Z>?30XVK+R*F M1H\^B2B_:H`S0SI3OKF#,R/Q&85VAKZO>"X33^-3]MT%\U#GYH3>=]W@UH3> MJ2!_MB?/5&T\,;4GM)U_@P\FM,E[@U/=;E:-:G93?SRA#1C4H17WA"UX\0PM M<*G.M\[0XF["%FM8AA9GI';K#"VN)FRQA&5H<437*<]TZ]:E;TK>=V])N+N^ MI9>\=4I>R?Y>.;I>JZ]2JA\%'V5?LH*^)BD'W"-]/930]D*/;7:_9EDA?M"E MN_7W2$__!@``__\#`%!+`P04``8`"````"$`+Z8\VQX&``"S%P``&0```'AL M+W=O(>'\!#'D`)3EM M>$:M5%77]C5+2((VA`C8V[MO?V-L`_;DTMOVWBR;'^.QY^^Q/7CS\4MUF7TN MFK:LKUO-G!O:K+CF]:&\GK;:7Y_"#VMMUG;9]9!=ZFNQU;X6K?9Q]^LOF[>Z M>6G/1='-P,.UW6KGKKNYNM[FYZ+*VGE]*Z[PYE@W5=;!S^:DM[>FR`Y]H^JB M$\-8ZE567C7FP6U^Q$=]/)9YX=?Y:U5<.^:D*2Y9!^-OS^6M%=ZJ_$?<55GS M\GK[D-?5#5P\EY>R^]H[U695[B:G:]UDSQ>(^XMI9[GPW?]`[JLR;^JV/G9S M<*>S@>*8'=W1P=-NF[32_0WV7QUD[^G[7G^BUJ MRL-OY;4`M6&>Z`P\U_4+-4T.%$%C';4.^QGXHYD=BF/V>NG^K-_BHCR=.YCN M!41$`W,/7_VBS4%1<#,G"^HIKR\P`/@[JTJ:&J!(]J5_OI6'[KS5+&.^,@W' M6H&7YZ+MPI*ZU&;Y:]O5U3_,R.2NF!/"G#IZ\'8%_ M'W1D\P;PY`WL.5DOS,6_]03CZ,.$I^AI$N:#'I>\X6IL:([Z/&@("ZSO$9[O M&ZK#&\+S?4,U(7G87-(L8O-$'@Y69\G0YY:?==ENT]1O,UBP,-WM+:/+WW2I M6Y%5+-XAS[Z79I!?U,L3=;/50#K(H!;6QN<=,5<;_3/D<\YM]MC&E"T\84&3 ME[KU51"H(%1!I()8!8D*T@G0099!&TCRGZ$-=4.U$5'M!9B(I0@A+$037P6! M"D(51"J(59"H()T`20A8JC]#".H&=ATI2=9RY'MF8\)(ADQ:R";>8#*H@TB` M2(A(A$B,2()(.B622+!3_0R1J!M8C-#-(``Q'5F"/3=ZI-)@,JB$2(!(B$B$ M2(Q(@D@Z)9)*L"U+*MT_O<2V0JU[,400>TZ,?H]1=AAO>#EJ9XW9(XT#=OMW MC(-:R^/@A`RKVD/$1R1`)$0D0B1&)$$DG1(I4-B3WQ$HM98#Y00F=,Q'8LCY MZ`U&8IY\1`)$0D0B1&)$$D32*9%BIZ7O]'![G&S46HZ=D\DD(^(C$B`2(A(A M$B.2()).B10H5!#O")1:RX$R8K%:CYZ\'B(^(S:(/22"Z2@G>#`8B40($8F0 MZWBP&5T3HKA.!B/A.IT220Y:R$AZL*IF3@O=[ESF+_L:8H!C_TY"6+"S\)J& M>I%UZAW#$381"B.?(]MAA9!AVO)R"48#$4N(480]QZ-57V(9IB5[3D8#X3F5 MD"P3+7Q^?'V8K$Z"HTGXW@L$B3DD!2%$'I0GK)RAH2_0M*&Y4*()N!5AN_UR M;5NVK:1%.'H2HXH$&ON+!7K87R+WMW#(TK"4K2X=/4%_LIRT?'J'G*S:DN1D MB$S/=4(453Q:'$%>P@>4B-@7:-RI`HZL%4M"BRR62^6\#'&S2*#1>2S0Z#Q1 MG1MK8BG#3*5FLE"TAIH*]=^6)Z_$QI'N:=5$5^QTE@E15I\GK,;T\#FRUH.D M@4!L$4/>69:M%*NAL!F;1=AYC*T2@?@.L8*/6G75I,*F=R[K1ZNK_Z\?K]&F M^C&TA(4^6-KRSG+D5Z5/2M!9K8B^6\F810CG3_5M^\=(W`?,IPCO"R= M"LW1N*0\>I5#W*#U,MC#]/L8!1B%&$48Q1@E&-%KO'$03`9V+<>N3JJB.15><;FT ML[Q^I5=NL./L-@-F]X%[=N'+[`Z'D=ZU7[E07-^Q7[M0B][AY@(BZ"\?U1`<=P^%"&[B M.:YW]X7ON%`[X@907;FT6L)O(L>E-1-^$3LNU(IW.+BBY1&\T8?QPI7I+3L5 MOV?-J;RVLTMQA/F%&T18G@V[=&4_.K[VG^L.+DO[;>`,E^,%%,_&'(R/==V) M'[2#X;I]]PT``/__`P!02P,$%``&``@````A`.5WLK:H$````%<``!D```!X M;"]W;W)K&ULK)S90:'[D0AP$OV\_7 M?V\/U__]\N]_??JU?__C\+3='J_(PNOA\_73\?A6O[T]/#QM7^X/-_NW[2N5 M?-^_O]P?Z9_O/VX/;^_;^\=$Z>7YUB\4*KMJW] MP\^7[>LQ-?*^?;X_4OT/3[NW`UM[>?B(N9?[]S]^OOWG8?_R1B:^[9YWQ[\3 MH]=7+P_U^,?K_OW^VS-=]U]>Z?Z!;2?_`/,ONX?W_6'__7A#YF[3BN(UUVYK MMV3IRZ?''5V!:?:K]^WWS]=?O?JF6+F^_?(I::#%;OOKD/E]=7C:_PK?=X^] MW>N66IOZR?3`M_W^#R,:/QI$RK>@'20],'J_>MQ^O__Y?)SL?T7;W8^G(W5W MF:[(7%C]\>_6]O!`+4IF;ORRL?2P?Z8*T/^O7G8F-*A%[O]*_O[:/1Z?/E\7 M*S?ENT+1(_&K;]O#,=@9D]=7#S\/Q_W+,A7RK*G4B&^-%*GV:.2,8LDJTE^K M6+HI^>6[:N+]C"+5+:DV_;6*?N&F6BZ7*M4[8FZ[#..:(0E5:2_EUU;S2K27_9$G5^6*Z9,S+CT*G[0W31S9GOC0 MU7FG.*`?[/7\]7GIQP)@?[.V#,>IQ['B9&#C?&SYWO?EQ66_XW/?FQX4U]3D(?.D- MP\X$J8GAI//-#^O.JWUL\/K<'^8'5S77W6V:YY*TV;H_WG_Y]+[_=47W(KK& MP]N]N;-Y=6.%$V9:XU,*_?\R**5.8^6K,?/YFKJ6DN.!TOZ?7WS_[M/MGY2J M'ZQ,`V4\5Z+)$B8O&[,M#=H:!!J$&D0:Q!IT-.AJT-.@K\%`@Z$&(PW&&DPT MF&HPTV"NP4*#I08K#=8:;#+@EL+D%"L46?^+6#%F3*QP+S<89()'!09+L$I+ M@[8&@0:A!I$&L08=#;H:]#3H:S#08*C!2(.Q!A,-IAK,-)AKL-!@J<%*@[4& MFPQP`H-N6Q`814J\^;,NSAE&B^973LZHNAW?2&7,+?646,JN2/,D<@H.(&T@ M`9`02`0D!M(!T@72`](',@`R!#(",@8R`3(%,@,R![(`L@2R`K(&LLD2)V;H M!@DQ8V8B%]YXC!FZ=Y&;4X#X?LT-D885.A=%)Y%3%`%I`PF`A$`B(#&0#I`N MD!Z0/I`!D"&0$9`QD`F0*9`9D#F0!9`ED!60-9!-ECA11`'C1-'YC&.DDV#A M3FY80KE*PJ=8<,.GF0I5LN'C%V7NXE2(IE`75,A(NQ6RQ#_='9M`6D#:0`(@ M(9`(2`RD`Z0+I`>D#V0`9`AD!&0,9`)D"F0&9`YD`60)9`5D#623)4X@T%S8 M"00SL?;+-Q1+%V8X8\B-$4MH4&2"UE=!>Q+B6&\!:0,)@(1`(B`QD`Z0+I`> MD#Z0`9`AD!&0,9`)D"F0&9`YD`60)9`5D#60398X86,V(K/KL?,)S4B[L6%) M)G\`:0%I`PF`A$`B(#&0#I`ND!Z0/I`!D"&0$9`QD`F0*9`9D#F0!9`ED!60 M-9!-ECB!0%L=%P2"D78#P1(W2115DC@)G9($D#:0`$@()`(2`^D`Z0+I`>D# M&0`9`AD!&0.9`)D"F0&9`UD`60)9`5D#V62)$QMF8_."X$C$W>A@E,D3B%J( MVH@"1"&B"%&,J(.HBZB'J(]H@&B(:(1HC&B":(IHAFB.:(%HB6B%:(UHXR`W M1LPNSL?O)&;'6V401FX**:D4(E*G'(*HC2A`%"**$,6(.HBZB'J(^H@&B(:( M1HC&B":(IHAFB.:(%HB6B%:(UH@V#G+#QNSQ7!`V1ERE%HNRJ050RVSI&$61 M:B,*$(6((D0QH@ZB+J(>HCZB`:(AHA&B,:()HBFB&:(YH@6B):(5HC6BC8/< M&#&;.MD820\-;LR1X?%I]_!'8T\+$THH.9/7(AT.V",#NS54/"UU&V8;QP1% M>IQJ3@":C)(S8WLHD$H5LZ$#*+"*&:D0;44L54C.+$I>S5/KJ%@D.+]U$'41 M]1#U$0T0#1&-$(T131!-+:+S.J[]3*3,,4W)JQ35=ME<)%AI@6B):(5HC6CC M(#>PS#Y/-K!R`HB.R4X19,15\K&H=+K>ICD8):FB!%6+$>6@S`I:;2RW18J; M(4`4,A+S$2,*RHSYBGOCC$6*S7<0=1FE#RN8(=%CY)I7G=@7*38_0#1D).9' MC!SS)=GN2@;A6*38_`31E)$TSHS16?-SD6+S"T1+1E+[%2/7O!K4:Y%B\QL' MN5%I]O\NB,ITNY"BG&TWS+ZV"=1L5*;(B4J+LGD-4&!M.7D-;$4BE0U!=2(; MBQ17M8.HRT@ZL.4D9B? M,3IK?BY2;&N!:,E(S*\823^N$6TU164_C2353!M'PQTC5.M+QH@15_/.%)EGO3(QI:9\33.$2-&7P=5B M)#>+MD7%N^0RRN6"7ZDJ2P&JA8S$>,1(C,=LG#)ZIJ)J8M`119'RRJI!NRPE M'GN,Q&,_SZ-75AX'J#AD).9'C,3\F,VGK56J5DI^166/":I-&8GQ&2,Q/G>- ME_UJQ=./M2U0;-H^A&K=D?OB"SV^UDJ53#/$^) MF5VM))HL)8.OQ4@&7]LBF\9+^5G\Y(]'=LB6Q'C$2(S';-Q)V675S1U1/!NU MMA+BL2>*7*]^OD&;B+M)UR)*I]+Z M?EFM]9HBQ9W;8B2#L6V13;I>,@=1\16@6LA(!E7$2(S';-Q)NGHBU!%%N1Q, MNBPE'GN,Q&,_WZ.:XPQ$\8S'(4N)QQ$C\3AFCVD>KOB%:E7UQ`2UIHS$]HR1 MV)Z[MN^\6OE.76T19.)U^NA//C:/AQJ\Y,6U3*/CT% M=_8.*G;1?`^E^GGF_;*:"0U$45H+1LT0/8Y$D?/"F%':6G[5+Q25NPF+2#-, MT?8,I>:,4MO%NTI!W[\6+"*VEVA[Q4BDUA;9%*SNWQM'P0UAFJ[^#T+86%$A MG*(*19:$L*_N#4TS6U;388M*645<,K)4.M'WJ[6\*3(+R7Y!B`XCD9*:@L.8 MI=P[C9K#=EC*K;RZZBY6HI>OJ-9%?99R*Z'FBP.6.EN)(59BE*^H*C%F*;O& MJA2*Q5I))>,)"TG33]'A3*3.-/V&*43;[IR&8 MOI*8[&QO'"EWN%#+GQTNL_T;C8/<Y6%8CH*S21)'FDB:B% MJ(TH0!0BBA#%B#J(NHAZB/J(!HB&B$:(QH@FB*:(9HCFB!:(EHA6B-:(-@YR M8\2^B-3K]4+3/PGQ4KQE48GB25:0%;7_VA8I5@P0A6@^ M$JFL>;78B46*S7<^H*WL-K3L3C7\%&4.XYN(6A:IEE%[;6V1XJH' MB$(T'XE4MF64^5BDV'S'04[+F%>!+VB91-S=3[`HVS*(6A8Y+4-/]+D[>FV1 MXJH'B$(T'XF4M`R8CT6*S7<6LBW18`O)D`46D1_6"H2J>1;$&`Y%@'6Z3C(;2:S2O_XT*)GHZ`]4E21 MN4O32F50BY$\3]9F)`]0!HQ$*K2(#COX:B)&LDT76T3[<2S5<:3<:]:;#><7 MC$7<5+#([&=D4JCJXB9+21YJ,E]9+U M]UH:5[+%%)D]EDQ+J_W/IDCQ1;8L^H=-999*-QJK=P7ZCH#JQH!E9`2'Z"\2 M*:DHC)^8I<[XZ[!,XL]M9;/R.A?/']N+I(U/2)46R12^R5*"6HC:B`)$(:(( M48RH@ZB+J(>HCVB`:(AHA&B,:()HBFB&:(YH@6B):(5HC9PKT!7GGR[4-655B=U,X-"'5JDU,UZ(Z^D M1B5Y?FB26C?SS1R=HD7[HFXQ?<_O$=&..I09U8JX\=6%>#WXMU;]2,&*5 M&G2!C=PJT8JPWLPMH85AW:SQT!HMC*@DKU%H85`W<_P<'6H4,Z/%$GIUH6X> M[<42>H.A;EY&R"LI4TE>0-(3P5229XW>8:B;QW[1&KW*0.V?5T(OA=3-X]"H M0^^&U,UK'GDE92K)JQL]14TE>=;H[9"Z>50:K=%+(G7SOD=>29E*\OS0$]94 MDF>MY17KYGTMM$;O9Y%.7@F]QD2MDU?2H+HUMY^ MIV1<2-ZF>T^_8)K^XVA/%[_MC_3ET>2@\8F^-+NE=X(*YKLBW_?[(_^#*G5[ M^G;ME_\3````__\#`%!+`P04``8`"````"$`=V]^BWP&``#=&0``&0```'AL M+W=OZ.3-TK;P6];ZZ'M?ZWY^C3ZZNM5U^W>?G^EJN]6]EJ_^V^?67U5O= MO+2GLNPT4+BV:_W4=3=_/F^+4WG)VUE]*Z]PYU`WE[R#G\UQWMZ:,M_WC2[G M.3$,>W[)JZL^*/C-1S3JPZ$JRJ`N7B_EM1M$FO*<=]#_]E3=6JYV*3XB=\F; ME]?;IZ*^W$#BN3I7W;=>5-KW63/Y]AW%_-95YP[?X'DK]415.W]:&; M@=Q\Z"@>LS?WYJ"T6>TK&`&U76O*PUI_,OW,=/7Y9M4;]$]5OK63_VOMJ7Z+ MFVK_>W4MP6V8)SH#SW7]0D/3/470>(Y:1_T,_-EH^_*0OYZ[O^JWI*R.IPZF MVX(1T8'Y^V]!V1;@*,C,B$65BOH,'8!_M4M%4P,68ZQ M,"%<>R[;+JJHI*X5KVU77_X=@DPF-8@0)@)7)D+(S%P:]@,:"Z8!5Z9A6C/B M6J;UB,J2J<"5J\Q$X^)P/7AGLR' MF>X3)\B[?+-JZC<-5B/,97O+Z=HV?1,2CJ?,,,%C$GTOAR!YJ,H3E5GKCJY! M>K20^%\VQ/96\R^0K`6+V>(84X[8\0B:F50V4$&H@D@%L0H2%:0JR"9@#K:, MWD`&_PQOJ`SUAH]JR\'$+,4('L&;!"H(51"I(%9!HH)4!=D$2$;`,OP91E`9 MV%*F2>(8\LBW0XP)/1DSR9)#=F/(Z`XB(2(1(C$B"2(I(MF42";!+O,S3*(R ML!CA,:,!Q%$6RI8%O>?2&#*ZA$B(2(1(C$B"2(I(-B622["-2B[=?S7Q;85& M]V;P06P9,?H]1MEA=N/-J7=D3!^I(_9#':'1.RWB$2(!(B$B$2(Y(@ MDB*238DT4-B4'W"<1LL#'8@M[>W.8C2UWZAW8Q"?J`"1$)$(D1B1!)$4D6Q* MI+'3PG;Z=GL_VVBT/'9&)I.,2(!(B$B$2(Q(@DB*2#8ETD"A)GA@H#1:'NA` MEDN1S2Q&D(#%@-GCSF1ZRLX4CD$\$2)$8B2=C#%"FCA+.;">MGQZPE3>`S3A:*<*N8(Z&=<"2T4UG;=8EM*=J9U$JVB990#]C$*B[1HRVM MCNC"G$XF<92)VO$HD04!1_TW>+_(0X98BBU928\8`C M,>,A0RR;3-,S%)T(-XHY$M()1T(ZE:7)TEX@D\:!H)V)5H=3DW[L?+M2=#;DS44Z1&PA@3NC`WO MO#V'AL3M#;7`3]M#>QN+$<<3,1,WQ?.2#STOY5'L>=;"<5WT6I@^3W89=O-W M7?YX"3?N/]GSMU#4 MXB8[S]_=O1%X/GR'X`:!:?BT\L9W8L^G]3>^D7@^?'?'WYT++6?ZPZ.U?LL/\&?44HX`S5FL*L? MZKKC/^@#QC_,;/X#``#__P,`4$L#!!0`!@`(````(0!H*;^C:`D```(M```9 M````>&PO=V]R:W-H965TQ'?OXGX="M7,QE)_/.?%YL7T2 M5A_.]_Y5^6XU'3;D]/VT-]JA[& MOZMF_,?C7_]R_UZ?OS>O5=6.R,*I>1B_MNW;>CIM=J_5<=M,ZK?J1"//]?FX M;>GK^67:O)VK[5.G=#Q,P]EL,3UN]Z>QLK`^7V.C?G[>[ZJTWOTX5J=6&3E7 MAVU+\V]>]V^-L7;<76/NN#U___'V952##/CI7SP_C MK\%:1'?CZ>-]%Z#_[*OWQOE[U+S6[\5Y__2W_:FB:%.>9`:^U?5W*2J>)"+E M*6CG70;^<1X]5<_;'X?VG_5[6>U?7EM*=TP>2O1YXQ5IK75SI4^C>:67*ZU)GT;SLI=3E=ZN M6M)MNWV\/]?O(UJ"E,#F;2L7=+`F:Z9,5(3[POFSNJ&"D4:^2BL/8XH`E41# MQ?[S,5C&]].?5*`[+;,9D.$2B9&0U2C-IC[(?)#[H/!!Z0/A@"D%H8\$%>O_ M(1+2BHR$\6%C@`U-Z+EM)(Q*ZH/,![D/"A^4/A`.8&[3VO3=GM-"&=XG3+ZE M$NT(+-\+[M9&R01TW;XHO))(>I'>=2`9D!Q(`:0$(ES"`D![C!\`N5'>N`*D M%5I#=)7>VV!YYX5$"UT*22_2AP1(!B0'4@`I@0B7L)"0^VY(+M>"%.X\-S/> M:#+K-@(_Y_V@&ZAE'R@V#]J*KY^'%.;ST"3L%V,")`62`=-'=5(]=7@[BS@>>LE>J] M190C*A"5B`1#W&79-S@EJSJEB6PJV]?][ONFIC5',@.E'-%&J/LDU7S0,6%F MOPDT!JIT2!% M:S?V3N/,2!F[T?(#N[G6"&VN"HV"59^*TMB]>'5AI2C2/*RR57$J[8.PZL;& M+2F%0M:,K+Q4)[)7H;"2E$EUJE$L"_;GXVP21^%RYOSSSO+,R-LZS-%J@:BT MBA<2)*P4A$BV+M>'2#0"H0%0B$@QQEV4'YKC\N:9#M7&TFYK9 M;^BXZC8`>Y`E&EUH.I0.:SH`Y<:RN]WU4G_6=/0"9H+"SH80"TEX4^O92?.= MSB"ZJ-UJH>G04GW3$<0?-`>IT6"EY&_AF9&ZONG0&F[3P8W04TKGC*8_Y]D7 M[[`OC<;%R0DCI29W-^%F9X%KER=%-J1.G5YN6<@5__C1R#M^/"\2*V4*)=7( M'#\?MBQ&WCF0T&J!J#2*?6]TQRO"VR:%D<>C*:0DW!`L*>U5L$(?-"_=9:AM M5D_WN^>I!@TW+W;41#RFS6%-$&:(<48&H1"08XK&03:$3BP]. M1M5",IS?'OT\_S0Y5$\A;13= ME=TKF@+(4"I'5"`J$0F&6#2BFYK33IH?[08YV4:4(LH0Y8@*1"4BP1#WS^OS M/IUMN@?S]W&#W&S32R/\$$VLE$EMBBA#E",J$)6(!$,\&CZ?UY]]_MB.L'ZRULYW2=#A6MD[?0)/VN9Z<7F.#2N\[,#?=_NV\4;0K.464(=%A0\C*QKI?G+R1Z(96>M>#801^<9A M]\`/1D(:Z0G/;4>FC-%C6X1AT8H:G2W-#1"UN@^ M8VB$HD9=-X[0@\QU1H\/<:2@$?E@$4?H9&PO=V]R:W-H M965T&ULK)Q9GB^^;_6&[>[F[ M[%]=7UYL7M:[^^W+E[O+__SF_W)[>7$XKE[N5T^[E\W=Y1^;P^6O'__]KP\_ M=ONOA\?-YGA!$5X.=Y>/Q^.KU^L=UH^;Y]7A:O>Z>:&4A]W^>76D?^Z_]`ZO M^\WJOLGT_-0;7%]/>L^K[[YE4)\WCYMCW\T02\OGM=>].5EMU]]?J+G M_KT_6JTY=O,/"/^\7>]WA]W#\8K"]=J*XC-/>],>1?KXX7Y+3Z":_6*_>;B[ M_-3WZN'PLO?Q0]-`_]UN?AR,GR\.C[L?P7Y[GVY?-M3:Y)-RX/-N]U5)HWN% M*',/P>TQ.I!_/N_UAL#FMJ40IS-1BK M2.O=$U6`_G_QO%5=@UID]7OS^6-[?WR\NQSVKV['X]'D]H;"?-X2,[IU>!VW!]/_J*R-&::,NGS?96=ZHST^<[*]JE#M/Z0 M`9SWC=7MLROJA_=5N$]&ML6*HV]MWSY[JKKA>ZO,YO3IAW=6F?QLJRS&GN][ M??93_?"VBO;:T=,,QL7JN/KX8;_[<4$S'+ES>%VI^;+OJ7`\#-L>?!J8?S8N M:4"J*)]4F+M+>@`:<0>:3+Y_[(^G'WK?:0)8:\VL0V,KYJQ0HUV%7;A@Z0+? M!8$+0A=$+HA=D+@@=4'F@MP%A0M*%U0NJ`W0(WM.'M$H^"<\4F&41]RZ,P9B MVL`QA!6<9>&"I0M\%P0N"%T0N2!V0>*"U`69"W(7%"XH75"YH#:`90C-+?^$ M(2H,+5OFH)EAI2Z,8<;=:;)=;,FC6R; MYJ=$TTN9`ZV*T+K^CHHHM5T130:GZ7<.9`%D"<0'$@`)@41`8B`)D!1(!B0' M4@`I@51`:I-8#4^;"JOAU0YE>*L.!7I__N9-BHIDFZ()]3YC,`^=7G(2<:=: M`%D"\8$$0$(@$9`82`(D!9(!R8$40$H@%9#:))9/M'FT?#H_4I7:]D(38X`` M60!9`O&!!$!"(!&0&$@")`62`,`T0+1$I&/*$`4(HH0Q8@21"FB#%&.J$!4(JH0U1:RO5#G*?-L>WY&ZK?' M+]K9<1>?,;*'AKO_%A5G7"!:(O(1!8A"1!&B&%&"*$64(IT]0Y[VL.898]&YE`!M%!G)S7CB6J)R$<4(`H118AB1`FB%%&&*$=4("H1 M58AJ"]E>J%/3.[S0ARQSJ+1H-#J-GKDZ(U'##]L;U_8^1R/3"T`^9Q15P$AB MA8S(7F/S-K$W;Y&H>'#&B!)$*:(,48ZH0%0BJA#5%K+M4<Y*E;>"?$0!(],U MG9$^#-=N7-=.*G$-4,+AI<^EB#)$.:("48FH0E1;R'9-'2]-USK

UIDV:-5M3WCZ/^M"]'V,;YI;K0)K=&[>]1U$CT$04:&:%#5M'> MTW#KUG5+A[\]C?U8,K!"8>72J2B,L+?.+7/1,6QB MXF:($248/A65$?[&.41GHN+P.:("PY>B,L,[TWPE@Y?6\@V49UAWV&B/O: M)K;(,K%%1L,O^EHE/7Z)R$<4:&3$"EE%(<7$&^>V.!(5-T.,,'PJ:C,\,XA M,!,5A\\1%1B^%)49WIGUU%Q^-I"MHGJ/&R:^'-KHCY5F]ZVR/V188?"_6[ M,C5`)ZJ?A,_<5K"9Y'\UBW``D-1&35U"XQ81166YQD[@RAFE928 M8(FIJ,Q8SB-FK#KWB#F+I,`""RQ%=:;`BE5G'[%F55.BU9<&[O6+.RG\MGO] MLXVRL15KPM@[98T&LN&=,Y(NMV`DJJ5&0YDH?%0%C"16R$AB11@K1E7"2&E MC"16AK%R5!6,)%;)2&)5&NV5+9'[[N6&>"U#"-K8-\Z:^&<5<;`9B0;U:5& M],%3E8^J@)'$"AE)K$@C^N!8,:H21A(K922Q,HWH@V/EJ"H82:R2D<2J-(/ MCE5;ML>=5UB3L?G3RTT(-0Z2&=7CCW32'T8\Y2SJY^S2C(N&$G/6FHTO&DF MV?YH.IU.KAVG?HSY$D82/64DT3..3EMYHQV<^3K'C`4C M"5\RDO#5F\+75D;;:'7Q8AKMSI5ONE08M-/_^+KYSSY^^JR1;`$&#U$5:32B1>//#8HQ8X+A4U1EC,[4/6>-U+W` MX"6JHW.U[VV,MKNJ^N4O^]^>RECN=\BU>^D46^=S>Q\H%72Q1<:C6B^EXSN M)FC)JD$[(=!\T#4AM-$I%$]`188@>65HCI37L4J&K5&NSO35,VJID2[)ZG;GW,]Z8U[KO82R>I M&LFD-U>_]5?+C:`%HB4B'U&`$04(8H1)8A21!FB'%&!J$14(:HM9'NDKI-, MC_YB46]OGRPO](64W+7.!RTR3K(+1F+/$I&/&`D'3ID9$TD$V<9B43%0SU& ME"!$66(Q')P4/`A\1(%&1NB0593?<,NYQ(A$ MQ>%C1`F'E]O.5%1&>+C?%Q6'SQ$5&+X4E1G>O=\7%8>O+61[JFZ#WN&IOCR2 M;8:+31R)1<3/$B!(,GXK"'_K M7@V+BL/GB`H,7XK"'_C3/.5J#A\;2'+Q%["W1^8#9R>V!J9)JHD='P"U89 M)B+R$048V259>M%S1`6&+T5EAG=F_4I4 M'+ZVD&VB>TWT4VLBV>5.NAI9WK8JR]L6F??[G-&XR4,4:&3$"EE%TX`,T%OG MLC42%;=.C"C1B#Y8E:(J0Y0CC2B#XY5BLJHZHVS(%2BXHRUA6PCU0V1.:7^ MG)$JBC-(-;(6KQMGWIO3PI-1N.>02.ULHL?<-)D57OY/1P-)I/QM7..]5DD ME]\!%ABZDR!$:NL;@+W^ZR2$A,L,175F1(S5IU[Q)Q%4F"!!9:B.E-@Q:JS MCUBS"N_WZ0NIY_O2V\Z:31BG,^E+]G=SEDE:(%HB#FV'5-$X[WMNO^K;?+GS>[+]LYINGI\/%>O=-?8UWHEY$ M.N'V.\:S_L!3;Z71+.F#,:>.L]VI`R'_,5D-\_$JYNYV>4W7MUT)9??>G5S M[^;RJ5?HH4V/I3250ZMIO2$7>70 M]$PI7>70M[4_=;:CJEA'O6;4\)UZU;@=^D\C[Q-9C@\X&WEU3T/[%4UN1CCS4)&IMPQ0Z,7AJB<.4&:7,.E/FE#+O M3%E0BM^90N[J.//2D:D>`?2B$[G< M-5CH[1EZ1H4]$H&I70-"_H=/Z5TU7HVF'@S6C6Q!G07Y,T[4^AR%-7!YB' M[GP\=8.`73U0[VSJ];A@&K=F8=>+_/4RP\8C=XR\]0+8UTI$TKIH?>AZ&4 MKKK1VQ24TE4.O8'FJ5GT$H]%[>IYZBP13Z'4] M3[UYUY4RH92N)Z47BRBEZTGIM11Z2IGUA_2\W2->GKGEYZGV5!>H54:P; MO=M+S].50J_X4D_LFG7"/DT[;9[>:>AOP[QNOJRR5;[+]N7P\73YH&6G>OF M)=E]^_1C_OV>!DY#]V%8L[MS,9K'TV]_O-VGN^'^^^?YU'H/XB2, M+@]MI=-KMX+'^W#R\M#^X\?YC>UW4I2[[+W3M$E>&C_#)+V]\???[O_B.+7 MY!@$:0L4+LE#^YBF5[W;3?QCN'OVPDL[5]#C6S2BPR'T`R/RW\[!)$U0[^[?(G;WX M]>WZS8_.5Y!X#D]A^C,3;;?.OCY_N42Q]WR"?G\J0\]'[>P/(G\._3AHD/: M`;ENWE#:9ZVK=4'I\7X?0@_8L+?BX/#0?E+TG3)L=Q_OLP'Z,PP^DLKW5G, M/JPXW#OA)8#1!I^8`\]1],I"YWN&H'"7E#8S!]RXM0\.WMLIW44?=A"^'%.P M>P0]8AW3]S^-(/%A1$&FTQ\Q)3\Z00/@_]8Y9%,#1L3[S#X_PGUZ?&@/QIW1 M76^@0'CK.4A2,V22[9;_EJ31^:\\2"FD\9+]WFTE8<%D=<+G5YJJ%<7@ MLRAVUU%'H^%8O6ONHP)3(7<&QKXH>FM;%32$??E:Q5P,^TM%[Q1&8XD7! MTLK!;0/+9FM>9VGGS1U%/Q7X\J6.P@3(RUGPJUS2,&IP+[BS/CJ3P^6;3V&^H'^UGF$A,Y4G)O/0AJ[`4DT@";T_ MD/EOOL.B<,O8B8U,6+$%"-8EF"RA@QF,C!E8,G`EL%`AWC9`9(28A%B$V(7-"%H0L M"7$(61&R)F1#B$O(EI!=E0BN@4&":\TKBD5GYN"@3@K2R[8@R:8I_['JY9![ M30$MO,O-(1%BPTI2)]GVRDA!B$S0DQ"+$)L0N:$+`A9$N(0LB)D30 M+2&[A$&'LX0PL#G!Y(..ZRFQ]!_G43Y;:!F9@S`]?PXPD1$/PHR+OT@Q,@) M)')V?ADJFB)EYQD/P/EF$F(18A,R)V1!R)(0AY`5(6M"-H2XA&P)V56)8`\< M$05[:FR`NQ/ZP)%'W(RR]O[(PW)<0HB)ASI6UPQH.X%X18!$+(DT@Z/:9!>\2"47A.R(=(NCZE(CWIBJ[<\"5W528 M"'=!P<1_M<:8B.AM3JK>$F(4!#:`RGXZ%KLRXT'8%9,0BTC;/8JK8K285F MX:-B&#ZE!Z-I%PXQ2B-9U0#D5A0VH5G150_3[/4-,T92R-I5E88\M1&6% M-J+&"N=8H9+E];$FU;4H5;"N):R+@=18UVKLJ[JV)5GC"S!K.NUI`RWP:BR M$2ZBQD9LL1&5$1[WI'2QZ6@U^(,8O=0^DS@BUNPDM]FX>2,HSHI4+]Z3E9& MTN?8E19T$"4/<;,AG"&B.TU[X^C7O9/7)`FQI3%+$2EN(VHC)HC@D-905( MV\0"H\J"2T2EO(.HC%HA:I1?8U19<(.HE'<1E5%;1`U#L\.8K)CH/KOT_G?W MF8J45@JD\@DQ9?=<%E7.<-`?3B`5(:>Y)"\8%_-W%<@A=3ED"H?.)AT0KM MFRJ<8Y3VJQQ"ZEK2NAQ4:>S<"J,@Q5>&@.007F,UBN20/HRPB[-S9BBU&5 M$:[)(;P-)(>P>WG3+/H17<'X?WIDPN[=\C0J4.5FA5$E,BB:46129%%D4S2G M:$'1DB'HA5%:XHV%+D4;2G:"4AP6+GO4'W7@IO7%AR3LX;ML4X&$@]Y( M.HU-L6"9O0R9A29%%D4V13-5I0M3(H6A%T9JB#44N15NV%N[;%0K.3I_ M"Y<_P#\'\4LP#4ZGI.5';^P-6Y]=@#G.7_]-QCK53]D:ENJ=L%>8-?&3O@Z/ M:G.!+I6U[.GH?X$@UI3`'I; M#=6W5!WN-Y3;J@Y7T1JNZ7"-H7RIZG"9H=Q1=;AW`N_RD897LE?O)5AY\4MX M25JGX``3JI>=^>+\I6[^1UKD[>Q60H_PLOW`"[7/98Y#E&4XA^L`OXZ M%O````\#`%!+`P04``8`"````"$`_UA9^FD#``"Y"@``&````'AL+W=O MS`R98!8QLIVG__>XUX,:$5:G4EQ`NQ\?'YU[[>G7[7!;.$Q62\6KM!B/? M=6B5\)15A[7[^]?]S<)UI")52@I>T;7[0J5[N_G\:77BXE'FE"H'&"JY=G.E MZLCS9)+3DL@1KVD%7S(N2J+@51P\60M4CVH++RQ[\^\DK#;1@B<0T'SS6 MT#N>'$M:J89$T((HT"]S5LN.K4RNH2N)>#S6-PDO:Z#8LXI%TWJ.F42/1PJ M+LB^@'4_!Q.2=-SZY8^9(G@DF=J!'1>(_1RS4MOZ0'39I4R6`':[@B:K=UM M$,5!X'J;E3;H#Z,G>?;?D3D_?1$L_<8J"FY#GC`#>\X?$?J08@@&>Q>C[W4& M?@@GI1DY%NHG/WVE[)`K2/<45H0+B]7.RH36IRM=N.!M-YWX8`-S94ZGN&5Z3G4BI=_&Y!>D2$9MR3P;$FFH_%B M&DQG2/+&P+`=",^!V2\'>HUZ;<8=462S$OSD0(6!/ED3K-<@`K+.A8;!^/(_ M6\`/)-DBR]J=NPZL6$(NGS9!.%UY3^!_TF)V`Q@;$7<(3!O(,QK!G0_0B"RH M$5.)HG==X%7TN">H0_0%@5$?(`A9H&HLTWQ;P:[!!"#$.-OS-3:0OLK)AZA$ M%B@.6^:L)[,%O2730/HRH=#/S1S>?UVA(5BK,5EL([ZNNGX"S<=7^X)P;L1; M539[CPX$VSK:R-C45WP>L6:"?7^8MQSXV6(QTR[Y:_>=\ADRV@CX+8IF"!< MF!7KRH\-J)\+;&YGI\';N4"P/7D;.?/@/&)YL+1G:LX=+)W'CQ(8VMH([8! MRYX!!M0W((`^.\+-/BM=JD7W^$`W$7]^#B!_%A!&?@)7X[B;:PN,L/NTD43X;BLPCV M[`!^'L&.&8@OHG@Q%%]&\1+CGED!7!QJ/YD7Q M&@R&ZP-7<&70?W.X(E)H5_X(\IAQKKH7G,!<.C?_````__\#`%!+`P04``8` M"````"$`ZTT3K28#``!R"0``&````'AL+W=O/I,T04FJ0-6MTB9-TSZ>'3#!F!D.TW[[W=MP,4D MJUJI+R&^'!\?GWOMR_KFJ:Z<1\(%9>)K"0U%BYK20-O"L9K+&'( M#YYH.<&YGE177NC["Z_&M$$=0\S?PL&@F;DEF7'FC2R(^&DPA+TBYV8F"K ML[?0U9@_'-NKC-4M4.QI1>6S)D5.G<7WAX9QO]@WT_!#&<#MQZ\\E8>,&W7.84=-L=3HH-V@5QND+>=JW]^4/)28S^.Z)DIR^< MYM]H0\!L2)-P)ZQ!P6]SU4()GMGL^]T`GYP)R<%/E;R)SM])?102LCV'#:D M]A7GS[=$9&`HT+CA7#%EK`(!\.O45%4&&(?]/-$S!>`=_9$ MR#NJ.)&3'85D]=\.%?1<'4O8L\"S9UF\BH]Z/#R'51?N_-J/`K7H^4)>IUJ; M<(LEWJXY.SE06"!+M%B5:1`#V;#[CL'X\3\[P`=%LE,L&W2-'-BH@!0^;H-P MM?8>P?>LQR07,#8B'1`J72#/:`13/D"C8E$:50J5Z&0(O(@.)X(&Q%00&/4! M@A0+5,O8M,BW%20=)@`AQMFY#4D-9IR]B$J%0L4ARTSL#4D/>@UF08RE0GU M.C;S\KD;"DV!M1J3Q3[B=U5GZTK-RQ?[@N@ERU:5P8%[NPX%MG7TD=#45SJ. M6"O!.1FOI,_<8NY>@]IWGCO%9,OH(^"V9@@BB:V&-`T%ZJGC6Z#UW.AP/;B M?63DP3AB>;"R5](>S/05^UX/%),MHX_8'LPF'AB0\:!K$=WM6!-^("FIN%D M[BN_T!5F`F;UK33FYW$$VA9^GZ?QL,XO8B/8CC&(&2"W\WBG6Y]DW@RB]/9 M!7RRB'JSGF2ZSC5%]^49QFGRTOX5=]R/3,!6EZ+#^0[Y@?:"&PO=V]R:W-H965T&ULG%G;CIM($'U?:?\!\6Z[;S0P&D\4B+(;:5=:K?;RS&`\1C'&`B:3 M_/U64VWH;FS&[#PD8\^A.'6JND[3/'[X7AV];T73EO5IZ],U\;WBE->[\O2R M]?_^Z_,J\KVVRTZ[[%B?BJW_HVC]#T\___3X5C=?VT-1=!Y$.+5;_]!UYX?- MILT/196UZ_IK] MOLR+3W7^6A6G#H,TQ3'K@'][,_M)5J5WQ.NRIJOK^=57E=G"/%<'LON1Q_4 M]ZK\X_6$&Z#1'G4A_[FZ;$7Z)^R>&N-W[WV4+_]TI2[W\I3`6I#G50%GNOZ MJX)^V:FOX.+-Y.K/?07^:+Q=L<]>C]V?]=NO1?ERZ#<`62D$GO8_?A4M#DH M"F'6+%"1\OH(!.!?KRI5:X`BV??^_[=RUQVV/I?K("2<`MQ[+MKN\Y4 M#]('B'S)#'D,N=Y%7)403ZJ%L_]#W(HH7Z?'NBA#YNOH&FN<8D5S`V(KT@ M5"F`WL`1,C=(L)P@%A,0'[F2@P5-JX M,27.K1/$"`,3#'?NZ:=S"(L;!+F?FP)O?4A\$"5VZX60J\F)P'A@G"'FPFA M/&:$!F."%CEH9`ML" M4B)L>1+$!A@$$HA'(U3!Q&+<(QA<8.E9>HWSTV!76Z.@EBD!NEL>32Y68C M`AFS>,C/XJ9 MV9(X_FTE1Y/22B((F=("Z/;>D2J=GN0+R("3H6X)>,B%Z%3&Q$3 M&!72[$P?88&(Q[%D2[C(1NC41\086"MGNL0JCEG$'/ZI#J/%94&MZ1;9"1T MZB3"Z:Y$8W0'QA%8F+.(4ALB!8,6'.:`+=XB-Z%3.S%:1HMGNL4S"0A+._ M274Z)!>/@>O@&:YC5SG8/ M$LFQ`+9TB]R#3=V#4G<&:I!>).H9C4]ZS[2/%>.WMZW,,9#[/+B_RE[+\,@Q M+$.]2"PG803ZGT^'C0EB<4#DF(LMY"(O8>@ELX&BZ5L["!-$$&S=9Z#V/P< M,[E3RFI4.8X6L),5Z$\!--S!E)J05C,F32\R>I]OSF6KZ/9W^54_#)?PRP('-/`=SQECMI7GE<<;33F>FO8>BHKN'LV M6P'7&5&I!N(S"<4C895YD M,_RS3#7`C4(:Q@)'L.!G#U"4PL")AF%L7&J8Q-TC.;.,E\Q'.;Z(3?=1'+X MH7423>DB1&"R%#M48/PB#.D88_2'_IOA#_`: MX9R]%+]GS4MY:KUCL8>09!U"RS3X(@(_=/6Y/\Q_KCMX@=#_>H`71@6<@),U M@/=UW5T^J//UX174TW\```#P,`4$L#!!0`!@`(````(0#NBH^\OP8``+,: M```9````>&PO=V]R:W-H965TXV M#[]]OYQ'WXJZ:OKHV&.I\:HN.;5H;R^/AI1E^F1NCILVNA^Q<78M'XT?1 M&+\]_?K+PWM5?VU.1=&.0.':/!JGMKWYDTF3GXI+UHRK6W&%_QRK^IU\+5^ MG32WNL@.7:/+>6)-I][DDI57@RKX]4WVY>\NMQ`XJ4\E^V/3M0877(_>;U6=?9RAOO^;CI9SK6[ M+TC^4N9UU53'=@QR$]I1?,^+R6("2D\/AQ+N@-@^JHOCH_%L^GO3-B9/#YU! M?Y?%>Z-\'C6GZCVJRT-:7@MP&\:)C,!+57TEH'XIB] MG=L_JO>X%]/+0RW"W=$;LP__`B)@='069LN40IK\[0`?@[NI2D-,"1['MW M?2\/[>G1L+VQ.YO:)H2/7HJF#4LB:8SRMZ:M+O_0()-)41&+B<"5B5CN>.ZZ MCC>??5S%82IPY2JR)W>R0X;N%N#VBWN]M9C\7`5>4QGZI$;OI,&9DR7!JZB MF;S'.PVA-UU#N+&\[%CN;-Y9_&=AB94`QT<4A;4>.N#3?F0F'),S,\/"50N MZP%\8#WPQM;<-=W.K@_6A\F'EGQ@,J8JBK]Q&LE"3 MS2TC:Y3I$V%>^M11,1G^:R[`)"`JST3FT9@9(RCS!B;PMR?;#O0(F8WP%RKG__"7 MR!!_N3-+#J3AEF8FC^!-`AVL=1#J(-)!K(-$!QL=;'60ZF"G@[T">F;"_$%F MVC"MA]=I7IND%:S(:FU:T[Y92QI#YKDH8U\5R)$&(K(&I$0D0B1&)$$D0TB M6T121':([%72\Q;F/O6/`,_N1`0&5A+((TPTO8\S6T6=,]M$2+<1F2-2(A( MA$B,2(+(!I$M(BDB.T3VNFY#<8.N#TF#_KV5.9?EQ7=+PQ4M@W+UUTB4CG M-?=HR0C=6)`5=,6()U:.@!(;NB9'R-**?2V"N'2(2(1(C$B"R`:1+2(I(CM$ M]BKI60L[DIZU`Q;")H5[2+['C+B",=6E-C2U8`2!W8QBH=:E:]%D/`0D8A) MTTTE&;!8QC2B_X$2D00E]X@LD72J8B1TI8^\CL1Q7WNDY#8_[3SA-HOM. M,Z(X38GJ-"4.7!2G9WT[UB(]SE$))$D8Y%C")M:P^&1`1QZ0TB6R2=HI@= M(GN5]&PEITIU2W:_@$ETWU9&%%LI4>X]H$2S=:[9H+XO8>(1$@Z%C&JK=I. M+Q%!7'J#R!9)IRAFA\A>)3U;X>30LY7N=#^YY!1OMN,&Y3HKI-B=L=0KNE M>XU(B$B$=&)'+C(R6!K^[Y$!`EK$=E2HG0Q13$[1/8JZ5E+SE@];^^7;!?> M=Y$A;]&='1S3L[4E;\4;+<2Z''`$0R[\,%U;JV(694T[:L"A;V&Z&EXR9G;.-O6[%_QJ.[U#3O542UHR"U8LR@;GC5B&W;Z0]ER+74 MC:K[5TB'B4SQAS)C,EP1DUK(QO?J&,6QXE,Z8X2L6(0E&P4,.3!UQ2`.K+54VK&ZM=:\-#Y`[]RU.ELJH.\EV/(HE,Q?Z8X2\H2:^ M@D5BK:5OG.D+MTM1OQ:KXGQN1GGU1MXF=X\D@>FK[GCNPU8(!'2^\#?=--/X MUO/A:8[C4\^'YS7F\"K]N5N3-)TE><4^$+^T?'@=@W66M@_O$C!_=OQG,`+_ M8^GX#6_9:[++ZM;PVHW-QA"8=CO0 MFO[H0+^TU0UV1_##0=7"CP7=QQ/\.%3`\7`ZAG/OL:I:_H4D$#\W/?T+``#_ M_P,`4$L#!!0`!@`(````(0`E.=G;@,``4```9````>&PO=V]R:W-H965T MRZ/"UP MA;A#&US#EYRR"@EX94>7-PRC3`VJ2C?PO(5;(5+;+4/,WL)!\YRD^(&FIPK7 MHB5AN$0"]/."-+QGJ]WT%6(/9V:NY16#5`<2$G$JRUK2J-/QUKRM"AA'6_ M^"%>V[U,J&O2,HHI[EP@,YMA4[7O')7+C!MUQF!%4C;+8;SC;WSX\3W;7>[ M5@;])/C,!_\M7M#S!T:RSZ3&X#;D26;@0.F3A'[9`@&NY/1CRH#7YF5X1R= M2O&-GC]B2:9 M#;V;.',E][,![AUP%P\$DEI6^F)"UK]:D%J19HDZ$C@V9&$CA]Z"TEQ9=BL M&P;/"W-/![JM=F7%`Q)HNV;T;$%]@3K>(%FM?@QDO0K(?,\4ENBO?_P+ MHE"#CI:W")$@DTA7230]90,(\9,L"^&2Y9[+(@\!\3>F!Q)9KH(N"V+I@@ M&I>,!HUS(3O98/-?SX4$FY-WD8$%PXAAP]^#SJR:Z^2+[MFC M+]#,=\JB47PO!T@QXW@0P_%[(3Z+X0B(&PO=V]R:W-H965T5^^OGP\W"=:0B M54X7M&5^TE>[?^^&%YYN)1'BE5#C!4E:H3SY/9D99$3GA-_BRYZ(D M"E[%P9.UH"37@\K""WU_YI6$56[#D(AK./A^SS)ZS[-322O5D`A:$`7ZY9'5 MLF,KLVOH2B(>3_5-QLL:':L8.I%D[I.F25?#A479%=`WL]!1+.6[^,Z$N6 M"2[Y7DV`SFN$CG..O=@#IO4R9Y`!VNX(NE^YFR!)@\#UUDMMT&]&S[+WWY%' M?OXD6/Z5513#GSY0=C@J6 M^Q8RPL22_.6>R@P(M,&2]``/PZ)6:Z.W<:3H+(GP': MV5&I'A@RNDYVDHJ7?QJ,3LAPA"T'/%N.`/Z^,F#:#H!G-^ELU9B]F.,8&-2#L$KA;(,QK!BG?0B"RH$5<016^[0$_T0%"'&`H" MH]Y!$+)`L5BF1;:";8/!8C#.WMJ0U$"&J-W48DL4!RVS(&&;0MZ3::!#&5" MO?;-O+SMND)#L%9C5K&-^+KJ@G!@COGZS[\PGAF056:SMPA!L"VDC82FP-)^ MQ)H)-DH_9=QT813B\=)NW:LW'C+9,MH(V&TJ)HSG)F-=^JD!#1<#FUKO.'A] M,1!L3]Y&>A[T(Y8'L3V3/GC"^>3M%B"1K:-V!8L!A88T-""`#K(]1YHM#U] M%^JY8(4L&Z"S6;-I'X)H,G^[$9IJ(4Y4@/;BGA@13A$_3>`8'.,W4;!Y,8?ME&2ZFR'$\P2V+47\/,$]LR%^"))%Y?B<9+&&/?, M!'!EJ,F!?B/BP"KI%'0/1OIZG45SZ6A>%_!8+@Y<`6W!?WW")=#"AW+Q]VQ MYUQU+SB!N6ZN_P(``/__`P!02P,$%``&``@````A`&?U`2D!0``I18``!D` M``!X;"]W;W)K&ULK)A9CZ,X%(7?1YK_@'COL).` MDK0J"]G(JEF>4(25"&.@.KJ_O=SC;$#OM6CZE:]5"4?QR?&APL7][]^SZ[ MMR0O4G(;J$9'5Y7D%I-C>CL/U+__"K[T54HH]LQNI);,E!_)(7Z=?CG'_TW MDK\4ER0I%7"X%0/U4I9W7].^))D4=$A]^0&1TXDSZ(2ON9GK;CG272L!F57 MS=1U5\NB]8R!S__B`$EAMR(DF\$S("Y4NCA3!8`V-#JH$=KER3$[1Z[4\D+=YDIXO)<3MP!G1 M$_.//R9)$<.@DW'=A33XP`?BK9"F]-&!%HN\#U80?3H_E9:!:;L?IZI8! MQD<&J`5")3Q M9P1";>#&UB@:4W?:"8R8QH"9B,J2)&,A$2DA,D4D0&2&R!R1!2)+1%:(A(BL M$=D@LD5DA\@>D4.3M$S/RC_4A,2D1HB4T0"1&:( MS!%9(+)$9(5(B,@:D0TB6T1VB.P1.31)S5X4K]3:AWZ!"\O:?PR(JP->>Q ML.`YQ)Y.U3C_UJ":L7Z"/FG%-7'%[G#!BP=1$TJ:AMY.>"A&W#A"9(3)' M9('($I$5(\9CBJ'0-9^1FK4I)U:31X+ M,$9DPHBK5TV(J1M2:4[%<;X:`2(SY#H7&MK:@O4VRS$<>ZZ1&2%7$.AJ5VE MN:[%<>ZZ062+7'="\_Y<]^(X=STT22M':.A0]9DN;=E_TLGSBJ,#V]G5!%K, M1C7)_48M\AY%(;QR4X9,5G`AMUU>MV>=,D':-0,.<^19M%VMMR>:=M>N]Z7 M:-0.8=(LVX[VZ[I>I9T"6W0J"URWB'-ONT,3;=M6=)E=&B.:L5+W[:;S?\[ M-U&(FF=U>U,&3&;CSE3+HUQ+;(>F8IA(E-&K$=A!T@S0SYSI%D@GR72K)!/ MB#1KY+-!FBWRV2'-'OD"]36;0SKI%4 MA]DQES5,0:V8\V:,J16>5L.+9E][J25BJ,)^[/O1%F(>N#YT- MYCO7A]X$N"96`C8)[]$Y64?Y.;T5RC4YP2+JU6TR9]N,[$M)[K"XL%5(2M@> MK#Y>8#LX@59?[T#[VL_C^5I7&V[:@M1+TYG8IH'KG!R+^KPT__PC^C8SC;;+ZF-6 MDAHOS7? MBFO+U:K\(W)5UCR_7+_EI+J"Q%-1%MU[+VH:51ZFYYHTV5,)\WYSO"SGVOV+ M)E\5>4-:Q@>ISGEMS"Y16BV,!,Z"V&PT^+E MZ083?VJ[#M"-)]QV44$E32-_:3M2_8K8A8]7];=%AMJKF,DMS:AJPGBU$ZNO M]?V%]0K1E0^`,A]Q7> M4!GJ#9_5A@-WLY!B!&?P)CL5VM`I`Q"B0JDK`801(1KA?8P25@1PP"A+D MS.29;QC'@9&(2%+B:"LHPAT-V6M(I"&QAB0:DFK(88Q()D&.^8IHH3P&:$; M88#K!XI+`^F_7!(4X9&[#4DTI!80Q(-237D,$8DER")2BX]KB4\K5!V;P:? MQ(8A+JL1-$=L-63'$&^E$<.ZK@Y`BG0H2ESZ,$]#,\95I[!D)V;UYPA`ZT)?D(3VC\O[@SB"LQ@/),J6/60(&B<:A!0SM@/)O7LHFO&Y[QGB3EFT MN<@/@JD\B4AK%&O"B<9)%6%[AEQE?(=Q(\D=.$A)[OS0[J,BLFD#`MV.`D_9 M7MN!-`H\AK@S8>-^0-@6A0AS74^IEY'6-:$$XV32L)H&B!?W1B'<2/)-'I M_/^N]2JR;0,4P'%LY)M:_0<6&D7;`'GCAMHVVG,6ZD/0H?)G74?J=9AREE#A_9\'DQGRG3H_8V&#XQ=;%UV'V.G]`HW9[S%9=D:.7FA M=RTX&:P6`A87P36B`@J^H1?$1S@X:SW@.^&<+[1\;47KF&@^H>-%TI?X#[ MX29X@&_]$4'5T//9#J#TZGO@AU-H'>!!"G0'<$@[!1?6: MG?&O67,NZM8H\0G,M?OV["K+GOIR!5,AQLGZ>"VO][@9\D,!P][`F4Z1,A M'7^A'8@?.5;_````__\#`%!+`P04``8`"````"$`772==ZT,``!(.@``&0`` M`'AL+W=O$68M]7^]HC-M$&^,`>GKF[2=%96ES#IT>^;,Q>#^2/V24JG44L6GW_\\ MO-[]L3N=]\>WAYQS7\C=[=ZVQZ?]V]>'W&S:^V4NSM?-F]/F]?CV^XA]]?N MG/O]\W__\^G'\?3M_++;7>Y`X>W\D'NY7-ZC?/Z\?=D=-N?[X_ON#;YY/IX. MFPO\\_0U?WX_[39/UT'U[Q;(3YPV;_EDL4HM.O:!R?G_?;7>VX_7[8O5T2 MD=/N=7.!]I]?]N]G5#ML?T7NL#E]^_[^V_9X>`>)+_O7_>6OJVCN[K"-6E_? MCJ?-EU?H]Y^.O]FB]O4?0OZPWYZ.Y^/SY1[D\DE#99_+^7(>E#Y_>MI##Y3; M[TZ[YX?!O&28W`E^/Q MFS)M/2D$A?.B=.,Z`L/3W=/N>?/]]3(^_HAW^Z\O%QCN`'JD.A8]_57;G;?@ M49"Y=P.EM#V^0@/@_W>'O0H-\,CFS^OGC_W3Y>4AYX7W0;'@.6!^]V5WOC3V M2C)WM_U^OAP/B\3(T5)BM%X!-%"O>E(/##4O'757RM`I]:Q?FX"%1W[0]\ M:I'2?=$IE+T/-"34&O!I&O)1E\#\NK8#/HT&>>2&+\NZ('R:#OAN4"Q=!^1& M00=B)QE%41ZF&@H;Y7$\7-H`/^!ZQT/&P!_9+3]%X/)P3A0?\A^_H#J3 M'D4:@5^56?X`_3IX\&E(M#H_XP7?IP8UR@P4&3@YB#%@=M#CH<=#GH<=#G8,#! MD(,1!V,.)AQ,.9AQ,.=@P<&2@Q4'ZQ2P`@,6#A$8'N3,[-T,Y@Q5"O8MJ9SA MNB5[X"N)C5K@3&();).J,3'!(4A=D(8@34%B05J"M`7I"-(5I"=(7Y"!($-! M1H,!9D(,A5D)LA^$WIE.X_/C`$6F0NR$&0IR$J0 M=9I8T0/[72MZ,J($MM88)LK:#A--?-/+:D(\"IR:)NG<^UPMMM[:,$4JW!>EHDEPTJ'#O&AMJRX?L9XQ0NF^(`,A/30V6F? MG01&Q@BEQX),-"%?3XW-#>F9,4+IN2`+3<@A2V.3EF8S=66,4'J=)E;HP5'I M`Z&GK.W0TR05>@E)AYXFJ0PE2$.0IM")C4VJ[QX[W;6,$?:]+4A'2'>-34K: M+]@AW#-&-T79""DA\:&I)V`QYDQ0NFQ(!,A/34V-Z1GQ@BEYX(LA/12VP$ M6:>)%53J=E@>YC^X&BH1.]8T2<5:0MQI@G9U`5I"-(4.K&Q(=>Z'MO/M8P1 MNK8M2$=(=Q,27F]UKPM_3Y"^(`.A,Q0V(T'&@DR$SE38S`29"[(0.DM-R/4K M0=9I8H4,W%=:(7-["536=FQH`OIF_^WZGCV!J]JH;-;)6D8Q)V#%ZHD17+ZI M+8,3%@OJ/UNZ880P%)JBLMC84!M%92U=&=Q]I#KBV[6U,Y788MX1#>AF%F.] M[64V@&GW,Y68T4`T8)A9C#5@I!N@W5THE-TP9#9C(X3NGHCIL:&/"GP.4G%.EO0VU20 MK)R`^;.#5E1C%Q'5V,NJT>$7Q'U9<("(Y(>(2'Z$\HFW_%+HNR%+%&-9;(( MQ>(2'QFBP=N71=\-V,&LJBZ0H2!8X>#6$-%DK&NDDZYSW6ZP^&K(8DU$)!XC M(O$6BEM)EV]YVE20NI,1OJ([72J(/>QEU\BV-'TJ>/&`5I1'X>(J(\CK#') MPZ%;)782(QEJ0DBTIXB(NV9K5UTRD&1=64N2RT0D?82$6FO-((LG.PT[5W? MVBIAQZ^ZWDZGW^3QZ0=/7.KVFH>U1E96YO.UB@5I"Z4:P-#20-0ZI M(,Z:$:+$6V[)+?`KM3&:D!LF4GLJK6:($FVO&!;X^C5'$])>2.TE(K):::13 M,%N_UU8!.X35W?J_#V%]0T_SK+>`X&H#JWUVF6#4M565F9."OKI@N(`4=<% M_62?[Y;F5MD(X7CVY05QBAUL\(66L%,,9$.+_C8N:-5K86ZW5'-J;79`= MB7IH93>"[1?[:'6S$0/9B&%V0=:($5KI(U98\+RRSY+Q&(WH>G8BYR2%3E5 MC/4,K72%I7YY!=8B,_1B"I[JHAPFWILOT^`X[ ME)\]^U9/.I.43_WV`M:E"EK!W?6OTBEG5!V!:AHQS["=;9VLL.D- MB9I2/B:KM&>8?(NL4+YM(=LSZK[W`YY1YNQ49>()MKXEU MLLF-R1J2OF8K,@S0KY%5BC?MI#M&74!F/;,/]NQZVO$]+1+D.4P@6I.@GR] MNRPX;-FLDP%VIB%14Z-493%9J3.,Y1;9(#;0M9;E)OO%INNCVUKN9V`&D4 MTF.)JD0U1/2DM8Z(EN,&(K)J:@0]P-[$B&A3W-+(I?G=MJSL/D/&_$B?E3GK M\B-(+O=@&U;65OI\H>R&#GY$4_RUOQA=_JZJ^Y>7\]WV^-W]0,=7[U'9G#RZZ&'\$K M:^`-QA^=('J$&N0WL-6/UY0?@-[J4CE>_D-;DBM3O^J8(WUS?L&8M@"45 MOKEF2/%-&;[)J@=^"_5X/2ZQ$A7XC=3539R[\-NIC%95O`A>!Y6M??2C1SAP MR2]@QM5,IL$^]>HFOD-;&,CM2.5:K"-@V^RG`+;&/@FRRFP7L,W64Z9A!$\ MTI>U3,,(WB?X,4(WO_(X4('O)+O@@C>-0O^3,X&&^Y)TP@E<>).^&$;R5 ME<&+$;Q%D\%+$;P$(?D@C.!5",F'802O9F7P8@2OTF3P4@0O1TA>"R)X6U+R M.(C@]4+)IS!?LG@%0B9+OPH!D\5K$"Y9O`FS+HO',.>R^AO#C,OJ;PSS[:J3 M-[,$?L?WOOFZZVU.7_=OY[O7W3.DD<+USOB4_!(P^<=%WR1\.5[@%WS72X47 M^,7F#M[/]S#_<'S\7C!?X"#\N8WH)!@``\#`%!+`P04``8`"````"$` M%.(,IHL%``"?%```&0```'AL+W=ONNX:659;G'"5MY/ZBB_PRZ%N MJKR#U^9HM=<&Y_L^J#I;:#KUK2HO+R95B)J/:-2'0UG@35V\5OC249$&G_,. M^M^>RFO+U:KB(W)5WKR\7K\4=74%B>?R7';?>E'3J(HH.U[J)G\^P[C?;3$6#VHX$G$PD>%X&ET8O`\^=[,F,B\'RX)Q:=HW[* M-WF7+^=-?3-@'<$LM->.,=R-[IEBX%20N'6M(HDFG@C/,#@I<.4$S0>+2NS$B MV>$K=M#M=T+.I^Y4%B^KFIZ4=VQR8)NEFR\1D5VBR-@EQAFYQ#BS?K=&4UL9 MQ5;\SD<1:TBBJ::"0\X`4'44;\3O7'4W1B1O8/X>2!7"EDU@")RY8B6A0-U, M&&DF\FES)\SVE&%L0E-J7FABY"C^!<+'3[21&LK%9RABUI;F=)6`%,5R[N MA`ZT)7E(:O+Q\7XGCZ"@XHE$V+'%$'CC08%OMSZFI'ZDI2>VR,CWU+$2?H M#9OY"I!62768A)--]4XF:0;ALCW%-W=.$;R!NJH![PA;-D;AH#^+^4F5DS MTBB_1)CPAB(LF9P0N4A)MUB+233=5.-DBJZ#5,]WXQC)&U(/F!.3Y?=89"2 M.J$\Z6O.&N4.AY!8DEL&L>SQX!O`4X1B/2KAT"=/KRZ:5)OUXZU?BD-R%LU4FUC@(V&0)%'#&)9-NSJ:(3ZT$)AP;I ME$.AF(%,ED:N[V@FL2[V0;))IP&P8A.'1$H'9J;3DK[`WUP$]_IFYK MG#-\&R5Z>^G`^D%[&6>Q]CPG"$/U."(W/Y]8HZE=R MPP$!R[F`Q?7+4[]_/B7,N0%:/B((/JSNX$\''A(X_N=$3MO_L'(CJOO MX%ZT\N_@:R]:W\,W7@2UKJZS\2,H\70\\2(H]'0\]2(H;._@?@1%'>"6<`N MAZ[Y$?^>-\?RTAIG?`!SIWV9V]`+)OK2U5&ULK%7;;IPP$'VOU'^P_!YN MR][0LM%"E#92(U55+\]>,&`%,+]V>3O.S:7+)!&B=2793V<.9PY,PR[ZZ>J M1(]42,;K$+N6@Q&M$YZR.@_QKY^W5QN,I")U2DI>TQ`_4XFO]Y\_[T!KN9%Q41,%1Y+9L!"6I2:IVW.!9QA)ZPY-316O5D@A:$@7Z9<$:V;-5R7OHB(>3LU5PJL&(ZL9.K9 MD&)4)<%=7G-!CB74_>3Z).FYS6%&7[%$<,DS90&=W0J=U[RUMS8P[7I#D&R M/6:J$"]6UG+M+%R`HR.5ZI9I2HR2DU2\^M."W(ZJ)?$Z$KAV M)$O+]Y;KC2%Y(W'1)<+UE:?/$^U6O3'CABBRWPE^1C!@H$\V1(^K&P!9[T++ M,/CR+UO`#TURT"PA7F,$%4MHY>/>VVQV]B/XGW28:(YQQXBX1^BV@;Q!([CS M'S1J%JU1MU+COK`A>B)H!XQ%01&304M8`!?'YW>(YT$0S+R:#M^8-1B7'CN M8.1R#(D'R%24/Q>EY_F#G=0L,`LCF5MGK"'J0&_)'"!3F2#ITKNW/=-@HV9H M6A=QS)"YTPD:[K[XYVU?0.I6GU$B`:/A701;YBG^#(R>A\%Y:)U]]&PAP18V@W)Z3T1.:LEFD&)3K6&F9%M&N_/2C>@+>PNKF"=6W^%O!U MIK`J'`O`&>>J/V@CA^_]_B\```#P,`4$L#!!0`!@`(````(0#%Y@X!608` M`+<9```9````>&PO=V]R:W-H965T6.CT=BV\+FH=^7YL+'BM^6-I6V^7G77ZJSWAC_\2M M_6/[ZR_KM[IY;H\8=Q8PG-N-?>RZB^RPO+6>K MBEOHJKQY?KD\%'5U`8JG\E1V/WM2VZH+SNVZ=]`_)7YKI<]6 M>ZS?DJ;<_5:>,7@;]HGLP%-=/Q/1;$<@4'8,[;C?@3\::X?W^V%+!@'/+_-`6>T7P<\OV_,BI'`\]Z%.#16 M^M`+\R[?KIOZS8+S#-'07G2'9`'O#SF:(2(/PH""'Z",DC8=G8X""(KQ9. MSNMVZJU\PK17C`9WY31)`(N04;T(8Z$.E`K`.)#J0ZD$F``TX0GH"(_Q\\ M05B()[@-/@<&UTQ4QP1<@JN$.A#I0P#B0ZD.I!)@&(V'%'=[-F'28?O-U&" M]"+M-UK.5;-\H-@7A$4KBH2"!%ANH%$!A(;2&(@J8%D,J(X`/+[@"2=>\\ M`80%SA#,(JR=NMI.^TSH,Y<($>$2`XD,)#:0Q$!2`\ED1'$)F"^[Y'H!XK%` MA'O+^8I]BDQI82$'.6"(;#A:C=5H"(40)XH,)#:0Q$!2`\ED1#%T?H^A1%@U ME"RH0Q1#=7R7"B$A$&$AM(8B"I@60RHA@J5G>49KF1PMP3'_IHW! ME9V>0CJG29YPJ/8S1-IHBDQG?0V8C-%,VV,Q+DPWD)BQ#CDT$3DL@#K5&5- MQ3AGS61$<01IEJ5Z=\5@:):XQ418M9@A4"G%,4BE;:W@1#B>QM2Q"6!^;H=C]SI9#F6_K0B$S'QF3`Z-B@3`TF%EK31 M^I9D0DAW#(+F_W;/]-J:QCDD@/6RJTTDY3,$@)YW!HWGM'4XB&4:X0?.T1[-BF?)D^@[1@T?8Z&2X8L@@ M'B[:H>C4G28'(D)I8/BIPZAAK@]O7)T2%]TAT.(M!8A%)+3\\);9F21U9: M7Q8.4MQ'D0G%)I284&I"F0I)I,6[/888`V;'`,44DQFD&JR7G!)6P;N`\<, M)AM0;$HE)I2:49`JLFDQ9),_E;=1:Q/DSW!H"&W!TSJX](["`Q.H#2@PZ&8 M3R:G`R'U0?DUF3,%4EU"FC'))9]78-*)ZX'/($B^0RHR:C!3%$48N5^4RY!K M**&DI[B(2_'B_G499AIR'59)YB,DE2_X.(L>M"J8OBFTS82PYV'C(PIIZ5FS(ABDN&+(()Z>OZSF7%X.63$W9TW,B5N M-J&A1H16IK,N/R5U$V:R]N=15M1Q5D4^JJX"REN5H@8]$%Q%Z-<(>8\FDV M:%,N=94V&T:!5HT:TAC>[@C6?-$?@XOFQ+UV:AD\NI_(^Q,/KGM,'G_JP36(B3_.O$
O,&9\CZ:>#X] M29I&`".D]3!U`@164QU',&U^24_X-_SYE">6^N$][!=X_Y]N$7[_1+5U]@ M&^'RO.[@PKS_>(0?2#"TQ/#B85O[NN[X%YC:$3^Y;/\#``#__P,`4$L#!!0` M!@`(````(0!IWGUP.08``,9```9````>&PO=V]R:W-H965T,+"K5.M7N"ZYUEV<:4:D6L8#NGOGV]P1( M3'(8JWMJYF'0GR?_+/_D)2?OGV/+]I[F&91NKI__P] M^:NC:UGN7P_^);F&/?U'F.G?^G_^\?21I_9.0QS#12N64\_Y_G--8PL.(>Q MGS626WB%7XY)&OLY?$U/1G9+0_]0%(HO1JO9=(S8CZYZJ>"FG]%(CL8-D#/AN(^=XVN`4K]IT,$/:##KJ7A ML:<_$W=/FKK1?RH&Z-\H_,B$SUIV3CZF:73PHFL(HPT^40=>DN25ALX/%$%A M`Y6>%`YL4^T0'OVW2[Y//F9A=#KG8+<-/:(=QA5X5BKDZR)07=$?>%8BG4:;-+OF%QH":Z/0 M@.>O-Z1;B<"S$C&_/Z$#2S]@%4>.$+,JGKZ@0]$JV,3VZ'&/BK?"!W(T#D M40F'508??GW$2)O)P`?>YD^:9Y3SNE@F(S_W^T]I\J%![H&9F]U\FLF(2\!1 MMD#_O`E\[,5`TN%JCQ3F9X.#8/%D,$R?^^;5OO)>(>E&50Q`QQ#Y(@ABZ#K MD,J.5#!6P40%4Q7,5#!7P4(%2Q5XEBI8V"C0JVMBI8"\``^SA'L'L_AT> M41GJ$1O=`0-WTUJ(2R"%1FI8R"B0JFIBI8Z"A0J6O!4L%+!6@4;%6Q5 ML%/!7@"2(;#>D2$F[$WUNPI;([04[!_"&B&6,N"#,H;F,[Z0;,43'L)-062, MR`212(S1.:(+!!9(N(ALD)DC<@&D2TB.T3V(I$\@NR,/([_Q<3&Y6!W`C5 M<$-,JR-;,JB"'KG&0[AKB(P1F2`R162&R!R1!2)+1#Q$5HBL$=D@LD5DA\A> M)))K8%"-:PUZ.LG/4?`Z2,K35LU,V';3P&0GB$P1F2$R1V2!R!(1#Y$5(FM$-HAL$=DALA>)9`\<8"1[ M:FR`XQ/S@4;+/I3$+(_'=(:RGESSF@?2!S'I-2(;)+WE,8TW913T(X',>F]2"03X90F MF5@>^;ZXQJB([&U)1&\1&54$EC_/IL1RYZ,>1#KR@219>\1A16DG4(+)&TQV-$Z:[LMC!&E;.1;O>!"3WHM$\I;>6XC'^<<+ ME$;+)E8$'G>#;"41#JN@+L^FH]IBICQ"XSH52988G6[7>(HHSCA0JRK4U39 MC,>(;50JFU>5D2;.UVEG@778/4L43T>CWE0SXK7(P99^W2S^R3(35&BA&6!>HV!))>RAF]1GI M-2JV0=);%+.KR(/AV(N%)OAENTW>%VHR&8SU.&V#1D2,D2%6I"YA!%7)O.8 M174PPFDB)H/>I!72L6!18) M0Z#F"A8E#Y2:+'`CMO4%E1'>L2AAA'&^8$%%K\M95-ZPEE='<9B>PF%XN61: MD+S1V],BJ7-<7NUZ;1>V0,@X"M\X+FR$F&\=%\XL-;SMPGZ'.5P=/[=J^(!> M=?QE@LO]%AG8+KP%HGYL^4^PT#@'P:6"R\PF(]L%T[.F`\<=U#7@:'C#NOX MR'$G=0,Q:KMP$L+Z4\>%\Q#F,\>%HVL-;[MP[,%\Z;AP^,'<Q+.TU[IV;"5QC6VY+&4R\_:[(:+5!'Y:L3RY&6<^-GX` M[`8(-"%^^/=?CP\7?VY>=O?;IX^7SE7O\F+S=+N]NW_Z]O'R_];!O\:7%[O] MS=/=SPO2.%I]_'R^W[_/+V^WMU^ MWSS>[ZVSYLGNO)U^_)XLZ?_??EVO7M^V=S<'0H]/ER[O=[P^O'F_NFR49B^ MO$5C^_7K_>W&W][^>-P\[1N1E\W#S9[:O_M^_[QCM/Y7[?; MQV>2^'+_<+__^R!Z>?%X.XV_/6U?;KX\4+__?G:FZ[YS>?WIP^$&_>=^\W/7 M^O?%[OOV9_AR?Y?>/VWH;I.?E`>^;+=_-/X3B$J?`VE@X,'RI>+N\W7FQ\/ M^WK[,]KJ8].[O_W-[I;N,E[U5HT!VY M^>OP]^?]W?[[QTMO>#48]3R'S"^^;';[X%Y)7E[<_MCMMX__;8P./3JN%J$ M_FH1A^+KC84]79C^<@N<Z??&Y[1@+[6H+_<@OQ8-`?CD=O[P59'FX%_=4B MXZN1TYMX9V@,M0;]?7]#1EJ$_KZ[(1.M07^UAG>V6QVQB8X5%@VCG?/5SF& M&/WCW?UQ.,;4/[2<[Z/'8XV]8_W-X;CS?E'`:?&:7-__TG(.1PNZA^Z2^_P M-0W8IBWT#ZWR#E]SV#D2=V\>1-?-U'28Z?R;_1 M,W4I%'F.:V:DXZSWVJ1'LYU2^:QD/E[23:+Y;$:IL9 MVCBFQ9PMU%2J9'T;+&P0V""T062#V`:)#98V2&V0V2"W06&#T@:5#6H;K&RP M;H%K6 M&X\F1S\"60`)@(1`(B`QD`3($D@)`.2`RF`E$`J(#60%9!UFQB.I?9HDQ1JWQ MA,A'M$`4(`H118AB1`FB):(4488H1U0@A%5B&I$T1K`YD>4WO+]OS79`N M5()N__W^]H_9EIY#9-0Q+WJTX]=Y@&:'2LM6'D,SIT%>D]94V_HY(A_10B-G M>-0VH]CEW'2C2$8L6-B!#%B!)$2T0IHDRC5E-SL9+GM^M86[-"K+BI):( M48UHA6AM(-/=:E_ZS]W=[&X-=S?(<#<@7VU&:8IN62TT:MW#0-A[Y!13,8CRR@2:XP9B05)HQ. M5KBTG3'7F\PM%82J4AQA1DCJ3!G=++"PJRP3V]=>N[(NJ6E2'&%%2.IL&9T MLL552&]+.IYWL3TX5JDJ$(SL-3^^8S`4N;6H[]!;OO1?T3MP!J;C?+5P/2 M:A5<,)X#1B)?B1-SI$49^F@X&UTXJP5,Q(M!-&HKTTM=WA:(3A`NW.6$BT MQ`%[8:;4:#R&&=$@4Y[2)-F MZ@U.,Y=P2,\%M:/`:I0O5EQPP4C&0L!(9J]0(YY+^@-WTK=&=H3%8D8BGC`2 M\:4E[GA#MV_%;XK%,D8BGC,2\<(4[P_&3G]BM;S$8A4C$:\9B?C%//!1>,9#P$&GDR'D)&D\/#@HY"].Q7G1&;2D8M1.T6C)JM&F2\)R!=9-3 MMA'Q#,5SM"H8->N-\:6EVPCXA6UVBU8M2(TQ&7_L1>KW9YB!NA@"@5:RW1(&/R:)`G^TI?+5CMA8-&$FJ!MJ(C1Q)7'2O2IF#?/82'ZTQ&`[H; MYDHE$BF>FF)N@U28B-6)"I=LU53HC'JNY]G/K92-9!>>886Y6)VHL&"KIL+! M:$`3C;WF+ME(JRPPEJL3E2X8BM=H3,8#]R^=4O7;'2HT`PNE:8Z-?>LM\^O MI3;:6R"=[1('S=11#!5P,DW.$?F(%H@"1"&B"%&,$&T1)0BRA#EB`I$):(* M48UHA6AM(,.3ZH2X$Y%RL>GCZB!:(`48@H0A0C M2A`M$:6(,D0YH@)1B:A"5"-:(5H;R'2B2@BVA^,OG(@I15>CUK!#Y"-:(`H0 MA8@B1#&B!-$248HH0Y0CA"5B"I$-:(5HK6!3(^I;-T9'FN2>Y0BX-$SH^?O M8:49^XG:R_J%6+%\@"A$%"&$26(EHA21!FB'%&!J$14(:H- M9+K'3N6]:VWM8H:/4=MKVDJ0KZV\?K/@@2SM0@S$88T,E6$4HE6$$:4(%IJ M1-L1ED_%JCM[FHD!E\D1%8A1!6BVD"F^U02Y8S1U>1X"\AG1 MK9?1Y5IYKH58\6T($(6,FF/OZJ5.Q@M[]D9^UBL6#Y!M&0DB\>445O>M5N? MB17+YX@1M+ZDE%;'EI?B17+UP8R_6JGP-XW+#$SI@[OTZK3<#<@GZTH$([N M]NSW'`NQXAX%B$)&XH^(T4GY6Q8/D&T9"3R:.3\IE8L7R.J&`D\B6CD_5 M6+%\;2#3W2JU=,8P;C)1QC!NT)!\V?8-4#GKK:2J=-G)/&\8"0S8,!(K$- M:,'-'8P820(@UHC6!VR5H-52HZ&TV4D-6:,I%TY([$J-&JUJV0D[:HT:K6K M-JQ,]]@)J%^L.C'3Y#9HV-[^>XZ59IUKYKN^6;YC-K+&L@;++253CI2=HWR MK$,K]Q.(%N'C3"B)&LCV-6'S9)RM_FTB)=NA9M2_92JI&9WL6\:U-^]7 MG'Y_/!B[5D(N%RGN6\%(BP92=\J5M=]LQ(#M93H[IL9)BI[<\8H;I(]QBAN MT(!2`ZU1;.6/YZXN"//9R01OM"(]E'MYNC<;]O/U$#+!8R$O&(D8C'+.XT M(6%FJ!(IT.X&1`1T(Y6"[,:,:]+=&-(+TX$U;G(L5C"2;I2,I!L5BS?=L%X& MU5@NQNF\W^5'K3&1@7\T0:&5.'.[;.KO?&F M;)B="PO81HJ%C&0H18S$F:DAY(=$\?6=-_,PZ&,)6M(32DCJ2ECI+LQ=)S) M$&:$8WW<^X+B7C)2,0K1DTW(":.LMW=,&+"LU-.[UK%'53,3)1&0QI!QWD" M%K1S+BACP-=(36O'@O@X8:OQ(4QKN-GF//'EA7VE40.I>Q5=,Y9S0:]/OV[J5ORF1;[AP2Q/V,D3P)YXA\1`M$`:(0480H1I0@6B)$66( MOO20&6QK)=1C&3Q.T?D:Z3^',4K$F:HW: M7@/DZXO9\'$0!S6R+2S8&@5(8H1)8B6&K6S8&+U2A9,#+B5.:("48FH0E0; MR'0?;<4-]YW>G]$]`S\UB`8P-WVNK5K(9T2W7D:7G4=:B!5K!8A"1K)SC1BU MY2&/%(L5RR>(EHRD0RFCMCPL&CQ8OD<4<%(6E\R:LM#ZRNQ8OG:09?56:J M/6N^;U@V^:WV/LN#E-<, M9.H.&(E5J%$KVQ0QDGUFK%$KVY2@U5C5KM21E)CQDC:E3,2JTC5KM1MN M2J-6NVK#RG2/RF&U1^,O9EEE;CT-&V1L93$+1EDL5;"]E6747M;`RGZAK706 M;.1.O,'(M3(Z@4AQ1(:,9'T<,9+U<:P1W1_U^!M;&\-$2LBSH6/7`GU+NPI" MWSN79\RIGG;\3P[#R)2W+>"D?2M9"1]JUB]Z=O(2CC54J[;V:8J+3.&6&B MLT#2P!D=F%,!\(LLF+9J1;C/2")\H9'.@@W<$1T\M%(%`18+&&-W,G:M.2QG(^E<@166:%4Q>J5S-5]_K7-F_/R>/)@Z?&NM M2!C)LW".R$>T0!0@"A%%B&)$":(EHA11ABA'5"`J$56(:D0K1.K#BH<;?;BK MC2>;#R4VGP][W+Q\V\PW#P^[B]OM#_41Q(&:98ZX^4+CS.E-U6^.:;J#Q.Z M MR>8N5=[5H^J[N"?^]//=!,[NM&GSU9V\>&4OB;283^:TE5`5WID-) M3[K2=7LIL395R2U42^F2BCAE1FU8-99#V6$IBI-@&4H,315.9ZNP.ZTE6& M$D!3E17`,I0'HE9WJ5'@YTE:%33U-U%`;5Z/#35)UCZKI"_NDL0X>P#)U6HU9WJ='!)KK258:^9#!5WRE` M-?HNP51]%@"OT&<`:#;INC)S7%+KNJ/TL_>I^AD[JM'/UJF>KBOTL_.I^ADY MEJ&?C5,+#E>NCPZBK]0^WWS;9#\H?-^O2OOWW=;O?\/U3U]?$+QY_^7P````#__P,` M4$L#!!0`!@`(````(0`^5;'M@@``!\D```9````>&PO=V]R:W-H965T^V`$UP# MF+=R'^\_?3\O(\ MIAZ<^B,^JI>7XU>[M5)Q;ZJ0NCGD+_6\.Y:7AWDZ[C[@[Y?77M\NG776Z M@(OG\EBV/SJGX]%IYX2OYZK.GX\P[N^&G>^X[^X#/IXWPGT=UF\-]+_H^90O?MUN4_ M'L;68S)FK4[_4".#N:).3.;$@MYC)U<:VJPA7%G#Y61IS%;6$H)? M:0=WNU[#E;4S%Q/;G"_ONFY?:;E@+>'6DK#O=)NR=K!];8APD+KN@K7FX:X M8NW@RH=H?D@;`W(3BE))CH='QNCT2<#_'/;`V>`N2?F\9I0-+0[HKL^>AD M&CQ_R#\?&>J49G^WF-R\S1_OZ^I]!#L4#+BYY&2_,QSBC"\CFA']POK9NH(% M1;P\$39!8@;:\O9,7_H2]Q0_3ERJPY$(;FIC<@C=Q=;#5 M@:<#7P>!#D(=1#J(=9#H(-5!)@%%3%@H2$P+%OOPGL]SD[2"W5W.37.FBK6F M-F0-]PD\5TTVO4DO");1#Q$?$0"1$)$(D1B1!)$4D0RF2C:PMI'VI+GZ8T; M`7$#>PF$Z86T3&V=KYG1-;5[DUYM1+:(>(CXB`2(A(A$B,2()(BDB&0R4=0& M816UKVY$Y6L&9EU6ZUA:ZG:WY4G0>P/2D_@/'!#3XBUVA-&S'YKVB#B M(K)%Q$/$1R1`)$0D0B1&)$$D1223B2(8/.04P<@3M;2(F)!:MCV4NZ_K"G8T,!I8S18\P5@) M08_0<'3@6;8F=1G)5UITDXI@P]&BMW(9LM0D!1>'U12\I/4@KDC)D]_IMRD75+:$RBY#-FP[TK-H MH3Z+ML)2$I]04..?.Z>OH0ADQB(AK)[K5X,A17W%6$48_>)L!+N35-+B%18 M9@E3AR;GY!N'9,5O.989DX2E2A?(A@>D)/Q2%[ZWXEWWR(D;)A$:!L)+<6UH1%`HK[BO",;N$VR58I0I2%69 ME`>RRK^V7;,B0TYQAF3Q9+4<4E1">+/N]>[W=:_Q@(4O8VY5DELF16\HR>OZTQC.=-<>\(/%\GG2$0+.+H:+=2B MK4PM6"3<\&`Q1R)8PM'58D6S%Y8VMK.A!^(ILX9J4UNF#-6RLAS1I$)CT(I M37Y-P:S$@U=CL0I"5BSU$Q(0C$3$=CJ@=-C+1<#BB.HF0'\HD_MH61[QHSQ>&Y/RS+.WYO#&8 ME4A/D!?IK<\NJ09&::Q@F>XEW1!M8V5H#Y(- MLS!%(Y0?CVF7].O%PZ\ZH2NC.'.UTEJ?47ZD"''.%P&R@'H0=#=^`G"D^= M>)JO-?QTH4M6G8.C07O+@>]5<.0G&_P/#7!M._#5`&X`KS(@\F!H&,1ZE+1#<2RX,]1E(W@SG#?YG!G2$:H\!UR.,=QH-"'Z1KJ`52B M<?KP;17&7Z><Y:^&%&MT$< MX(?P7``#__P,`4$L#!!0`!@`(````(0"; M5)G&0L``",T```9````>&PO=V]R:W-H965TO7LE:DBS)YO;/[X=]XUM^.N^XUW3N6DW&_EQ6SSLCD]WS?_]Y?TQ M:C;.E\WQ8;,OCOE=\T=^;OYY_]__W+X6IR_GYSR_-,#A>+YK/E\N+VZK==X^ MYX?-^:9XR8^0\EB<#IL+_'EZ:IU?3OGFHXE$\ M/NZV^:S8?CWDQXLT.>7[S07J?W[>O9S1[;!]B]UA<_KR]>6/;7%X`8O/N_WN M\J,T;38.6W?Q="Q.F\][N.[O3F^S1>_R#V9_V&U/Q;EXO-R`74M6E%_SN#5N M@=/][<,.KD`T>^.4/]XU/SENUNDV6_>W90/]O/5/NX=H=\RA MM2%.(@?B^+D"X>!(+,+9;;R.0GAH/^>/FZ_Z2%:]!OGMZOD"X^W!%XL+< MAQ^S_+R%%@6;FTY?.&V+/50`_F\<=J)K0(MLOI>?K[N'R_-=LSNXZ0_;70?D MC<_Y^>+MA&6SL?UZOA2'?Z3(45;2I-,X%.9=`8WHWZ_-Q@-W^[24R[PJ5R< M]YM`<>7UP#SXQ49Q/X_'!%'&Q8\>7C57&ZJB[B MR\(SXC`2,+!A9,A(R$C&R8B1F)&$D963-283(VJP'#&B5K\\ MP]N04)?!P4:=2-+K5;/>5)N7(B5=QE%.I5FSHC'B,]\@DI#7<,9#,S1NJA$ M6,4E(R$C$2,K1F)&$D921M:,9#HQ8@'+%R,6FAAU M84T@5PK"Q`R1)'J()-%#I(@6(D8\1GSF$R@"W:T:OEV)T#K3 MB1$QV>^(V)";49,$CUBDN@14QHM8HQXC/C,)U`:(V)#:_&RJ$1X[4M&0F8= M51J]67M6Q"H16L>,),PZK32ZM35IKRL16FHYBC MA'NE"O7,JEH3_)I46-7,0&8@Q8Z9GUZ\8H:HLT>Q+8K-_K2_] M5;S`:/_I09@\,S`ZDT0=6KQ.Q7X>;@/R?%L==3'57FZ-%%XF)&\?$34?0-$ MI%IPKR57A8C(T)$7BON%7-5@HB\4D3DM>9>F:$R8R0V]WJ,KB]OQ2;=NMDB M,@;VR+H#3E&E#VSE-:K&^ERI.K23]#`CJ7Q$Y!4@(M6">RVYD1$7A$B\EIQ MKYBK$D3DE2(BKS7WR@R5&1ZQBW]'>-2FGSK(Q)$(AHH^UV5^A15E'&&B'K6 M7'NL)QDG=YX/!ZTK4A[/)^/B-P#1.2^>(O[DN<+$9%[A(C<5^@.^SRZ_]CS M==(QJ7\>^WRW_F>M1##67SN7G`50N%>K"2_/<`+7G&D-M'7+5" M=7N,6JH[@DW3[EJK=#UNF=&1C/ZXO3AUZ,OSS",Z$MDCOZ1M9B=.DI%W6:F M4`_NSEHTVI+9NQUY(0`\T'=A!$-G[O,#@304N44K)V!EBBB`D->8$2J MU>X0I4LL+;+QZBA\A)>7DJJ^6M4:4?ACOV-)6AJBS1[$GB&.1:3WKCFDO8 M6#LQB8R=F$3&3DRB(;7%W&'(X\A72/,$!FW+G;Z2RJ<\Y8T.4<>1SXB"G>` MZ/J!,DH:JI>]&`AYJ(HQ5',4<)1RE':XXR`YE1@YV1$;6?+)Z%W!I4$AGA MD<@(CU+A^?"@:^V;YW#C%M8].L[R./(5TJP#5$';TSQO;YP7I)HJ1+I7AFB M/54BHHR:/3LG)A7:QQPEW#XEE6YOGQ63"NTS`QDQ[=@G6==C6LK-F"JDQU0A MK>%GJ+&FG/D<>1SKP!5,-%J0;3ZR()4V`Q+CD)N'Y%LQ_9!Y&D0ON8HX3; MIZ32[(?6"G5-K3/#&0&T3[%^DD0^7$5;$'+`463T50A(XAI0>1(0^]2.5S MKP!51A!'UD9M02ILAB5'(;>/26W,@NBJCT='\64$4M,N'U**MW>.@Y;DPJ] M,@.9013'-[]\3Q1+7VO25<@8H%)EQ%:B'AT5S3$C(8\C7R'-T`5S)DT0$?6 M:GI!FR=)4I:U)A53,#F8&TSY@^M+>%DST6 MR.H$2:^K->]-,:.VMU7H)V?J)('KMU>9S#HMZV]DXO.L#IPQ8T>+.R43AO> MA"Z?P+`4\8YTN9IE1U(1?(5@J\5OVICD_`JLYI(HQJ:C7INEFY`[?]>^!? MES#IN?"6#[\\6(BY8IK@;`><\72JB8%FD3]I:Y6$V?H3F`/PKVFD#M M39E!BMBN\3RPSW;%KHVGP'8;:E!W+;"E@Y2Z/.'0%<\XN5DT=.%=CQH^!Q738NA2H2L>B7KB6BNNH2I:VZA)EHK+H$7[1574(P=.$M M&5YV,'+A78P:#IVQ[O+@83/TTKH2)GUW4BXSK,E@VG>G=7S6=^%M+5ZRWW?A MG2W.@[X+;Z75\($+KT(!;U4%PT\T7C9/^6IS>MH=SXU]_@@3;KM\(GR2/_0 M?US4T[S/Q05^G`%[(GCU'7Z,D\/K0NT;.%]^+(H+_B$J'[><_]_````__\# M`%!+`P04``8`"````"$`GHEBV0#``"Z"@``&0```'AL+W=OHI#7>N,^8N]?;SY_69\H>>(&Q<`"AYANW$**)/8^G!:X0 MG]`&US"34U8A`4-V]'C#,,K4HJKTIKX_]RI$:K=%B-E;,&B>DQ3?T/14X5JT M(`R72`!_7I"&]VA5^A:X"K&'4W.5TJH!B`,IB7A6HY3I?'=L:8,'4J(^RF( M4-ICJ\$(OB(IHYSF8@)P7DMT'//6WF`M%UG!"0LCL,YQMW%\1)$+C>=JT$ M^DWPF0_^.[R@YR^,9-](C4%MR)/,P('2!^EZETD3+/9&JV]5!KXS)\,Y.I7B M!SU_Q>18"$CW#"2@<79\PWF2@,)/I3"EM`0"\.M41)8&(>U/=,,E%L MW'`^F2W\,`!WYX"YN"42TG72$Q>T^M,ZJ8@TR+0#@6\',GO!>&5=VV#[X7- MQPN]EKS2X@8)M%TS>G:@P(`>;Y`LUR`&L%Z$%D'+\B]50`X)LI,H&W?A.A`P MAU0^;L,H6'N/('_:^>S'/I9'TGO(K`$]S1'$^0".$D5RE)F4I/>]X87TU2< M]!XV(1#J`PA)%"B:@6A!Z)L,]JU/`$2TLC/3)=$N-LOH0UA%"B.(!3!:=!=36!1-&D0Y857ZBG>Q< MR-XVN`U>SX5T-C?O+`,)AA9#@I6YD[IW%LO_D$`"F2PZBRF!71C:R98@@$;R M=@V4M[E];QJH8)@,&:#!&;NI4I@O)HOWUX"LJBT-VI@2C&WJJ%?&EVJ2[> MMFFVC:+"[(@37);<2>E)-D2XCK9K;6Z[]3[PH5VKCCN:T8W`?!C2?V49RH:.T-YC$6?OV:`>"-B`PO!^H@#>#^EO` M&Q%#PU(71$ZIZ`=R`_WJW/X%``#__P,`4$L#!!0`!@`(````(0`'-72[,0$` M`$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````"" M%<5;3+YUP28-2;3KOS?KNCK1D\?POGGR?%^]4$WR2#1FEU?%<)2T3IX<T%%Q3X)),I\6:!^"I1A[ ML0?-?18;)H:[UFD>XM'5V'+QSFO`LSQ?8@V!2QXX/@)3.Q'1B)1B0MH/UPP` M3`TH,$$CTE&\'_\XC)HJ<]R5`,2.^VFX#]NXRIT">=.SPYMK$N_W!?Z=%5(,=E0XX`%D M$M^C)[MS\CR_O:LVB,URLD@)2?-E10@E[K(7PM\;HWWV034H\"_B6<`&[Q_ M_CG[`@``__\#`%!+`P04``8`"````"$`T-M6,6(#``"%#```$``(`61O8U!R M;W!S+V%P<"YX;6P@H@0!**```0`````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````"<5]]OTS`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`VFO`NKN,"I82072G-(=,3R`XWO[1E['ALOE=?8AEK""C!0 MQTL%_C5-PG4^D(9K/?"U,Y,&KGD7KOKXJG#UQ./3L$(+D,;Z'/]'GC[OSH#/+,^`9[9$QTB@/D`P%X]>_>]/VYXGY1^=%_+J;FFF]#F M"KO_,FV^YCE=[C;[SR_2&[J]VJ(.```3 M``````````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``& M``@````A`+55,"/U````3`(```L`````````````````100``%]R96QS+RYR M96QS4$L!`BT`%``&``@````A`$M'16(W`@``?1T``!H````````````````` M:P<``'AL+U]R96QS+W=O@\```\`````````````````X@H``'AL+W=O```8`````````````````$&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`>Q=^+!`@``&@<``!D`````````````````+2```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`";23ID!```5Q0``!D````````` M````````_C(``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A``EC_]P`@``QP4``!D`````````````````%D,``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`"KPT'(;#```0'$```T`````````````````7$T``'AL+W-T>6QE/.](X```5N0``%`````````````````"B60`` M>&PO&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`+6=SL6!@```AD``!@`````````````````TI4` M`'AL+W=O&UL M4$L!`BT`%``&``@````A`%6"$TJ6`P``G0P``!D`````````````````XZ(` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`,'7HS;D!```B10``!D`````````````````HZ\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)>" MMM$0"```U"0``!D`````````````````ALT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'=O?HM\!@``W1D``!D` M`````````````````>T``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/]8 M6?II`P``N0H``!@`````````````````R1(!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`.ZC[R_!@``LQH``!D````` M````````````BB`!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`&?U`2D!0``I18``!D`````````````````PRX! M`'AL+W=O-`$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`!3B#:+!0``GQ0``!D`````````````````C$8!`'AL+W=O&UL4$L!`BT`%``&``@````A`&G>?7`Y!@`` MHQD``!D`````````````````#%8!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)M4DJ<9"P``(S0``!D````````` M````````M78!`'AL+W=O&PO=V]R:W-H M965T&UL4$L%!@`````Z`#H`R`\``",`0`````` ` end XML 15 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 13 - Segment and Geographic Information (Details) - Product Revenue by Product Group (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Segment Reporting Information [Line Items]

Product Revenue $ 21,975,312 $ 17,023,346 $ 57,593,873 $ 51,585,242

Orthobiologics [Member]

Segment Reporting Information [Line Items]

Product Revenue 18,899,873 12,830,566 48,750,277 40,620,339

Dermal [Member]

Segment Reporting Information [Line Items]

Product Revenue 401,355 267,766 938,966 1,066,409

Surgical [Member]

Segment Reporting Information [Line Items]

Product Revenue 1,452,946 1,136,248 4,581,496 3,955,134

Ophthalmic [Member]

Segment Reporting Information [Line Items]

Product Revenue 366,138 1,425,609 938,134 2,818,407

Veterinary [Member]

Segment Reporting Information [Line Items]

Product Revenue $ 855,000 $ 1,363,157 $ 2,385,000 $ 3,124,953

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Equity Incentive Plan (Details) (USD $)
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Restricted Stock [Member]

Sep. 30, 2014

Restricted Stock [Member]

Sep. 30, 2014

Restricted Stock Units (RSUs) [Member]

Board of Directors [Member]

Sep. 30, 2014

Restricted Stock Units (RSUs) [Member]

Sep. 30, 2014

Restricted Stock Units (RSUs) [Member]

Jun. 30, 2014

Stock Appreciation Rights (SARs) [Member]

Sep. 30, 2014

Minimum [Member]

Sep. 30, 2014

Maximum [Member]

Note 5 - Equity Incentive Plan (Details) [Line Items]

Allocated Share-based Compensation Expense $ 390,578 $ 368,603 $ 1,196,361 $ 1,156,929

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) 7,000 139,240

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) 0 30,700 9,365 0

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 4 years 4 years 1 year 4 years

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized 4,200,000 4,200,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 3 years

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue 25,473,089 4,095,833

Proceeds from Stock Options Exercised 17,513 1,804,773 1,379,294 2,932,649

Stock Repurchased and Retired During Period, Shares (in Shares) 133,774

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber (in Shares) 936,097

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice (in Dollars per share) $ 13.54 $ 13.54

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue $ 21,800,000 $ 21,800,000

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm 6 years 292 days

ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermRange 10 years

X

- Details

Name: anik_Note5EquityIncentivePlanDetailsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents share based compensation arrangement by share based payment award contractual term range.

+ References

No definition available.

+ Details

Name: anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermRange

Namespace Prefix: anik_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents share-based compensation arrangement by share-based payment award, options, and stock appreciation rights, exercises in period, total intrinsic value.

+ References

No definition available.

+ Details

Name: anik_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents share based compensation arrangement by share based payment award, options and stock appreciation rights, outstanding, intrinsic value.

+ References

No definition available.

+ Details

Name: anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents share based compensation arrangement by share based payment award options and stock appreciation rights outstanding number.

+ References

No definition available.

+ Details

Name: anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber

Namespace Prefix: anik_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents share based compensation arrangement by share based payment award options and stock appreciation rights outstanding weighted average remaining contractual term.

+ References

No definition available.

+ Details

Name: anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm

Namespace Prefix: anik_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents share based compensation arrangement by share based payment award options and stock appreciation rights weighted average exercise price.

+ References

No definition available.

+ Details

Name: anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice

Namespace Prefix: anik_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Unrecognized cost of unvested share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares that have been repurchased and retired during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 7 - Inventories (Tables)
9 Months Ended

Sep. 30, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

September 30,

2014

December 31,

2013

Raw materials $ 6,843,441 $ 5,926,030

Work-in-process 2,325,667 2,308,233

Finished goods 4,413,348 2,762,522

Total $ 13,582,456 $ 10,996,785

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 10 - Commitments and Contingencies (Details) (USD $)
9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Product Warranty Accrual $ 0

Product Warranty Expense $ 0

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-Subparagraph ((c)(5))

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

+ Details

Name: us-gaap_ProductWarrantyAccrual

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-Subparagraph ((c)(3,4))

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

+ Details

Name: us-gaap_ProductWarrantyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 7 - Inventories (Details) - Inventories (USD $)

Sep. 30, 2014

Dec. 31, 2013

Inventories [Abstract]

Raw materials $ 6,843,441 $ 5,926,030

Work-in-process 2,325,667 2,308,233

Finished goods 4,413,348 2,762,522

Total $ 13,582,456 $ 10,996,785

X

- Details

Name: anik_InventoriesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 13 - Segment and Geographic Information (Details) - Product Revenue by Geographic Location (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Geographic Location:

Total Revenue $ 22,055,423 $ 17,754,438 $ 82,340,370 $ 53,829,826

Percentage of Revenue 100.00% 100.00% 100.00% 100.00%

United States [Member]

Geographic Location:

Total Revenue 18,455,167 14,485,821 72,935,722 42,251,336

Percentage of Revenue 84.00% 82.00% 89.00% 78.00%

Europe [Member]

Geographic Location:

Total Revenue 1,784,414 1,656,656 5,274,071 5,226,619

Percentage of Revenue 8.00% 9.00% 6.00% 10.00%

Other location [Member]

Geographic Location:

Total Revenue $ 1,815,842 $ 1,611,961 $ 4,130,577 $ 6,351,871

Percentage of Revenue 8.00% 9.00% 5.00% 12.00%

X

- Details

Name: anik_GeographicLocationAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the percentage of net revenue.

+ References

No definition available.

+ Details

Name: anik_PercentageOfNetRevenue

Namespace Prefix: anik_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 22 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Fair Value Measurements
9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

4. Fair Value Measurements

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements, a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value, was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. On a recurring basis, the Company records its marketable securities at fair value.

The Company’s investments are all classified within Level 1 and Level 2 of the fair value hierarchy. The Company’s investments classified within Level 1 of the fair value hierarchy are valued using quoted market prices. The Company’s investments classified within Level 2 of the fair value hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves, and credit risk.

The fair value hierarchy of the Company’s cash equivalents and marketable securities at fair value is as follows:

Fair Value Measurements at Reporting

Date Using

September 30, 2014
Quoted Prices in

Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable

Inputs

(Level 3)

Money market funds $ 49,285,168 $ - $ 49,285,168 $ -

Marketable securities:

United States Treasury securities 14,999,600 14,999,600 - -

Bank certificates of deposit 5,000,000 - 5,000,000 -

Total marketable securities $ 19,999,600 $ 14,999,600 $ 5,000,000 $ -

Fair Value Measurements at Reporting
Date Using

December 31, 2013 Quoted Prices in
Active Markets
for Identical Assets
(Level 1) Significant Other
Observable Inputs
(Level 2)
Significant

Unobservable

Inputs

(Level 3)

Money market funds $ 34,266,501 $ - $ 34,266,501 $ -

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V M,V$S.#4T,F,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I. M86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYO=&5?.%]);G1A;F=I8FQE7T%S#I.86UE/@T("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?.5]!8V-R=65D7T5X<&5N M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I7;W)K#I7;W)K#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,35?3F5W7T%C8V]U;G1I;F=?4W1A;F1A M#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]&86ER7U9A;'5E7TUE87-U#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYO=&5?.5]!8V-R=65D7T5X<&5N#I.86UE/@T("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?,3-?4V5G;65N=%]A;F1? M1V5O9W)A<&AI8S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O5]);F-E;G1I=F5?4&QA;E]$/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]);F-E;G1I=F5?4&QA;E]$,3PO>#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-E]%87)N:6YG#I.86UE/@T("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DYO=&5?.%]);G1A;F=I8FQE7T%S#I7;W)K'!E;G-E#I7;W)K#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,3)?26YC;VUE7U1A>&5S7T1E=&%I;',\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T/"]H96%D/@T("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V)A-3$W,3$S7S!D,C=?-#,V,5]A-V)A7S$P838S83,X-30R8PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B834Q-S$Q,U\P9#(W7S0S M-C%?83=B85\Q,&$V,V$S.#4T,F,O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)S$P+5$\2!#;VUM;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO"!+97D\+W1D/@T("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)UEE2!6;VQU;G1A2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^)TYO/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)S(P,30\3X-"CPO:'1M;#X-"@T+2TM M+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S M.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N M/CPO&5S('!A M>6%B;&4\+W1D/@T("`@("`@("`\=&0@8VQA"!L:6%B:6QI='D\+W1D/@T("`@("`@("`\ M=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ+#(U,"PP,#`\F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E M;G-E'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M+#4W-BPT-#$\'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y-BPS M-C$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E6%B;&4\+W1D/@T("`@("`@("`\=&0@8VQA'!E;G-E'0^)SQS<&%N/CPO2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\ M+W1D/@T("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&5R8VES92!O9B!S=&]C:R!O<'1I;VYS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,W.2PR.30\"!B96YE9FET(&9R;VT@97AE'0^)SQS<&%N/CPO6UE;G1S(&]N(&1E8G0\+W1D/@T("`@ M("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VL@6T%B'0^)SQS<&%N M/CPO'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`@6QE/3-$)W=I M9'1H.B`V)2<^("`-"B`@("`@("`@("`\8CXQ+CPO8CX@(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@.30E)SX@ M("`-"B`@("`@("`@("`\8CY.871U6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6%L=7)O;FEC(&%C:60@"8C.#(R,#M(028C.#(R,3LI+"!A(&YA='5R M86QL>2!O8V-U6UE7,@86X@ M:6UP;W)T86YT(')O;&4@:6X@82!N=6UB97(@;V8@<&AY2!I M&ES=&EN9R!A M;F0@;F5W('!R;V1U8W1S+"!A;F0@8V]M<&QI86YC92!W:71H('1H92!5+E,N M($9O;V0@86YD($1R=6<@061M:6YI'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@6QE/3-$)W=I9'1H.B`V)2<^("`-"B`@("`@("`@ M("`\8CXR+CPO8CX@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=W:61T:#H@.30E)SX@("`-"B`@("`@("`@("`\8CY"87-I M6EN9R!U;F%U9&ET960@8V]N9&5N&-H86YG92!#;VUM:7-S:6]N("AT:&4@)B,X,C(P.U-%0R8C.#(R M,3LI(&%N9"!I;B!A8V-O2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!T65A2!A8V-E<'1E9"!I M;B!T:&4@52Y3+B!);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+"!T:&5S M92!U;F%U9&ET960@8V]N9&5N2!T;R!F86ER;'D@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6EN9R!U;F%U9&ET960@8V]N9&5N6QE/3-$)V9O;G0M2!R M969L96-T('1H92!T87@@8F5N969I="!F"!B96YE9FET(&9R;VT@97AE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q M-"!O9B!T:&4@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0@0FQO8VL@4W5P<&QE;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T("`@("`@/'1R(&-L87-S/3-$'0^)SQT86)L92!C M96QL6QE/3-$)W=I9'1H M.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE M/3-$)W=I9'1H.B`Y-"4G/B`@(`T("`@("`@("`@(#QP('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,30L.3DY+#$V.2`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-CDY("`@(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X M="UA;&EG;CH@'0M86QI9VXZ M(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG M;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T M>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@+2`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ M(')I9VAT)SX@("`@#0H@("`@("`@("`@+2`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@ M#0H@("`@("`@("`@-2PP,#`L,#`P("`@("`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$)W!A9&1I;F6QE M/3-$)V)O'0M M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$ M)V)O'0M86QI M9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3DL.3DY+#8P,"`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!C;VYS:61E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$ M)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3L@ M86YD("A,979E;"`S2!S:6=N:69I8V%N="!U;F]B2!R97%U:7)E2!T;R!U28C.#(Q-SMS(&EN=F5S=&UE M;G1S(&%R92!A;&P@8VQA2!A"!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)W9E6QE/3-$ M)W9E'0M M86QI9VXZ(&-E;G1E6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O M;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C M96YT97([(&)O6QE/3-$)VUA'0M86QI9VXZ M(&-E;G1E6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ M(#(N-S5P="<^(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`X)3L@8F]R9&5R+6)O='1O;3H@0FQA M8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("`D("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M<&%D9&EN9RUB;W1T;VTZ(#(N-S5P="<^(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`X)3L@8F]R M9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@ M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("!5;FET960@4W1A=&5S M(%1R96%S=7)Y('-E8W5R:71I97,@("`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@(#$T+#DY.2PV,#`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@(#$T+#DY.2PV,#`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@("T@(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@ M("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@ M(#QT9#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX@ M("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^("`@("`- M"B`@("`@("`@("`M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE M9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@ M("`@+2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-2PP,#`L,#`P("`@ M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@ M,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P M861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T M97AT+6%L:6=N.B!C96YT97([(&)O'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("`D("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M<&%D9&EN9RUB;W1T;VTZ(#(N-S5P="<^(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`X)3L@8F]R M9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@ M6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`- M"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE M/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#(N-S5P="<^(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$ M)W=I9'1H.B`X)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L M93L@=&5X="UA;&EG;CH@6QE/3-$)V)O3X-"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q M,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA2!);F-E;G1I M=F4@4&QA;CQB'0^)SQT86)L92!C96QL6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)W=I9'1H.B`S)3L@=&5X="UA;&EG;CH@8V5N=&5R)SX@ M(`T("`@("`@("`@(#$N,S`E(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@ M("`@(#QT9"!S='EL93TS1"=W:61T:#H@-R4[('1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@,R4G/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`W)3L@=&5X="UA;&EG;CH@8V5N=&5R)SX@(`T M("`@("`@("`@("T@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`S)2<^("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W9E'!E8W1E9"!L:79E65A M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'!E8W1E9"!D:79I9&5N9"!Y:65L M9"`@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0^("`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L6QE/3-$)VUA'0M M86QI9VXZ(&-E;G1E6QE/3-$)VUA'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([('!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`W)3L@=&5X="UA;&EG;CH@8V5N=&5R M)SX@(`T("`@("`@("`@("T@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@ M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`S M)2<^("`-"B`@("`@("`@("`Q+C,Y)2`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`W)3L@=&5X="UA M;&EG;CH@8V5N=&5R)SX@(`T("`@("`@("`@("T@(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('=I9'1H.B`S)2<^("`-"B`@("`@("`@("`P+C6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E2P@9F]R(&5Q=6ET>2!C;VUP96YS871I;VX@87=A M2!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE65E'0M:6YD96YT.B`P+C5I;B<^("`@("`-"B`@("`@($%S M(&]F(%-E<'1E;6)E&EM871E M;'D@)#0N,B!M:6QL:6]N(&]F('1O=&%L('5N2X@0V%S:"!R M96-E:79E9"!F&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&1U M"!W:71H:&]L9&EN9R!R97%U:7)E;65N=',N("`-"B`@("`\+W`^/&)R+SX\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^(`T("`@("`@5&AE2`D,C$N."!M:6QL:6]N+"!A;F0@82!W96EG M:'1E9"UA=F5R86=E(')E;6%I;FEN9R!C;VYT'0M:6YD96YT.B`P+C5I M;B<^("`@("`-"B`@("`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`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@6QE M/3-$)W=I9'1H.B`V)2<^("`-"B`@("`@("`@("`\8CXV+CPO8CX@(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M.30E)SX@("`-"B`@("`@("`@("`\8CY%87)N:6YG6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!R97!O2!T:&4@=V5I9VAT960@879E2!T:&4@=V5I9VAT960@879E'0M:6YD96YT.B`P+C5I;B<^("`@("`-"B`@ M("`@($)A6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE M/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M8V]L'0M M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE M9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@ M("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@ M#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@ M("`@(#QT9"!S='EL93TS1"=W:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT M)SX@#0H@("`@("`@("`@,3,L-C@R+#0T.2`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG M;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T M>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("!%9F9E8W0@;V8@9&EL=71I=F4@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI M9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@-C6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I M9VAT)SX@("`@#0H@("`@("`@("`@.#0R+#,P-"`@(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!" M;&%C:R`Q+C%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^("`@#0H@("`@ M("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$ M)V)O'0M86QI M9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!";&%C:R`R+C6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A=V%R9',@9F]R('1H M92!T:')E92!M;VYT:"!P97)I;V0@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S M+B!%<75I='D@87=A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)W=I9'1H.B`Y-"4G M/B`@(`T("`@("`@("`@(#QB/DEN=F5N=&]R:65S/"]B/B`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@8V]L6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE M/3-$)VUA6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@8V]L6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O M6QE/3-$)VUA6QE/3-$)W=I9'1H M.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@ M("`\='(@6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@ M("`@("`@,BPW-C(L-3(R("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@6QE/3-$)W9E'0M:6YD96YT.B`P+C5I;B<^("`@(`T("`@("`@ M26X@8V]N;F5C=&EO;B!W:71H('1H92!A8W%U:7-I=&EO;B!O9B!!;FEK82!4 M:&5R87!E=71I8W,@4RYR+FPN("@F(S@R,C`[06YI:V$@4RYR+FPN)B,X,C(Q M.RDL('1H92!#;VUP86YY(&%C<75IF%T:6]N(&UE=&AO M9',@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2P@=&AE($-O;7!A;GD@=VEL;"!I M;FET:6%T92!A(')E=FEE=R!F;W(@:6UP86ER;65N="!I9B!E=F5N=',@;W(@ M8VAA;F=E2!N;W0@ M8F4@9G5L;'D@6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT M97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`S-"4[('1E>'0M86QI9VXZ M(&QE9G0G/B`-"B`@("`@("`@("!$979E;&]P960@=&5C:&YO;&]G>2`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,38L-S`P+#`P,"`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@#$L.#(X+#(Q-"`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE M9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@ M'0M M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@2`@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@ M8V5N=&5R)SX@(`T("`@("`@("`@(#$U("`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX@("`@(`T("`@("`@("`@(#@V,RPV-34@("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO M='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO M='(^("`@#0H@("`@("`\='(@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@,C@R+#`S M-B`@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q+C%P="!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F="<^("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XQ<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE M9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,2XQ<'0[('1E>'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE M9G0G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@ M#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T>6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O M'0M86QI9VXZ M(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A M9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@2`@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@2`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]TF%T M:6]N(&5X<&5N2X@5&AE(&%G9W)E9V%T92!A;6]R=&EZ871I;VX@97AP96YS92!R M96QA=&5D('1O(&EN=&%N9VEB;&4@87-S971S('=A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@($=O;V1W:6QL("`@(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L M9#L@<&%D9&EN9RUB;W1T;VTZ(#$N,7!T)SX@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X] M,T0S(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q M+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P)SX@("`@(`T("`@("`@("`@("`@ M5&AR964@("`-"B`@("`@("`@("`\+W`^(`T("`@("`@("`@(#QP('-T>6QE M/3-$)VUA'0M86QI9VXZ(&-E;G1E6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@ M#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ M(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@ M("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@ M(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI M9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T>6QE/3-$ M)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F2!A9&IU'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("D@(`T* M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,2XQ<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A M9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q M-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@3X-"CPO:'1M;#X-"@T+2TM M+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S M.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO'0^)SQT86)L92!C96QL6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E'!E;G-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q M+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT+6%L:6=N.B!C96YT97(G M/B`@("`@#0H@("`@("`@("`@("`\8CY$96-E;6)E6QE/3-$)VUA M'0M86QI9VXZ(&-E M;G1E'0M M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,BPX-#(L,C,T("`@("`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,BPX-S`L,30W("`@("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@ M("`@("`@(#DV,BPP,S$@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("!06QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX@("`@(`T("`@("`@("`@(#,X,RPR,S$@("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX@("`@(`T("`@("`@("`@(#8Q,"PT.3@@("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#$Q M+#DP.2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#(T+#8S M."`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@ M6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE M/3-$)W!A9&1I;F6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQT M86)L92!C96QL6QE/3-$ M)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M:6YD96YT.B`P+C5I;B<^("`@(`T* M("`@("`@26X@8V5R=&%I;B!O9B!I=',@8V]N=')A8W1S+"!T:&4@0V]M<&%N M>2!W87)R86YT2!O9B!T:&4@<')O9'5C="X@5&AE($-O;7!A;GD@;6%Y(&%L2!R:6=H=',L('1R861E('-E8W)E="!O2!I;F9O2!C;VYT2!W87D@8V]N;F5C=&5D('=I M=&@L(&%N>2!C;&%I;2!O2!A8W1U86P@;W(@86QL96=E9"!D969E8W0@:6X@86YY M('!R;V1U8W0@8V%U2!I;G-U'!O2`-"B`@("`@(&AA2!I;B!T M:&4@56YI=&5D(%-T871E2!M M86YU9F%C='5R960@86YD('-O;&0@34].3U9)4T,@:6X@=&AE(%5N:71E9"!3 M=&%T97,N($]N($UAGEM928C.#(Q-SMS(&QA=W-U:70@86=A:6YS="!T:&4@0V]M<&%N>2!A M;F0@=&\@9&ES;6ESGEM928C M.#(Q-SMS(&-L86EMGEM928C.#(Q-SMS(&-L86EM6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!D;V5S(&YO="!E>'!E8W0@=&AE(')E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)W9E'0M:6YD96YT.B`P+C5I;B<^("`@(`T M("`@("`@26X@1&5C96UB97(@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I M;G1O(&$@9FEF=&5E;BUY96%R(&QI8V5N2!3>6YT:&5S($UI=&5K(%-P;W)T2!/6UE;G0@;V8@)#(L-3`P+#`P,"!I;B!$96-E M;6)E2!A<'!R;W9A M;"!O9B!T:&4@<')O9'5C="!A;F0@GEM92!#;W)P M;W)A=&EO;BX@07,@82!R97-U;'0@;V8@=&AE(&9U;&P@9&5L:79E2!R96-O9VYI>F5D(&%P<')O>&EM871E;'D@)#(L M,C`P+#`P,"!W:&EC:"!R97!R97-E;G1S('1H92!R96UA:6YI;F<@8F%L86YC M92!O9B!D969E6UE;G0@:6X@86-C;W)D86YC92!W M:71H(&-UGEM92X@5&AI2!E87)N960@86YD(&-O;&QE8W1E9"!A(&UI;&5S=&]N M92!P87EM96YT(&]F("0U(&UI;&QI;VXL('=H:6-H('=A2!R96-O M9VYI>F5D(&%S(')E=F5N=64@:6X@=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P M,30N("`@(`T("`@(#PO<#X\8G(O/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA&5S/&)R/CPO"!$:7-C;&]S M=7)E(%M!8G-T6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2!D=64@=&\@ M:6YC"!R871E(&9O M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"!R971U"!Y96%R(')E;6%I;B!S=6)J96-T('1O(&5X86UI M;F%T:6]N(&)Y('1H92!)4E,@86YD(&]T:&5R('1A>&EN9R!A=71H;W)I=&EE M"!Y M96%R(')E;6%I;B!S=6)J96-T('1O(&5X86UI;F%T:6]N(&)Y('1H92!A<'!R M;W!R:6%T92!G;W9E'0M:6YD M96YT.B`P+C5I;B<^("`@("`-"B`@("`@($EN(&-O;FYE8W1I;VX@=VET:"!T M:&4@<')E<&%R871I;VX@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S+"!T M:&4@0V]M<&%N>2!P97)F;W)M960@86X@86YA;'ES:7,@=&\@87-C97)T86EN M(&EF(&ET('=A2!T:&%N(&YO="!T:&%T(&ET('=O=6QD M(&)E(&%B;&4@=&\@=71I;&EZ92P@:6X@9G5T=7)E('!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Y-"4G/B`@(`T("`@("`@("`@(#QP('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2!H87,@;VYE(')E M<&]R=&%B;&4@;W!E6EN9R!U;F%U9&ET M960@8V]N9&5N6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD)SX@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD)SX@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([ M(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@ M,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`U-"4[('1E>'0M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("!/ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@ M(#0P,2PS-34@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#$L M,#8V+#0P.2`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@ M("`@("`\='(@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("!/<&AT M:&%L;6EC(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@ M("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^("`@("`-"B`@("`@("`@("`S-C8L M,3,X("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#$L-#(U M+#8P.2`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#DS M."PQ,S0@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI M9VXZ(&QE9G0G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XQ<'0[('1E>'0M86QI9VXZ(&QE9G0G/B`@#0H@("`@("`@("`@5F5T97)I M;F%R>2`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@("`@#0H@("`@("`@("`@,2PS-C,L,34W("`@("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,36QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/B`@(`T("`@("`@("`@(%1H6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N M.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D M:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)VUA6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I M9VAT)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@ M=&5X="UA;&EG;CH@;&5F="<^("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@(#PO='(^("`@#0H@("`@("`\='(@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3@L-#4U+#$V M-R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`E M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,30L-#@U+#@R,2`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`E("`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@."`@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O M6QE M/3-$)V)O'0M M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q M-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)VUA M6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N M.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D M:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@("`@("`@("!'96]G6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!L969T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@ M("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@ M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@ M("`@.#D@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@ M("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S M='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W M:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-S@@ M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX@("`@(`T("`@("`@("`@(#4L,C6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#8@(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SX@("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@ M("`@(`T("`@("`@("`@(#4L,C(V+#8Q.2`@("`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@(#$P("`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`E("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T M6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@-BPS-3$L.#'0M86QI9VXZ M(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ M(')I9VAT)SX@#0H@("`@("`@("`@.#(L,S0P+#,W,"`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3`P("`@(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!" M;&%C:R`R+C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)W=I9'1H M.B`V)3L@9F]N=#H@,3!P="!4:6UE'0M:6YD96YT.B`P+C5I;B<^ M("`@(`T("`@("`@26X@1&5C96UB97(@,C`Q,BP@=&AE($-O;7!A;GD@86YN M;W5N8V5D('1H92!C;&]S=7)E(&]F(&ET2!T:&4@175R;W!E86X@365D M:6-I;F5S($%G96YC>2`H)B,X,C(P.T5-028C.#(R,3LI(&9O2!A;F0@97%U:7!M96YT+"!A;F0@)#`N,2!M:6QL:6]N('=A M'0M:6YD96YT M.B`P+C5I;B<^("`@("`-"B`@("`@(%1H92!F;VQL;W=I;F<@=&%B;&4@6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@8V]L6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE M/3-$)VUA6QE/3-$)VUA'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@ M("`@,C$L-S`Y("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@ M,BPY,CD@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@ M#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@("@Q+#0R-2`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("D@(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,2XQ<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q M-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@ M(#PO=&%B;&4^/&)R+SX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65T($%D;W!T960@6U1E>'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M:6YD96YT.B`P+C5I M;B<^("`@#0H@("`@("`\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/DEN($IU;F4@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD M87)DF4Z(#$P<'0G/C(P,30M,3(L("8C.#(R,#M# M;VUP96YS871I;VX@+2!3=&]C:R!#;VUP96YS871I;VX@%1O<&EC(#6UE;G1S(%=H96X@=&AE M(%1E6QE/3-$ M)V9O;G0MF5D(&EN('1H92!P97)I;V0@:6X@=VAI8V@@:70@8F5C;VUE6QE/3-$)V9O;G0M&ES=&EN M9R!5+E,N($=!05`N($%352`R,#$T+3`X(')E<75I2!A M(&1I2P@;W(@82!G M2P@=VAI8V@@9&ES<&]S M86P@2=S(&]P97)A=&EO;G,@86YD(&9I;F%N8VEA;"!R97-U;'1S+"!S:&]U M;&0@8F4@2!T M:&%T(&]C8W5R(&EN(&%N;G5A;"!O2!D;V5S M(&YO="!E>'!E8W0@=&AE(&%D;W!T:6]N(&]F($%352`R,#$T+3`X('1O(`T* M("`@("`@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!I=',@8V]N6QE/3-$)V9O;G0M M9F%M:6QY.B!!'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQT86)L92!C96QL M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O M;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,30L.3DY M+#$V.2`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-CDY("`@ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[ M('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X M)3L@=&5X="UA;&EG;CH@'0M M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X M="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@ M/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@+2`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@+2`@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@("`@#0H@("`@("`@("`@-2PP,#`L,#`P("`@("`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T M6QE/3-$)W!A9&1I M;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3DL.3DY M+#8P,"`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L M6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D M:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)W9E6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O M;3H@0FQA8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^(`T* M("`@("`@("`@("0@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=W:61T:#H@."4[(&)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("`D M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA M;&EG;CH@;&5F="<^(`T("`@("`@("`@("0@(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@."4[(&)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G M/B`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("T@(`T* M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T>6QE M/3-$)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@ M+2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@-2PP,#`L,#`P("`@ M("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ M(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M/"]T6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ M(')I9VAT)SX@#0H@("`@("`@("`@+2`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@8V]L6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3L@8F]R M9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@ M;&5F="<^(`T("`@("`@("`@("0@(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@."4[(&)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$ M)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXW-7!T(&1O=6)L M93L@=&5X="UA;&EG;CH@;&5F="<^(`T("`@("`@("`@("0@(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@."4[ M(&)O'0M86QI M9VXZ(')I9VAT)SX@(`T("`@("`@("`@(#,T+#(V-BPU,#$@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O3X-"CPO:'1M;#X-"@T+2TM+2TM M/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T M,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F-E;G1I=F4@4&QA;B`H5&%B;&5S3QB6UE;G0@07=A6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M M8V]L;&%P6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L M6QE/3-$)W!A9&1I M;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`W,24G/B`@(`T("`@ M("`@("`@(%)I'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E'0M M86QI9VXZ(&-E;G1E'!E8W1E9"!V;VQA=&EL:71Y("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T* M("`@("`@("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6EE;&0@("`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`S)3L@=&5X="UA;&EG M;CH@8V5N=&5R)SX@(`T("`@("`@("`@(#$N,38E(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@-R4[('1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@,R4G/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S M)3L@=&5X="UA;&EG;CH@8V5N=&5R)SX@(`T("`@("`@("`@(#`N-C$E(`T M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T M:#H@-R4[('1E>'0M86QI9VXZ(&-E;G1E'!E8W1E9"!V;VQA=&EL M:71Y("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0^("`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'!E8W1E9"!L M:79E65A6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'!E8W1E9"!D:79I M9&5N9"!Y:65L9"`@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!C96YT97([(&)O6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C M96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O M='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!C96YT97([(&)O6QE/3-$ M)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X M)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[ M('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T* M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T M:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3,L-C@R M+#0T.2`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@ M#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@ M("`\+W1R/B`@(`T("`@("`@/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("!%9F9E8W0@;V8@9&EL=71I=F4@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@ M("`@("`@-C6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T* M("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@ M.#0R+#,P-"`@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q+C%P="!S;VQI9#L@=&5X M="UA;&EG;CH@;&5F="<^("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,2XQ<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,34L-#,T+#@W-2`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O M'0M86QI9VXZ M(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,BXW-7!T)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,30L-C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QP861D M:6YG/3-$,"!C96QL6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@8V]L6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O M6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O M;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C M96YT97([(&)O6QE/3-$)VUA6QE M/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^ M("`@#0H@("`@("`\='(@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@ M("`@#0H@("`@("`@("`@,BPW-C(L-3(R("`@("`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@/"]T6QE/3-$ M)V)O'0M86QI M9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'0^)SQT86)L M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O M6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N M.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O M='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG M+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]LF%T M:6]N("`@("`-"B`@("`@("`@("`\+W`^(`T("`@("`@("`\+W1D/B`@("`@ M#0H@("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D M9&EN9RUB;W1T;VTZ(#$N,7!T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([ M(&)O6QE M/3-$)VUA6QE/3-$)VUA6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@ M("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@ M("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@ M("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@ M("`@#0H@("`@("`@("`@2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`- M"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3`L M,#DR+#8V,R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,3$L M-S4S+#`P,R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#4L-3`R+#8X-B`@ M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("@V,S@L-#(V M("`@(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@2`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("T@(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T* M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^("`@("`-"B`@("`@("`@("`T+#@V-"PR-C`@("`@(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^("`@("`-"B`@("`@("`@("`U+#(X-BPQ,C<@("`@(`T M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@("`@("`@)B,Q M-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T* M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97(G/B`-"B`@("`@("`@("!);F1E9FEN:71E(`T("`@ M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@("`@/'1R('-T>6QE/3-$ M)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("!$:7-T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@ M("`@(#$W-"PQ,#,@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@ M(#6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T* M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@+2`@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI M9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@#6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@ M("`@#0H@("`@("`@("`@,S6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@#,L,#$U+#4P,R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE M/3-$)V)O'0M M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@#DL.#4S+#(S.2`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX@#0H@("`@("`@("`@,38L,#,S+#DT-"`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D M:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L M969T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T M97AT+6%L:6=N.B!R:6=H="<^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0^("`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@6QE/3-$)W9E6QE/3-$ M)W=I9'1H.B`W."4[('1E>'0M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("!" M86QA;F-E+"!B96=I;FYI;F<@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@ M("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@#6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@(#PO M=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R M=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)W9E6QE/3-$)VUA M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`W."4[('1E>'0M M86QI9VXZ(&QE9G0G/B`-"B`@("`@("`@("!,86)O'!E;G-E6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@("`D("`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO M='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@ M("`@(`T("`@("`@("`@(#@X,BPV-3$@("`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@("`@#0H@("`@("`@("`@-S8V+#6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!3 M96=M96YT(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I M;F<],T0P('-T>6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T M97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O'0M86QI9VXZ(')I9VAT M)SX@#0H@("`@("`@("`@,3@L.#DY+#@W,R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@#0H@("`@("`@("`@,3(L.#,P+#4V-B`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@#0H@("`@("`@("`@-#@L-S4P+#(W-R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX@#0H@("`@("`@("`@-#`L-C(P+#,S.2`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@ M("`@("`@(#DS."PY-C8@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@ M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@ M("`@("`@(#$L-#4R+#DT-B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T* M("`@("`@("`@(#$L,3,V+#(T."`@("`@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@ M(`T("`@("`@("`@(#0L-3@Q+#0Y-B`@("`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@ M("`@(`T("`@("`@("`@(#,L.34U+#$S-"`@("`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@ M("`@(#,V-BPQ,S@@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G M/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T* M("`@("`@("`\=&0@6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ M(')I9VAT)SX@("`@#0H@("`@("`@("`@,RPQ,C0L.34S("`@("`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@/"]T6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@ M("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXW-7!T.R!T97AT+6%L:6=N.B!L M969T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-36QE/3-$)W!A9&1I;F6QE/3-$)V)O M'0M86QI9VXZ M(&QE9G0G/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D M/B`@("`@#0H@("`@("`\+W1R/B`@(`T("`@(#PO=&%B;&4^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE M/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C,38P M.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@("`@("`@("!' M96]G6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@ M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@ M("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@ M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T M97AT+6%L:6=N.B!L969T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@ M("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@ M("`@#0H@("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@ M("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=W:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX@#0H@ M("`@("`@("`@.#0@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@ M("`@("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@ M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[ M(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@ M)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL M93TS1"=W:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@ M("`@.#(@("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#$L-S@T+#0Q-"`@("`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX@("`@(`T("`@("`@("`@(#@@(`T("`@("`@ M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SX@("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@ M("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX@("`@(`T("`@("`@("`@(#$L-C4V+#8U-B`@("`@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX@("`@(`T("`@("`@("`@(#D@(`T("`@("`@("`\+W1D/B`@ M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX@ M("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M(#PO='(^("`@#0H@("`@("`\='(@6QE M/3-$)W!A9&1I;F'0M86QI M9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T M9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@ M("`@("`@("`@,2PX,34L.#0R("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T M("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("4@(`T("`@("`@("`\ M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,2XQ<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@("`@("`@.2`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ M(')I9VAT)SX@#0H@("`@("`@("`@,36QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/B`@ M(`T("`@("`@("`@($YI;F4@36]N=&AS($5N9&5D(%-E<'1E;6)E6QE/3-$)W9E6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@ M(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@ M("`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX@("`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)VUA6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@ M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\ M=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE M/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@ M($=E;V=R87!H:6,@3&]C871I;VXZ(`T("`@("`@("`\+W1D/B`@("`@#0H@ M("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^("`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N M.B!L969T)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!R:6=H="<^("`@(`T("`@("`@("`@("8C,38P.R`- M"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T)SX@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!R M:6=H="<^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@ M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE M/3-$)W9E6QE/3-$)W=I9'1H.B`U-B4[ M('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@ M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@ M("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@ M("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^ M("`@#0H@("`@("`\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`E("`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0^("`@(`T("`@("`@("`@("8C,38P.R`-"B`@ M("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@ M#0H@("`@("`@("`@-2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)V)O'0M M86QI9VXZ(')I9VAT)SX@#0H@("`@("`@("`@-3,L.#(Y+#@R-B`-"B`@("`@ M("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O'1087)T7V)A-3$W,3$S7S!D,C=?-#,V,5]A-V)A M7S$P838S83,X-30R8PT0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B M834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,O5V]R:W-H965T M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P M86-I;F<],T0P('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ M<'0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@ M(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!P861D:6YG+6)O='1O;3H@,2XQ<'0G/B`@(`T("`@("`@("`@("8C M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@8V]L6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O6QE/3-$)VUA2`-"B`@("`@("`@("`\+W`^(`T("`@("`@("`@(#QP('-T M>6QE/3-$)VUA6QE/3-$)VUA2!# M;&]S=7)E("`@(`T("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@ M("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`- M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^("`-"B`@("`@("`@("`F(S$V M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^("`@("`-"B`@("`@("`@ M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@ M("`@("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24G/B`@#0H@("`@("`@("`@)B,Q-C`[(`T M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@ M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@ M("`@)B,Q-C`[(`T("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@ M(`T("`@("`@/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("!#87-H M(%!R;V-E961S("A$:7-B=7)S96UE;G1S2`@("`@#0H@("`@("`@(#PO=&0^ M("`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@ M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@ M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX@("`@(`T("`@("`@("`@("@Q,"PQ,S`@("`-"B`@("`@("`@ M/"]T9#X@("`@(`T("`@("`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`- M"B`@("`@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX@("`@ M(`T("`@("`@("`@("@Q,2PU-34@("`-"B`@("`@("`@/"]T9#X@("`@(`T* M("`@("`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B`@(`T("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@ M("`@(`T("`@("`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX@("`@#0H@("`@ M("`@("`@#$R-"`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@ M/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B`@("`@#0H@("`@("`@("`@)"`@#0H@("`@ M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!/<&5R871I;F<@06-T:79I=&EE'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q M,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D($-OF5D($=A:6YS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XV.3D\F5D($QO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO2!-87)K970@1G5N9',@ M6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!);F-E;G1I M=F4@4&QA;B`H1&5T86EL2!);F-E;G1I M=F4@4&QA;B`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`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T+2TM M+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S M.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!);F-E;G1I=F4@ M4&QA;B`H1&5T86EL'0^)SQS<&%N/CPO'0^)S0@>65A'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!);F-E;G1I=F4@4&QA M;B`H1&5T86EL'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S M-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8F$U,3'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P M9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M2!4'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@T+#'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S M-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8F$U,3'0O:'1M M;#L@8VAA6EN9R!686QU92!O9B!';V]D=VEL;"!;06)S=')A8W1=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO2!A9&IU3X-"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B M834Q-S$Q,U\P9#(W7S0S-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F$U,3'0O:'1M;#L@8VAA'!E;G-E'0^)SQS<&%N M/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$U('EE87)S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S M-C%?83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8F$U,3'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M"!996%R(%M-96UB97)=('P@1F]R96EG;B!487@@075T M:&]R:71Y(%M-96UB97)=('P@36EN:7-T'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!996%R M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!'96]G'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T+2TM+2TM/5].97AT4&%R=%]B834Q-S$Q,U\P9#(W7S0S-C%? M83=B85\Q,&$V,V$S.#4T,F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8F$U,3'0O:'1M;#L@ M8VAA'0^ M)SQS<&%N/CPO65E('1E'0^)SQS<&%N/CPO&-H86YG92!);7!A8W0\+W1D M/@T("`@("`@("`\=&0@8VQA2!497)M:6YA=&EO;B!A;F0@1F%C:6QI='D@0VQO'0^)SQS<&%N/CPO M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T#0H\>&UL('AM;&YS.F\] M,T0B=7)N.G-C:&5M87,M;6EC XML 24 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 11 - Mitek Monovisc Agreement (Details) (Miltek MONOVISC Agreement [Member], USD $)
1 Months Ended 3 Months Ended

Dec. 31, 2011

Jun. 30, 2014

Mar. 31, 2014

Miltek MONOVISC Agreement [Member]

Note 11 - Mitek Monovisc Agreement (Details) [Line Items]

Contract Term, Years 15 years

Deferred Revenue $ 2,500,000

Deferred Revenue, Revenue Recognized 2,200,000

Revenue Recognition, Milestone Method, Revenue Recognized $ 5,000,000 $ 17,500,000

X

- Definition

The contract term of the Miltek MONOVISC agreement.

+ References

No definition available.

+ Details

Name: anik_ContractTermYears

Namespace Prefix: anik_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_Note11MitekMonoviscAgreementDetailsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 14 - Restructuring Credits (Tables)
9 Months Ended

Sep. 30, 2014

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

Restructuring Accrual

Employee

Severance and

Related Benefits

Activity

Termination and

Facility Closure

Costs
Total

December 31, 2013 $ 21,709 $ 2,929 $ 24,638

Cash Proceeds (Disbursements) (10,130 ) (1,425 ) (11,555 )

Foreign Exchange Impact (1,050 ) (124 ) (1,174 )

September 30, 2014 $ 10,529 $ 1,380 $ 11,909

X

- Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(2)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB Topic 5.P.4(b)(2))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 13 - Segment and Geographic Information (Tables)
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, Nine Months Ended September 30,

2014 2013 2014 2013

Orthobiologics $ 18,899,873 $ 12,830,566 $ 48,750,277 $ 40,620,339

Dermal 401,355 267,766 938,966 1,066,409

Surgical 1,452,946 1,136,248 4,581,496 3,955,134

Ophthalmic 366,138 1,425,609 938,134 2,818,407

Veterinary 855,000 1,363,157 2,385,000 3,124,953

$ 21,975,312 $ 17,023,346 $ 57,593,873 $ 51,585,242

Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]

Three Months Ended September 30,

2014 2013

Total

Revenue

Percentage of

Revenue

Total

Revenue

Percentage of

Revenue

Geographic Location:

United States $ 18,455,167 84 % $ 14,485,821 82 %

Europe 1,784,414 8 % 1,656,656 9 %

Other 1,815,842 8 % 1,611,961 9 %

Total $ 22,055,423 100 % $ 17,754,438 100 %

Nine Months Ended September 30,

2014 2013

Total

Revenue

Percentage of

Revenue

Total

Revenue

Percentage of

Revenue

Geographic Location:

United States $ 72,935,722 89 % $ 42,251,336 78 %

Europe 5,274,071 6 % 5,226,619 10 %

Other 4,130,577 5 % 6,351,871 12 %

Total $ 82,340,370 100 % $ 53,829,826 100 %

X

- Definition

Represents schedule of revenue and operating income, by geographical areas.

+ References

No definition available.

+ Details

Name: anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock

Namespace Prefix: anik_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 12 - Income Taxes (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Note 12 - Income Taxes (Details) [Line Items]

Income Tax Expense (Benefit) $ 4,125,355 $ 2,776,199 $ 18,872,435 $ 8,147,282

Effective Income Tax Rate Reconciliation, Percent 40.00% 36.00% 38.00% 37.00%

Earliest Tax Year [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]

Note 12 - Income Taxes (Details) [Line Items]

Open Tax Year 2011

Earliest Tax Year [Member] | Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]

Note 12 - Income Taxes (Details) [Line Items]

Open Tax Year 2009

Milestone and Contract Revenue [Member]

Note 12 - Income Taxes (Details) [Line Items]

Contracts Revenue $ 24,652,778

X

- Details

Name: anik_Note12IncomeTaxesDetailsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_ContractsRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Tax year that remains open to examination under enacted tax laws, in CCYY format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

+ Details

Name: us-gaap_OpenTaxYear

Namespace Prefix: us-gaap_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

XML 28 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Basis of Presentation (Details) (USD $)
In Millions, unless otherwise specified
6 Months Ended

Jun. 30, 2014

Increase to Cash Provided by Financing Activities [Member]

Note 2 - Basis of Presentation (Details) [Line Items]

Prior Period Reclassification Adjustment $ 2.5

Decrease to Cash Provided by Operating Activities [Member]

Note 2 - Basis of Presentation (Details) [Line Items]

Prior Period Reclassification Adjustment $ (2.5)

X

- Details

Name: anik_Note2BasisofPresentationDetailsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of a reclassification adjustment made to prior period financial statement amounts.

+ References

No definition available.

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Marketable Securities (Details) - Marketable Securities (USD $)

Sep. 30, 2014

Sep. 30, 2014

US States and Political Subdivisions Debt Securities [Member]

Dec. 31, 2013

Certificates of Deposit [Member]

Note 3 - Marketable Securities (Details) - Marketable Securities [Line Items]

Amortized Cost $ 19,999,169 $ 14,999,169 $ 5,000,000

Unrealized Gains 699 699

Unrealized Losses (268) (268)

Fair Value $ 19,999,600 $ 14,999,600 $ 5,000,000

X

- Details

Name: anik_Note3MarketableSecuritiesDetailsMarketableSecuritiesLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Marketable Securities
9 Months Ended

Sep. 30, 2014

Disclosure Text Block Supplement [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

3.
Marketable Securities

September 30, 2014

Amortized

Cost

Unrealized

Gains, Net of Tax

Unrealized

Losses, Net of Tax

Fair

Value

United States Treasury securities $ 14,999,169 $ 699 $ (268 ) $ 14,999,600

Bank certificates of deposit 5,000,000 - - 5,000,000

$ 19,999,169 $ 699 $ (268 ) $ 19,999,600

The Company considers securities with maturities of three months or less from the purchase date to be cash equivalents. Interest is recorded when earned. All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes.

X

- Definition

The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).

+ References

No definition available.

+ Details

Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments (USD $)

Sep. 30, 2014

Dec. 31, 2013

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities $ 19,999,600

Fair Value, Inputs, Level 1 [Member] | US States and Political Subdivisions Debt Securities [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities 14,999,600

Fair Value, Inputs, Level 1 [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities 14,999,600

Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Money market funds 49,285,168 34,266,501

Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities 5,000,000

Fair Value, Inputs, Level 2 [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities 5,000,000

Money Market Funds [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Money market funds 49,285,168 34,266,501

US States and Political Subdivisions Debt Securities [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities 14,999,600

Certificates of Deposit [Member]

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]

Marketable securities $ 5,000,000

X

- Details

Name: anik_Note4FairValueMeasurementsDetailsFairValueofFinancialInstrumentsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 32 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 8 - Intangible Assets and Goodwill (Details) - Changes in Carrying Value of Goodwill (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Changes in Carrying Value of Goodwill [Abstract]

Balance, beginning $ 9,360,884 $ 9,443,894

Effect of foreign currency adjustments (658,589) (741,599)

Balance, ending $ 8,702,295 $ 8,702,295

X

- Details

Name: anik_ChangesInCarryingValueOfGoodwillAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (Unaudited) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Current assets:

Cash and cash equivalents $ 71,772,194 $ 63,333,160

Marketable securities 19,999,600

Accounts receivable, net of reserves of $546,455 and $593,023 at September 30, 2014 and December 31, 2013, respectively 20,170,095 18,736,845

Inventories 13,582,456 10,996,785

Prepaid income taxes 1,343,576

Current portion deferred income taxes 659,040 659,040

Prepaid expenses and other 1,128,693 865,957

Total current assets 128,655,654 94,591,787

Property and equipment, at cost 53,379,965 52,413,423

Less: accumulated depreciation (21,343,322) (19,474,712)

32,036,643 32,938,711

Long-term deposits and other 69,054 69,080

Intangible assets, net 16,033,944 18,998,409

Goodwill 8,702,295 9,443,894

Total assets 185,497,590 156,041,881

Current liabilities:

Accounts payable 1,167,545 2,793,911

Accrued expenses 5,253,693 5,537,881

Deferred revenue 12,885 180,433

Income taxes payable 770,276

Total current liabilities 6,434,123 9,282,501

Other long-term liabilities 948,858 1,133,544

Long-term deferred revenue 56,573 2,054,941

Deferred tax liability 8,353,531 7,936,864

Commitments and contingencies (Note 10)

Stockholders’ equity:

Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively

Common stock, $.01 par value; 30,000,000 shares authorized, 14,800,453 and 14,289,308 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively 148,004 142,893

Additional paid-in-capital 76,064,383 70,606,031

Accumulated other comprehensive loss (3,595,487) (1,699,095)

Retained earnings 97,087,605 66,584,202

Total stockholders’ equity 169,704,505 135,634,031

Total Liabilities and Stockholders’ Equity $ 185,497,590 $ 156,041,881

X

- Definition

Represents non-current deposits and other assets.

+ References

No definition available.

+ Details

Name: anik_DepositsAndOtherAssetsNoncurrent

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph b(1)

-Article 7

+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5865-108316

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)(4)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 13 - Segment and Geographic Information (Details)
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Number of Reportable Segments 1

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 1 - Nature of Business
9 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

1. Nature of Business

Anika Therapeutics, Inc. (together with its subsidiaries, “Anika,” the “Company,” “we,” “us,” or “our”) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.

The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary information and technology, commercialization of existing and new products, and compliance with the U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Earnings Per Share (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Earnings Per Share [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 122,967 0 118,725 88,278

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

Fair Value Measurements at Reporting

Date Using

September 30, 2014
Quoted Prices in

Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable

Inputs

(Level 3)

Money market funds $ 49,285,168 $ - $ 49,285,168 $ -

Marketable securities:

United States Treasury securities 14,999,600 14,999,600 - -

Bank certificates of deposit 5,000,000 - 5,000,000 -

Total marketable securities $ 19,999,600 $ 14,999,600 $ 5,000,000 $ -

Fair Value Measurements at Reporting
Date Using

December 31, 2013 Quoted Prices in
Active Markets
for Identical Assets
(Level 1) Significant Other
Observable Inputs
(Level 2)
Significant

Unobservable

Inputs

(Level 3)

Money market funds $ 34,266,501 $ - $ 34,266,501 $ -

X

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 38 0001171843-14-005281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-14-005281-xbrl.zip M4$L#!!0````(`$`P9D4#/IB"?WH``)5)!P`1`!P`86YI:RTR,#$T,#DS,"YX M;6Q55`D``R=56U0G55M4=7@+``$$)0X```0Y`0``[%W;OVT M^^`8)ZNQ%4=VSG'9Y.TRW9FSCZE,AM9FCH(VC'/G_]2C3M%C0"T0CZ,F0> M)J%!W^^[Z_))^OA?IZ>COZ$082=!WNCQ;>1?_G@RFLWO77]T$R;D M5S?Q7Q!Y%KX@3/Y-?G].DOGYV=FO7[\^N.35V/4QBJ,%=E%,'XQ.3R]&],]_ M_L='2N02(TKB?/0[H?,]>ADI^@C`<]T^5Y31CX?+$5!4;?D1^>+U$0>CUUD0 MQI].&$+T\8<(/YT!18%G?A@G3NBBD^6;Y_17O^'[WOH#]F7C;/GCZM5%?/KD M.//W=Z=._)B^F_UP1M&?NHI5%>?>C0=(S<#T_1RQGYH>3UP`__K,!.?WYT MXC7VH.+E?WXE;S/0D[3V)_-`RK^]-DS1M-/ M)U0HIRL9?'B-O9.SBV5#;D2\YC49^=ZG$U?Y.8XG4ZC4V/O(C"Q$_> M+MX?D$>^1Q].?>)E124XV5E197 M%K)ZMJ6P("LLN!;6/MI3EBP@;"@)&%IF;"<\/`L2^W;LG166`=F6<+"DF59 M1BY0@ST4$1.H@:1`;>92\C[:12X[R4G)5J;IB9OL:>3(]4-418:F[8W`^8]% M^M>?-Z%+QB0Q>H@NG?CY%DV+'Y)NH1\^C>F@QT]\%']#LT>$^Q08 MC0SH:8;6C?/EJ.2<_0Z#WS73Y:X1IY/7HS]/QTDHU'SJ\QCO!EA#$B3$1A M/`Z]6R(V?)L;^S]L8@3VGI\AXAX$T3__OF-^4?V8NB-9]$B3,:O?GQR03N\ MYXWE]O&L%'8AM)V]\]M?MC%D!%!5X9K8%2J5U&1.Q]N#A?$LKG8J@SL".Q+ MS8\??_ZXOZ!40.KA/<+QX](A.JH@.TI9OP!2VMY8$,MI>6L/I-C%NN M";36?Q=C8Y`?'/^\1)CU5\3J97:![%PY.UF`.68L5'':;'CH8Y1.%Y1WR M6Q2BMV\._A,E7Q:A%Q^VEWVE" MBOOY+HZ;<+Y(XJ_H!07@7:E_>95N">/]KW\GG#K8?7Y+!9O'5"'ZWN$-'/3 MCSYQ"UA9R_R]IZHUME)M:611UVH?E%Y4>M^Q1CW46&,6#/(XNI0"IK95SW(O M56B)J_"OTD5II=RAGR)H>';!\&JRU.&9UU\N'0!%07@+ZG20_524BH&&8= M.L[KTHI"BK-]PZS#,.O0H;E!7A'23[KX@GTW0=Y]$KE_'MJX<_S+P=[FU'(I M5[TN"?5>.@4T41W_"/TDOKO_P4XM'96Z\PQVF!EVKW2=5P-6K?2?GR,B2#)Z M\NE2;80/KZ/0C24T0?#@)P&:3&]".H/E+9R`6:TN%^_^%CW(,49#U!B'+'.P M.C:W"SA#ECEDI5M+I8_GN%C-E$IB/)^3..<[M.;GSG]Z3N+[\=W]X:U< MRV-WA29%U6M]%QJ!S5K)]X5R/_1GB]GAJ?G."9\**L[Q MCSY97HY:GRIWU#?XYP$.Z"!WN]C@GP>I3\C;=S3X9UM][F)G%-3X^AS\\P#U M6:S'NZ+S_-$<>0_(?0ZC('IZ6W;W#VW.X@MQR01]]5^0=Q,F1,7^8X#2!9CX M\]LWYX\(ERS$U'#?Z=Q&!^NCD#\C->AY5WK>?9_9+"R^#K:P!SXO:ZT36L4, M/>AYYWIND>[M^(H?SP]HYHW%/QQI4VZ=J=Y_I]>)H?U#_3CQ;6CHW^`/\ M0;4[\NR=Y.SB_M9;TEB8'.6^6U4GN/VH,ZZT2QN;AY4V$,56?\YV"[DX$'- MW7JJK%RK]Q<.ZBP:T_=14[5BP?+70?H!<7Q`W8\]-V9H>.>$DDW;Y2S?%C# M7[VXP7308Z]ZE!:`-^K'!HWVJ-'=Q^/5\739AHM>1[);A2]#2OC]C4N;5U= MF[WZ\YL?).C/;Y/OD]]N[B_'3QBAPE3]H=C_%9HBC)%W1XPZ7`QQK00C[:W MWH.2FGTERSU.SO4J`4=0)7E`/FSZ`?]]ZM_QK=562EM8PNA^LW!V9:%0;<[ M\NV&TP)0BF_S]Q4.EK!+2^A]FZ%>MI?D&WKO7";+PYE[2!6< MH::7Z!%VPB3.[^:RRX/0]WY_#!K]BZBF9$,+Y[2>\#P&]+KG^F%Q"&3I") MZ![A%]]%-ZL-N3^O'1SXY+L'Y_7_D(/?#66_K61=D.$2K@GV\2)YCC"!6ECL M9.)Y(-3-S'0`5>Q<12"Y/VW!>L]LAN&RO66+Q%&_E.8=Q:Z M.2LF_YQ,KTD[T_1II;SOQ@>60VYQY"W<9(SJ,ST-L`YEU_%-ZCU@/.LS:"C>WWB_P$[V,Z0!G>BI4 MF^>JO^+:WM.KJ7+3ZZ!9F3[;>X8U`3?##IJ5Z;.])UF3?RSRYO>=<2^7FW$&YDCVW]YQK\>NFZ,5(](XDTOH!;@]/<=//_X:B)^S, MG^FT!:/E3>[ZKE]V7LG1-+^8:M!TES[= M?Y[FUU1=+W`T/[QC`RI4_%['SG!VS)7-%K^R:E"N9,_M/QOSZZL&Y4KVW/X3 M,+_:E"N9,_M/>?:_%JK2?,\-?(3>^1/<`E_KK^50E_1UQZ9?-+KP9%'U,E MELVOQ!H4?4R%63:_,&M0]#'5:=G97-?$34BK8'W"&-C'(]9RX@GJB(J+B#I M&"Y;YXGKY_$9WZ8&L\X]&YF<\?'U#(FTYO;NZM;'/V!W/7Y/8?A M,GQ4XP MF=[2`0%.WHC`KO^U\(N7[AR;F8@RWU/$&+B)A79H>W?%M-Y-;-=*KZ#0XGMXG'^8S?Q7PB4?`K\ MXKA^0)Y>!E&\P"BOW-%Q!?>F$CBH6P!4A5^F5>O%1Z7FW;GQSD?&JL(_=FP[ M_S\JR]B?`+`'E@**ET@,0:+O7"_K(@E5=Z,.3C['CF['(TO0G^I[D7LL4N. M,^103B[\.-`:I[_N+_Z>+9Z.%JW1[]G_LTV=XMP_.Q@%#->[A'A>2C'!_WD M^V&L$.&0QU(-9"++:2;_\T5,6P]5O932HFOSS)>`23M=4BFV]RWK- M6XULWJ52D#4'0G5C<_).KE.=;XW^O"FSS>8R)Z"S6?0<8O(_.C'QX@2(GE:< M7#H8OQ&_^,T)%FA$/[Y#TZ71C#32A^X2CYDG(P\Y/HS)X@_G2@G%Z9JFD"U M-4_"<$+Z3`+=X`78!J0_%$-I2W,;P[^$R7.8X#ND4OB2NC^'!,?EV>QFJ M-OEC`RX"C(;D,:N2\\^C>^0BP@;Y)OO&F-B3PR%<76UYBJZ)38W;:PJO6H M6B8T+&U[6.^S-.2M%AJ#N@4TW5C#8-O=4)$HT1K>%6(EIJ4+$KW%:.[XWH/S MBN(VG&I0-QE&V68O"B17Q^/3LW+3JW]D6**AVXK&^$8%D0LI<&HBR=9P,LE= MO\Y)1X6>#9\NTBT_:A]#5&`9-MS04Q4UGLELB[!:VH5O-O:[JMFI;));H1JU9K"K$E"W],P];(Q69Y`>QC5_`/3AC8;,H5AX`7ROOK. M(YWQDS&@UX$.UAH'GX8L/#5FJDHLWV'&D"53B-#0&30;/+=AD73 M'DE-L"?]4%M3A;#P9ZDDVX\%=?)?"2@>J8H)-,FF1'C81G:]M`NH]G,3V;I M)/GR6D/2&42AZS><77R-ST,_^'22D$!W"^CLXMS@1PGT3NG\U7 M08KMMVF\%OR&A)P2]CY^)9BL(NW11:+M>..V:V8!B^TBU=,>>YY/IPR< MX-;Q28Z\=.9^X@3,ARV6L0R%I$&+[;+54MOH2+;"5^.^"@&HL%E"WSKF9DT MC]"[2S%ZIJOF+VC9Y?@:Q?'J0KTT#+AO#]@)XV"Y+.[]L8B3;,YA,B618WN! MGT+=UK7<;A\>.7+4GTH5JKIZIAV\5%MAZ$<(<2QP^1=^W@D$37.#=G-Z4U M#2WZ49B$6]B>JG5K34=OAJ)HL,W=``MK@2]WK.0H\A&,Z#Y>\M9D@(A+3 M=%9@F\U?M%?$X>A;D`M%UIJZ3,=!ICI4IC<[DCECEV0QO,93+,WAC8,@ M^D5O!"5>?!4M'I/I(MA6N\9O MQ=D5N?]&WAIG4XG>?/]"9XIT6A_(@UFD5K:4O3VX"O%U!NXFCA>MI58#:4FC M;BS4`$^=H"3BF2P26@E)ER"Z%1)#2#:RENJ1,9T_'L+=0(TNP/:),:U!2HY MN$%E^:<48&WTV!Y7G?U)QB4EI"WG/3RF8-,"(#46WT3V:+Q1K$-&&Y"M7RFCM!D;FN+A'KM; M'&"8I/\+-:-K/-S#88L=``R=5H;TPT47NQ`)V2,I5N4`@'&V@!VP<8%R* M@NX3FTS3.'0?!9X,N]!-0#,[FSIS-$KZ8<(81U"A\0L#L3#(VH>H:W?T! MD%LC4+4)E1#)[UDLUH=Q=GL&#G8I;N-KHCI!%%:MIG5OT8E:E:$:BLGNY^@%G7`$4H!MF]IVZ.Y1$-""310B[`2T M[MJ;^:$?)]A)_!317,X0(ET2Q%M#%K5J%J68=C[`%DX`H:X M#K-LT,+Q4M&AH1F@!>BTKCN_EQLCKWH-4#@XV89BK0K:2VAN-V72JBR-$4XCJFG8@%V(+%+9$01!R&J$)+)+-6HQ-!&+.!DG/ M3[%,M1-AB-H%I+T-`YK"("9SNEV>V,VZ5$"92C$/H'5D9N$BJ."Q?N(C6>\JM4,RPTAA$FT6;Z1F=3W(Q6 MGTH:V=HV:\(B5&4C%36N4PA(]&F,53):X0Z!`:'='Q4K(&>JJ2:KK6XBV MB/>]!HK079:'+LC;F;E'8?P932.,F!+ZZU?2M8BPE][F=Y.@65KE2K[$4=H3 M62&1%"EM0\WSV1G@C5UB.Q&->."&4-/-GB2S+X;3()F8NL6.H8[><,1SFV8 M&M1V)QK20A:@/I-1R[2ZTR\\:%:!#C6JIG``EO(BJ0VN1UT0S65W!QQCD(+`)VH]FZ"=BM4[(` M"(_7%%VA:P95"+:$(#S5`3! M)_1]00\FG$PW"BP6+>WLRX@_1<3+8FNA&.S>`@DPTAHURR`0T+:)J]EVP( MV7&F#0,8-KNY>8_8$#+]3!LZ/49'D\9&T7^N_&"1($]VM%7X'IM1%,@#3;`U MB+H5T:0;;+15_W`EH;T@TTT"BL?V/U9XM@XYII]T+3`KD$TULE0R3+U6L?A M(=F8(I++28.`3#J55NZ8LOWBI$%,UC7#!NPDZ'YQTB`L:X8)+;,^20ISPMOF M^"/$R`EHH?'?HR`]>,CQ0]J/GH3K,U''V(_)3U?I6MEM>CRRY,X2$ZNRNN MZ`EL6,7,A&>J-HSF?"VPSIN=MKV&2JJKU?)B(])NALQA>AW$!] MN_+7[D3;R)<@6^"^`]%V8>=\T99\(+6;H]DJ,/(;AWCT2HX%V@::<.&Q9<)" MS6_7T(3W-%B&8BJJHI-"CCAN6A-`R8PMP3''MQ;.]7RER];AI:_NPN+KW- M$[V@B9<<:6;=BX6-H"VFI9%'I4U$;0T@9$08D"#W6142JH](&'S4G4RH+6; M`KK%T8M/[^@I.``I1<=I>MK49+H\4E:55/8V3!03;&HL>M7%\4Q M"5_9,BNE66Z&[Z5PV55/-4?)B2K7!M`PV3VMK1"536]VQ:&H@DB85MEUG?8, M%M?F,2)?7J'E_V_"S;-=Y-0/:(J6=\-ZPN6U!WP"M?:89A6OG2/A'`-6!7 M/B_)_`&U?V!5@60HRD(GG,@UJ!B%ZIH6Z+++2E:'9I9>6B)I<`,UUN6V@](Y M/\FK$,UMZ;:$3_IN^N@(P\_T'/;EL4HER1UGO]F9Y-+L1V;'J0,1)&1K5) M2!8`MP9`9IA"D4W!F<]S,9YG)$:I%N;J4[;A(6S1P-\`J;JZ$!#2H=X"T< MKRQ%N1K;.D:K$);("L;JG@84`LG?LF!NGG>N\1X8)JFJB@BQKM)7S`R-`NN>`'@0RF3(] M5"D3(CI4K,U?!44-V;7BCQM==^;^.P'P0\J)%IQLUL'L(6G"&%^(FQKV!P/ MI8/6'YP(WTE$B`@F\W%`926WTL`+RQS6U>,^KAUS_8JP MZ\=(SCDST"1]?HWCA654RXX);0%47P0&.S8>@N@XC-Z7_S0"=U]FD0M0=1J M$K4AA]U/HO(8+`V?=R@]L?XA(BW_[B?/S\O"JR\1[FY=RH":92LE:;4IF-([ M"N998Y/IURA\>D!X=H4>I20!%12..>41$XOY';F&!L@P0JF/F^5FT@%P\64X MV["@(@/X]72W&0R)4[S[(1/Z(Z8U22DC?T_>U_"W+:1)?Q7\'F3:<69'"3 MM'=4)5MV1C/Q$4E.XFQMN2"B2(&`0:'9.;7?^]UXR9`@B1(@EG:L8B"72_ MNU]WOP.;`\$_N#S?@VNTY@:Q^=9-E>7\R?LF`)0SA%J"O?&1MS',UR7;#/E M^(3YUB49GE+V$K%/TT=2?ETCTT`)=B:0GVQN9D-!H.1OG[^#-8!6YIP.8!E5S`'A7K&2VU:-R&F<^'WPQ, MB]@OWKBA'2ZNR!TM+N6&[\T9:2J=9^>N_=44;F"[9.,(EY2;Q;SYK++4^X7-D'_]K#!PW.[BK1V,3>D[DAJ:_>&L[Q&\^XWLO/V%I ME,J9Z$^O0@_N-9AGQ[WDHW-@S<)S?DP?A MRIN9KLB^$(5K0&GR4KCU?(OXO;'G..8$"^$Y"\VZC_N8)I$1_`_"K!?F/F> M@.X"2WJF8]^Y+X30F]>\'+]N50%N?)]_7N#O7.+7\M]_//'V_(C]-O0VFBZ MD5:8KWI"QEC!FPBOHL!V86>4Y!_`';7I+@J/Y'Y^ M('6_1$'A%\_/_^A%?N[''V#MIG5G`38@4C0QL5(ET`U69A#LV0R/FFCJ5X#@ M)8@+<]^SHC&@-X'10QOM)7X7$IK((0I3S!<#1P'H0$A?A$%Y#L36P,LP#@`;X(0`BGOA?=3;THI$2^]:Q%7[@`F$./,@G\G;_@$PPQGRX" M5$T.0XY)3/Z>S)E$+Z'"> MX]W1,2:1.V;6+HC&4\&D-,W1C4[J1+<^/$T_PPB!-PEC"C.N_.G9X"B+]-69 M"7\3W'93G<.ODFJC,!W^=N=CASS\C0TATC'P071T`X0=?YT![./(02Y[]`F4 M7\"%VMA^41/G^]!">'0#3011$F+U$&RJ8W\"!1%VWPZ^!E1R@7SPF8J$BRQ$%I,N$!W7"P7'GMGHL(2> MF@.O[9"HCCS0GBCLQT MA:_@FX+$@4/B$D?,2PG%4@C@(A^&8P!2C@S4P'T!,+IR%/EFTX-Y^C3" ME.BDFC]W+&I3%$KAGA]ZE_WA;>>9]$G+OSH3LC7^85Q\QK[]J@LO2="4O[ M`FMP%SGQFH_?FW.8'79_\`.]L''=B+JQ@/(7J(C[$YZ@1R]\[V'/V3F>3! MRP#8Q%:=-2;.\M:\D0J#B^3M>R"!&/?GL?)`UB9`O9!'\%<`LSTY1N0WU<. MM@9^7.Y,%WP9Y="^#.4OZDN>PSD8NNC,-#C>2MJCIF%7+!MOPGF#LT;B^% M<9OTK\!S;(MNTR;LB!>T-<"6:U17XS6>WA"@B00XI^8]&%I"7+`LL/C[\$/) M/LXC/XAPT02%QN]]7'LR9XH-F1F>&W+Q0_@$\E1(XZ@^6-FJ&2$W7]YO62 M<(U&M#VK,>FH.?`;^3.2(8KR?7$HFVG@N-@^ MM)3Y&:G?4TTXMKP09N"2O!E`M>ZLB@%?\BG[`JUUV(O9R)9U6F!V_`130D)<9L%.V/LF&W M&:R_=T=SO9.Y?_L8P$[$`9%')IE4G&&4/^/-0>9T53DXINM&N).HFFAB.\3 M=I[G[%%V5(@>Y5L0TLS&RE+O/RFOT`+$W+D`867,D<68)S=%<6I/A&`+B,8A MT0_;06_6HKN?^W1'D\P,N@,4(]_FX`83:PET9%`">X9EC(36%UZ#HX+J#8% MWF2P">:,6=W,-H(.R:L)1.;>OG(&72ODX4JCI),WI_G7`-)\#HP423AQM# M,,-(][0&-EI!;T:VVD_U`MB$,UFO$N&!5W.+$1I3_.X^MK7'DR M#IG9U3D\^)W2UX69[3BI7IH,)]@X,XFSX^L_BFUYV$ER(YX?-C$%L4"M)$:` M]R4`75'9UM`].0C`ZS$FWU7DTCH$OER@Z3,L3B52@Q!_%8B5YL)D(^B34G M2%4PG)IA:A$L`F]9L-2Z9-5-ZZCI5TER`'^^26YD[[QBG$:%1$: M[ZB]S%_A]70,OI;'=$;`%O1&'U'%&6I%L<+4HEB14AU-8J][7%C$\8!ZP..!G9W06A(44,ID+?SK;E/R1NL8\%;S8`:R%H[,\GT MHUH+ZC4G3Y1:07\I;4ZU>?6#13DU@M#;U8C?A4B2WW#!UJU$5]VK!6\RMSB M;15D:;:70DSU'@,<:-.7YV&]^FP%`C`#6.C&0,AZ!0,K(->R!&A3<>9RT(X(<0BRP9@\L8=@E##9L6+VL M_`P7$RXF`I9U(D4YX3+2.1EY:]K^$82#A8JWO`78P&<"Z@.U[WR,_$&'WO-? M"/[=[7-%TD1%'8JKO]0[9ZOVA/JQO=%5CMD$M:PL7@[>(,'%9&_$(+L^G)I MTDVWJ'+]CGAGYRZ=8B7"9<9_MRMP])\/BI9#85E31R-1J)LC`Z+9(O$?=+\ M,T:CY6$Y[TZ"=\\58U@Q\)Y1_(%;S#8LIB%)'=:Z/:S\OTUA+6Y^C%+&K('? MFE^I5>8[.J`W2):A-Z=+1.X,>G7^[XM"_0Z_W6-"!P3F+(2E,#114F2 M\'\5\YXF>;APM"8<#K8`!:C3^.K('T\Q[-VB64PT3)N&=Y,L"C;.3",!31[S"6;<87[%#/0 M3-_%[+-SQREE-16R76Q:0S1.H_%ABBPU`Z/Z[TW;0>KV)I[?"V!6EE&,#YJ^ M3Y\:;Z5<$_O)"F:479S?H?1#BSIGEYH9T#2G`',_/'<.'C='(^C6<1"]SU: MXF&<;\$6IW:(@LNNQ),H?_8U1OD3&ER>EXSZZ/(M8HJ7@J_W$8'6QLG M1]]/`^7.DS!"[&=LYE](TAH.,>J.J5RH?NE]N73-;N=.G>MC^!P4E_O.KK% MZK58-;>B)BDV'M6`0;#$9Y@T!U<6G;%:UD4XT^^%P39/3>&)KPBV4%KYOW MCBNL6HW0;`;O1DRM'1OW0](@AY8Z-UH4`"XHF]-_9@'$F8C7U^W'IJS]A52 M73-5;^\SAT:?YA!&<)>5L"7Z'P3VO=A!J2@YRXV53\"^K<;A MI.W6:M2Z:H\:"-5V=@8#>&@TS476D.:1UNC>X"AJ;Q6ZM4,W\(!6BQ05`J= M0@,J&#]\P8J,^J1PR@H:O;M/0+`@E$]I-UU@D`:(@BZF,3DUA8+#,T$_;$/<6"0K,L$-ZX M7R=MCN0]%`0O[I"2NX MU20/$%NRY7(!XV:UL8)0NL0!2,S0S0]_^EEI/S%^D'<-H;T;;MZC%7:2_WQ/7\GQ@,-@6>I+ MQL=.LCU]WB(PL(F8+)!ZNZ3ML-CGUBP/F&/WD/T%-Y0\"KIN"(YM9SORIH) MK]P3L`A/_/P5L^K6S[RE@@EN0[2R(ZSWXYCS^DGTX MO)LF_/-R7L$._0+\U\_ICO+,OD.87/.V6[V7;R;/3P`N'^^3/?/YVS_?`0X MLK.`[4TO5Z,CJ-%U[K#C`STD3]S$/GYD.WE+MDF[BA@9"=-7(Q/5HR/(3B? M\L=G1X$@4YMC:8VZB]9TU!Y50YXHZ#E(B7>>2Y9)(=4$P"QE83P!H"TNV/( MS;QCY%4[P6BYK,A=X]($&DC41GJHFP,#QF8EIUY?7\(#G+9V8OLM)P_Q&7F M"<@,MS=<=IZDO=F#T[=C^G^=C[BE2+8VT"&!KIVK(E'RM##C[.@49IP=G<, MLZ,3F'7K)0YDN^J`DU>+(W/)?!D,./LZ!1FG!V=PHRSHQ.8G=(>LN4ZL4]+ M`G`G`V/F0W=WDWR:JN\6%['R<.%@]?6Y!+!S047#FXN MU@'3O;.(C2NLWGBAZ=0DC;;F8/&>4^Q8AX7C7VQL[',5PT'JEH[,_)XM)Q M^M)QV`#"MOA3Y6FQ[VIJ8)U"P8J-'<9]W%$]LL1R7IJB<6.49JB23$)ILC" MCU7"FJOYL/?=&5>V6M'I5&+I!1G'11QD6L1!78?$W=KXOX2%:LNK%+.8G&$ MXI/51JJ9I#]6IJK>HA<(0+.]Q9+HY3+!)097WAZ9N_EHG%]W+I]YQY/-6^ M>GZ>:L]3[>M)Q%/M3RI]4069,0Q1E^1#GD+PU-?'(#LGG?K98;;&RX[)R4[ M)VUO-CHPSUJ7K.Q(4M%0)7V>;=[C0SWK@WN55(A_A07B=VUJTMTS_$.>S[M MDK'\9+_+)_OM;GMYT6EN078!H<.'<[SH]`G9H?+U1_F)@]@<7G0Z_H\7G3Y1 M->)%I_-@\+3CT",CR$X_":,WX3QF[!'/LZ!1FG!V=PQ;)R&\Z/33DT#.CDYBQMG1 MJ'7,V=`C;N\F>='I1U8HE%>1 MY<)12YO3JR++)8;"RX:B42T:O.@T MEXZG673Z!I4;.PD[N->ZI$ED_-R%$TIQ@M-0I]?S]/K]G4SS]/J6W;JGDK+("[]RV7F2Z:Y<9KB]X;)S4K)STO9F M_2%Y177IAM6BS^(1TW+3K\U@>NY:^,^;OR+[WG3P5^B:+40N38K,AT%UK-B MU6E9_7(>?)BDQ::_4->.G2:\12989&S/3"?XYS/IV9DV4H:Z;`PS M;!H#4U$WNQU$M$:(?$F'9?L+ZNDK^T"R@.+YO6D[`-O/?\:7KO.8CQ6X:27 ME^X;KZ-:R[^W`]MQJ9LG::#0R)"G#HQZ:LU;`-K8"NY(U M<@LHM<2,00FKU[FPZ`^3"Q8470FN+M'_#@KML#FT&^C$9IBT@<>HA,<>A:0- M>!6I`;QMT'8?-E21&?#R!1GCF7ZSQ4#5P-D#7Z]#BX&B-$)D`^;LB&0!Q>RG M#Y/7WFQ.W,`,P0Y>$0>TTWKM!6%P/35]`@X`L3Z:"WI=MVO;B.IK]_JK^BKG MB_5^+[.W:0GY?BUWJ>.VFWYD6V1GL3``@EVINC_`>" MZ5KQ-^9\[H/^4;U@&P8PN_0&L>@OGWO>CSU'!@5!V,/SCR+.'UVX9U.X)21S$&70]1Q0@_X@QD$T8SQYD51Q.85XL5L#5/ZQF:F6410P0"M"`_:(BH:'RJU'_=U5?K M42O%6ZY!!3V6+ZY6&ISVKD92\W5#!?D=RF\@O$'!S=O/"ACV?FN3@E90H$VA MVN8^IX'0'"1+97UP5ML7GI2P:***9&[O4GF[T+%3)J6Z2D;WS1N>J/8R-<9 MR/6^SI4=?!4F:"=LI`^L5(/R]+V$A)/JGY?)1EUU)7[JO3]CC,.-IJQG:3T M1I2I%<@.-H:P:63V>H)]W:78]2:U-TF'%[4.CEY+4EJN6FS??TD$%_+> M@RVH[>#&9/G=XQ:=6&)@I[F549Y2Z?5.U^SK/.92_!GMM`O[?=5:=2^SB4 MVAY8?E#%#ZI.EY3\H&K]I)L>5,D&/ZAJ,N/A#ZHVH:K4-^1'S4>I/VCD.?.3 M+'Z2=5QJ#OJ&=#1J\N,L?IRU"Y&>K7Y<18_SGJZM-SX1.M(87T^&>,NTA^ M4T>2J`^&-$SM.]48BH:DTN`^C)3KW6(4^Q3LT!7@7S#OS'2S,^BXG8-AL/! M"`NJ+$Q&8_#B>+UEV&51'AFB:L@,>OBH&^)(&6T$?QNQ?)N`/X=7:0D?G#P& M)H#Q:/PP>`\L"+$75]'J0?Y9<_""`E M2^]AEYOR:Y^KS5$L(!7+5H%1$:@/+J`$Z:3@)#,Z!O!JCC:5Q[&QL(#%S;( M4.CYP0KHEHC>##CX<@",1RKFH4LCDV=SQUL0TN+,1<$2V=0H-F497/CKU9 M@ULP350KB3^V`WI9`3R_C\^DX/-"\&"_`/8B\@7JP@L3WYM16&G0+U"43M,7 M.J:/YP(M-@:F))::AW6Q+D0T(',S&?H\-<\%0CC&!`V.G M/0Q@A[>2R.H@#LX.2H';#0+;23@%["'JEI> MKS&Y"^E.X+.5F=D$G&6(6\OT8,O7=_)`U.%#[)JJ`_!=1J`5\>>AI(F#0?RS M(HY4132T41F)BPRF@#A$OZ3!]V)0A^JF7IFFB.P0E%&T.3<:+;`)Q28J# M3G-(?Y"!4(,!FMP98!7GP^25"Q;09'4K\D]DK@$)075=>Q;-@'Q@F,&F+<#Z M?J.&$DP?7IK!>!2.6>Q9'DB"XVW;GQ$8ULEBC5A7.)HCU0!A&BR+L!>%@M+ M4=O(."56D;=G4_NT&.H4,22M57D M_C`QMTS\N8%9L&Z&R^/H0]K501:#H(VPQ$-&"&V2.\]-\VP2@@%"]H2G%K%WQLE%.`+G.U4^8.UR5Y^[`#_AN]EI^ MX#?QZ<"J;.LX!3ERRBG(I1SJD:0/3$VWI\.K?J%'N1^F3'N#6$AJV1?A3Y M[22QC:;$KJ&F@U:65..14[Z?[^RG0L;6MZ10F+ M?'D)>!,?[ERSO57U;+#)9P>L;$]&VQSF?\>MRGLO_$P`]?1@( MGO[L3%-U;/V!F19&O8V$6/`6\^/O\+GY9NU]E']?,!B%$)8T(AT[6_,EF\ M72^+MS7^W;G+!/X\=R)_10_DW\2'":EQHA!?)H=9K.--"[LJ1=<&JC2$/4H' M$,JI8P>@:6,'J$DC?:BJW:%N0;L_^MZ8$"M`7.C`\3QOTBN)%DY&Y($NY\X9 MULY9-D$[`=GT-$0>2MI@L"&8Y943'[LB\\@?3Y&!PTK=JO`;BD88Z[9<>,: M#VK(X#Z?^PEQ_QU13?Y2(P#7YU?7-=Z4KJ#@99;0#>`LU(C=]C0UDOPA^QL M_'U$#\7;VI2#;RZ-!GD5/`P"AZ/=;_%MQ3F[K$ADE/98F@'L+:2F"O\#P4% MJ]K>Z??B2.(H;-5X,U[IL"UH7Y;\<"_NP(Y"OQ\RJY0'N=72KOF\06 ME%R[@A0LZ7+B`5]AL-B.OL'E(QG4PP937 M)>#YI1TKE\9+$IQBDOR3+$G0?;WA)0ER4_&2!.W1LE.BOUR/X#2/IH2R+G?W M=&KWLQU>59,?3O'#J8Z3DA].K9^45]5\+(=3OIF`4%>59.?7IT"-7E5S8P8 M_`B+'V&=!+7Y$18_PGJZM%Q_BI6+C&LUPFM%!NU/GF=AF"461"EFZ`0WOND& MYAC'2Z=X1ZN`X;;J+>RJ+N--U17M])Q$WLXCGY0#_.7:5-EB.&0N)E=[=@;< MDM7%,/6P%X5)7D@VM2F:)1B)RMH,WKDM&D<1KM,&]EXY+1I''/[!.5&5>LR MO];)C92O7?(X::/5TV:UW$B#X]GB#8.HWYJV3W,J'.ZVCBT1E&B5Z<4DV34AFE!D8;]15VH]0VB;"K9L2RO(!\!\52K)X\:\7@N.BGG;^G41'SNTN-)([53R:@IUM\C4 M?)EYTF1JOL8"N0-E;B"QHX\2,SM6!/C38 M5B`02()P6N:8%O(?8Z<76G>5%J$]OWXM(8D4E3L%82BOXG"P]0>3W-M`K#^ MK.E:M,PLUMC%O,1+;^+A5_CQBSX<1FCH.X),1Z MT%BDUKPW;8>J6N@52F]CP6QLM1&7Y$W,@M)66:7E8KP)J6"W?ER[FZY:Q$ M>5^XL!T3@>A14K3"O#ILQ8"BR6SYUZ(]#>=PNNT!O]Z1"LC%R!ZZ>T('?H M$S.(_$5<99CU71#!W&$M``6J\X+GR<5/+W\0FLQXP2+`KV1,`ZOS[K.I$,.H\+L="9X&U7B`(V M5U+`I$3,>-:$YH7RQ7D:K_L6MG,R5B35-J1;3066K[OR,=3":XW@/P8M\ MN>;U1,D6QEVB7U<$O&ZU9M90M<':R.+::E:>?5XP500&'CX(L"I)O&'$X@9Q M@7FHEQ/`2[+:9J3E4R#H4AASF9Y[##YIH#P'CC+OG$!4A=GN5R"HL5^&C)-M M+=E43C8N;9V3MAVM\X;1@>OX%;MGNE$.G;()S!-:E\B.Y[W,3H!Q'#FM$ M!IN#V[HMY/9RE;B1^R\5(^F1'&8%N<=EN8MQQ7F)Y4U<:`/Q<%0/E%D.1\9 M'U71&"JBIHU.%%G.1\9'33040QRIZHDBR_G(^BNJJ)JJIU&-D].!#+L=,K MD5R-61ZQ-Y,)&8>%T\^`C"/?#FT2O-B`R/N/"EZ-2+MS[25GX)"8<79T"C/. MCDYAQMG1"].<7OO\Z""[(T9>7",`39;UK;G1:=(PP6C-<&0105$0Y>-BGE/DSQ< M.%H3CJ&FBK$K<9CP+YEJR&K(U'7](IY.T^>[IU<+#MA2G^@K[B>2B+.@K67 M(!77'RVI3P6(!Y%9-J]@>=&M0PY\F+1+444#M+U-_.!25P7`MP9?(7#M' M-^F:J4_57P4=YV1X<.D/.[Y M#/9)X;H&M4V22EGW644!_<]9,"5@21X'UHUZ%.LI<>! M<,<5XKP<`CF:Q](%W#.2G:5WZ#I0N>N%9\N[-Q]LF0C2?S<&GKGK1U\2()_.<9-`Y3^;I+&H\F><) M\I$G\W06-9[,PY-Y=D>$Q\=S=G07,\Z.3F'&V=$)S+JUT^;)/"LF?+S1USR9 MAPL&3^;APL&3>;A@\&2>KIU<\&2>#23DT<18\V0>+B(\F8>+"$_FX2+"DWDV M\=;8=ZM:"V\4IUP1Y?U;W#GCG#5Q>$][8<0OL\B3#UF:R+GU9Q2$V#"HM:0% M8V!((RW#;$MXRID9^T&K>7R^K`P,/=^^=GN\#H%8\W0+V"G#1OE$^-4\O4"& M;1[L\MKGUZ5[#U][_N+"#L:.%T2/MS]6R98=JT76X-`MLA(6VR3(S=R&P:=3 M'"5[,X<32FE@!V'24XAUL0$Q>R$4P>;-:Y;EZ`F'[+O>@V_.XR_9APK6MA\G MO2D1;5ARM`#\T,5(OZ8#"RMX(]02@TIS\,48(_3LV#QM=-RD>F0R%R0<2PQ MLKCT\Z&D1MU!:KIUJQ^;^T$YRG!%_/R5^0`$`Y&PP=U;GN#T0S>_VQ6E34(V M#7&HJ:FR16C=REJD[.PEH6Z.%(,45ECK.P>]=7]?>$OWG^5_"K>[2'9A!L M0-7]W,AV-7A-$55%%PUC4#%L5Y![Y!&%U9YR'O.WMHN=GRWA MSL/J13M0F\=WM!;?H8F:K(JJ-MR%'YTB#Q>.UH1#$0>&(NJWA5X^,,7TDH"@]V.&5?WAL]&B1 MD/@SVX57HP"_H'%PHR$4\_J+VUM,>%E4O1E[1QH<2'([,A- M%!P3>,HR98`4T<0?!A4IED#T[,X::JFERQ;5/?OPVX)`9'/(% M&9>S`@$.?:08DBKM``=NHR_=C_$F>FN"+#)-/=O:HG.=4;@[&:GHHL+." MC=768"0[AI_HAF%K:H!HJ.#A5H!1F&!W,-90`YPI\4:@?$__Z_7$_[WMW>_ M:O_WO[^/Y]&WSZX^LOX>W-]]7KB?+J'GP;^:/`?Y<]/-XO`&=R/_Y: MW\_E@>E_CY^_.DW:?;5G?QGKO[[ES\_O?KTEW3[KU__]?GV_?F;X=NI/K%_ M_GKY;OSK+\[M7-(^?+NZ^OW/\7]?!]%H_/%J_M:Z^R;]I-S/_WXX#QYN?K^: MO;N1WOYA+SX;]G_/WUS;G^\NW;_FT[>WK_]M_BZK/VN__I_P^OJJURNS!XGU M8#O.N6M=NJ'IWME@=,Z#@(3!$\B[+"Z>:+38BYM<:7#G&E[LEBQ MF7/2#-M$(@0F$C26(!&9/(A+L)Q>E`?MHO=2SV7!6_0QICCOR([L)-B5^>N M_=6D/43-.8E`/@+ANN_WG;[P/&F>J4@OV5/LA_1K^>4/(AT2&^29[H(-[1-+ MN#=]VXLP@B.EMIE1^RZF=DY;GCD'O3B6A`"HZ]>BB?./3)L1E,A8GC/03" M!!08WPS(\CLB_"L\@)+BOSAZ%)!)Y`B.?4_8@.;,`R7YF]4"8W$K03I+Z-4- M7$(E=][MP_.F/Y[2T2UR3QQO3NL-Y,E[^?&?L+_7>3I6X$V+`DA>`O.0IB: M]SB513"&)B1Y+'P"$]_;Y`&@9MU74?'A'4`!QPD8^@#DGUCE'0.`(J`.HSR@ MSD)L+#N8>TQ4Q#@:!V-M'GR8K>=-)L^#'VB[5_,6GO8P#B@>,$^/3VYH.T(0 M`0F2@"%&73L`J;8(%:$%!1F[O\8,(%9_R3^M#.DYD%E6I675$9B8`FPQ?%P MFPXG!Q9&0R0&C/J"F8P`AL M_-419X<6S\ME,TE9LMS;FFIX(0B#QD.L-&P!LWNA[-MYAX][8:D6W=BVU\$ M02?H(LN'#[RJ4-XE0$^+BH?OSKILZ;;U[[GQV)_QV)J]/_D>^#N_T@6?DVXC MTBV[+L$5;3WO%B:8J]AW/>^8;Q%62>6C)/!_#7BAB M._FCR$?^:$1!%Q&#BTC[V'O]\KSOAY>.NEBPL%%PHN%'L1BD_LE.IG>]+( M1>Q6B&5\]J&6;SY6I'=&Q!\ M/WEI\Z'%UZ`(;-'%H M:)B[%0(@'.DU25#&1JP`^3I\8?BR))#672"TJC3;J'5K5/;YDA>V$'HV[=1 MZ/DLW-CVW&!JSWG!C'H;G9S%+@_;%>2>%D>>:YHDCG3U(/S@3N0/HC24!-' MVM;'W)P-+;!!'FBB+#6+,^3&:=_<&!JJ:.@['(-Q;K3E/.I=X\%1CA^KH/YH MAC2=AQO56J.'A_W^CK$D>>R-!!'LG00?G!WHYX/RD`6%6G(^7!.[?;+1.2YT^[1PPS:;QQR3Q/[?=,B@FO.R/, M6U?]XL42MRZ6V(K+VBGR<.%H33BVO_#M%$VX1+0F$<\',NRGC%U2O%LDSO8A ML%PDVBNW.U1$2=W!?>H4:;A@M"88ZL`0)5WB@M'BAM1/C@`RW&]12!&[1KH M/6%_E!/VE=@VK+!=Q)G7V#X0(NR$I2A.(K#A[M!%EYCNRNB\5P5)1FCR[=. M6&F9+.VYSUPDMA2)D3C455%11QTA"Q>)8XN$C#W>U%WBH_@"\EA%`WR+T5#4 MIY8BY,4C3I?^XA[R2H0UFRN3XT.57LL]MWQ:Y%CU63S[LXG=[2><;X2%ODV M)VY`\D6VEXM>/YB!\)T.VFF,1K1P[7>Z(HOJ<$!+(F.AVG#J$];`1+3N.)U M(!`7JP#7E+[%&I`BIG#.L4+Z/<&"SV`8OZ27)0Q10^CKXF!DI"ZMKLS MI`4&'[OH\.NL]'2AJG1:?SFI^%[D%D5N$V(\$!])'1[@]V"-1:DOB][J:./-M!MVUK9M_[CNW@V.\'C:Y& MXW86L^/?3\8[B4&YKM.`I^O3`<;^XC"+0%#[..:VF6QH3M;,6L@U8\&XFJ M@>'[6L7H>\;S$1<].S`+-4T5AZ.NL[!;+LVNL>>3"?:1\R9XP@/+IRN,DSX0 M9MH6(=B!(3QHK+T`4T,?BOIPM`,W>(#I(Q.)@8:GUJ+2 M/IHMR3V_Z]WNKG5VPR-B>F4[PSV?2LS-='AJC40;OZAG; M@T_-PZ=F\EE^!19'0X.#U]]Y_HB?+(^4A5#V@#`MB#4\Q"NH"LZ_I@9&P, MH>G:7U].&00WJ!^I MA#>E\MD3O6\^V#GL";4HVM_Y2R?HPEO@\A:XW'CLRWCP%KBGWB^0M\#E+7"[ M9F\!2Z7$=[ME`L%%XJG12\!2YO@;M;=`5O@7O:_.,M<$^4;[P%[DGRC;?` M/7'^\1:XG46-M\!M-9ZI>6@];X&[=B[>`O?4.,);X':##[P%;B?8P%O@=HTC MO`5NI]I9\!:XC4YMFR/)6^!N;J-Y"]QN<82WP.T'W@+W`ZP@;?`[1(W>`O< MSCB/O`5N'<-Y"US>`O?4.,);X':$#[P%;B?XP%O@=HD;O`5N9]P^W@)W0R1Y M"]Q'45^&M\#EPE%+&]X"]Q%@SUO@[AP9:UA_UMH(5F)5E@J M`CXLE[]NC,+91UG_G$'<9.YVS=&H)#J7[D>6_GT59W^#Y;S(LKXK:_KDF(, MC6/9)$VJM4G;8-,SU&FU&&SVC"UI@IML$4;&EJA'/QQU%J32VJ]E8@I0T-6 M!H?7;4VIU>V&>'P+7KBV\\]GH1^19S^VJKV:6C;\29X=B.<4ZEM[D2L@GH+ ME:TMMM\4A9X&NQB];NFMU=6'8AM&=#3I$&._2-/8=V-7-+Z.6!)F^USK8, MOE[V%YJ!/S140]=W!G\+6V+4^PEUH)]]W,8_:-/&#$I"$F=QU+F2&QN65NW ML-:NK`[)TO@R->!76],VK4EFQ"ZIPQD11INL?-H60_KG1HUD M_Q5JWF55(U]?'\D][;V=WD[=7MVK7>W-7]E,(PLD@0Z`#9OFP/+,+'`:_:JJR9A\OR ML"K6]K7"73-,F7CB$BFKQ9JC5K8`/;;&^%8QN:JCF'6H.4&YVJPNY7>\[O[CKR0Y.C.J>_]2[Z?O: M=NW,U/D\9%-YZ/X,7&7^8?\EQI^CWRS%T(XX`TX\X1VNBY@Z(D_`97FJ?0A M\OG=J>'H'I%VLFGYW>R[9U6:,N$M.5S$%&AV>GR.D$O>HV=R1^%$3YYY MMI-F<.R9??3DC9-C/PX:4RW,GRQFSU^JD`<2UG:+]Y:[?GYR0S?R)'N!CB M"'R$7?)U)NQDF^>?]/(#AV@F=O+0:T8?&<\7?/_!B5FHZQJQG:FS<%HN3=\V M%+,9]3(IGDFS.('E,Y\XDI8M[0'=CQ#1/WH<+7FIF$3PW9Z<$/4FK\PD;!T MA1C..8G$\WML!^?8K_TU&N&+0\F]/LXKNS#)I:L$M4Q:J85E1]".LY<.KI4 MAG0X;MO.KNMTFJWG)X3_6$4U)X0.Q%@08FVF;TDG6\-S\%JD:&Z"O<1#Y\D^K_,W#O@C#( M`IJ^#U(OC--5LBGP.?@M?XXM?D(MB[L.N@T=7VTL'L^6Q>N='`1LGC9J(7- MP:+9''?#.W?XL7/)-/!N^Y%C8E-'_[;1@]K=N^].3+ZMOV\_?XU2+DK2AS^7 M-$II6D9P!Z9.QPS#@MK[F%J,QG>R=^'WM#SO]W:011O7=>D)?FY$6E3(.4 MA=K9G(2A&'\"%KU@U2%>%D#[3ED0QSNRG?WV'MNEQ8UH^2'SIJK@,<2K< MP(Z(K\(2C.8(%#TMI/O$C80/T"AK!O@`AF'O##D5Q%X7-TQ%)KHS/6Z'.)=YSXH9(YSIFE[(929'.)=YSI4;(IVK+V(BG4ND M8;:NF<018I4Q#?5\(/$S'4#0-%O55:V2T=@RS[8&'`]5.[4T M6U.1B8=!5:9ML7?["]NZ[4TFPP37R:ZRKW:06!I)XZIR+IS""P%%2L[6?A& M\D![4T91'+G4?+1ECAJI/AB/<9)-S7[6(A8:+^[$/0F$X2J1AFJ]GFV.7<\ M5.VD@C@)PJ1CH7H7+Q8![RI[%?GO8%J@,(V\5]$P]I#@;+2.L8I<:1E[KO6 ML6"'@/DT#$#> MGHJ6K_D0E]+7$H@+]TD"G8\+6#M`YL=2%&; M2SCRDEVLCA\&H-UA"!"N(+R'89=`O"<>9B#!\,YG:5>0MG3,=M"Q<>2@&8N MP!\P2O#KA0$7'#R;!XD/4\!`E](U?.QY+J[^5?H7;(%Y0QS&IXL(B$?3+6ZX M]\#+-&,CH^3"XQ+8,PC=9,@Q=.=>(6MZ MP0?8S^D"'%.E5Q8;DI,'?@$[W,)Q/&4?SJ0KF>^XJA2_OGAB6 M$;T'(P+JQ2B/TL?(MPB8'Y06;,^)<;D)DZK\!^X@]I[X7B8&WBD&5AJO'Q" M6L9AX#UQ\0B#19!Q(M(_E\R87TH_N0@;L@T9_35A7KQU2:!T#OA.7/`;#! M`Q\?:+BX"R+.7:0B&W9G7B\&4791VLH,O@,1QXO#V8>PFL/ZA=/";)<7=9& M:P,>-TZ^].OE[:5TPVW1Y_A2,HBB:\12=52CC5U##Y=?[[^U\?;=[FF6/J/ M]6@B7JD+0(%12`,P7KN/(/"/\2KTUY!L`96(<&G#:(Y#M$,9:.G046!RT;8 M9Z^D,8Q?`%T+K.-GUBF"N>YON$YCE`>ON#[[S%2=A$S88#5)PQFG+9IYC^ MYP-4=#MT'U-@5:VHL(EBR0]2-$U=F**7K1A8-[;`!]%#'#Y0 ME$BPC4D0K])\K04=X@NS1RGZS9M5+Y>I")=?S'=>)2DSJ70U0_]MG7^_#:'(6XO:88DGV0+DO?@,D$PZG\!AR!: MT1^[?2=_ARL<2I[Y>OJH4`W'"7"MB"X2.EM%/M/H[3'\P&?+"5L4P,6!Q\(XHGGX@&3` MT.\J"OYPJVX".J&T6'-\,#IAO.10W8'6Y4O#XSP`OR6(`&\?HZ,[C+60/0F] M7T'0C!&#NX3UZ<$-M^+TOX15K8'?(%]P[U'W'KC$UQ5QBX\66)2(^X%'KQ M?13\E3M".Q0#T\"^J`=8@D4MB,&9><\]8G933)"`&_3?%<3:\"[`N/'`=GCT M\_NK"CIK[FYPR0$K4,G]1B9N-=%(!<'UW34K\-[NQNX7#=Q`/C.4$8WJ)#T M'>@+DC'8_V11)(@HR)::RQ;G8T+!)4E9S,C=CD7.S3M^0R.7!+X,P;=L'>E MJ8R8?"<'WLC0J]BH>TF&"SYAX.]YL`JP81EUO'Q+%YP#\#QP0P.>P!IX'R0& M)"P`<4S1>=E,S/#B9/P8=64FA,8R;H4J4U4ZQUC"[50Y!=`!OY#B;`_Y_"SN4P'3 M2!>#>@D1G)\K887ZWV<)K.]M3BX292'A^@S\,VI)B8:^'G(/%LNX/O(F1OI M%+Z$";;$Z%26H.@C3^WWU5[6SHK>Y?OXGT%:OP'\$NW+@TTN"/'SS$4<.2* M'W_[%(1`LX)D:XI]8FO$F[F&_>+:03#UY2,:9+`&7J^=\YQV$W20Q#VOXAF_`D,]=H!:)99E$L5Q.-0V]H@@JJWV M`EH[%&C-S(&VOJV^RJ,_@#NA+CNVJ>P#F`8E!7@&@GW!KPZT`(`MQCA.4; M#V3S0!-FN63=)U\AS`#S$W60<8L=]N^P2(=`_EE(R@;'XY[=]QC6?MF;IK& MX&T6AY',!V5.]\3H4=@;(O?@E`TSSN!+<==X5]L-4K=HB81T^?XXQ/"N M4H<=N^TPF(U?G'BRD2O"PV72T4]@EJA$S?P@ M=!6Y#VX0%F>6191(?8R3I"\L;,>_[QF$'NXJLPBKK.T8T,H_GV:$C/_?$HT/`CG]X68)C"B4 MEI0`\,U62916MFL0L36Y0?$#F#_8Y$BP9U)V'L6I!I]]S-Q"U4MRBQ/`C&R? MG@?74KJZ^YUM\^/ND;LH#HKOV+8)2#9S"_`]=P4^2<)IB_+GKNS'`MSY^N64TX<<5\"[;N]O"A5&P(#`[^4-JLIF6JV0)\:U$,K.`!"R"!YT M#F>\1PL8H0U!0$I0;E@Z,6'&7!V>I+'>4\A)`:;'+1T9EZY%M=I:8N3D?=@J0:V6::QO(M5W(S6E!;I1IW@ZY-1#DQ5Y:VF6OS&F2B=_6NPWYL3@. MF8]8OPFE@Z\,KG+Y:+TR-:!,2`1`6:XW5<%RI0;@7J/60T0R+_#YL[)$P?D MMX]X(@?K03X/+%U+/`PO/XR#P#U%WY+',1 MCY9POX+]Q$KJ>4YOC7M^.:5((T]26N_'W&WRMK'L?LD2\=(\_$Q_D2]<=(Y MM.D_O!-!>R^6^N[C._:;A209#ADV=Q#O7<],U6';C`#@%"E@=6%!G7-Q`_J MO5[IP\`V@#_QD_(/-1N;1Y\JO%"?@ZB=GH>MT@(I1M-1CK18%`98?L2NY`) MLNTE6Z].):^7;$+:1I6VG@9[G,LUGNLN!D/O?JD'RQV^"P#E^\`[M'FE)!^ MY1=08#J$XQ#;T@3_SI)_K'!.35,4_#O'/FGV\0R9):EN#?6?)/)J8J$TUS M)LR_$;RKY)[U-YH<]UZK/NF&2AS= MK!EVLB]-HXHFDE4W18.T)&I<$0CCF&`GO0ZH#D?+^!%Q/O7 MRWDV=\-%X$V,8:]4A<"-5OI<_R.X,:P;IAK$G&18\SHY@F$_7V"FB=CKXH9 M;,6&L-^J&?:YD9M6V%^;8])^NC$L6WL"\"^+2=#6X^ M-M`Z6NS";@CA.'_L!Q4.L!JJ M3AQC^-L;S_.TP,WEYHN,7U&9:@#88\0G`:(9Z%#2Q0E;NQ<0U)9+A3B6`;1 M%'4B9!&B,1714"PBJQK1],S?(5HO%#1,"QB.%J?Y'TA&B]5-!1B0`"BZF>Y MH-3YF/RS"31;B+&M6JE_P/VFYT08%_>613[ON+ZD"5:SN?>L#3F['BT,I:P\ M!NG7B)0]STK>L'_#IG=!Z\TVC-^OL'%!YVKIP:W,^+-5RRX5HX99G>HN&\.% M03H.]`P?SX:]KZ-GPHNH4'X6LIVH0EGH2POC3U^:ONNK<`_D(HN7S`O)?RW& M;6^&Q5T1:6>&G:960T]<]`S3BI5J- M$0ZG>B1"[>%^Z]E,J9/E/_-=A1^F&WL.A?7HLX]^'=R[,=!8ZI9F.>%F5`\ MH7@3%L\7H7@C+/D'YJ,4[=/,FA8N&T<4?^,;X`W>W\1ZZQ\R^[@V:5F9SJ+ MQCSX!W/UL4#/%(V5)H?:(7RT>]2_'(?FMT+S^FF>3G3;(+:JGEX3H]_SZ-Y MZLZ@4]"\:87X!Z[W6PA_6"7QDAY"Y=?E="K$LL&:]#MC%%60`W+$/@$;#EJ` M7Q?Y%6(:)OZM&78JR+TNCCA348CGCX.;U\M.MCV);,^36[KVUD.9#CP):""E$$4Z1U9]JD0V#**KHGYK.J)Q>H!: M-]-Y!XEID&8X'^O\Q&(:%D.QB&7H1-?LB9!%6`QA,<8XT>&?-51[GD/EXL%> M8_=]-E&X>&#AXM1O]IT0.6.A=I`%[7&AI"A;%&6+'>;:YW0:1+5T(EN]TJ!%E=:`'#%/P`91MMBF$I) M3$7<+3L5CB@]+C04A8NB<''$';E!BTYTHF@R,2QQ2:,0CAW:&%.0"%&X.`%) M,(D&L;_=SV.?%'F$<`Q7U=JC$9(H712EBR^Q$,E6B:;+1+/DB9!%%"(]!T`O MJQ#IA8K%-"R&H1%;=>"ON,=T.J(A+,;PISK\LYK2Q;__;95>W+ON\H=;>K^@ M4?:%+F/PPJ+[]T'JA7&Z2NA7`/"G,/;^>,M&^WOQQN<55JM=S_@K.'@^1BJM MH@!&FOWOFR6\_T;RX@BQ9)]X^F\_)_%"^8<;8?!;G;[UN01^=GCG?Q.(D?]]5N@]QU0BZ@7KJ-;A"Z9Z_,.1%E.4^ M"]FZEN4L@EI.YLB\($W(Y\YA\W0VR)@OLV##Z1"+=4IE@I,:S]CFJO^[2JY1]2GQ[W7JD^Z MH1)'%S>&38!-S&&O5(5`C=:T7HT0Q#<&-8-4PUB3CL>9T87]#:7H;[L.RM2<`_Z(938+(39Z>"0!16SFAVDH;W'Q9 M[M&,8ED$8(QX%6RFJD1Q1"-&X1P[-!&)9I=V`TA'.>/_:#"`59#U8EC],J) M?B[R//_F4E.%_C,J0QT(HS?FGBP=6JHR=673J/T6%6(8QE$4XYNJCRYLELA M&H-=J"NK&M%T494N1&.K88%%#$?KD[PO1..EBH9"#`A`5/TL%Y0Z'Y-_5C0M M'4J.[`OZY5@!O2-+\MZYL$HFIKLF&:XX+8V%RA"XBZ;1FR M:EGC@FB403R4BKILJKF.>.":#;(L]R;P!-T0QC7,"L1@EL`4PU+6MLN;,; MY:X%,$>SG;$!2K:]!MI1& M66L'3]%,5;='!T]ME+A6\'3#5G1G?.IIC7+7"I[F&(:BZ:.#IS>OMNN\GGH` M35/1NG"W)X!&\UK;#J"BJX:Y7W?[06G@!:S8ML.X"JK=BZ M/X+8-F-TK1?[VDBT)^>-E?4NN%50MWT MX8]HC=9IS9)G1LB]0E0GVFV:F<5Q:CA5?6HTG`H,T%>MY0G0V['T=;=%> M1!.B9R';B9H0"7UI8?SINT\A&,O?`L7HJ?H(HN7/TB`2_YK,:[???2\NY-C/PX:4RVT.B_,A.()Q9NP M>+X(Q1MAR3\PY;SHD&S6=&G<<^EN&>M?(YC5EVXS-Z/I+C4[TUGTWL0_6(Z+ M/3A,T3MU[1XG[<6@>?]?:9#EW6LW3B6X;Q%:5,Q7/Z?'O>32OQ[VQ M(VK>M$+\`]?[+80_K))X20^A\NMR.A5BV6!-^ITQBD8G`W+$/@$;#EJ`7Q?Y M%6(:)OZM&78JR+TNCCA348CGCX.;U\M5C?M2V09\^ML3I-C"2R:$@S8SL16 MP77U9IYSY,\0CB&:X(T!8D8[H9T(0D]S(2I,0QE9IYSY,\0C@&$X[C/:53 MFXESV6+8[NU2]:O4[:V',AUX$M!`2B'J\(]L[(2V3"(KHH6#=,1C=,#U+J9 MSIO$38,TP_E8YR<6T[`8BD4L0R>Z9D^$+,)B"(LQQHD._ZQHZ,(`G7RMXN&> M8O>]-5&L>&"QXN<@:J]5'#T,.!OFOIJ:.U&J$H5SY3QYUY<(HJ.A%S4L>$+QSDT\7X3BC;#D MBU+%KE-,MV#4HFC&<12CV['+PJFQD+MH((I9V?011,G1?G3JIYN@IQDD(T M[>CK#U]5F]2"=TF@?.I#.5!3' M'-,3.QZ\KE:L!^G41HNQGW2ZHLF&-:;W?SQXG'3&F33&FW(?M9FJ'8[2M! M7](=#1ZW=!T"@'X`-@9V6[`HE_)^J]L/E,90Z?2@-`8?IP>ET9T_'I1"VK_0 M-$M67K9@NC^O_T!!"`__RX'(`MH^CY(O3!.`:CU-D=7.KUE>T#K3E#U M_9Z:>T3M%&&EP5^4)_5L]7]J[!-5?Q+6X;`MBY>-.T_-:K0G&E'/QJZ>O`JHB.]2Z@?9&D)X"$VY]ADR=^'Y<[0M$% MF:)@G-6.LPW&(/(IOBM?&D%4SXF/D?2>>KP%%4BS2B2PU=[>+%THR?)C:)X M%7G49Y_F"H+E[4`"0O2%#2:1C`GI8PZ,Q#],,B>I""2KN[<):^TF1!B?0Q M<\,GR8?'L[@\`]_WM57%^C&%E]P[_CH\M"P&@+E`R^3$GJ_`GV-DR?XQ(U\ M-_%3"=@"Y`O2.4!W]\0&Y:ZT&TF?@$F@A$"KJWL:>4_2=\5$JOSCAT]7Z]^4 M'[\'84FD__!97A^A9773X5([BA=)/$/K`?J/PX#[RY=$<]=P%HSV84K0>0 M(Y+`JQ<@$XAK#?1)0X#4)<%9QD"7$'T$( M'(2#(I$9J6;QLGFTG\![`Q8#RQ%[N._[G9Q'^"M)4"^3CV^#R\6U;YQR3(,AI=Q+/9!@,&;QJ'/L'I5R$> M!^#P55@\;OT0@6\@B"&RK7/,=5TEMND4TI7-$TK9-Q&VO%OPEG>TIN4=@L^F M7')M"H$@91.Y?![SN";65Z8K81@_(OY\E4]7"Q@5NET6P<\+UD!?W,./3'3 MPD05J'`!5."N M>C-7N<".G]#U6GE<=#6XD?P_(/^2^G9_ZN\>S3<>@#K%GQ$]CY[2E&[W5T M"V%>@OX:6V)./GT>/$H_T8C.<#G5KYVL=%DM1?`EQ%=[V)H>1"^,\?Y M]S$X:1\52&6?/S]2()Q;,RCSBJ(UAWEJS3B:D=?WWA"9@WPEK1LU"Z^93A M'6X0WB2Q1ZF?2M^]#][59)2MHWZ?0TU165^\><[1<::Y8,H="1BWPLN-'.! MZ.KQ]<&"!X/P0"&&8>P,^5Q7IH\$,72ST8< MIA>W-/4A:,1S]]AXE\JOJ&QT&A7%$"@9ZL`WB8MRXA<@%T2S15L(15;4J$0 MI\>^^G/1=T"RC^K263=E!H>OAC.!W6B"_;?/<80[G:73 M99AA,_CU[./-E_:/-"?GKX^+>$[1QOQ<9D,_-$)N79 MLDYD4AY\(ME\V"LR44FY7ES0612/C\/1"9E=^1$)N6+2I42F91"'#;B(#(I MA3R4Y4%D4HI,RMXL/_O<)%)>1"9%(J1"9E5.S8S(@E-^ZU(4"B=N;)CQ]I6TZIBR4Y#'EH^>7MV9Q<(G2T(BW/H:@9D<4"; MG\^VP.RH'4#N";12A7D;!-W4['TP5.:_<9_8[BL$_M5DI#889+GYRH9#NP` M!J5LPR98ME-#CX-9:82Y)]\5734Z(3$`&ITZ;2-,BF$5U%[$!:',LJ-L9 MH7(C>S1,3K9Z9XP:ELP]C4RX+P>9-@/A5BNPKMC3YS]ZW%E_O\(SDS2YSC[#\VN_'B)27QGVB[_D.V+:?3+-R;=+Q]? MW0B,=%LT;_`/(B+S8X(:UQ))^BN&?2MOZGZ]N?ZKTK6>MU/WZUW]=^FY&X7T&P=7MK_R'[Z7/ M,1<>A)1A=!@>"/\%WA)0`@S[T-,HY9F8%P`$5F)4/OSN:[P,/,E2[.]_,.+ M[;%OYVY"+WYR4T"E<'6D?\\I;R2.%C?-N[=?/2))P`(]!#ZV&'QSO"S8\3P,@#3#_(8"7;EA7;E(A M2HG,!]'7Q&0X"P)R%P.Y+($9,:!Y-^P.P12Z0%,,M"#=Y%GWW@%#NXN#LD: MAS3'@7<6)_A\EM#\TH"M><$Z^T'&NOA_G:]2+H0U@5S-G449SA<0FW'#%+H?`+UUD%DX5I-**"^,,;QP` M'+S0!;T+"O)X94GQ8!$M0>_%]!'3VB\[R>1-U^(V3.D`P\=;:%%OSW[%E MA0W;@-YC$(95N@+)\PD3N@2FH8O%;KO8@!S\`&\FUNFBC:R1I;)C!SJYMZ^VO:#'9MQ>R`V:/C5%<9C0#%P<(&66)BVK\&&1SZ1VX MRB"."2#.'18<(W]?2E?`!;!T3/912/@XN9@S3N6V@]M!$',^"C>@IFP0J9C\ MR^:E?"9^241N>N!]?D<$".I:C=8SPL"N].@^<5WQ8R><9@R]/MG_$H0TA% M@(;Y/HYA40'IRX69C>H5F++1X+\%VG4^8FXWTER3HA1,-K_E`]_J[.:4FSN-U=YT0K!MLAURLA8@GA(DC8/=B?=![,<@6'U8P-SM;3N?M`P7D!?D=/N+: MAU++;5S!'C[7_[@PQ8]IF2[(G(T\\^MG8/2R&X!C;)R`.N'G'D\]Z:O4!);' M&RZN5]JX<6PI)T8)7+\J2PT'.!'UAF3F+H+P"<(')=(_T?#!XHQ.Y@N6,@NML+6JIN_Z_.S MXYMV,[K923EJFZ0X1_C[W_Z\2T^H?;_4$L#!!0````(`$`P9D6=\6YGZPP` M`Z:```5`!P`86YI:RTR,#$T,#DS,%]C86PN>&UL550)``,G55M4)U5;5'5X M"P`!!"4.```$.0$``.U=;5/;.A;^OC/['[+<+[MS)TT@4`K3=B8D0+D7"$T" M%.[U6CF% M%L3`@7IE,N@UK\=\S^5:J5EF^.>ABIGED/_JCEH`NEGU@1B^CO]^\AQQH>U MVO/S\P>-/DHTA"&Q7:Q!PCZH5M?^S?/__QF8&T,&00AY5;BG-I3RKUOKUSW6Y6=^O;N_$OT&P:R'@>`P,K4-"SR92L`-AU@XX.-'VH[]7JC MYC^X-7_R<,H^"#W_W.!/;Q\<'-3X7U\?)2CJ05KL=NW'Q7E/&T$35)%%'&!I M#("@0$_/+KPHJ^[IZ%:L&^!)P157P,70=I7,L:>[(F+BFR%K6`C$< M08O0MG=F44-@+J.CRN.VRS&]-PT=-O0(2;'3RYR9GU:R/;)HOJ7V59>D1 M($@#EMY&ADMY.0;80M8#N888_?!P%B=Z52%2J3[C+HBR[$Q@B2;P4L%2#2N MJ6G8I21,Q[2U934PLA!J)#=1`X;F&MP-G5.#0J;"J0,M'>J^L:RTW+W<)X=B M&[86PC.8/[2Q#V>``32^;+FD^@#`^&>3$.B0EHLQI3O,GV<2=XQ#0`;<.WK? MJS%>:]!PB/$9[I:W_:JJ$(ZX%I`@X#^31RN(\":;R/]<4G\\##D/5$CKFGRTJK(@:;__2&V MS00E'7ME_FQ,?=N7+>H:GR%Z&#GL1Z]=KRS9!<"/T&%=HP%;2T. M;NWEB>7$V5'ABC4<]DN5;X+-4A;`06\A(Y#Q"'%W8(:RE,/%^>,HT%9;)) MXX]ZLTNH1(I0^6O?(\)L>$3ORN@"5QB.`=+[8`J)"IY#Y:\]SV$V/)[W9/#< MAD-(85G1IHXN+57(98K3Y2/$AN_%[G2B##@DWE@6`:V+=D=5U52D6> MI];^XIB0T97%YP'6E)YG$>.O)&T+D:FF7F]PO888F=V11,IATK)HNQ2:%. ML4T4C0NQB&O2_/;?3Q7@@!U-6%X?MZ&8YL@FIB$^M:E;6E1ODF0Y"<6LA[# M09#IE)47Q)L9PTT'6`^(1K2O(\[Q5#-4CC1! MM)K14ZD4(TCXVKJ?)6(7P]/L@ZNFN2:K-1IY\-00]Q^K,!>>4MO6G:V$$O M_'.A'U24.BL$Q30C,5CI065J141LB6++C%W$3[2[<`(M5V47 M$2!M1A<1T20S`/5$GR_W\ODG]5TD`FRSND@46\)P,YLN/R:EJ>N(F0J,X!H`VV!,7`$0!6 MTJ&340-3$.NK3QKVA&-@WJ2'3S-$;+XYMPDYL3$%L^9>1IOU,;"(QZ#^RR4. M"[QI^ML94F>D./^19F;Y66[1J%"(JF+E5WH`&2];28I7)#I"$EHW@U(WH M]&G8DSN)%`@R:.9J9KO@(D2>&:5`46PQCQ1@\BM.Z6.D0M00XXD2&98&43H03Q!&BQ" MA2!4^3YF125"/$D.(%LVX;[9/TB9E1;P,C:>%A!G2%OF#WJ;579&H0HO=> M!`H/LPN\B96,TZQ$$@M9L$'=`VV44$WD86(@P$[CZM0I93(Y7O;-(JEI5&8&&;99$B;B8-=S7$Q MA6[1O&9QLEPKS#J>VO<\1U7<[6JKD&L\Z8G5G`&]3TTHFJR)@2N8_IN:B MJ"(NM"NYQZ:LS7C6_:LU5P'H5X7.AY\^S5I59YYM&LZ@@.;0P#:^''4^HQ MJ!7(`GAV1BO(9R?H-VG=#5XA!V+:%50T2Y7FECL)6X`0H?G;J.8G,PGRP>?E M>\V7VF?[P,I.WJ7`_9^2.IT2]:9%JQZ(PJ\M#(&!7J#^C:;Y M+%\!R&('>OMN'X3(T+_U.:1]A7$R-;+("WK:^-G%\.]=?MQO\2K^[-QI[ MUH]!I]4^FYWVGSX]WM[U]LSC7>NLK8]:'^^O[QNM???^;/AR=#-^OKF?N-9+ M[Q"/?-[OV_<[1Y_-.$3=3`O/\@]O+-/AI.+6G,RWMX'^,KMUDYOZ^:C-?QS MW/CC^Z_KH^NG^N#;S;>[P67S^-/):&^(SA_/+K2;[\9@7-_M3+O='[^TWWO$ M/="NNN,3_6%:/]V9C%^>F^2Y_Z-K7O3K)_=H=O<1_?YT5__6:MS_0OL?3;SM MW'^"C0=C[^]J]?UKL`J+SQ?H<\MK8LK:=:R??RJFYW8Y6?\F$CAN],465IN M$"B[@>6536[\%V&@RA82!U?VFG(**H+Z+D0=\2G9!M0G73N/7_$I>C%9=/=< MUDD6=L$$(,K;$\0->EH=DW8Z8+7'+S)[I7D(X"B5"DM^O\3OE6R@Q4US=S+ M5]V)]7:Z<^%0IYI-6&XLEUO/HUBB10[K(QK7,SE'`$RW[U"':4RP01(FZV5 MB#Y9:UD^#C>/T)IJ-6VW8$S=`W_BL*L6+Q-MT)QI,I\QJRUPO.;FFB!=OV MLY>%8&RZ1)%$2?SWC(Z"-\F,`VG/]_9BT<&%QH?J-&8S[:\'18IW/_&X)>\>TBVQ'%,^^E\7=E9]+!6U$^+5U MMJ=X?RNIVT5PB8@EKYA.)^827SZ\FU'[-G+IN#Q5(.$4$?@+1&S+0#16M! MN+V5`D9N#=L6H&`1\ M9^-MB$M?.&F[JI?QO/NG_1@]\A[J8D1-96S4E#T2 M^?VE2M$$^\I&7#(J?06LYY%2^9Q22+X6PW>=7<@O M0^S;U+!;Y(Q&\PWJ)S8N;E-29ELVN3ED%T`TDF5N"UV:;L^-Z0S/;>NA#['9 MA@-%%XLL-9S#B.EF&(&Q3<`9-M:'_EVV?EID<7T6H5\^&7?65#!JX6MNFF MGNQ(N(_F'54_,C1/>"_9.ZI^W-@LY\+GX^$0:DYG2..%$;`>8)<.#QTKNCI M(K15\#=T\CQPZ/-5KAQ1P2VO(]2; M$XK^`"]=]PH#"A]=C5C MXPCVO14IESOC&@DNLO[MQ&1ARJFPB3(S[#G_-8BXT?V:YS>:7E&H01BI[ M[2"U#`L$R3Z]]XISPBY4'$&=WU.J5(@PTL8(L4!0POF\HMVXMV_;OVPOX,JS MOOUI[5Y,N6(F:HX->P:A-T593$V20.`ATO%F2,<;Q-XX=P+Z/TBQ-(S MA97Z2Q)],MZ,&FP9_EW6IQA8F7I)=`$;XJ52,"'S+';HEF2&AR5(IG^UY MW=G:395LV7/C2V?;,_L;"JU19.0A!VU(D;_/O!X<%9N%C>N/A@%,3T MKVZ,'Q#]7?"`"/V9_GT>Q\N?CXX>'Q__YM/1BXF`H3XJ(_>+@\/`_#]C_ M_N7__<0G!'$4/Q\\)7BN0H?#H[?';Q^\_.[CS\?'Q_9M^B7[# MQ\'W>R="!T\+/XA^?95#]G1/_+^%9';T^OCXS='Z@Z_23_[\Q'Y1^/SC&_[I MDX\?/Q[QOVX^&F'1!RG8DZ/?+C_?N'.T<`YQ$,5.X#($$?XYXK_\'+I.C,-` M@JZ#RD^PGP[7'SMDOSH\>7WXYN1O3Y&W(9%^QHLW:/(`WAVE?WS%&79P\`L) M?31!TP.^QI_CU1+]^BK"BZ7/2.>_FQ,T_?65$^#OAXS9QQ_?'#-D_\9^\P?Y M@PHW"GWL,3&=.CY;],TU0U!`":,T.7YDC/@R7BU,+,C:(Z"B!K<**!TH59K$,'CM)LA M_69.V3(/?0^1Z/RO!,>K6PKD1)GDCA'QM3[HS1R943)P2%T],DP@&U-5# M#,4@0QF"UZ=.A-P>DT]M4Y[FNT!4",JFY#,F;2X=\1[%S[Z,;Y"8$QQCI M,58,B=)KCMBW%PXF7QP_09?(B:@4%Y0O>M16@#L"^]2:Z"62Z%3$[ZF+DF+ M7"$@T[KP_MPA`0YFT34BW2U2-V%8IBI'T8TC@GBD.AJ:@&`8>)^HA&7$\PP MM8)!%$X<@+O4QAZC]CWM8BM!7BTCM),D?]QX+HD0=[YTY)N.IK\W0%BU`F< M'--=<8%C;K"4&72_CFZH<#5U8=ZB(8WL9-+'/OEV$0/N#('+2$(5J(#UV>5AS@ZL`9=C=G;R[0H_4W,.$F\P-XY5#/$V2JX"956=A MH'++?C08^&3P#+-;'+6TH+T6H''U%D4Q+8BO`6=TQ]F):%K07`7+._S04X+ M>@5@C)-:%^T(%T"K%G'4HY[6M!>`1X-'%J?HK1J&"F.2 M9DDHE^(<8C^)J4,2;5_:Y8":E#2Y4U,F>`=`$:)VY3NA2H!@D\VQ.X:,( M!V<.(2LJKDPW"UNJ>K9;"JI11RO:6M6M5@3$F-%=D]"C6\X$4:U+T/TJ^_D3 M"9.E'KW-$,UMQ&5ZXP_8?2J[Y-!:13-$LR&1 MZ!IA2,,#K'&_U@2O@_1Y&]+KX!DF?>>8ULMI1:B M`<\T#%U^\!L$WCFU,>:W]1/ZM<#RX:5#7%F2ZJ#UL4]K"SH'5^)AQ>LA",, M#CTT=1(_?G60H'&\QJ!(L`@.L#9\WA`BWN$5'D;^&KVZ`%@DR'75FK$.>LKZ0Y2519 M<8"9@7VFR`MDH:<8!1[RUH2Q;[^3_^BJ) M#F>.L_SCAL:P?/.C9(1_6(C\^NJ8?I:K\\\N#="HOIW[_%/4)-(->/MW/XR0]^LKNI455JDICQMZMG`( M#@=/&%:/"HBR#<&X<(3NM598!7T4"JK(H5UYE>6AY$,S5T0+9&+IQAYPVQ# M`Y!);+""LP9W>GKI6,2#,+`JIF6+.0S(KHC^/.A00MH77@!R,BQK!,2"=U MEJ0GI_34?I805D0]N=1O^/&$!(2(P33C$,T]^#OC3+!`M:9PYT9P>8]A_ M6#[KP?%9F(0%S+H$-10[P)`&W(JU93\R39&CX].2H.B"-J,90FYUZ/9# M6K4,:S0S/9^7UJ%%$^0BJAX4]16`854BZ_HO/LKIWJF98)Z;=@?KN]F5U<( M1#(%^/MA+T669'Q_8]9`K@E:.MC+BH+-L[T`?S_87F1)QO:W9MD^1%-$"6%( M4KI@W5(=NOT02BW#,AF]`S&-K#B`AAECELHJ4`QH,;5H(8^CYBVIGH.9\-X; M3QV`2THD$VM"4=#6RD,/51\3<(E(O&W=3SNQL:JR_9>>P3"2.@;:<6HUW[ MD3N.-C&M,0[3#9B31>SM/P0;4L3Z;]]Q%D4>(-%2&+\@_^^DDB@X-H,;5:W M/,EDA#$Y-,:-FNZU$B50`%^+S[+S;6G1^?B^.M!4%12O&Z`$T8XCHH;PE48 MN)]L:+XH!%(CPUD@N-(:1V&%(NFZ+"/G]R_<3#P6S[IACBP"N!M_=)63GN M-<>06J#%(_H]7=_Q;##Z@]`X3I^D&&=5+]V M5BRCWL$=1`F3U1BM665%%Q!E7L%D)[)'0+LD`@FG`IE=SZ5DS$CEAIL>QK%U?&OJTT(5F;5R'KCZI2E5L/`YL2UG?M MG9E;(\Z^!!/:`JSFILP&IEDSN7VS.=AI&6A>B'7H]E9^M3R4N8/0?5G19;JI M/L&TCV3R#+5WEWH5L"DQLZQ@U4DB]"`/522R@J2$;()(DTDK8'#`-8<>S@ ML)HX5_5M1>X`OJ;P/,X(Q[]V,#U<3'P_DRB.+N]'T]I.`1<\F,3.L7 MCDHZ`B&GY@A52Z/;-^EIZYAF-S'T\3??3,,60.@ M1,`^E!0JLA3FL7PQDTG#J3'AU'L\F;8=)P:=`:[$;#US(??0XZ+$IDM$V+D MV)!$L]#@G]L0VXX\>U@W`<#;&(:V.O[':RC$JZ$U.&K?>U\76<:DX(&1/. M.(G9+&+V^J0K">51[J68"CQKOJML>R_6Y;XE@W8?O)\4^QIS0FTEU\5658>N MQZ\8I;@E\33+C(C@MJ@J5'L1^57RJ?E!ERG)`.]/M?CV4T:BW:GZO58OLMZB M>?(M$F,O^>Z7?/=+OOLEW_V2[W[)=[_DNT5R=!T?=Z;S+5 MP;K[<#<)ZOE79,%M;L4>U=060%U M=-W0DBGV8V%IC#O\JI068X8.["P7241,!PHITZ]$^P>7$2P%ZG`$D^,=_#E M\>ZI$V%W@VE=-23./U4$^PT@^IQ5DF!1!F(ELZO'VZN,7(Z('1?C,C"1J6@ M<7E#J&`43"[V\S>8R\P0-UK#-TE;!EC<[52=@TE(CP(YU:0I2D;?FKP;3 MJ0+83R@1[9Q>(Y`>5R5EU#5J4?(4H-Z>CQ5XL98#@-%5$7`7$.3X MK&#\[Z'/IZC0U3JQL%VN^`X(C^:A!=CD"HW4OCF=PDEJK%T!- ME&HS)JKNZ=2RSEMH`5':6_<#+:&U4AEOR59'L"T%Z8.X84U-5F5V%`!@SQ@ MAA1\';H>G[JDN+6VTL:KYNZ?LO!XM-!OZI;"/'FE6Q#Z\G[EY?WR_N5E_TU5; M0S+T5ZV6D>R$"P''/A$SU@N=K(C]6`1DAC_X#]"V&P=.GM2!K&/XE"A&B[# MA9A9#4#:48'N]&!BK<#TC"5:Q5LP0^64LEA-T$$10J2U^&QNMN"BK>>TS/-2 MW=K-![JHDR^$ARC8?@(8JH"+,]:FBNPDUPVUYA#7&T#"/.Q_$TG7Q_`B'/ M!HP6RY[`1=O$;#',.=/+HJB6^\H MV.US#;.O2^"U)7P]M2^]LY!@U`B>!?Y.JH`\NCU"&T\B0038X&3<#V.=A%? M$[1TL+>>]YN]WZ%+X54"Z<ZD:T4)<]Z'\ASQJE2GBB$LK[$;Z0LQ6L]D` M`A>S%ZQ=0/5N<>VLNM^!UTB?FU1WF"HS7]N<0"G,/.V=R;2,]YE%53ML!>II MOXM\O1]DC<2Z$6@9Z7,STAVFRIQ]S!II[JUUU_ZW`OUS$W(-HXT_AV[8Y=G; M^72.4^>^N0;_LPJ?Z_@LTXM?NZ"CF"YBYC&=93D5,"^7^4".NQM/AFU+1B MI_+(5"%5'3"+]Q/:M1WRG`(:Q$Y]>Y9(';A_)9B@2X=\1S'S]]N74R"7PE( M>V)_$CIT[0U!+:&_EIBEF)U1#3/DB#<&:[!;3B`BRE@IN(?V6(@":U9UM]Q/D MLY%PMR&E[RN.Y_.T5<1%2+JK;M:F91^U09_Q9MNJK^F9H&5&T7CZ.0QFMX@L MAN@>)(BNQ&4O>]A"DM6<`[MWK0CA.G+="MB?581T)=1+C@%%%CV#L/^P8]D`/WD#/$I3P]\-L5X<:J>%S548HY,K M)TX("J>G280#>D)H,8-YB".V,@KNEI)U2C_\'7)R6QVZ%@_:.3_&TVTG>9`@ M9A>+Y2Y_$L(K!"D"-DEF#^PH^FO613DI]<$1=1T].,;GST+#1];?%#%+D$ M+[-7RYQ-XP;-D@AUJ9!A=VV'(J&HL-EZ=YT=DSIC?#.5%L/!0R]29;+M%56 MQV8E0QO8"PN,<&@2=B'JB%Z9!AL5&DDCJ4HS%E=DM-3;!C9F\O'$QX"'E) M#P>4'SS+TR(^V\#;LAATM&XMOC:7\"+`H"94C]#F\#H9F>:-I(%U/=]YWJ6= M-NFYF9H"?D"LL!`$#>>YG/<64ZQK_(?\FNLW[CSSS=8_0.I[';HV`U-WH(J?2T^ZZ,M&P4J M['PD9%VO??Y/HR!V@AFF9[.T_LH8NC$2-0): MW.I((0U)$4+.85M+2BT(AD=FR'1_M&-_'[#'A9JJ\MO/.WB"R9`N'Z?B@ MAZ0Z=/H[4.F1^QIXX8UT1R:E2XK=B$U""_+&I,WOGF5X6N#/-:&GOB1PTQ(IRL!O!YXX3&>2.N1TAOADZE8U MF=WK<$]8N,IGA1I^]O`\ZE<[KU1MK$GMD_'(%:6V+3^U:B_B"M2\P;P4HJ:` MTVO`C$O>.)@P8;-@A!?Z=U.;DN#Y7U(NV)5FL?]-BI1#6O.I%Y6=MM6C?N M''D):PFW4PPY>0A=+[S#5.K=%IC%"6+]'=<%+`I#K,4]B:L-%7H:EJ"O0Y) M=^I>V^^N^UW^NI5^&39S\RX]W`^QG[">-1T:JAHI^U,ZJ\WL/N];2NQYEI'3O[W[47;=./S^+\NNM1'?+@+L,41JQ6S49W.-EM2@IUCT.DJ^V-7B2TE4O:HGD>7V8;GB93BGJPE4U6 M73>P2XOR3E=;>W'\`6LRV"K6;('(XWQ+9?F)^LT?]U65-2U#^@OL M1Z(_T06A48P6D93K;X=!U=2T4=[N3ALUN#;[3!1$#-R?+]H/.:$N]G66G!U MUZ#"(9F<)Y6O_SZDKW5D.Q33XA&_'7:@YO,TX_[CV+LX6'ID[BQ[#B8RR4&/SR[\>'A[\ M]]?++V__Y[]_'V;=5<#=,'C]](!\__./UGW>WJ\C_\.#^ M./;__[I[NSSM??M=__-N^"W^_'9<+3Z=/O73]^_?KMYMSA_&XR&WOSL_>]W MO[\Y^Y#\/IK^./VR?/SR^T,2_+BY0LZ[Q3]O;_UO;\_?+]!?JU'\X[?H=_0M MO)@^7!X-'I8G'QQRG4R./GT]7GP/IO]8OOFO?_YY=WKWU_']W[_\_=O]U>#\ MIXOYNRG^_'UTZ7[YIW^_/'X[?II,?OO3_8^;/GH7D^6%][LZ?C3ZX?EC\=! M]'C[VV1Q>7M\\3M>?7N/_^.OSW^]NYY3T:-_[MV'[YW_.3B[F1P> MZFXA=SI<`1,_P4XJ74C&>#NF9/L(QG##KT%G-!^O)KY9[,K@U6'FCDPF(4-EO MR4+VMI\$6.AOCSX0;EUI#@NLDBX6F`3R2,HKN`(,=G M-'VB7#I%TY!5P3UUK`F21%DI#(6EK@/&M$[CMWL:=KC;__#NF MQDK<^>HS>D`^5$Y7$G,_\KS&#$OX9JZ!]U#Y1.&:=BD9%IF("H@14`W.<:: M#+&:K0@E+<=IV:>1L!'228KR]QF4KDCB4OEG%O[=UZ[RPNI.W#I)62`MML? M)UYF,%S:1OU]5T0WK,B#$;[%@F,?US2%?FXZP$;DMQ!T[>-V@:7G5#4%L M7!HOY#5D!K]=&"89>&>!4+2>[$+VUR+/8H3$O%]]03NHJ@.G=6+(JUX7"A[ M$2/A+OI$:%]W[_7SU9^KU7N_,S)[TVW\GOS;.7WIB2_ZDL8;?E=A@%:I0GC MBR3P``LFC#U0VI`L7"A3U@%IZ$R-"^E,?V1O6)!C?G:C)=ZFNZ%+E.%4^?1 M]03M1',VZJ,X)5O0D0U$[-+(;5Z=&K_)T>"]<4/GJQ-=_Y?WY2.S177<_40 MK)9/P5S`-;!,)O!Z6+HC4@5"AJJBU(.;)4TY#KH5$U:(TW7,'1.L5H[1 M.6%0+J>Z>,.F)A=J/;I7@O9O^W2WN(D3S,!>]6V!@P4E\I>#MDR[,"!CRVV8 MMW\<`=R1,0^^@YO[FINY';W=8;-TZJ8MHV$NNTJLMGM!)^!)9<2%06F6&XLOD3Q//0F./I^01`:T?B!H"B>T%T, M0G`09%H2?V\"4%`5D'#++?4UWW9^0`@S)A:SGJ[$_>/S6=XU;UDW1C=&WI?0 MIV!\@QX_84CVVHFKG_#@?8!G`[NKO5:B_161Q`J;4,-1:?C37VT& MT@>9G&>/?/00/V`/!=Y>>>@"T58N.?NITK#T=?GB7RZAK.9KB&<`:/[/+$T MN4-N&DQ%`E@6EO:AXRMBVH\P0-ETPQ=)4QOL\$_T3B)(];S-[MW=R&,78T` MBYN1HECSAJ;(9.-%WYS^\^F4&NAXRNFG7F?W0E5(R7`6(M^-40DS1JX&DVA M=F1+V%&1@?=GDG:$CJFCJT!57DF`OBC+O MBZOY+-5AI?L(ICQC2S=:R<%1V@=$WVO5:I2/<)HXCYXBLE5D M4\/[\DV\F#SE:)Y MEAT&E4<1T_[(H\0AF/98&VQ7"'8&(8-OO<%AM>8))!YH[IS82H"]5F^OPU4#6F]YQ0 M;IH?6!,!?3]:"[4UH03Q!5F`_7.":BBT-5\X"`;:=4"2ADRJNEX2ZE8C M7.I4^:!W>D+UZ#I?LWM=!Z$?SE;I91-J-K)V;OYN!D541@^W5_>QF5&"91 M0Z-Q9^I3LXU8Q:6'BZ53=DXJ_NJ^^K98=S54>>C<311)Y,_,SAY`5NY-; MA$GY#K3RIJ(9CN4B-Z.I!2F^F4U4"_'R.F4_K2G:W#);TD0=DN&P<56Q7[ MC.]`0NRY(0+9Q!).B9;TJF!9K9(&E5TE]^`J/A:>)_QE.0JEPIO,])T',S@3]KE'0W5]VG25 M?<=S&6]XM]$ZB;#0K%!JH\>]E51#?-AJ6$4G26$`)7K-B.UZ8X:1)37:0GNF:5>?K65QJ?Z.ZC92AB`#WW4Q(<,)U_7@N;HJ,0W#AAW4\9 M;O```VD#EVO/9D4O^!.Y6,6\61D=K/Y-V#<#U?6Q#:)TW6;G:<;2>V[D)KE M\[Y!/MT?->CFZ%$O,$$/$C0_2K[^1,)D^7ZW'WHCZMK)R@))'^$4[$9ZT/]@<;L6K-N^I.+(AHA[45V!MX0M62ZCD.5IL%/BY\Z6]X.?N4AL337K'-,='47:DY0]Q@=X?"_'8WS:-%_+RI/HY-`B%5Y)&Y>2B9$;>NZ;#1EDD+>D.3Y4:J4: MF(E0U5DGB_F"WF^WZF1W`6_J^W,)6$@^![-K,X\IHM7#%,F MJ9@<=VN7W>,^D)U&Z_+H0&;&^,''^TREJVWN5M`?8901[>#/NM0ZN1!FJ/ M2G=G:(5>,!%Y640HV-[4!)916"1N MC%A/9<6NB,U0YY];^IGQM(`>+EE3C3EY(ZNZ#&:HH>L("'&FL\EOL@F0U!ZSD ME\[(1J5%%R$IH(:08B4NJ\UU8.18S5>PKGPBU1$^O._0L7(K:8E.[/9"L9+ MU:YUGZIAO'G-!A5%X?2:T!4$<3Y+VV;H0`U8]6R,%+`V^98:!&H9E49`W>=, M5"11R(HT,\5>WN.$QR2:T3_W\LU&V%&FMT@GZYR/V0? M#+RTVR!4L@2$3K!]4S[%(FLPA4M+$)G!E%_DJ%;>8ERN`R,#%KKN1A(VRN\ MZ961`=Q#-0GT,'D=226PF>'ID0I()HATVHVZ!#D1N@W/G&A^34(V--H[96.F MG,#EL2(/$K%2X8\Z5)NE$PIN,-=H5)EO,-.$ATA(QYCN<4ZLS]EH);32SH2 M5&<<5(IYU0FR&6MO_$4NQV<:^40VRLAT`GL%9DJ]QS0SJ'UW?E?"3V>4U=# M2<4/Z-IW3!Q::\"J'UJE@+4YM-8@4#NT-@+J_M"J(HG"H;69?8.K8-'AW@L MWP]UVBPBZ,=X.5DM+81]14;!Q?A\EC9UH\@["Q>LRU#J!0EAO4_YIGFZVGXF M2^YRZK8DTM"7+@EVG!P(G7"!I=0Q4F@-A;)"$.%`56I`4`OTU@-F>P.L;.B M3UG3[UK'4856`W7!G@//N2JRVZZ1DN0TZ(_,6QZQMV"CPZ#'>2^`>^(H1V2\0U?$X%4PSW8)5Y#HI)PKOBJU;>JFLYIDZBI8@>8G?%2'>SR M9\NA^QTPKA,BLM@A"C+#L5,,MS5T)'()[LN4M>J)_I+R=)$LX,1< M1&!9I()\0UX2)68`/6"Z=)Z`65Y`T'.6%YD!-5_(YW^G3E5HT]GL`Y#+(CG, M-L?>Z-P$JC(6JG2AT4=7N>CQDD?1Z>R>49!>U/,!V58N`S3(W%>5`1$95()( MF]@U<]CC!1XK\XWMW,G$"ZC5TJG2KO5%T:=JZ&R9&5&?7>KG/S_OM"3!@YF M94GO5)`$7TV7S9UKF-"`<&TDEZ_2LXZ6XM)O@J#!TH-2@F+;L.8#8;<_IV] MAZ6,^L9ZY[CA+,`_$(A+@R-V+WT8H.QDIIGW2]]2.^%/0OFOV.=`W%K'[#\ M$KMWNEDA9XD!=%JC-1C=]\TN_+XB6F4S`\3YG?,G1%PZ<2'O[!-C@KPA?P:?A=74J"6\0KX]S)R4N-P)N>/ MQHAK1]JD0BI]D/C)(Y8-:+0W=/W=G5[IA=<=T[=E9SY[\ MUHIH+.'?W5)%C9!3"Z\A6/`NU,GCL]ZS_5'1V4)?E'>MA)?:W7=54&'6EVB MC]_DPZJE$./_I5A1S/U7E2G_M>69^>A^/MSAS"%CNBQB:]K^TI<+T=<`B<> MVF$HFUN%2[_8A.J)A_V$:V8U,DQ=0H+G+;RH>;$]F/J%5#@4M^1[WVBI6HYV(,R[$Z,2HV` M%D:5C9[ZZK"0)UYE#5^!+B!$FR^W-&2<^GN0<@^N!X=)8R`%;$5F)Z5P%3J M7JVZNY-+'/OEV$0/M!U#F8$\>.)MJ?;-H.NA[QS=&J>HB0+4._MH`0Q:E/ M,L``M_J:\4ZHBD.<9+BD8'N3UI>;(BFB!#D91/<<@=NR(90$EA[T`!$1;OS MKDV&IW#[4CUVN&?Y4GCM]A215W9Y<<.VY;!#?/Z7E:<=A_-OR"%R@=7NM^PF MV[5#$\'RH9ZWY5MCJL:@I+KT M>CL#%?KE_,JVRPN^#&-=7B[\H4=#U51\X:Z0@,;K)BE;%B-:QCPPI8=7UB1 M#A!_"SR)/)(%5-J4L3:?[EG[!4"6<$UBQ4C MLMA+O>E$7+BD$G,)2B@7(4%X%H#+1(C'[K,`%:F(V0240#EWB(^I$E#2V,4_ MG%#$B"P:2D5FN]"$2\P`;N0?5 MD)RR):6.IZ>NV$0+K`[F$X=3%@M?#I/'(UBQP=T>(H4[)%,57D+G6;.7B:< MHH!R#N2-414JVXU6I"^5&WD&,X3C?#IE\^(?T`;OQ(E1^A8EP<$L&PP?!B`9 M307LEFN:5,6HPE>X.1OKXT,$6#:X@\-F:T9E.>UR"QQ-A5YD(5$$'+(@]\K M$13XTO,"KS_..PAG]V!R[HV`:D@6WYK8/X#/P$[1DSYF#&>2SW$I< MVOM]VD=N/$U!LB1IA@-D\ZC!9G,H6X,$\YI?QZ]^/UA_RR>&)6[,^U:>$>3A M.-+LO[+U''50=UQ(2VEPH!ZQF'5#&IQ(C4'UFG;ALWN.;%!9,?5/F$((S)YJSQVTX2%O)!=YH ML70P81YY/!U=3X;7)/R3'G05+NDTP-J]A&CT,;E-3YUC0"\S2DN)66(HV48 M.?YX2M'272!>48I8;\&EXG-9%7B69S\JR4N>22#U,EO4H^"!(@O%%WP50JG^ M]KY83,WZX;)B._Z7I<5YH["MK9[-'3#F7.@@MYZ^EHY^M=B,M`.)J!=LFYG M]WM6!TYH'L$ZY<<6ME]8F$8NGRT(7.^02I8ON6.5?,<)PEA%`4%SAR'9]E^L\#;^C$ M!KA="=G2UJG_6K.-#MJ30_#^@Z&`>\@G\X:RG6--^5O:G'LB6ADN-5\6Z@I MI.ODWL?NA1\Z-9<_:C+)@]P#OR3@@\SMH#K#!Y0BCU%UX3L&#`(SDK=@BJK M2QQH',.JS^(ABER"^1@+@YS.0]V'T$;,#HEAHKH>'[$J!W]$0_.G?Z"5,2=? M`FLGZZ#IULLLD1B0J:\O@2^DD0 M.V1U@7U4;EJG+X@RV'TRAQV6&)\^N<7%49S1&'<6$F.^J`ATKR+,$C]DIC!J M#W2AJ5/&H>0]@B]9"^J3!VA:# MW0^'5,$2F>%[+02P/8!?T-\83!"6`>_%OES)%8EA<2U%D(H=1`AYT/MP3AA MC-1PMKH\_B]'#!6;-L\9\;]02P,$%`````@`0#!F13W-G[+P3@```O$#`!4` M'`!A;FEK+3(P,30P.3,P7VQA8BYX;6Q55`D``R=56U0G55M4=7@+``$$)0X` M``0Y`0``Y7W[<]RXD?#O7]7W/^"2JY1=)ZTE>YU]))>JTSO_P60O^_/!,DQ@@3%C^`3QG.9/8&# MM^#UFQ_?_O#CP0'X<'<,7A\_+W]\)C]TOO_RAGY]^,,//[RB_UI_FL>\#S'8PU?_N'A_ M&S["5;`?IWD1I"%!D,<_YO3']UD8%'&6M`%A%^0O^U7G^V3G_8/7^^_.?SF M.8]^]Y>24'@;N%='+5S`I\NJ7??++ M_L$AD]7OM?!BAE63(E1WIE6M'RU>E;(S9L3_)/<)71!X^G$-:!CK1`4(![^!"G09!#$M)S6]=B`=TI5D0XVD:32+$0UTAXAV= M)[[?J@`/.P+4V@(N`O09%L%]`F]AN$%X>X'Y\08AC,F&X9>AA8+XVAHU-.F6-=?2HD489ANLFSCA.MGXW,A4E:2OK(%\[ M!D-/7Y,D^T(.S6<9.LDV]\5RD_31V51@+0)>]?8NNPJM0]P8#7\1I^`D2Y(` MY2]][])&M%15VVN&6_:Y^D3AI&A+5X0-K2S`]_MMMQ&+5"MZA/_NR]/#FV5 MZ$UFZM-2D15!(G.Q=RG@'8?N")"OC),'YHOG&L%U$$=WP3/,;2R>#GRWBZ>- M6K!XV"<@3L-L!4%!/O7K%O#DT19];UF3NH)7$)L?`FD19[#(K?KH\K0N54+ M"26B>%;YKV"=(1I-C1@$@=KX41P%>;;U:(@+IFK%]//T>0W3'.+S^E7Q"%&) MPJ)ZJ:!U[#'F8R,KI7,HVE2$2W'8@WRP7@+LZYPJ_T=R$IEB`T]`VH2O&RS^PRUF!BK^'>?XC"!HD MV(%KL/CVVZ96JYV8X72,-?<(!5`MA6ND^%Q'PV7$"-35\Y:M(BXED]N\FA: MW""-/^,#RIKD=^1=A_$23X#GZ)$A5"$.?GAS0-5!#8B;HZ<2+2+KE:4/^P5$ MVU`#.<<"IIFB)AZB^O1WEJ=F&+C`?(OO$U@?:$^?PV03Q>G#NRR+OL1) M8L/>.%UF4>F0I`PF%P-9><'>DOA/1JJ+MANE%21#Q;\=+Q@?AV-2BDOC9B\FZ?X* MM<0KC4#./(H#CF.31:O79GPBAK)=UN77OE5!BI>CA5G MEB-R`=$&1N_CX#Y.;.>3BI&YSID2$2+6&/)]?>/EU7D9%-F.RDAF.GDF^;!] MEM$SG._R=?/[8,3M474A?@.?8+JQ:=`%F/QD072)$"S/ZF.`RJ\]&W2YJ'A9 M#IQ9CC3HYS3U@Z;AV#?H'&1^#'J?$&$@J@XAD8P8^-;1#>. M@-`#<+P;3L`W=R%I!GFV=2H;4J2W=],2VB$O`55=.TQC;9(L+F,6XO)$"@- M'0"2^H)D/FHS++^V^@Q,?,0I=6?_LZM&8F2.-RLA(0I7;`)'9P9NCER'Y',V MWJY:::+.S-$@3F_YPCK&J?:9L0]46Z:M[VP357D4H6E1LJLZ4V6L7%BI;R MIM%QEA9Q^@#3,+93CB!#Y[C!@I@241IZ,Z(L]6Z/`2\NLP"PX.77FV6@C@[ M-=T#3!B1A5[J[&V1A9^M->[@H9D\Y"-/+^H1(,XI9_8H)Y_N@7__YN`0G\P0 M>"C_@0.]UZ_/=@[.#@`^6.`2-+YIGC,4/PKC/9`FE6_QGE.`G4T!653D%Y+ MY"YG@B)<3QGM(C79R6#G14(CYHK8&]G6RA]%]Y8Z$ M&E45[)E1W[Z?FEC%VL9EQ)C"TQ[L<[JYN%(PALUEB$-,AJ96E=OPC#9/G@"' M5DU\Q$Q#A[DJ\8U<:5-;92^5:I%BZ9>M7RZV2D71ZA#&K;+B#'=`?%1)4OM MGB=Z.%PJTBYRR2DT2T6GB#?T""$Z1AQ^N_<]_M=OW[ZA1P/\U]??_[#WYN![ MZZ<+3UNN2&EVS\`]OD^CJ"Z/%2IH'?MQ"B0I;GR8<SBND<)%1Y8^S?M1"X M.$'(T+D/[`DH4=(VV;G!LXIG!F&IC\F4-R!:^^P($+E.B0BH$-'BW;."3/8 M!X<."K))FXE`MGQ"D^+SKT?#YH-,DK/!7/1IX&PPR($1S1.CB'8A#Y+K M(([.T^-@'1=!TL)H)3%L&O3BXAA>D29O_5`0+K$[,?I?EB.]6ZTU"7;R1M3 MX\28NX-663]-'2%/?R#X"-,<'WKA+7W69Z?90C&#VF9D11N[U"0Y@DM]%]$ MOVSR@A5I7RWO@F>@S@%ONY/08N[0=C&!1,QK?9M:AX@K85 MDS+=W,C?P"(4QB=!HB4`N:=QAK+.(RM),(H8'5JY(?I$>AV-1!`-M+KB5E= MF&VE5)S\&+M.=X?'+(D@RDD;C6)K0ZLX6+SD!O?ID.8&YZW/__#[[U\??O:B9JKP%F>EBWIB&9%J/,I6[,LWAZNW5CA[Q4B+!;2A0DSJ5Q[TZPP$K ML^$\[^7'#AKI@^"=+V6.&:MOD,"D9YWK8 M`4E&&\"RCO]V(J,RA(Z#HA)2A/'0<@SX0[!:_PE$S3COWK:2+MQT:'YCPJ) MPB0A+2'ID_<)Z5<=K>(T)J<_DN%G4<44,3OW&97($D42RL%[X$QC;6]0-C0;Q#&ENJ^ M=W`X;YRY2X'TN$9:Z@>D%KK?$<^7519):=>I[,UQ1"K[5<6&YM+?AG+PT+CO MW,>A0MYE$>P66&8N)W.DS=D8S%,5I@+;G!5S11BHD@IM1W[4BVX[&VB/7PUN^UB8C M-[OW%.R,GHQUH(7=A667\:/7(T;)EOL1/@@N[>3FB5"YC@<(Z!#?[3[%.7G# M%DMH5L_7#HBNKX#\5M(/QI^R45(#N_4QZP(_AZP`>`%&^Y*\DT(MA]?T)K M`>,]V:ZKWT7@)>^Q0X)@G9(7?LK5Z?DF@2N0MB;T9^,VQ:J'7_1@4H^=7PD_ M1ZVGEFYND]"O(XM+&N^(@F=PJ';#&7C,$U-M@CRH^N2(77UAGQK$>HSB<8 M/SP6,%H\8;?N`5YN2)N%JV6O?,Z:2ND1X/AV6(LX@0+2?P-?&"00E!(V0\M MO>P575(U+3&\]!X.-%/MM+J<]!]'I\VC;S-I_P:;'(L8RS`XA&+.$C"35FJ M1)('[JDB5+4QC07R;8#^D.8)"0)CQ_S1+ZR&X0I^2(>97> MPG"#R@HQ%)/\\A-ZNW]-G_RTV1_`&JVN8["V)B(PG@U8\(`!`F(O:W#TPHZL MI2)X]FTG;2MC[PT56S(8^9"/1O^"(3]"]+(>;<.2Y0Z?T!H\BD(5B$#R-ZL M"K>@:("`H(;B_:!N5P-5EN`$[!^30R2ARM=ZLK8ZAI.,%B29Z9Q6M-4YTG2 MHL9_9$I'XKJ.Y4R+4F\Y^^>=8'5@KR`0X/;5A(@1A$T M6=1+735'$2PB`7/X+X$5];BP6>(PCBG:DS;E8)LW2W-\Z7.DRA0)_MB-#_' ME7D@B/&
E=Y$I;,K!RAR_X12A0)Z^;J+^:F6QSYR95J=[;C"I=WH5\C2![! M.&$/&;+BFD5:ML$O70DW>J9$R3P44(54\2N89&C=9&&ONMZBUY0%C@J]<1,<:CD7\Z0'[C&S:-.U!NT5M((TK-' MV:7: MVEDC6#?ZMHMT)K9MARSA72U[)WTFS;6592I7-M[D+=BV5@\0U]NI`/U,E$]( MH+SW3]5QTQT<%#<2J9/P(TI]9)ZD3Y3'G"<[[W2O"[+V_5(4^@EW1`ZXR< M-",\7P3J2U[A["%FS9@C\24LCH/\D5ZH1C`ZVG[(R6)P=)>C@=U#SJ@Z=9" MUQ!#("W:0APOVWUUPSJ\?X[K6@JP4[;$!TV&>?7!%N21)C?98OP7YL8P8L` M?88%,=5--8V51!LEQ!/JIWK@1HDT40`2T_,8E#>&JWI8JYS+[^%&2]R=1!QE MGHS(]`HAC&@/.OVQ=6R%:2TDG(Q@-%Q`Q(Y->4'3JHOX69EQX2O52D.=. MLM<0!XP3+GKZBY%A4UILKS$_"]+A&/]'SIP8NS$V.=A\83T9B]-1M+`]:P M&NA;&[7E+[5^T4CFW\"Q.@S2<4;8KCR#W33#' MD#MEKNN\,UTERF.6Z2KBYHBE4'F2-S`A3OE=ANGX%!>/CV4OD[,,N2N5,Z;% M0T:L:T"[;^(TWBU69'K%_"E`0.J3F6@+,<+O@0H\KT`QJH,[R!CQ,81:G\# MUPSSU9D-MU!M#J!]U8.VT)UEN0T>U\+M_O$^'/'&#_UGTAN5FE82 M$=_@`U$K_$"$QWH-$/29=(8A3V)\S#)\@V"=_"Y.,(??[;9%TF&SG$_&C$E MPF[,U0A`A@`ZAM?RR-,FKB#3E>:`088=SCJP[W=K-<)[:OD6+YMZ(PB9M=ZI$:6J/[ M+2A'4Y^_'@_:```)BG4,5PG2NW>FIPIMK=3@F;FF+IZ"."$VDD2K@XZI+-L5 MDM"UG?>655$[#:DH$B4JOJN^`>0CS\$]3=&V54^'"V-.H1(\8;A9;>B]RCN4 MY7GS4`'I)%4^H6RI+?1XHAPGNXXF>/@E#?YW^C9JBJ.<:G#/.HS5!3YJH MS4[]NT1]!>K?(7A8_IK%27]PD_DE)XF7I'@A+SKZZL5P,.[2"V)7<(F/)?B0Y**!&]U-$:07("V9C9G%(51-FYJAI@@&G,EE@Z:NB:\+#5FT4 MG^L8B8R8P9T!M`;-Y3D.%6FVM6J0`?IACB"-/S=PKY8L-R5(SE,,=T,3J_@ M1D92M3GXXJ7-GA$YF36: MHRTML3Q.@CRW=3$@1N;XZ"4D1!0?(Q\!^E7_AL"KB1)C6N?N+,U/@1=9"G< MEI[FV2:-+%X."#"Y=9[X1(@N)Z./V/7S" M_+_#_/CI60-^F-[H!ZTNU=ZWBD5Q"S8-H?X87Z/64,^3]>;(J=@#^WM MI#)T;K=3"24**E8.V@-T&#CD;:Y>E4TL3:Z&"7@P.AS1@OO:K5]GHU2O394 MJM=S5JK7>DKUVI)2O7&K5&]FHU1O#)7JS9R5ZHV>4KV90D:=^YJV2XU9:6I M)%DCI\6HM!2WEQUDY5M1)&O=&T38H?SN+,E:(,%#"[-$L(Z34&S1TLKX'/ MO)U&N_CIW\8,UUTJ-!JXR//-JNS$0(H5[[+3O(A7&&4K3-ANVX%/4/2OBW7S ME.]-_/"(::'5[%JQ8VO(79UPK,Y"'#LT`&"#Q09J#"";O2ZVT2&Y(J6O[0Q M@Q(U''/H(K'B5K6T7"KPC..@#9M$MYE64207F8I7V3;`OA+41/<0CS.Q1@ M(Q$2"@BAE)0+6#QFT4VV4[3RQU,2%CH7WX,GNJO/1^='.HD?W':%<&8 MSK&]973>]#(VD=8Z7ULT5J'=]GVYO)TI,XB>8@Q=;&#\I=]$8_OUUN. M]E@^@4\ZH9DXB4FGG#3ZJO;+#M%NXS+6YS.T+"/V+=C&,(F\!V<:7U#;,G M!-/(YPVAPM8-
8WVE=UYG%&'>(-9BTF!C50>"\ M64,;^T"/S=ED/_%$TDEZZDW_/1Z$3Q;EG\'@?MF'<_#\B^_F8_\>2+I=M_8 MG92Y_$\#E,;I`^F%17<:F_=60EQN._L)J!#Y^QS@+\O;Y/XD6TO??P&A-?I MV2>;MLD.0H/>V#&)PT6?8YD@UT/-6T2W.&HPG7_Z](D4!SZ&AZ5\+&@SGJ MDHD8ZSL/'0:-R(/\!,F]"(P63Q`%#_!R0PP?PTD1Y5>;(B\PJTEKU.B73=EQ MQH8-,R7%<;3%D$R!)M^VV^SO@=O%#?Y?HM@WMPOOJ;PCE:-M(\=PS3@:0CHD MI?B?M\W%OIL4S6_$EEAKSTWPY2(H((J#Q%JGO#XBE]4G M7`J$X9LO8%5]XWMGDLJ(:PIZ,YQ"0SYEZ/-Y2E]/RNVJ2!>3I]VD0X1`3<@W M^W&ZORZ_\GLI)!<45T_ZEB\J0E'2)$.=+L&_!` M/O+\JKQ,3%P=Z<_05$<(A"]QDN"#WGF*O=^'^#Z!Y6NW;GQ6/0(<'[6TB!-H M6@6#'JH:**`$,^3M^E!((YUHZZD^V[1/6,SWZ@+7=(L%@UWZQGP2A`[RKO+, M)`]W2`XM9UDRX3'%M-@>%O!]_`1["G>TO0A^R9#=QA(:Z)V7U:K3)MDJ"[A/ M07`,V#UI-(#!B/I3>"HPTM>(3L&1)M?,+VE.2"U3MB;)-^%CFB79P[;,%+=W M;3>$TN4!<(`648U0-0HTPZH2A?Y5GY?:'S6Q=HI[%%AA8".YAI?VICP.$-J2 M:.<@9;IT0PPEU4-&G#&,7.,VW3\K< MI3HJGALIBP"4TS(L-9I$[0@W",$TW(+6-`,\W**-!":4)$DS)C(06^ZX[*. MZ)R'A57]=0$LC^X[GR)1A5[S-6A_[LUU,I&8V+.7\,**H_\AA\M-\CY>6LD0 M5L+KTF]2(4C4H)M^`,@7?GTD'6&J.><[@R;Z89WW?9_81A-23>C;IHS8 MXN%0A,MI(I^("G'/B/KSF9T#!T2WT]U!/.DQB>#7>!M.;2I-%X'K$%<'N^A1 M^_;V20"/X&6P@CPM$+C<@J$6GI87O4$@(4.4 MTUM^#.C7@'SN=WM1D$'M1$LF:IS%>TQ?\<[/TRI`P-I5U'N3U"!%`HW"KGN&J(5!K$4C9.+Q;5Z4!=NIIU-B@^%YC.GO,?X'\C3Q M'4D(IHT;N9HFMSIB(&ZV)25:1'XW^QX49``(R0B_W005!;-KB>03'_7.;XG@ M&F5+?"S$#E20G$&K)FD`H^LG2J74B!R>UM=@";V_/ZHDP\[;@\.S-KN-98"K M,/4[[)@;61T^`!\.#Y<24?E(=?OP0#_V>XQ7$<6NG1%/UMCMP2`+M`F+#8K3 M!P(?/4&+UD6&SNTY2D)6'V:$3N[E9<>,L.BZW25&9BP:<3GJGB$B"FH&Z]Y M`/C+4I.C4"7Z"#O;)JHFLKD<)DC4W1<;9:Q65LB+R_E4%5E28AAB^FT(4 M/0(8MI\) ML_I6Q"!2U_J$^=SE.,`&SE`;E27<3>E6X8=Y\!<\N^HO(4;G M.B-)2(DP#XF,`'C(8(,)3^E'@Z+L)AW)&6#JS]W"!V(P;^":)&VF#S;528C+ M;6]Q`16B?CGEYZ#^WGOT7%5TG>:DLDD;YQIU^RVH?J+#?>]NVFK@Q+3#'?W1C(\3>?K!5OLG% MX]C!Y]$@URGV5`][%F,>[X++)-:YQ17-UBRP>86Q^P^)B5S<Y` M"Y7Y[?QJ!!%#CJ?R&PNW&_1`[LTTI+@S9'(_42[&+G:1?\@^\OW2IH3%M2PY M$S(M,+Y:/Q:/0;**0QWSNSMH:I=NP.[NH!?9W/HSSS4%4D8WAI8W\-I4J1_=&AB@`C33I7Z(A4>Y`88->I]KB(HZ-,G#8X@L76J M$R-S_3J6B!!19XK69YQV.EY"2T."Z\26I/,U.^%](!6_$86L<[[C#+-Q)2+? MD/I$B`JSZ8>@_'(.NY8Z[7U$$S.3,K7$#,^+8('>+6\A)5)4MN$^$-=;CA< M"D2;2_TQJ?M@W_H]QU?51BTJ`:? MS1DF2>3G;T[GR,(C@TEZ3R,'3.C)QQCN,`'!)DB3X@J7W%.41W)(QOSI"" M&8YHJ-%)0%ND$-HC=]G#19DJI91$^F8'J[YH0/@_GQ@K M@#!]<9!5ID&L+I:RO(RAV&H=B94`.;N_5%&2<78V$J]MC-(G]"66VWCE+EB M?H')2[JU;MXJ/!9.N6N(XHPX^ZC@;8XR2D!"-=T>O)#J2<]2$I[I2BR<^YJS4T]NEP-7MIZ/ MW)LKZ-U&.<=;XX?0YIGQ)POEKC_==WW%-;TD-63,R3J8Y6I`"5.L@4G[47 MO@=0>M.]/BUGNW==CV/E\'51"E4,\'T30]$52'\'42K.5J2PN<=7J(R4$X M3[:2TR.S[%!H&A&E36`B0()SC"CVJ5M&(UI`\C/V9) MA!?_Z;\VPA#@-#JCC-MQ\H(J7:+&0.>+H_/WYW?GI[=@<7D";N^NCO_VUZOW M)ZO#[_[$SC]^X?SNY_\1B9T1=_612T6&5NO?KVU(W7T:B#8M-H$H3VS:WUDQNOQQF7FF:J_:`RCQ!.O!'SR%J/9.D8(0,]>AJ M#5%`@;ES1(G:O4A1.:ZRX>($&'./N^[H/WH^]0UJ#@.HT^I/,U2^XZ"O(X MO(1%6;E\#='M8R`J5Q<-N%!X$4%B`NJ]$QFT%.!GI3#PW1 MU,?E4L: MXNIFHJDPP[`6AEQWGB79E_P,$UIO>T-9::+G$52!.7T>09$HV7WPDHP'1)8@ MJUV;H`;A=_?2%6'S)((.9\Q"XDW#^[OL!I9Q`FLS>%=AO](J+A&V5,
AH M.U8%I\7HLHOPE(2+0NP-#E!D`%58VCLM_IW\+21JOV:X2.W7H-Y[B+_;TXF M.#^Y0,:_8=-@!^93-MM",U>LE$#Z6SSUZ-K^$F;EMJ6S[63&R5N=,R#X382 M:_]%&W563>$DG=/,)_29`!\^8D2(A2=!+B"L(\G00%$?=A"'.&#D)'0QG M<1I@0SN-=LF`>=,N"5&VK6L(,Q3NQ1$R->N(SU$I M&`>+Z_:C?1($&E5^2$HOFT_!SW?PN0!'F)>?VTD5?_ZW_7WP\Z>+C]_^]\__ M"->;YY_2MS]$OW[W]/#3-OUPLOGR[COTPW=_>_W+A[MMGGSW%/YZD/Q7\?V' MX_?7T4__3-Z\3?]Q?W5\O[S]_^NGV[>KTV_3\)'H\_N,_/_SSS?%W MFW^>+W\]^KC^\O&?3YOTU]M+&+Q=_?WN+OGIV],_KN"_MN?%K__(_PE_RLZ6 M3Q>O%D_KP^\"=+VY>?7NT\'J<[K\V_K-?_W]EP]''_YU/;9?S^\_E%^/'OR?WZX-NKYYN;?_P2_L=MOODAO+Y9GT4/SP?O7C^M?_VR MR+_<_>-F=7%W/O3'^/_R!ZCG_Y^>Y3^NG@7WZX_'7S[7X?P/_[XW^#X M]F9_W],EK5B/V[%K@189XX?;?(XA7E^`O,0Q6N6I4"H/G5\AKK,"F');\2 M_:'J8V-Y&5#A^))$GT)1F)P!`BU(U&^EL,BJ;4/CKUM/MRSFNM)684-.FO=> MQ[L0^7]R5?@4)QA]D6`/L."O+9V"\,-HON1514W(0,/-`!%2NZE+[NYMG2ZLQMR<\3EM7.-'M1==\IKHJ8B5:2_S,CJ:NN> MJI:9J=E9$"/ZNF[3F]NNFLD1.E4S2FBXA\\ACVYW!HUJWU=2:1M#1OFPR0: M5D:\+F!`$$17Z0U19U((0IT%-TJG2H/KTZ`N@8/:N0=2`"!;#W60-CWJG4 M.GI574U=X6JS#BL-@ZT\VUR%00Z48F!R"$[,X3`=PUMN7@_RFO2A)(\ZH#4\ MYQ'^6V-+KY8D)P"F.3T&L6X@M%$YI=@;8115?]KU0J.)1MNW9&0MX#%/;^/0$.NAS.MQ,I&=1X`F8+EY].HV?(31)L&X>S@6 M7P)4UBM' MA82(J[9]P`/#5>=#_C7F$')=CIEBB=N''(ME'I700T.WN11BSWUJ7]UB/% M=1MF,S(5#')?5_=`F>I/XKE5-O?L#H8C58AO8/5Y:U9-WATWYA"64A-4]OYLH71W@;Z(O#)V'-]E6?0E3A\)Y^G!69VC&&785U' M!E&3`I`J2X/AJRH+]4U4XRV`AMPS[0Q6;-6SF+R`L5[ M["I$%&\$E\TONV0<;2^"7S)TG`2Y-+`E>GYN8``7,%D.% MC/W87QWW6T`Q`HIRP,[]VBMZ5WS)I\504WAU53+VY$CTT?G]MD."24NE]O M`A(-]NN@",7)]TGX3#!-25^$8;9)B_PZV!+V8/VF'=AANW+'D3MB2HIC3]J0 M3&&SP1(:8."H>68`00NBBK?BI5'<./WIM)(;P=@)PK=]9"Y/BX/8?=G<(<(4 M3#!/G>=[]Z6J!WSKK,0N4V-]GU6<5D)C%?'<9:2"CB8ANYLM"8%3I/"M4@3 MY8,W0@E[H"9JPTV4XM."K@^[\9D#\$E1`A&[,DZ1ZJK@-5I@NXP/<(7ZLN! M]8.X,U5+=3%WDG34V#(F:9?U30B>G5T\2/"YOW@0$R.\>`-.?"8857S<_4P M+,_NU<,`"T8:;D"-6TX&5^!%;[-@9`4$M?S),.=79V) M:1!=`-<#0#7":P7/L`QJ;1F8ZT1/H?(>\'7DLAK1X38(:D+BF!>B9WFX&J,O M6@]'2SSAD8XP[_V_H^T=AD'J@')73K`Z&4Z?9M"G3\D!:.L[`T9V?@N+$W+ MYYTVIJTT?)]7CZFC@JIUBYJKY27\PF[3,-9KE7XCV'Y=.QE5OP$BT64K?'J MLQ-G-2'$>?FE"97"@&S3'0FK-H8&&G"@"P]@@&`+"\!`SB>@,4J!NA%<4]:. MJ.5"$/'&4(PI(5B>(.Y1G&&KNGSW:T.NF0]XGV'_/EHV_H+^S"-%BM"KWG M6JW0Z?3:PL8,%+I$+S,$&K0PKW[4RG3<.F\G4JV&RQWK@?-#ZVDD,JO,NZ M#:@Y#30UGAK5ASKY"I`_-I-H/ABA<(AO_(-]P%X7QL[5RB=E,7>M$8&YN(0^\T M"P+/%$T8>>LAM='&=X#29\`J'BB8VP%M3^+]1I#C[QX0)`"U]@"Y1`J9)H"+\D5-[R'+-X-(@/&V5EJ3YN&]#GN! ME/VU^,73-.VA'2?XF(9AL;(JDL#%D.@9B0$H[H/+@S2)[44YKJZO(R/K[<>W MKZ,GM;;=4."&<72XKEA9;(K'#,7%UI9C(\#D-O&.3\1P=5+]^4R<%KG8N"5) M_1F;YK^=8(!Y$8?'YH7;>V=Q/B(7$9PN!2('%[V[:["S"(()59Q[$5SGA4 M0\9=);P,5M:.4!)L+G5'3(:&O=D#9-!LKJ$/8@T2-@^>`O1 M4QS""0_%.1)R92$V]6T88:,4#>LPBR_ MR=9-10>!Z^AB![OH=@+;I/CN=R@R36>2=--&/C(_A%G,8YAG6U/,5T9JLX7"R708Q(%FZ9M@C/ MBR"QJ$F:%+@T1WJD"2-#)1#ZD@,#`Q@<&BQBD/8`A343V:F%YTW4/699QJ$ MOLQ2DLUX!]$`V;/69^OUA@;"7-?+<^O;TZN4?8+#'4N,0S`6K"`\GBE/HT" M-<6`]FD:;`L46)"FNC4P<+4$&-P?@M7Z3R?S"&F:2[Z.<1IR4#=^5>$,:Z3 M.%]G>9"0Q]:S-43%%J,D[U2O-:_9=."YCZ5K4"=62@(!5""(#:V`4-M9@YE! MMHJ!<-MJ,4JLV8)#?CZ!0"=T@#A:.=63TB^/W(6G_B^KT1OSNMFD2:O'WI ME$VCZ:U"JQL8DN;>\3)FC1GJPBL;7I\:8K?W,THT"32,CJVB%+NC03/G M)>ZV,Z?.&N..W0G]=Q@U3RBV'S,]?29_A#9441&S\]H2);)$12?5X,YKGIV' MH2RW$L6U M0:;S3-/IYR#314MBG::(.EC)WXMWX$M\2W0IF_ZN\K-IFV-@2_EJ7K40C)UF:(L&,N,8\7:V3;`NK;`H^:9=9 M^H2QPI`_"XK@J3][Z016=F-"9]9LX7CO+FG;=JSJ0-7B]EM);U^!.H%5T8W91JU15AJ:LPRQG\AW M5C9:QS-PG$/A=G:^+,%>Y823?FLM@GZ;%DZ-)R8#;'P#5O?$\KNAUV3>T%D M89%&@H+=TV>(PCB']<&!SN\\+5"^C7ZSQE#K\W MHKQF0,QC:33/`?A7CQ'A0H+Y!J[Q8GDD]-%^WD6,8'1"&QV7>,L@CI4SO0Y^ MMV$[#`H%E&#J$'H)B1\S\]8C0E,S>NTB=/AG7+L_-@@O7H!7 MFR(OL,PPN9<;Y:P1E_2X21=P/2W9GN>&@AG$KGWI=G=CDN7VRLL%G==SY!@=YZ+(J1%I>&M0^8)!-0R4XWSKK))0 M.\HXS`;C=A_7(LV8?$I(/M&L5V$(<+[@IT"3RXFUQ6=/"$)9ST8U!]#=CG M7I.$Y`+KEF@YVI>'=P!:;$&4X#)J[;(RQ[VK);3SD#;9'43DKF:G2DJKQ, MXF2;E9J/<#[HQP>;7K(!9NFSF3#_=HJ['<:\J/D-?U88$_M3&^RCOX#%8Q8YT3\#AP;+GT!UZX:$':`\W# M!B4PN>;Z>6+05$^Z[PX:<='8EIXNE^2]\R=8=ZJ^"0I(-NXXW<3I`WN0-TNM M'/PUL+NUK^J$B6I)@"@U=&I36:9)9TO0#`'5&.\=MH9EV%:>@M>MKS1HDST&7D&@=;!E=VDI-W$EX'Q_\Z\GB;TW@C7 MX)9Y1=@YK7TE\,C+FL?8NWK($+N;L?G>RR!6IS?4P_0(GWVI!N;@YY.,Y/', MX!TA59%V7WE18H%QU<9E5L`W%P'Z#)G)K2ZA3_`/<9+S_NF._%4ISFX.W6$\ MWIA(8?-H?.A[`_9!,["=`O&"@7TI_.)G"MUK1^F12M'J+SV&MTZU^GV;)X[;<"VWX#GH$N'ZQ1XSM/UINC&48^V=/@QZ0GN M0NGIM7U0<_61$39,Q.3EI3D>OS%GZ%KM"K>VCC:'C+K6^R9:@1M7I^;M[ M./#E-DVF2AWW:1HQF+_G-8X"_2/$--B<-AJ8C&QGX9_W/CJ5HW\X#&=2(P= M.UKB8R\ZV0;O\E:FA5<4`R=?<,\"?J+ MG\J,:((XE#>O7=,R_$N6S/X&N2LS8U&BWF/$B^"5#-YR&:R@Q?"A)@ENY^H>TI/>^EF44'N;#_]3^<2F!NK)AVC/XK3+C5=W[<;A<1M<'H, MJ79U?D:AM2F49JSN&#`@P^GC M@/KTB9J,4CTX%E^#FI@H`5MC[X$R+[P&L":0%JQ`D$AQ91-@=O53ES7A%?`>S!Q2L'^,P2.SMVV)DCO=M(2$" M56M_V-^N/>J46&X<11),UZSE.7$X#]\PR,31K(&WU)1YG]UNCM2< M`(7P5WNP!W-L&/02&V/2KYW$=8]F^[);L( M1G&=%-?Y)]:VK0.%JEAIDD;>Z4@Y?0.[:X^P5#`BHL MO&L43Q9X$MWI&MOQO!^1:6.,W<"K&8_]9WB>)(=K`U^$.8K6Q\##LDT M1\A'0]=+NF;#%W6E[3VK!L>8TE2ASSEA>NYY8,`G+J>`Q1(S.?K[%MI,.) MP]L&T+>L^B:H"J[CLE3XLR(C5\"7W]K5P+F>O-6(6JT?@DVW]DIFGQ_56:5 MZ0XZ^&!0+GHQB/X/.0HNTHADE]K-S;1"I]/V2#9F(.IN6N9CTW'SB3'85+7. MA8\M1H^DL4%N6,_3R/L_D;8$?X4%X\W,"D;KS[&Z[OL-"VPU"S&SC1)<)O> MK$F=L+]=,X#6&-`A9:2;ZND7[/R;75DJJILT_BV.^].M#P`LL?;VVB5\+K, M,U,A2/%)DGE$@W0DWF)1,R(,57VAX<7<0$_7V1I]A3GX>(!08K":.=4`N8\ M^JY`E#2^?DBZ#1(0H((!:B"2C=1;\%Q#HMWPN"JCC%VT`0P&ET&J`-T6U:B2 M-8G:\??7.:K>P.V,#M-&Y-'>!<_7$,599/'PNH/"=;I'%[THR2-X!N5GLRF; M%8BFX?B(%OLQUO M$,(#"64'7&=V7:9`Y2`LOP1!"0J$#!8H"#`0$FC?^'-DAF;8$YL:2Z:^+U5 M%%8GB?^^`X%Z1@I(08'/%!`WWBLV)/-3"0="1NFMX>#LJG>Z[V#:$7>;\U% M`KE[A'A!E!^#`G]-4B8+_.-%G-`X^-7EU0AF+KS MY7$"UUD>TPY`5YBAJ&PI=8GGI[Q$TBS=KY9)Q,#1&MF,``0!A>ASH0S-L2<< M-:8XE]5NXR^\IC>K31(4,%JL2'N1\H5&!9'%35.U@/5?:V"!H`7,[SI2G'%/ M@%J<\N)`[%+X#F5Y?AP@M"5%1JMLH[3TB`E$"-!R(82X>&QQ#[VA#PO67)F M/"A'(9X-7R$E9]!A37W;H>3!9;"@OL&]+Q?I<9?TX]RJPDU]I+.TP@NQ6VIC[9-8VH:,+J#S\51DH6?%==: MWNIO6.+93VCK;^)FQC5R]F/?HMYOP8IV!`$"1Y/U9,SLPJ0_638GIJHC^29(RF\V3-3E]LB9H/UF#(WXLX;/;+CEG2")TH MSY.![E,I]]C=7G:5DU=-_:&#AS54B`W)BQ\NP< M0K7D^.%IH7@3&7_!>-8@EW6]O8S[Q7,LN84KHWWMV@+RO=]43>X4.!<#PHGZ MB-4R>%=XK0,2!5P#>N!/CW$D:P_=KJ=9]>[+'%:;FNT^@L".,$_WJ<9/D& M09J!=P%EY^>ZTVL+$,"00`4,%B``@,_E^!\-JO7G3HG'%\"X[#O+' M:Y0]Q1&,CK;U[>BSM:0+P0&!]QE@$`"%2APM`4U,-!`XRP3'XFH>I/G):: M<,_#MF5"J,ZBV!8BAT?`4,B]G4E=GS&;.[KFY0?OY?S7N3M=/?"!Z"9'"I MKLB3>_T%Z$$@451?NXQ+JC%3Y?[#$O_(SU&\6D-[W?; M`2VM\@6QN(9IG]_R2;L/Z$L)&E#M.H&3IKST9[M^322.'389>$T M@4\P)XG7$23M1^2+@'T-Z.>L^8K_XP5_#CV>RZ;JW(Z+B1E0^TH$!15!BH=Z M/8"/YKU#FW^Z6B?9%L+665\A_%6-ZH2_1)$N#P03JHO"`4>N-\'AJD:6!6P M$E([9M4+3_T&I.-R;SA/0^[QX@R3EH8:A_$$/S!3YX2%6ID39P#I1>)O15!. M@UQEDXFJQT3=?GAP&74Z4S0=FGLKR(=0Q!/B"61H^E[VLT&Z>&OFCM,T)(E# MF.9TC^V#_GJ!>1XZ[G$7BW>%[M7KN>K=1`C0M?5\OSZY@3OFK_`<&`179C M&'$I=E,3&F@T7H?A`09P%H'.S-!S8TVE2&2'XW22%N))]1 MR?\A6W_=.)QB_,F;)=G1=+\!E/8Q#4Q-6N(BBTFE#R`LQ[>$1D(T(ZT5U#H MHJ[AS"'HJ#%AGCCUF.7!Z]2D<7BY4MFV@_;K2K9DV<(I-=HID.A.O50K]:/ MQ6.0K.)0O@2;[V:Q3>Z2W>,Y?UX^\EMYE`RLB6:(WQBE$9?=IK)>H>(QNX^S M)'N(PX%@8_?;&9RF>,3W>2R!O%<9=>$^T>^)YT/\:B M&%!KVBRQ^G8F838._7T^B^;H)2@@H&9`MMM/G;TUGUQO%WP?,13.$R M+LXP`54QVM625JNQXK7C#)%38$JM0G.]`FO!/=,"PN2FZ!P?XLN"WIZ/:PQ M^'3_O(I_^EPRX4K_0+KU1;=8882,,HO0?GI+([V?=I[$A!-ST,PC$_P;; M8;K?([XQMYU&J3["`J(X#892L9OO9J'NV3W6,N?EX\H%8^2`2U^JH?X56$C M+N]&J=3=QQ/&2A\38NXV)ZGRPRMRKN7^YQF'2BYBTJ`W)4]%`C<`:KH31< M7PX&K='@YVJ\[PH>#?+4YYL+ MPUE15S;"'G@:JOQH#[#/?"^M#LT\EG,FY?C-^6H1WT#Z_LI=AD]>G^+B\3%+ M2$NZLPSQFWH-FCT&D)@_$LAHP038MH/;5LNI-EPO88NQS)!91S/&NGX2O&?+ MJ^OS:RS=HGV'KK/?54"PT21@RB9B-23/YE)]RDJ;WP##G.Z`%7%8R3HO5`S MCJS,SHA9+,?=:JR7>.H6.>GM(]8#XB_=9GK_<`T2ZV9+X'WM@410HOM^4 MIR^\1UT'G>7FQ6$73Y?KGP]Q1_N-YPC&_U,>N#'L59;2Z#IU2]IMB;N!%C9Q M.ND8C19BC?: M/-_L)CJ8&U01>/>V5$")W(R20?N?R2A0#0/E.$]+6UEP7=,IF_R(+?D&/L0D M])T6I&7'5#JS`]6)51=AEZM'\RUM=>-=)_CRZH"9WZC#,C'+-FD18"V9W$" MFW?QRK!+EA'QS8A`7)%J#\&Y=?>+K@&Y=)5!MXD708B=MX$)&5)M;=W M3E">72S.!'C;N7">+69KKCLJL>.@@`\9VDZUZKI`W6_2'?SR)4<_!=6W7@[) M`\+H+K7^U$9LO->;^R0.SY(L**82?1ND"Q/`Q2P7>?DAH%_ZR1Z42J`K[]U9 M=?("E,5=I1V=F-9%?0<-M)G&P&`F[(++/R:(L`XY[@`WQ&L$63(/G MI4EG[/C>B';U(W>TS^3:77P[5/:9I)?6[$MO9P\1Z?R+`M[T/(0BF3=.4OA) MKZ@XW6`-8.YZEN9'<)DA=I-Q%SS#_/09GYTS%-$\TO,"KG)2UD^Z3&5)4CZJ M"S&9P@O5SN&EK)9H\((&,;BGFO##L6]!SK8`46_![H$@(H"SR5B)Y8DF""6_8N.#>JU,,K.#C4WP#RD<>C`I?GU?F@/Q/_&],)7$)\:HE8 MDTW-]5B-KAK$^O=;Y--36XA9XZ"/`YUSF]T@-\-BSL'E<-;:[+^ M5P@VR]F&9EJ','XB^5WZFQ8%`!H(L]RT=F:IO&EQN>-:;C3%@I/"1DX50TE^ M90**8JJ?WR6E,DWN)98R>TR]C2H\6@9&)PMC\L$ZO%'F$C`4XV;![5[LTE=P MFRN4W"S&%R8,PG2;:N(NX#K9C=E$V M?':NYL[T]+;/#D\S.CUI^-5[G#=&A&<""A2TNSS1B+6H,G/^U:/ MYP/$&,9P#QKC.>W_0'-L.;&4759=U1B$];&UJT?T(:,84Q MW6_PGQ/(WGY8K#)4Q+_2W[4+Y5OP01O!'JA14//>1KG7$KOI11J(H[Q5&5: M:7@^8-']BMR#EWE(YM=LY=;?0.+>M\W##1#/66WS'^+9B"V_A(B/&41_T@?2 M?6^W$\I='?7.JNSPCJQQJ-W@7Z!TAY M.X-Y'R`5^QM,P&G7RO$NB%,2YK]R]=K8DK=LCS7'(JD3T95F6[88V@-)4&? MW5.A#]GY\43G@HGIDCU)ZF_5A+]&\#N[+R``L4L?YK"WP!F:#F^]JK'`_ZT&R=IJ MY:::W6^TDX7[=QSS<+:%!-EN;:C.BJMX MV`=3WUK?^JNPDTFCEP>W.SM##:C,]AW^;KHMET)S54W91CJTM9)OO&<4M'F] MNWW6DW";;ZR^1[:__$.`/<$_L6URJ(V7%SNLMEGMD?--=6`#`KZF/1=V\;W M5]8RR._IS-C`&UL550)``,G55M4)U5;5'5X"P`!!"4.```$.0$``.U] M6W/CMK+N^ZDZ_\%[]LO9M6IB>RY))I6LEFV9VG'MKPL>R:37;M2-`E)R%"$ M`IV-;_^`"0E\02N!DX_6P,K:E[L;7W4"CT6C\_!^O7Q]\!`'`3@2\@_O- M`1S_OVCU7P>O#\9HM9ZY\&`21.2O;@0?`/E=\``P^9G\?1E%ZY\.#Q\?'[]S MR4=#%V(0HAB[(2_.'C]^I\']']\3)F,,:`L?CKX3/A#H_<';][^ M]/[#3T='!W>WXX,W1\?OTB^1;_@P^'KOA.#@:>4'X2^O[K'_'<+PS=' M1V\/MQ]\E7[RIR?ZB\+G']\FGS[^\.'#8?+7W4=#R/H@(7M\^-OEQ@_19LU^.55"%=KGTJ4_&Z)P?R75TX`O[ZF&!Y]>'M$ M:?PG_;H,O7>)_&+DNCH%W]K0FBXXDOA4B M6B>!XR.RJY@E#@L`8.LEQ$Q-Q"XLO;03%'S(G9\"2/P]1(%Z`&&[FB!03+U MR`E>1TRSS&_2T./6>9)%N$!!N]4>OYV!!1TX]0V`%D2)70GP1SAE?SZVTY5 M_T#>W8`PPK%+0A1B@60WY4')!:Z&E.;I[OC]%7@D[H[BQ&5F%"L'>Y(BUQ'3 M:\[,0.66_J@Q\,GH:8:;';4HR-Y(4+MYLZ(8!>$;R&E=<2H1C8+,=;2T8YT/ MY1D+V&E.[9NVV%4Q@!+VW-H0ISU5,91A-! MK9Y0NXH(RUU/2=NTN%LVT/P$GH M@Q`&8P?C#5%79IN%)54\V\U%5>M$RUI:Q;V6142;TUUCY)$EYP80JXO!_2;[ M^2-&\5I.WG:^A;B,J_]\K\]4M,SACJZ.O.BA=4_4;KCC^@Q3WDD!I%.T6] M(1'K&.&4A`=0XGRMC5X'Z7,5T9OH:1:]LL]3D;N6F%Y+:=HPJ8C/0U?W649C M3E=E,%R$]2:\:[\2J-HH:EW`/GLKY+4+$+:+:=MXZHT`E[BVD?%W,16V#HT\`&X2T_W[D'_B^OXO#UPG'6?\R(F(G;3O<;YFL40BK[Z)XH MQW&C(LJ9J$F-TMP)[Y-"I8S<(47_$/A1N/U-HH_71\=9O=)_"O'-IA#Y067A ME4'QB^&6O3$3L"$_#,TNV>2\Y>2Q8[PL4!.-C=RD3^63'78JU:]HG#=5(L M]=I=0G]GZ7.,5G&%Z%ZW2+L`?S+J^/OCM3-94:".@=#-'J"9O508+07VZ8: M"J["!+R(C@[<,X)W0;@&+IQ#X)VBE0,#(]C7,CO\9T\\@65^!4W4XY5IXRC5 M1A\&TVY/N2DO$_]-)KZ<.:4;@W&,J8PFURXVHWZX<64=R4-?@U#.>`Z(['-` M_NY=I.#6RI8(EFA`065C)UR2<(K^A^ZK'QR?;HE&42&39T%?(SS`[.@U$:# MSNN5$T8=>I92,^LT1N6">4VL1N2ALARZV]W2HRJZP);X`+B)D1Z:Y`9%"3 MC?RLA[#450,N6\[=S5KC%8.]#+"B;U MZZ9`?RBZ82Z>9=Y[HYS7@1.5+1SR&HKE&R#)%OK?E9-D1+`FAIC3Q M5AB40=]K9&M[5RKJD\T89AK^7FF-T[$O-+X?M!^6"!AU[>909;,0H#5)N)-MS9KN;S]B%!I:#QLYVG9'O@U^&VPV-P[QO;IP<4IV!>= MD7_[($$Q\$8KA"/X+?E][3@,;3+TR&9Y+>;,`6G3A,2^Y4-J3`%84/Z[.4+O M%&%H,]/(S_JDKS@_:-OKB"[2Q.[HH4]87:N4."RUNN:\^E6(KWVS'8(-&QT M)/,#Q:(;8B5G3ZX?>S!8[&^DFL@;N"<9]U5=&' MQ;VN4W$+QFBT&FAQ^4=R!RJKB`SCWTD\3[+LO4>A/8O$D9OW,+8E_%!F M.O^Q\PU3L0.3I`;N%EU4%&;KU&RF1-FQ3.K:V=#3UXZ.TJ<;(6 MCO-B%5?,%=";=T4<&Z(@LT&_F6^D%T$^?8WPZV6G%S4&/[9"1)$>7$JDN5 MZ5%@`[?!!JI-"/9H=32KV'IF/9I>A57;`&6BOE59W]"(6DMU^.I M8665JV?>W^L<5=HZE=R$[L!Z[<115MG(=TF`)M3?L-4T?>3^T,1+X(+.67 M"&CLR@&+C>V[.B+J8\D)[$G/=>BPS.CPL'Y^(SJ)%?#0$MW)Y`\]+KG4Z M_K4#R<9K[PAV0CE!#220&CG.B3WXP'18HR;RM]E>,9P(PS@(DCW MTN[F%CM!Z>@>W_&8935HDSG)+8S7.NE34SK&0U!0SA2VI+"G#NZ'=(H)] M`[A"?=L,H7,575_?-AN:/-MC-/YYUNRJ\PO32^>6E\PR/MQ4OCFR8EO#2^ M:0+\I?'-2^.;7C>^\7WT2)=(LF<[1?%]-(_]:LL!D[4:0@+TQNPJ2T]AFRP& MJK7ZN&):EH1'4YP,T$N2?OMGV$PGM&LY]V?!;=0W+XXVP2,B8"A:,X6B(, MO^WC;',ZKG`Y4!U64!-2ZY1]52QR[64A^TP)ELN`TU?,E)U\7RV<2NUW>2N?#2 M,ULY#=41;)636+DQD(EM/]C//H M5ZKYS>D\)924$U;(=Y3NYQ)!/G)YR?T/O< MGU',D)ZYH6S\^F6\21G4:DU35A9WQN`WS&'W&@7-/:6'ZIHY7=6\%-K74% M'OU(P[3DP,NXR!_]:VD2N3.Q_<4IH^%DCDU/TAQ\860>'OG#?0TW429!!`A: M42I09D=7$!;28T]A<3!UZH'-IARJ:V(+!==_PYA7Y,I%.;3UN)]+IRMAT"#:5Z6N;33-(N9M0MVO!":]A M-LVL.[QTS:TZI]9,N$ZJ:45%L.2O,CH71M=F^4$AAO[CJ)N]15_GW5I0,@U] MZ.P`I:FKEM!"R$7(:HZGQ@I/OA0L%9Y52?>78"!X]/[+?]"?O).FP,#O,T MF`$WQFG/'0Q#\J?3Y,R(3"L0>2:;UAF3U7JNH,%^S"OVF.XHFWWB>D#[-V MWB[1D1]G;-,TA/?T[]1F?+A/IA$&;=D=>NE9BIU,?0SJ3UM'$KM?;?"Z\ MMBN,>L7K@;6K>I]!<\);0/'ZE?D]M.N^ZISX/XY<+>'^3"WBBCQ>\7+M[ MN7;WCP(=U\BN1ZN(GUQFJ881$_)A8K MQ/XN%1FB!MI>G]&EMO9;JO`6W0`7!2[TP4ZN6T3^24=XC=$#),'MR4;5!_5R MM+1]D5&Z9JCM/J)(.+K0R;;HHQ7"$?R6_&C"TYO863(`(WY3?'ZO`6;+[UO MZU_2'C)D2VY,[362,_:TN\<=4WPZPAH2U9 M6?U`AHSPYC.&$3A%CT:\G,'E^2J:!:FM9U3W1WFG,%QG;R-,YZ,P!%%X;$+5 M+1QM;;J,:[T-:8F[6G47(64G^K,G%X3AK?.4U?+3N):](#'&;J2X34D@UDW MXW:DJ"2)BSHU9B:6P5DZP0$DYQ0B>&3J#;_PI)0'D>,Y/.R!E$\-320E;V8 MA0$QS%.0_G<25%]V,!-0<6!J<3V4/=Z4A5T&_H86B^:&=I) MFYO0=P%&B:UAK:(UJ?D:@[4#Z;N)B3#9#4$RXJ0L(QU_-_KGDN3Y&`8?\!)[ M2=,6D\A7`J(;"V%RMG>08,`HV-C:;KQ2OXI=.YONPX(MTV>E^0JB"@U!BG<5 M]7D^D1''(#_&SA1?YONR?E24TH"S?9L"8320!"NT\DC[QV/E2T,#_^6P-FD"6OR>M MX9IM)05V%U++[2C%+,!]0&4F,MCGS`JM7`J#(\F-D)=M7U-Q&P=,\DHDQ\A MBZ\S.ILLRSUR_XHA!I<._@HBNN3L[P@:1;@8MP'U^6P[4(Y`!^B/4CSDMG% M!`V'5_F5HS)(2:2O:7/M.$-$&L>2W M2>/L3KR[GOMSKO!H6:WHO;[I.>H.>/0'LPM#4>^AM3/MQ\!<,89MMYJ+)9"=Y+R"=2CB+Q_PZ6@KN0U-;H!/@X=;1,;Q M&4;+9=H!YASA[JX`2,LR.).11UUK>"CY#M$ZDWXZOT#!XA;@U2FX-[(MJ.5E M5VKH/)ZV&P?T->$I!TM%@+OJA,_D,WJ0^.#PS=!A+BWP/_%RWG%H)73X]PR7Y%3)G25F_EXR83AB#$ M?WB&(`:OPHF=6A?_9G%'9%K#>$,&_X)K`B:A\D]5U8DNSR,&1 MFW5EJ!6=!-2%LH>79%8K`\943Q1B@^4D^TD7KXX]C\%8W@=I1%. M2@/!9]1)Y01PVKO12&#$>"PH#K:O%OR1W?G3L0)R'N)=GD$LR2MAL-+@C MMM=!S1&U'MMLY>RTV81-NIES0SM-I_DT6K>CUK`&_;Z]3YMICL)7,("/@!: M-J0E6IS.\Z=+V6E4\B)XJI8&OU_\OOQRFNQJ6:9CTJMK>4D?598I&G7$>F:V-WQM2FQZ%0;-+'Q.\P:\;9I`2JHYO=-?6Q$Y^,2OU,MD2 M+W2YZ,CU9$6Q'1]RV$'>Z:01'W96Y?B(["57,.W:2%;%,0KH"3X(W.WI@%P M?4]T5"+:S=HH)H!;0@/([/G!&(26%T;I>RB]"Z>$-S#7QN/CR]A!+Y>HH!V M3'='"PR2LP)YYRQUSNG&(=N9JCW/44/=;):RG:O=`P1N31??X6C'./$U#LO/B@N;1O%>I@SP`Z_`.GY_!1ZSM`\9]HPNSZ(" M.5<1.YT7$+K&9`\:!VY:JD8@_`BD8?6D9D^&G"6(\A!0N1)>$>?'#)+$=. M'EG6>27F>10D=UYZW%IDW"__XJLR[J">VY+L4N=S[U4EF<$DY/4C.(O&EP M0ZV!!C[)[8]NBHUY9;"^FDF7('.C/'R_8U4F[[U./9C\VQC5T+K;J^_?%FW#@JF147ZF$7 M->_-HTR;KA?N/!.H1_3-F$=^K8+9SKR(%T=)P#ST?FR^75G2X9U$UO3>$ M'?UQ^F9&EX[6PMNV9PD64_-C.NQC]:JZES\^U)OG.LQ::P/HZSH.49C#=][7S;1=96?Y M$$RY]+X12DVO4O2DQEXMU_XLJNSWVJ[6>G<9_K1RM^Q6@J7T(K`.?3_16B.E M&@@-O%1JG_4IT9ZGGGA7=YRPY6)TH>.R4S@TYI!;M]6:J(3) M]4HZ^XR>H%'R2M;T/_AP?UVY/]W]./=^.+:^_[ M__9]\-O]='PZV7R\_>O'KY^_S-ZOSMX%DU-O.?[^][O?WXY_B'^?S+^=?%H_ M?OK](0Z^S:Z`\W[U[]M;_\N[L^]7X_-)/KV6_@[^(+.YP^7AZ.']?$/#KZ. M;PX_?CY:?0WFOZ[?_O>__[P[N?OKZ/Y?G_[UY?YJ=/;C^?+]'%Y\G5RZG_[M MWZ^/WDV?;FY^^]/]QRR,/[C7-^MS;_%T]/'-P_K;XRA\O/WM9G5Y>W3^.]Q\ M^1[^`WW^]Z^GWGMP/\?1';I%X,OOM_^8_>_!>';S^K5L7'8WFQ$K23(3UXAF M&$A4.XOO/;+\AK1JX!L[@$V8<./"9L%PO!;`H0YM7!PM5MGS<< M'O!RS]59,C@MBYQB@%>#@IBMCAX()\J"O@[H%**I%4V,?$MKTTP8+"]K.U:K M)?HN],/A15K3CE2G;ANO(J3G?A'C,+P+L#`\:G$'QT8G(`YHL5V3QT;":=0 MMM+-71H0KWYTI"([LZT+\E/O;LHU-_:MDKZD7A#UK1M=6LT=A(B'9J"U.R MO3GV%VD0?/LH53'GP0T3[R_U25:O+&C.6729"=.:Y)QO+2$_:3^)EMF(ES( M\.83U3EU/D#QID>;M92&8)FN]VK:#`B+3G5':N3S>Z?_X+$Y[&[W%R`!^"; MRK-R]7FZLQ;B"V0E_6KJN%)L(Z)RU`&Q^92)TWL+&>TQ&R=J3(6AL6T MHS8=O>E61V^>HX[>:,Q$LNB_[59';Y^CCMZR,Y%J.LI/UU493]&[.6-:HU+ M`-O5>QH4R0=T;J^CT,TX)VY2-I]<=.@@/"DQLYFH,!V0E'$MY<7ERF!0`#;I MUOD\#CR#QYXUG/HS7;+-MM`'I@:LTMGFRX%T#W0E>"Y]K#;[O9Q,2RF)YX!: M[=B/LZO,78#N:?$DG863\(?\&9$YVH=9X?M^+!W$)[IE'9;GFE-97:0SY#A! M8TZP!(_<1.B$2_J\0O%-9D8O"/3(C=S:R<86M.WY9>P.8'7V#>+VSZ:REB/ MN-+1S13LU4YHUV@+5%INV;R<0/9%VPGD1(GSA'`(;CH0;>[7#^NNQ!X$3H+ M([@B<5\.LWPC+R=(^WJ-UD0D-UW2;^!B&85)SR_Y^Q\E06ZK@DP+@HQ:!!$Z M^C3&7/8"":L!86;,9C3&>_#8N6"B6;NWN9N`+8#`/$?]&\V5]L(F#2?8^_[# MM,<7#2N4`!6:Q]M`-FPX0?H@O`6.T0NETJRZT9\":(E\FY@^/4<`S`)R+8, MA-$-&9<)MS`AIM5+YMQ=J'O@@G]ZVM'K6#/^4[=(XSIC$53%B<;=LOM?(I^ M"S_M#N=&P/N$?$+&)_HR;]_FQ/Y;1+"\RP%N`5\?& MC-Z,M#;/PGIE[8:,0<.%H?Y,[Z?P`7H@\`8UN1>$MGB3NE?6;M8RAGR#GG) MP-F]9,!\;D/T!E7I=02^-S=JTKN\M1/\3\#:DG`&ST0>!;@J:;U^S]E7`: M1R%M6IH58K@F9@$Q`6PM8((ZS7N@(,+RFP3V"2"W19S-Y\2YI_-DB&3&:FN6 M5F.Q'&3L1-P2N2!1%/#;SV.FXVM8ELC[\\X[4#2F0MSB&++F?DMO=6/>0"W M4833,OG4B=WA!%\K@J6@3?\,7P^R0I4'BAQ_/\=;BIK[R.)1DBY[PNM+:SO M24<^NW=W;IS'2Q+(8NCXQCH95AE9.1-H`+[0T$'V5X+'6;68GT!4P^RH= MI=^#=HKUMLE44X**PK:LN&3;6[.+;QU)+MQ%(HK=\V7I;JC-#TLER7:V$/F M$56)@<0QG22_2N;/Q`N"B5_-F;59IO;UAK(&X2>PKMSOA?AC%V4%F!O]8A? MU7$+%\A$,-?0?.47L9':WK>XRX#Y/%)LW$FZM\:F-IM1IPN;SZFN%LUS[ M)QW@9$$Q?3>#=D2@^_R4-TW1F&Q@S,/8]CU>-25R@JO#^R"9^>%]O#\`,^AV M=;SL-IQ6=;A:!+5%Q(](\<.6L MF)6X=0!]3R`TE[Y;&#\8:>B:U07#Z`Y$P5L.C8K&73L5>G^N+"J_,WPRMF M1NN<_13;W;DF7\Z!D]30-J1KH66OL-J4 M1FM1LU7W61;P"D1G3ZX?TV/F[8#-[&LY^`YI)66J7PQE^3)(HR'F70CFL7\! MYT9J>+GX/AM#X$-9?J]A^_G5\9)6!8^)I'KN6:I61S'T`[ M6[I13%LR4_'P`S#H5DWL^CLU?%RGW]1!">!;C!IMCM:)HS)$734/8E!_`O1>N#@C0#4E2_U&NKJ$'55,"O% M+4DW_:S[J;EBY7IF?5]:.>"R76JL.1CCVY9HN5U"W\H)LV@_N;5MZ+HZDX]M MRQ/9_A7TPP1-=Y.Q'N0^/@T(!];0O>"6A%AESM#5DJ!5"DK)4(:R(G[!JUR M.WZ;&0>M;ML1SQE(5NK&BQC/H$SPE7W92)\<-8F43C"X+ZL8S^=TF[VVQLG MV@U04[(E>1:8RK5GY/BF,B[US&Q>5#$T-Q16F'J4%>[\WM%6R]]V%D@RF=\ MS?HMT58SI&BRQJMQE9:K78HQ6AM\U5`WW(RATM);&"4WL])#AFW/B:2.6!\ MSVZFA@M!YG"MY6QP75><'.[VWIFUO<8(C[0@%GQ(ONS6_B,Q9R5N[=BUJRX M3VG>EPQ=B\Q-+D.BD MDLRA[PJDQT19.>3LBW)D0-3:=CDPBSZ/.RM8LVAN_!&T694BC&8=;3T MCL$H\+)R6F//&[>PM!<':?'AVBIE%KJ.;CMY1WZ,!8,$IR2>R(BC:F:2=C> M+7':9]5J@4,;8D>P8L6F8WLI2)#.'?$]"C.&+Z MJGXD9]%;\IGIO#!&F8#_=(-DJ-'EJ,#Q'N""DD7JB.EX#=-Y&==>#K$.?4A5'H!%K6'A]AR6BFX4?=G/_<-9[K$B)1J,OH$F(I M>T=1>T.?:0O1_#K'),-,]"V3+62G,'33R/V62'?BTY=VF8D[;8W%:]G)U7\U M8"6PFLE)).D:R`JGH;C(F9[K\%A4-NHNUUU&MKFGV&,\!@1CW4K6)2A4IR5.U6YQBTD?2CO-"J-LJSKL M%#`EG9)`P8ED[4&8J/6TH6F+$(?9T@W#7:>%_9#)_K,$C[F<(P];VQ&!:5L1 M4D%ME5&/UT?^0%)##CGFAO@TJ0I^!A;JAD1C>6+U^&X$-7R4+K% MS>G[L[]BLD$G:SEA`1_`M>_HVYQ.YV.THOUN$MFSGHC)65/RP/@]62N\;?ZO MF_VKE$1R6]P&9,6VNV$9+:X#43%M[AWB\;V5UGB@QM+MY%]5%&2VE_,G^<@7-`Z[)\%V8SI7)^XNST+ M#S/B16CRH-;`J,<,,@![#P9!KC`H.<`%\'0LOHG#`U&7SGR5L/>1F`+(&A( MU-W"B/8OF@0>?(!>;ZW`YN1M=(1F2FY!JOR&BAHWB>(+_3^2FD.6:$14Y\ M:KYJN0U`HTE1/.M&;+M70T7PSS!:)ND8>N"PA.M;=$:,)=H8K/X6%'OJI:& MMG)UIO_3!'\:,]>'4#H5YR=_)[MM9ER?M74WDJ/CX]S7Y%WC(0LOJEI.60SM ML>NV<=-UXFOIBRB3(#U2A[+MK+%EA!SD"9E1%]ZGK_NUOZV^-'BVB3?D/2Q MN5TZ`7.DO3)4=E[F6HP8Z;":M7S'%;'QIO\WR<0TJJA="#'O3)0EGQ]W%N9 ML4&F=G2\]257YS=5,ZZ%K-'=86"!R(P2&4/;^EK./F_T^-?@N47VC/$18L` M?@-&ID1SP@YO#C2H.`UOEDE/>L:&E;I:,1]'3#:<=V:Y2L MX>$VL3,L MBSB8Y=ZVN7?K%/>/%UCY`+@A><$O&0,V9"V@AM9XMN9#G)CS8%EIND?;"64 M$[%NP#K&[I(:<](P(X)$B-/D/&:&+R9,?S890BFFORI MG^JF<132CIYDF%:D7J2DV9'7YX'G;X&=#_$-][`-A9@.WD M>XU)$&K9)!M%&]229TM]VS1S=^UA._%$V=B^8[F&M`VUHK>M>79Y#-+)0$M> M>0/HF7C2="U(+G_$CD_;Y_7'_ M0P3AGIK+2J''Q8O@7Y_YF#J!2'9P27#WM\`E$2"Y\&ZD%DB+8);;DK281J$^ M2(\B=+VZ8,D]?YS0QT06\-X'HS`$44A?%D'(>X2^G_=4.6/?4B+K9YG/_LJL M2?\5$T`A/4C,`4?P6V8L95Y&_+69H^TKT5J+_AG"Z+ZZO8LN=[Q$9E@5C#M M3T+=>IF@FQGOT&=#-2@D\9\1"3F+XY:%%-^%N:!4J6QS"7TJ5C3 MJ^FGR6R\$TO@UF$SA5ZY2(,A4LQ;L+!]'[%Y,.8N(7+QM7I%6DS-8G@RI\.> M3QYBJVE>Z60=6XSSC3=_`4XF&^9K7[+8G9>-("@$#.&;?$68,F4.Y@%[+[L M(Z&P6JCT7)[3HK?=?TQ>\6CE.3!/Y,?2XH,L>5DHEB34`&&$`G`)HB7R.E&\ MA!1#=7(9P'5<$+.<#7XS"<@OPWS5,K^2EGMCE@WF8PF=G(M;EEX"8M:BD( MSP5UY"32$XU4K#>"XC";78Q:KZ"ZAA^"+5R@3%,K7,EC@Z.I.^V.O<%F1"46MH^' M6Q&O8)G4MFYV2@FH02F;[X;FEUJ.-D,T$4FF3J@U!(.NWB?T`Y)$#2F131X M8VZR83.R.MDTFV!A5\1&J3+K2G@'&$`%X%Q#3#YV)Y^^'7`ADE+$\RJ$.;F M_UI>=G/\_'JH!TM'M^LJ==H9N;NE8= M$"8F>\.WL>S9FE&VSZ)Z6M#3TR09!I!L#3?3^9F+`K2"[F@^=R"F)2OI.WUD M5^OX!I<600D&I$%1;`VM1V9;]S?RZT\JA-/EFK"K?6..3T&9']-Z=!0D16&5 MA:DFY<3^9K\7F9K1RK==4GK.<9=[S@KQ:"HLDU"LSJ%BC5[;S2NK+B#0%M MU15J;L&:JG@=P_:TTZJ&VM'VI+TREV]S)-)SW:C4P_FL\/4$!&`.S9Y\E%CU M+IU<.:M@+E]EP.QX]B[M.I_3QUH?P$Z^&R<":3UT#(-%]OHO"LP\P,[/O6=9 MO49=BX"JJ5Y\N2'HZ(" M,^@/.'M#"QH!0>]'PK0@GQL"=U),$=XE7!4+UG(&-R`-;WX%RQ,UBO4\I)> MJM64--Y2I+&/1D/(TM3`S>K68XV'>8]I`FQX5_N?)<\HAF[4=^;DS$AU&A MKD>R&"U'-.F1ESPP/+K>7)_W:33\#,77?9;$1.L_&DG)7VQJHET94%0D_2B M6!=D\14S4:O;;?4X=KM9>4=%Q1&B9`AP`_FWJ)L86DO4N'VH\J3OTT(JJCI M"@5C)US28)7HWNZK\](-=K@$!^GZTC'T;OMM&`.3<2@R6#MF&E_+L+>;NI=:(/0&((U M(=QU9Q;&H#C/V:K?ZZF7,97#'+>^)_LL9"=.D9L\[D:#CN29UEP23SPQT42- MG8NH"QQX"(E:K0?@'RFU&["@!35.$-&ZC/H9@3N=POT<$B^F4Y.Y!_E.:F6 MJAW#%E$!->EZ4!1ODE#"6V'H>JN.SY35S'=_[T#WWD=.0\!931)[D8&8"UA@=XI"%T,D_[R&N'-4QU..,(&)??DEVPXDDU&@)9+ M^!,2,C_]"C;:YNP265MI$859N@Q,[F$M^5@[6Y%WA\`S@D+EY&:8E/PGY,<$`KPYASXH-W:21[],=G@V7P$F_S2U%9TDW(C4G@ MN4!8VQ13)#K`.+"$2OZ9'[4Y_3/P_5\#]!C,@!.B`'B3,(R;KAF)`5]'?H`J MJ$4J_PZ-ZGX_O:NO;6O)CNDR:8&F/QK+E3S9;N?K][3GZC87ZO(SR@A;46 MFRWJ"AO.(NWM2]H&D,^3'DX$WP#/%OSW^Z"R)NW]\R&E2=^3G[\_U!+`P04 M````"`!`,&9%G$U9040``#WN```$0`<`&%N:6LM,C`Q-#`Y,S`N>'-D550) M``,G55M4)U5;5'5X"P`!!"4.```$.0$``.U=[5/;.!/__LP\_X,>/O7FAB80 M(5IF0GAY7(%PD&@I3K^`3=#!7G!C(]#U0_:K':)'R)[Y MCY"PO]GOXS`,#AJ-IZ>GMS8CI38BD.(V)#R!V!S\Q#P__[[GP^\DPZ!O(L# M\)GU;63MR(M7BF!]0>0\\"SY[KTX/G`7'1 MQXVY/OF3MYB,&MO-9JN!?!I:O@TW$GH_\N343D@:X22`#48!";(W0&B1$0PO M+0_2P+)AIIGEHP M4\&P7T`V[&].Y8O;1723_S3K:6C1@6B5_B+$VFQN;;:VIHYR'^0R;:UO[_? M$+^FI#G[/CRGP<69>,+7>A!/SS%Q#N&0RMRPX\;WR/+14,$G90;'[=E!I+U MZ833AO,B[#;B'S<.F7D`P`W$\GT<6B'"_J$P,VYLXGD0('^(#]-G["D7_R#5 MX1H.@=#]@(_;QPVO,#EEB.>C0D+4?:8(X/^XO>X6\'K1`8LD M%+O(X3'AR'+YW'TSAC#<`,B)!^!O\K>2:$Z,5)`9#(=LXF7QZ8;9FIBJ1"SS M'>A3%GGF68$)Q!,7ASZUN1@]@OOWQH+#+-=1@Q=CW_4/Q[T;B3Y@E)7MCY MMEG[66P)](T7<%IH/86JD<$J[W'K1O'OXNP\1A#1FZYM!"HBVU,&&^OBC%X MD^U1!KI^]&O8H@%/)]E M#"BP?`=DN@5QO[6SKQOUMALVRR`OZ`]E.K^Z`0`F"R0^XP":]210T!QNQFSV M'&/7@82>?(]0..%IYQE>-9PRN'<;]LVB:!S\ASP57'>VW($ MQM1QJR7%C4>WA!=(F=6>5V9-W>Q@ST.A2-J8O7T2@R,GS:H("P"I)SP MT"B8@I0KF+M,2R!X79<".Y;SS(WS/QJ#'GR>HF(A$FY63"JT\ER$+5NX(C; M-4\_(!XQLC&RN_X0$T]>[#W,$(I+Z"(X)CPCI.6764.G@&[W$CZQI!!'(H&XX>YF M$4<"GHJP0/R3EU5$6&1,P8PKF+MW6_%,G2?_UFP&)W0ZAUQ6UYM4=:CP9N8 MK70S1@UEF;JT`DLML2DZ;LL+,YHJM1;0&M(RU6H%H!I2XYI_6UZK4=:N:_=< M1PU;`:2SNB4\L-O)=^^/E6T%?!(2(W+R8LU"G;MVNC77NQ4`%FAB3ENW MY64;<_5;AW(-,P6])/PK<$L"J:R MP).!44UE7&FV2A>"4@S+;%W\MT$KCD[_^?GB;N>O/[_80?1\[^_N.S_V'D?W M$__V.'HZVR/[>Y^VO]WV)]3=>[1_--W?P_>WG?,KY_ZKV]KUOPQZG>/NYS_ M_?W#Y_N;7>]DQ^\>.^/.NZ^W7UN=O>AK=_CCZ"YXNOOZ&/D_;BZAM>O]T>^[ M]SLG[SSX?=(-?WRA7^$]/AT^7C3:C\'6GD6NHNO&V>>F]^`//P6MW__X=GMT M^[TY^.WNM_O!9?OD_>EX=XC.'[H7]MT?[B!H[O2>KZ^_?+-_O:'1OGUU'9PZ MH^?FV?9C\..I39_Z7ZZ]BW[S]"N:W+]#OY+1WO#\W.V%(ZO7_]3YM.]\A^\O M_P=F^OD@/@Z3'Y:!\/#4^1;OHTLM^OST#"KB&6LOU`#_4S66J)^-N<':DJ&>\%:MLJO"EHS6`7KK(5H>ODF"R]73D!;QW>LOZ#/$)#1'+T^&< MS]Z$V'[HQ40LK1=_M@,V8LR%^,-K-!J'M/W$7R3EG?]E>C"'37EMKX#M\'7J M3&;`A08A!JG8"W.)D!4DLHM53_QD7GP0RP]B!>KZX4HU8-4THR0TKV=;\FJB MJ@ZLG61J)&5(\M6&S9SC&+E1"!UIO3Z#:$&AN@A+RB:4$W61K;PY:3[PAO< M:^SSV"]6]S,XYWXT8"JO+>;J_G-@&O:]UXB5?PV@FH+M)$,6P9@>6FQR%L` MW;1441@\5%X_Y$\+(R@#N\[HB]XV,68#!RGR.Q8A$Q:TDAP[ M\T(N>]]$H1:FPG%+7FLL"WPB#$`^2,69)=NZ`R^U,E=%THTBS8T(:PXGUATTT7MKN5` MOR+8B>SP&CY"/X#2?+W&<%1D,^CS-3F,N2.XN!B6809>=(]2.3A]U.GCX1( MM1$L9P2SH3_']FS3E-845&U,_JXX&KD>:YAKE4I5+ZI6WI"EC`%:Z@(S@V+# MG693EC[,U[#F8;F9N@"LY??:S7EUEB(1`:0RU#-\ M,=2/L2WV?[1]YX2M7/D^A853TEH4U6LF:N4I.P`XP=BAJ:#T/].Y#XT,M\< M$$_C9YGO$\3/V6/D!9B$P)=^<$+U58OX8QAIB-,TX7]MINTV^:/-K>W-UM;; M9^I,KV\O097/+Y`OIP8:;NEQ-!_WT(AB!!BON7(L@+1L`'=D$YY;]]T-8"54'S=8 M._YA!$$5L!'`3E^T"%-:&K'&(SXKV(1DG:"&/NYV%I4T'EO MRJZL.6HG]]RU,ML.6H;MAQ59VQ>3+,%>\V.I]@/T59NQJC.\!055&TZ<[L% MJJ.63"B="MFWME720R&96IGD=6`W^VZR-WTW61WE"DO:.%1[VL+KN.IHIQ), M.V]DR%'F:)8=50K)&7CL".^6I/=375RI))'0KW^KH6DA):HBD%S",'YU M4M%`IY9/-\4DL;'"RADEU!AGCZ_R)1]-.<>T0K-I(2F5QLD_UB&^U7%L)=\ ML87;N##N2B4NA275QD3G6T3C'09]?`UMS%8$+IQ:1Q^S?_.V.SVB!SH'$TJ M/2;K54?C"M.$9-8^SKI\YQQ9`^16;&!REO,/7CJ3MJ"H4EU;E'ADFR8/X' MJN35>N["1MVK#Y\W74BZ=>YYP,A]`.>T,1^U@\R+?^^;H5D%&M8)7S8GT> MK$BC8(`I$K.3B.;Q7'7)9O.($'&C\;Q6'O:959")3^AY5I8G$U.DQ_&L0? M9&0PP$5TBO3)K092\Q5R#GC,`%Q2UDQ[6L@9(Q-4$3/[!:2=RX[HC8W7. M;-QAH]3UD]^D(W^_'BRFOAYU)?0IKP+78Q0[5L M9W6%U.%J5?X5,ZGUJ&**+K&_I.VUY!"B]CC,V8]_R"5Y6(; M\\BB!Y\G[&H5@1=MWJO.)X5"[@OH9C&&:\8I+RS$>P-+V';EIUBCRN(J=X MY830BY#F41[M3`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`75@KJ,N&J+[@7C<&RY'KKHUE.)MTU#20F)XY/I MWJ,**2$12_M"+"(COJ6Q.AHL203OF\]'T$?#E'(3Y6GKYZRMZ!U,.%+B$J! MM)3Y;5Y>2$HQ MZ8GK6./+&.E_P]02P$"'@,4````"`!`,&9%`SZ8@G]Z``"520<`$0`8```` M```!````I($`````86YI:RTR,#$T,#DS,"YX;6Q55`4``R=56U1U>`L``00E M#@``!#D!``!02P$"'@,4````"`!`,&9%G?%N9^L,``"NF@``%0`8```````! M````I('>@``86YI:RTR,#$T,#DS,%]C86PN>&UL550%``,G55M4=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`0#!F15T?`Q0````(`$`P9D4]S9^R\$X```+Q`P`5`!@````` M``$```"D@3NW``!A;FEK+3(P,30P.3,P7VQA8BYX;6Q55`4``R=56U1U>`L` M`00E#@``!#D!``!02P$"'@,4````"`!`,&9%1=]+-!DO``#HT`(`%0`8```` M```!````I(%Z!@$`86YI:RTR,#$T,#DS,%]P&UL550%``,G55M4=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`0#!F19Q-64"E$```][@``!$`&``` M`````0```2!XC4!`&%N:6LM,C`Q-#`Y,S`N>'-D550%``,G55M4=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``-)&`0`````` ` end XML 39 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Earnings Per Share (Details) - Basic and Diluted Earnings Per Share
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Basic and Diluted Earnings Per Share [Abstract]

Shares used in the calculation of basic earnings per share 14,758,781 13,682,449 14,626,933 13,534,334

Effect of dilutive securities:

Stock options, SARs, and RSAs 676,094 1,276,516 842,304 1,139,545

Diluted shares used in the calculation of earnings per share 15,434,875 14,958,965 15,469,237 14,673,879

X

- Details

Name: anik_BasicAndDilutedEarningsPerShareAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_EffectOfDilutiveSecuritiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Earnings Per Share (Tables)
9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Three Months Ended September 30, Nine Months Ended September 30,

2014 2013 2014 2013

Shares used in the calculation of basic earnings per share 14,758,781 13,682,449 14,626,933 13,534,334

Effect of dilutive securities:

Stock options, SARs, and RSAs 676,094 1,276,516 842,304 1,139,545

Diluted shares used in the calculation of earnings per share 15,434,875 14,958,965 15,469,237 14,673,879

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * / var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Basis of Presentation
9 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Business Description and Basis of Presentation [Text Block]

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S.”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. The year-end consolidated balance sheet is derived from our audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of September 30, 2014, the results of its operations for the three and nine-month periods ended September 30, 2014 and 2013, and cash flows for the nine-month periods ended September 30, 2014 and 2013.

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the three and nine-month periods ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.

A revision was made on the condensed consolidated statement of cash flows for the six months ended June 30, 2014 to correctly reflect the tax benefit from exercise of certain equity awards. This revision has an impact on the statement of cash flows as a reduction of cash provided by operating activities of $2.5 million with a corresponding increase to cash provided by financing activities related to the tax benefit from exercise of stock options for the six months ended June 30, 2014 of the same amount. This revision has no impact on the statement of operations or cash position. The revision to the condensed consolidated statement of cash flows represents amounts that are not deemed to be material, individually or in the aggregate, to the prior period condensed consolidated financial statements.

X

- Definition

The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Accounts receivable, net of reserves (in Dollars) $ 546,455 $ 593,023

Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized 1,250,000 1,250,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in Dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 30,000,000 30,000,000

Common stock, shares issued 14,800,453 14,289,308

Common stock,shares outstanding 14,800,453 14,289,308

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 44 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 12 - Income Taxes
9 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

12. Income Taxes

Provisions for income taxes were $4,125,355 and $18,872,435 for the three and nine-month periods ended September 30, 2014, respectively, based on effective tax rates of 40% and 38%. Provisions for income taxes were $2,776,199 and $8,147,282 for the three and nine-month periods ended September 30, 2013, respectively, based on effective tax rates of 36% and 37%, respectively. The increase in income taxes over the three-month period ended September 30, 2014 was primarily due to increased net income. The increase in income taxes over the nine-month period ended September 30, 2014 was primarily due to increased net income, which reflected $24,652,778 in milestone and contract revenue associated with our U.S. license agreement for MONOVISC. See the previous discussion under Note 11. The increase in the effective tax rate for each of the periods ended 2014, as compared to the same periods ended in 2013, was driven primarily by the unavailability of the federal R&D tax credit in 2014, due to its expiration on December 31, 2013, and a relative decrease to our estimated production activities deduction.

The Company files income tax returns in the U.S. on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. Our filings from 2011 through the present tax year remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. Our filings from 2009 through the present tax year remain subject to examination by the appropriate governmental authorities in Italy.

In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward. We have concluded that the positive evidence outweighs the negative evidence and, thus, those deferred tax assets are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance at September 30, 2014 or December 31, 2013.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
9 Months Ended

Sep. 30, 2014

Oct. 31, 2014

Document and Entity Information [Abstract]

Entity Registrant Name Anika Therapeutics, Inc.

Document Type 10-Q

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 14,504,014

Amendment Flag false

Entity Central Index Key 0000898437

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Accelerated Filer

Entity Well-known Seasoned Issuer No

Document Period End Date Sep. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

X

- Details

Name: anik_DocumentAndEntityInformationAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 46 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 13 - Segment and Geographic Information
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

13.

Segment and Geographic Information

The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements.

Product revenue by product group is as follows:

Three Months Ended September 30, Nine Months Ended September 30,

2014 2013 2014 2013

Orthobiologics $ 18,899,873 $ 12,830,566 $ 48,750,277 $ 40,620,339

Dermal 401,355 267,766 938,966 1,066,409

Surgical 1,452,946 1,136,248 4,581,496 3,955,134

Ophthalmic 366,138 1,425,609 938,134 2,818,407

Veterinary 855,000 1,363,157 2,385,000 3,124,953

$ 21,975,312 $ 17,023,346 $ 57,593,873 $ 51,585,242

Total revenue by geographic location and as a percentage of overall total revenue, for the three and nine-month periods ended September 30, 2014 and 2013 are as follows;

Three Months Ended September 30,

2014 2013

Total

Revenue

Percentage of

Revenue

Total

Revenue

Percentage of

Revenue

Geographic Location:

United States $ 18,455,167 84 % $ 14,485,821 82 %

Europe 1,784,414 8 % 1,656,656 9 %

Other 1,815,842 8 % 1,611,961 9 %

Total $ 22,055,423 100 % $ 17,754,438 100 %

Nine Months Ended September 30,

2014 2013

Total

Revenue

Percentage of

Revenue

Total

Revenue

Percentage of

Revenue

Geographic Location:

United States $ 72,935,722 89 % $ 42,251,336 78 %

Europe 5,274,071 6 % 5,226,619 10 %

Other 4,130,577 5 % 6,351,871 12 %

Total $ 82,340,370 100 % $ 53,829,826 100 %

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Product revenue $ 21,975,312 $ 17,023,346 $ 57,593,873 $ 51,585,242

Licensing, milestone and contract revenue 80,111 731,092 24,746,497 2,244,584

Total revenue 22,055,423 17,754,438 82,340,370 53,829,826

Operating expenses:

Cost of product revenue 5,724,800 5,377,568 15,418,732 16,530,070

Research & development 1,999,867 1,618,012 6,160,740 5,029,974

Selling, general & administrative 4,044,538 3,188,669 11,401,399 10,536,462

Restructuring credits (196,084) (196,084) (442,869)

Total operating expenses 11,769,205 9,988,165 32,980,871 31,653,637

Income from operations 10,286,218 7,766,273 49,359,499 22,176,189

Interest income (expense), net 9,937 (32,816) 16,339 (108,755)

Income before income taxes 10,296,155 7,733,457 49,375,838 22,067,434

Provision for income taxes 4,125,355 2,776,199 18,872,435 8,147,282

Net income 6,170,800 4,957,258 30,503,403 13,920,152

Unrealized gain on securities, net of tax 431 431

Foreign currency translation adjustment (1,679,968) 916,474 (1,896,823) 507,119

Total other comprehensive income (loss) (1,679,537) 916,474 (1,896,392) 507,119

Basic net income per share:

Net income (in Dollars per share) $ 0.42 $ 0.36 $ 2.09 $ 1.03

Basic weighted average common shares outstanding (in Shares) 14,758,781 13,682,449 14,626,933 13,534,334

Diluted net income per share:

Net income (in Dollars per share) $ 0.40 $ 0.33 $ 1.97 $ 0.95

Diluted weighted average common shares outstanding (in Shares) 15,434,875 14,958,965 15,469,237 14,673,879

Net income 6,170,800 4,957,258 30,503,403 13,920,152

Unrealized gain on securities, net of tax 431 431

Foreign currency translation adjustment (1,679,968) 916,474 (1,896,823) 507,119

Total other comprehensive income (loss) (1,679,537) 916,474 (1,896,392) 507,119

Comprehensive income $ 4,491,263 $ 5,873,732 $ 28,607,011 $ 14,427,271

X

- Details

Name: anik_BasicNetIncomePerShareAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_DilutedNetIncomePerShareAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of credit associated with exit or disposal activities during the period.

+ References

No definition available.

+ Details

Name: anik_RestructuringCredit

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of nonoperating interest income (expense).

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 7 - Inventories
9 Months Ended

Sep. 30, 2014

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

7. Inventories

Inventories consist of the following:

September 30,

2014

December 31,

2013

Raw materials $ 6,843,441 $ 5,926,030

Work-in-process 2,325,667 2,308,233

Finished goods 4,413,348 2,762,522

Total $ 13,582,456 $ 10,996,785

Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Earnings Per Share
9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

6. Earnings Per Share

The Company reports earnings per share in accordance with ASC 260, Earnings Per Share*, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period.

Basic and diluted earnings per share for the three and nine-month periods ended September 30, 2014 and 2013 are as follows:

Three Months Ended September 30, Nine Months Ended September 30,

2014 2013 2014 2013

Shares used in the calculation of basic earnings per share 14,758,781 13,682,449 14,626,933 13,534,334

Effect of dilutive securities:

Stock options, SARs, and RSAs 676,094 1,276,516 842,304 1,139,545

Diluted shares used in the calculation of earnings per share 15,434,875 14,958,965 15,469,237 14,673,879

Equity awards of 122,967 and 118,725 shares were outstanding for the three and nine-month periods ended September 30, 2014, respectively, and were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive. There were no anti-dilutive equity awards for the three month period ended September 30, 2013. Equity awards of 88,278 shares were outstanding for the nine-month period ended September 30, 2013, and were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Equity Incentive Plan (Tables)
9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Three Months Ended

September 30,

2014 2013

Risk free interest rate 1.30% - 1.39% -

Expected volatility 53.28% -

Expected lives (years) 4 -

Expected dividend yield 0.00% -

Nine Months Ended

September 30,

2014 2013

Risk free interest rate 1.16% - 1.39% 0.61% - 0.70%

Expected volatility 53.28% 57.60%

Expected lives (years) 4 4

Expected dividend yield 0.00% 0.00%

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 14 - Restructuring Credits
9 Months Ended

Sep. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

14. Restructuring Credits

In December 2012, the Company announced the closure of its tissue engineering facility in Abano Terme, Italy due to the Company’s inability to meet strict regulatory standards established by the European Medicines Agency (“EMA”) for Advanced Therapy Medicinal Products, which became effective on January 1, 2013. The restructuring plan involved a workforce reduction as well as associated asset abandonments. The Company recorded restructuring and impairment charges in the fourth quarter of 2012 of approximately $2.5 million. Of the total restructuring and impairment charges related to the tissue engineering operation, approximately $1.2 million was related to the non-cash termination and related impairment of an IPR&D project, $0.3 million was related to the disposal of property and equipment, and $0.1 million was related to the disposal of inventory. We completed the restructuring plan and related activities in 2013. Certain previously impaired and written-off equipment was sold, resulting in restructuring credits of $196,084 and $442,869 in the three and nine months ended September 30, 2013, respectively.

The following table summarizes restructuring accrual activity for the nine-period ended September 30, 2014:

Restructuring Accrual

Employee

Severance and

Related Benefits

Activity

Termination and

Facility Closure

Costs
Total

December 31, 2013 $ 21,709 $ 2,929 $ 24,638

Cash Proceeds (Disbursements) (10,130 ) (1,425 ) (11,555 )

Foreign Exchange Impact (1,050 ) (124 ) (1,174 )

September 30, 2014 $ 10,529 $ 1,380 $ 11,909

X

- Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 10 - Commitments and Contingencies
9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

10. Commitments and Contingencies

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any patent or intellectual property rights, trade secret or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure. Based on the Company’s historical activity in combination with its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no accrued warranties and has no history of claims paid.

On July 7, 2010, Genzyme Corporation filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The complaint alleged that the Company infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC® in the United States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company manufactured and sold MONOVISC in the United States. On March 7, 2014, Genzyme and the Company filed a joint motion to lift the stay in Genzyme’s lawsuit against the Company and to dismiss with prejudice all of Genzyme’s claims. On March 10, 2014, the District Court granted the motion to dismiss with prejudice all of Genzyme’s claims against the Company and the case was terminated.

The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations or cash flow.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 8 - Intangible Assets and Goodwill
9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

8. Intangible Assets and Goodwill

In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”), the Company acquired various intangible assets and goodwill. The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets. The in-process research and development (“IPR&D”) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects. Until such determination is made, they are not amortized.

The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Intangible assets as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014 December 31, 2013

Gross Value
Currency

Translation

Adjustment

Accumulated

Amortization

Net Book

Value

Net Book

Value
Useful Life

Developed technology $ 16,700,000 $ (1,828,214 ) $ (4,779,123 ) $ 10,092,663 $ 11,753,003 15

In-process research & development 5,502,686 (638,426 ) - 4,864,260 5,286,127 Indefinite

Distributor relationships 4,700,000 (440,953 ) (4,084,944 ) 174,103 863,655 5

Patents 1,000,000 (107,910 ) (271,208 ) 620,882 719,574 16

Elevess trade name 1,000,000 - (717,964 ) 282,036 376,050 9

Total $ 28,902,686 $ (3,015,503 ) $ (9,853,239 ) $ 16,033,944 $ 18,998,409

The aggregate amortization expense related to intangible assets was $518,699 and $521,387 for the three-month periods ended September 30, 2014 and 2013, respectively. The aggregate amortization expense related to intangible assets was $1,593,260 and $1,555,796 for the nine-month periods ended September 30, 2014 and 2013, respectively.

Changes in the carrying value of goodwill for the three and nine-month periods ended September 30, 2014 were as follows:

Goodwill
Three

Months Ended

September 30,

2014

Nine

Months Ended

September 30,

2014

Balance, beginning $ 9,360,884 $ 9,443,894

Effect of foreign currency adjustments (658,589 ) (741,599 )

Balance, ending $ 8,702,295 $ 8,702,295

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 9 - Accrued Expenses
9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9.
Accrued Expenses

Accrued expenses consist of the following:

September 30,

2014

December 31,

2013

Labor and related expenses $ 2,842,234 $ 2,870,147

Clinical trial costs 962,031 882,651

Professional fees 382,423 383,231

Research grants 562,558 610,498

Restructuring costs 11,909 24,638

Other 492,538 766,716

Total $ 5,253,693 $ 5,537,881

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 11 - Mitek Monovisc Agreement
9 Months Ended

Sep. 30, 2014

Deferred Revenue Disclosure [Abstract]

Deferred Revenue Disclosure [Text Block]

11. Mitek Monovisc Agreement

In December 2011, the Company entered into a fifteen-year licensing agreement (the “Mitek MONOVISC Agreement”) with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc., to exclusively market MONOVISC in the U.S. The Company received an upfront payment of $2,500,000 in December 2011. This non-refundable upfront payment did not have standalone value without Anika’s completion of development obligations which included obtaining regulatory approval of the product and resolving the patent litigation. As a result, we recognized the upfront payment over the development obligation period. During the first quarter of 2014, the Company received FDA approval of MONOVISC and resolved the patent lawsuit with Genzyme Corporation. As a result of the full delivery of its development obligations under this agreement, the Company recognized approximately $2,200,000 which represents the remaining balance of deferred revenue relating to the initial $2,500,000 payment in accordance with current generally accepted principles on revenue recognition. In the first quarter of 2014, the Company also received a milestone payment of $17,500,000 as a result of achieving FDA approval for MONOVISC and resolving the patent litigation with Genzyme. This milestone payment was fully recognized as revenue during the three months ended March 31, 2014. On April 15, 2014 the first U.S. commercial sale of MONOVISC was made by our commercial partner, DePuy Synthes Mitek Sports Medicine. Under the terms of the Mitek MONOVISC Agreement, the Company earned and collected a milestone payment of $5 million, which was fully recognized as revenue in the second quarter of 2014.

X

- Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenueDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards [Line Items]

Expected volatility 53.28% 53.28% 57.60%

Expected lives (years) 4 years 4 years 4 years

Expected dividend yield 0.00% 0.00% 0.00%

Minimum [Member]

Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards [Line Items]

Risk free interest rate 1.30% 1.16% 0.61%

Maximum [Member]

Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards [Line Items]

Risk free interest rate 1.39% 1.39% 0.70%

X

- Details

Name: anik_Note5EquityIncentivePlanDetailsAssumptionsUsedtoEstimateFairValueofStockOptionsandStockAppreciationRightsAwardsLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 57 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Marketable Securities (Tables)
9 Months Ended

Sep. 30, 2014

Disclosure Text Block Supplement [Abstract]

Marketable Securities [Table Text Block]

September 30, 2014

Amortized

Cost

Unrealized

Gains, Net of Tax

Unrealized

Losses, Net of Tax

Fair

Value

United States Treasury securities $ 14,999,169 $ 699 $ (268 ) $ 14,999,600

Bank certificates of deposit 5,000,000 - - 5,000,000

$ 19,999,169 $ 699 $ (268 ) $ 19,999,600

X

- Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.4)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_MarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 8 - Intangible Assets and Goodwill (Tables)
9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite Lived and Indefinite Lived Intangible Assets by Major Class [Table Text Block]

September 30, 2014 December 31, 2013

Gross Value
Currency

Translation

Adjustment

Accumulated

Amortization

Net Book

Value

Net Book

Value
Useful Life

Developed technology $ 16,700,000 $ (1,828,214 ) $ (4,779,123 ) $ 10,092,663 $ 11,753,003 15

In-process research & development 5,502,686 (638,426 ) - 4,864,260 5,286,127 Indefinite

Distributor relationships 4,700,000 (440,953 ) (4,084,944 ) 174,103 863,655 5

Patents 1,000,000 (107,910 ) (271,208 ) 620,882 719,574 16

Elevess trade name 1,000,000 - (717,964 ) 282,036 376,050 9

Total $ 28,902,686 $ (3,015,503 ) $ (9,853,239 ) $ 16,033,944 $ 18,998,409

Schedule of Goodwill [Table Text Block]

Goodwill
Three

Months Ended

September 30,

2014

Nine

Months Ended

September 30,

2014

Balance, beginning $ 9,360,884 $ 9,443,894

Effect of foreign currency adjustments (658,589 ) (741,599 )

Balance, ending $ 8,702,295 $ 8,702,295

X

- Definition

Represents the schedule of finite-lived and indefinite-lived intangible assets by major class.

+ References

No definition available.

+ Details

Name: anik_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock

Namespace Prefix: anik_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity (USD $)
9 Months Ended

Sep. 30, 2014

Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]

Balance $ 24,638

Cash Proceeds (Disbursements) (11,555)

Foreign Exchange Impact (1,174)

Balance 11,909

Employee termination costs [Member]

Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]

Balance 21,709

Cash Proceeds (Disbursements) (10,130)

Foreign Exchange Impact (1,050)

Balance 10,529

Activity Termination and Facility Closure Costs [Member]

Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]

Balance 2,929

Cash Proceeds (Disbursements) (1,425)

Foreign Exchange Impact (124)

Balance $ 1,380

X

- Details

Name: anik_Note14RestructuringCreditsDetailsRestructuringAccrualActivityLineItems

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of foreign currency translation adjustment increasing or decreasing the accrual for a specified type of restructuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b)(2))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(2)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

+ Details

Name: us-gaap_RestructuringReserveTranslationAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 60 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 9 - Accrued Expenses (Details) - Accrued Expenses (USD $)

Sep. 30, 2014

Dec. 31, 2013

Accrued Expenses [Abstract]

Labor and related expenses $ 2,842,234 $ 2,870,147

Clinical trial costs 962,031 882,651

Professional fees 382,423 383,231

Research grants 562,558 610,498

Restructuring costs 11,909 24,638

Other 492,538 766,716

Total $ 5,253,693 $ 5,537,881

X

- Definition

Represents current accrued clinical trial costs.

+ References

No definition available.

+ Details

Name: anik_AccruedClinicalTrialCostsCurrent

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: anik_AccruedExpensesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents current accrued research grants.

+ References

No definition available.

+ Details

Name: anik_AccruedResearchGrantsCurrent

Namespace Prefix: anik_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

+ Details

Name: us-gaap_RestructuringReserveCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 61 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Cash flows from operating activities:

Net income $ 30,503,403 $ 13,920,152

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 3,576,441 3,579,474

Stock-based compensation expense 1,196,361 1,156,929

Provision for doubtful accounts 24,098

Provision for inventory 220,207 165,803

Gain on sale of assets (442,341)

Tax benefit from exercise of stock options (9,236,708) (764,181)

Changes in operating assets and liabilities:

Accounts receivable (1,840,407) 4,667,839

Inventories (2,923,628) (3,430,655)

Prepaid expenses, other current and long-term assets 183,481 531,449

Long-term deposits and other 25,497

Accounts payable (992,822) 124,679

Accrued expenses (989,291) (642,430)

Deferred revenue (2,078,543) (2,150,000)

Income taxes 7,771,001 766,598

Other long-term liabilities (167,123) (373,712)

Net cash provided by operating activities 25,222,372 17,159,199

Cash flows from investing activities:

Purchase of marketable securities (19,999,169) 0

Proceeds from sale of assets 530,865

Purchase of property and equipment (920,132) (235,803)

Net cash provided by (used in) investing activities (20,919,301) 295,062

Cash flows from financing activities:

Proceeds from exercise of stock options 1,379,294 2,932,649

Tax benefit from exercise of stock options 9,236,708 764,181

Minimum tax withholding on share based awards (6,348,900)

Principal payments on debt (1,200,000)

Net cash provided by financing activities 4,267,102 2,496,830

Exchange rate impact on cash (131,139) 36,870

Increase in cash and cash equivalents 8,439,034 19,987,961

Cash and cash equivalents at beginning of period 63,333,160 44,067,477

Cash and cash equivalents at end of period $ 71,772,194 $ 64,055,438

X

- Details

Name: anik_AdjustmentsToReconcileNetIncomeToNetCashProvidedByOperatingActivitiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_CashFlowsFromFinancingActivitiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_CashFlowsFromInvestingActivitiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_CashFlowsFromOperatingActivitiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: anik_ChangesInOperatingAssetsAndLiabilitiesAbstract

Namespace Prefix: anik_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow from the sale of other assets as part of operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfOtherAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 62 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Equity Incentive Plan
9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

5. Equity Incentive Plan

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. The fair value of each stock option award during the three and nine-month periods ended September 30, 2014 and 2013, respectively, was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

Three Months Ended

September 30,

2014 2013

Risk free interest rate 1.30% - 1.39% -

Expected volatility 53.28% -

Expected lives (years) 4 -

Expected dividend yield 0.00% -

Nine Months Ended

September 30,

2014 2013

Risk free interest rate 1.16% - 1.39% 0.61% - 0.70%

Expected volatility 53.28% 57.60%

Expected lives (years) 4 4

Expected dividend yield 0.00% 0.00%

The Company recorded $390,578 and $368,603 of share-based compensation expense for the three-month periods ended September 30, 2014 and 2013, respectively, for equity compensation awards. The Company recorded $1,196,361 and $1,156,929 of share-based compensation expense for the nine-month periods ended September 30, 2014 and 2013, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective recipients.

There were 7,000 and 139,240 stock options granted under the Plan during the three and nine-month periods ended September 30, 2014, respectively. There were no Restricted Stock Awards (“RSAs”) or Restricted Stock Units (“RSUs”) granted under the Plan during the three-month period ended September 30, 2014. There were 9,365 RSUs granted to members of the Company’s Board of Directors under the Plan during the nine-month period ended September 30, 2014. There were 30,700 RSAs granted to Company employees under the Plan during the nine-month period ended September 30, 2014. The stock options, RSAs and RSUs granted to employees and directors become exercisable or vest ratably over four years from the date of grant.

A portion of the stock options granted during the nine-month period ended September 30, 2014 contained certain performance features, as compared to established targets, in addition to time-based vesting conditions. The compensation costs associated with these grants was estimated using the Black-Scholes valuation method factored for the estimated probability of achieving the performance goals.

As of September 30, 2014, there was approximately $4.2 million of total unrecognized compensation cost related to non-vested stock options, stock appreciation rights (“SARs”), RSAs and RSUs granted under the Company’s incentive Plans. This cost is expected to be recognized over a weighted-average period of 3.0 years.

The total intrinsic value of stock options and SARs exercised during the nine-month periods ended September 30, 2014 and 2013 was $25,473,089 and $4,095,833, respectively. Cash received from the exercise of stock options during the three and nine-month periods ended September 30, 2014 and 2013 were $17,513 and $1,379,294, and $1,804,773 and $2,932,649, respectively. During the second quarter of 2014, the Company acquired and subsequently retired 133,774 common shares related to an employee SARs exercise, to meet minimum statutory tax withholding requirements.

There were 936,097 options and SARs outstanding under the Company’s incentive Plans as of September 30, 2014 with a weighted-average exercise price of $13.54 per share, an aggregate intrinsic value of approximately $21.8 million, and a weighted-average remaining contractual term of 6.8 years. None of the options or SARs outstanding at September 30, 2014 or 2013, respectively, had cash-settlement features.

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either authorized but unissued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards containing service conditions generally become exercisable ratably over one to four years, have a ten year contractual term and sometimes contain performance conditions.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 9 - Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

September 30,

2014

December 31,

2013

Labor and related expenses $ 2,842,234 $ 2,870,147

Clinical trial costs 962,031 882,651

Professional fees 382,423 383,231

Research grants 562,558 610,498

Restructuring costs 11,909 24,638

Other 492,538 766,716

Total $ 5,253,693 $ 5,537,881

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 104 182 1 false 40 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.anikatherapeutics.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.anikatherapeutics.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets (Unaudited) false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.anikatherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://www.anikatherapeutics.com/role/ConsolidatedComprehensiveIncome Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.anikatherapeutics.com/role/ShareholdersEquityType1 Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 005 - Disclosure - Note 1 - Nature of Business Sheet http://www.anikatherapeutics.com/role/Note1NatureofBusiness Note 1 - Nature of Business false false R7.htm 006 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.anikatherapeutics.com/role/Note2BasisofPresentation Note 2 - Basis of Presentation false false R8.htm 007 - Disclosure - Note 3 - Marketable Securities Sheet http://www.anikatherapeutics.com/role/Note3MarketableSecurities Note 3 - Marketable Securities false false R9.htm 008 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.anikatherapeutics.com/role/Note4FairValueMeasurements Note 4 - Fair Value Measurements false false R10.htm 009 - Disclosure - Note 5 - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/role/Note5EquityIncentivePlan Note 5 - Equity Incentive Plan false false R11.htm 010 - Disclosure - Note 6 - Earnings Per Share Sheet http://www.anikatherapeutics.com/role/Note6EarningsPerShare Note 6 - Earnings Per Share false false R12.htm 011 - Disclosure - Note 7 - Inventories Sheet http://www.anikatherapeutics.com/role/Note7Inventories Note 7 - Inventories false false R13.htm 012 - Disclosure - Note 8 - Intangible Assets and Goodwill Sheet http://www.anikatherapeutics.com/role/Note8IntangibleAssetsandGoodwill Note 8 - Intangible Assets and Goodwill false false R14.htm 013 - Disclosure - Note 9 - Accrued Expenses Sheet http://www.anikatherapeutics.com/role/Note9AccruedExpenses Note 9 - Accrued Expenses false false R15.htm 014 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/role/Note10CommitmentsandContingencies Note 10 - Commitments and Contingencies false false R16.htm 015 - Disclosure - Note 11 - Mitek Monovisc Agreement Sheet http://www.anikatherapeutics.com/role/Note11MitekMonoviscAgreement Note 11 - Mitek Monovisc Agreement false false R17.htm 016 - Disclosure - Note 12 - Income Taxes Sheet http://www.anikatherapeutics.com/role/Note12IncomeTaxes Note 12 - Income Taxes false false R18.htm 017 - Disclosure - Note 13 - Segment and Geographic Information Sheet http://www.anikatherapeutics.com/role/Note13SegmentandGeographicInformation Note 13 - Segment and Geographic Information false false R19.htm 018 - Disclosure - Note 14 - Restructuring Credits Sheet http://www.anikatherapeutics.com/role/Note14RestructuringCredits Note 14 - Restructuring Credits false false R20.htm 019 - Disclosure - Note 15 - New Accounting Standards Sheet http://www.anikatherapeutics.com/role/Note15NewAccountingStandards Note 15 - New Accounting Standards false false R21.htm 020 - Disclosure - Note 3 - Marketable Securities (Tables) Sheet http://www.anikatherapeutics.com/role/Note3MarketableSecuritiesTables Note 3 - Marketable Securities (Tables) false false R22.htm 021 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.anikatherapeutics.com/role/Note4FairValueMeasurementsTables Note 4 - Fair Value Measurements (Tables) false false R23.htm 022 - Disclosure - Note 5 - Equity Incentive Plan (Tables) Sheet http://www.anikatherapeutics.com/role/Note5EquityIncentivePlanTables Note 5 - Equity Incentive Plan (Tables) false false R24.htm 023 - Disclosure - Note 6 - Earnings Per Share (Tables) Sheet http://www.anikatherapeutics.com/role/Note6EarningsPerShareTables Note 6 - Earnings Per Share (Tables) false false R25.htm 024 - Disclosure - Note 7 - Inventories (Tables) Sheet http://www.anikatherapeutics.com/role/Note7InventoriesTables Note 7 - Inventories (Tables) false false R26.htm 025 - Disclosure - Note 8 - Intangible Assets and Goodwill (Tables) Sheet http://www.anikatherapeutics.com/role/Note8IntangibleAssetsandGoodwillTables Note 8 - Intangible Assets and Goodwill (Tables) false false R27.htm 026 - Disclosure - Note 9 - Accrued Expenses (Tables) Sheet http://www.anikatherapeutics.com/role/Note9AccruedExpensesTables Note 9 - Accrued Expenses (Tables) false false R28.htm 027 - Disclosure - Note 13 - Segment and Geographic Information (Tables) Sheet http://www.anikatherapeutics.com/role/Note13SegmentandGeographicInformationTables Note 13 - Segment and Geographic Information (Tables) false false R29.htm 028 - Disclosure - Note 14 - Restructuring Credits (Tables) Sheet http://www.anikatherapeutics.com/role/Note14RestructuringCreditsTables Note 14 - Restructuring Credits (Tables) false false R30.htm 029 - Disclosure - Note 2 - Basis of Presentation (Details) Sheet http://www.anikatherapeutics.com/role/Note2BasisofPresentationDetails Note 2 - Basis of Presentation (Details) false false R31.htm 030 - Disclosure - Note 3 - Marketable Securities (Details) - Marketable Securities Sheet http://www.anikatherapeutics.com/role/MarketableSecuritiesTable Note 3 - Marketable Securities (Details) - Marketable Securities false false R32.htm 031 - Disclosure - Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments Sheet http://www.anikatherapeutics.com/role/FairValueofFinancialInstrumentsTable Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments false false R33.htm 032 - Disclosure - Note 5 - Equity Incentive Plan (Details) Sheet http://www.anikatherapeutics.com/role/Note5EquityIncentivePlanDetails Note 5 - Equity Incentive Plan (Details) false false R34.htm 033 - Disclosure - Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards Sheet http://www.anikatherapeutics.com/role/AssumptionsUsedtoEstimateFairValueofStockOptionsandStockAppreciationRightsAwardsTable Note 5 - Equity Incentive Plan (Details) - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards false false R35.htm 034 - Disclosure - Note 6 - Earnings Per Share (Details) Sheet http://www.anikatherapeutics.com/role/Note6EarningsPerShareDetails Note 6 - Earnings Per Share (Details) false false R36.htm 035 - Disclosure - Note 6 - Earnings Per Share (Details) - Basic and Diluted Earnings Per Share Sheet http://www.anikatherapeutics.com/role/BasicandDilutedEarningsPerShareTable Note 6 - Earnings Per Share (Details) - Basic and Diluted Earnings Per Share false false R37.htm 036 - Disclosure - Note 7 - Inventories (Details) - Inventories Sheet http://www.anikatherapeutics.com/role/InventoriesTable Note 7 - Inventories (Details) - Inventories false false R38.htm 037 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) Sheet http://www.anikatherapeutics.com/role/Note8IntangibleAssetsandGoodwillDetails Note 8 - Intangible Assets and Goodwill (Details) false false R39.htm 038 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets Sheet http://www.anikatherapeutics.com/role/IntangibleAssetsTable Note 8 - Intangible Assets and Goodwill (Details) - Intangible Assets false false R40.htm 039 - Disclosure - Note 8 - Intangible Assets and Goodwill (Details) - Changes in Carrying Value of Goodwill Sheet http://www.anikatherapeutics.com/role/ChangesinCarryingValueofGoodwillTable Note 8 - Intangible Assets and Goodwill (Details) - Changes in Carrying Value of Goodwill false false R41.htm 040 - Disclosure - Note 9 - Accrued Expenses (Details) - Accrued Expenses Sheet http://www.anikatherapeutics.com/role/AccruedExpensesTable Note 9 - Accrued Expenses (Details) - Accrued Expenses false false R42.htm 041 - Disclosure - Note 10 - Commitments and Contingencies (Details) Sheet http://www.anikatherapeutics.com/role/Note10CommitmentsandContingenciesDetails Note 10 - Commitments and Contingencies (Details) false false R43.htm 042 - Disclosure - Note 11 - Mitek Monovisc Agreement (Details) Sheet http://www.anikatherapeutics.com/role/Note11MitekMonoviscAgreementDetails Note 11 - Mitek Monovisc Agreement (Details) false false R44.htm 043 - Disclosure - Note 12 - Income Taxes (Details) Sheet http://www.anikatherapeutics.com/role/Note12IncomeTaxesDetails Note 12 - Income Taxes (Details) false false R45.htm 044 - Disclosure - Note 13 - Segment and Geographic Information (Details) Sheet http://www.anikatherapeutics.com/role/Note13SegmentandGeographicInformationDetails Note 13 - Segment and Geographic Information (Details) false false R46.htm 045 - Disclosure - Note 13 - Segment and Geographic Information (Details) - Product Revenue by Product Group Sheet http://www.anikatherapeutics.com/role/ProductRevenuebyProductGroupTable Note 13 - Segment and Geographic Information (Details) - Product Revenue by Product Group false false R47.htm 046 - Disclosure - Note 13 - Segment and Geographic Information (Details) - Product Revenue by Geographic Location Sheet http://www.anikatherapeutics.com/role/ProductRevenuebyGeographicLocationTable Note 13 - Segment and Geographic Information (Details) - Product Revenue by Geographic Location false false R48.htm 047 - Disclosure - Note 14 - Restructuring Credits (Details) Sheet http://www.anikatherapeutics.com/role/Note14RestructuringCreditsDetails Note 14 - Restructuring Credits (Details) false false R49.htm 048 - Disclosure - Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity Sheet http://www.anikatherapeutics.com/role/RestructuringAccrualActivityTable Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity false false All Reports Book All Reports 'Monetary' elements on report '047 - Disclosure - Note 14 - Restructuring Credits (Details)' had a mix of different decimal attribute values. Process Flow-Through: 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Jun. 30, 2014' Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Process Flow-Through: 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Process Flow-Through: 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) anik-20140930.xml anik-20140930.xsd anik-20140930_cal.xml anik-20140930_def.xml anik-20140930_lab.xml anik-20140930_pre.xml true true XML 65 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 8 - Intangible Assets and Goodwill (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Amortization of Intangible Assets $ 518,699 $ 521,387 $ 1,593,260 $ 1,555,796

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 15 - New Accounting Standards
9 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

15. New Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. Thus, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The new guidance is effective for the Company beginning January 1, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 supersedes the revenue recognition requirements in "Topic 605, Revenue Recognition" and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective retrospectively for annual or interim reporting periods beginning after December 15, 2016, with early application not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In April 2014, the FASB issued ASU No. 2014-08, "Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 provides a narrower definition of discontinued operations than that provided under existing U.S. GAAP. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, which disposal represents a strategic shift that has, or will have, a major effect on the reporting entity's operations and financial results, should be reported in the financial statements as a discontinued operation. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations. ASU 2014-08 is effective prospectively for disposals (or classifications as held for disposal) of components of an entity that occur in annual or interim periods beginning after December 15, 2014. The Company does not expect the adoption of ASU 2014-08 to have a material impact on its consolidated financial statements.

X

- Definition

The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 5

-Subparagraph (SAB TOPIC 11.M)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e31137-122693

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 11

-Section M

+ Details

Name: us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Note 5 - Equity Incentive Plan (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
Note 5 - Equity Incentive Plan (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Restricted Stock [Member]	Sep. 30, 2014 Restricted Stock [Member]	Sep. 30, 2014 Restricted Stock Units (RSUs) [Member] Board of Directors [Member]	Sep. 30, 2014 Restricted Stock Units (RSUs) [Member]	Sep. 30, 2014 Restricted Stock Units (RSUs) [Member]	Jun. 30, 2014 Stock Appreciation Rights (SARs) [Member]	Sep. 30, 2014 Minimum [Member]	Sep. 30, 2014 Maximum [Member]
Note 5 - Equity Incentive Plan (Details) [Line Items]
Allocated Share-based Compensation Expense	$ 390,578	$ 368,603	$ 1,196,361	$ 1,156,929
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	7,000		139,240
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)					0	30,700	9,365	0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years			4 years		1 year	4 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	4,200,000		4,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 years
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue			25,473,089	4,095,833
Proceeds from Stock Options Exercised	17,513	1,804,773	1,379,294	2,932,649
Stock Repurchased and Retired During Period, Shares (in Shares)										133,774
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber (in Shares)			936,097
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice (in Dollars per share)	$ 13.54		$ 13.54
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue	$ 21,800,000		$ 21,800,000
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm			6 years 292 days
ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermRange			10 years

Note 10 - Commitments and Contingencies (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Product Warranty Accrual	$ 0
Product Warranty Expense	$ 0

Note 7 - Inventories (Details) - Inventories (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 6,843,441	$ 5,926,030
Work-in-process	2,325,667	2,308,233
Finished goods	4,413,348	2,762,522
Total	$ 13,582,456	$ 10,996,785

Note 11 - Mitek Monovisc Agreement (Details) (Miltek MONOVISC Agreement [Member], USD $)	1 Months Ended	3 Months Ended
	Dec. 31, 2011	Jun. 30, 2014	Mar. 31, 2014
Miltek MONOVISC Agreement [Member]
Note 11 - Mitek Monovisc Agreement (Details) [Line Items]
Contract Term, Years	15 years
Deferred Revenue	$ 2,500,000
Deferred Revenue, Revenue Recognized			2,200,000
Revenue Recognition, Milestone Method, Revenue Recognized		$ 5,000,000	$ 17,500,000

Note 12 - Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
Note 12 - Income Taxes (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 12 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$ 4,125,355	$ 2,776,199	$ 18,872,435	$ 8,147,282
Effective Income Tax Rate Reconciliation, Percent	40.00%	36.00%	38.00%	37.00%
Earliest Tax Year [Member] \| Domestic Tax Authority [Member] \| Internal Revenue Service (IRS) [Member]
Note 12 - Income Taxes (Details) [Line Items]
Open Tax Year			2011
Earliest Tax Year [Member] \| Foreign Tax Authority [Member] \| Ministry of Economic Affairs and Finance, Italy [Member]
Note 12 - Income Taxes (Details) [Line Items]
Open Tax Year			2009
Milestone and Contract Revenue [Member]
Note 12 - Income Taxes (Details) [Line Items]
Contracts Revenue			$ 24,652,778

Note 2 - Basis of Presentation (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2014
Increase to Cash Provided by Financing Activities [Member]
Note 2 - Basis of Presentation (Details) [Line Items]
Prior Period Reclassification Adjustment	$ 2.5
Decrease to Cash Provided by Operating Activities [Member]
Note 2 - Basis of Presentation (Details) [Line Items]
Prior Period Reclassification Adjustment	$ (2.5)

Note 3 - Marketable Securities (Details) - Marketable Securities (USD $)	Sep. 30, 2014	Sep. 30, 2014 US States and Political Subdivisions Debt Securities [Member]	Dec. 31, 2013 Certificates of Deposit [Member]
Note 3 - Marketable Securities (Details) - Marketable Securities [Line Items]
Amortized Cost	$ 19,999,169	$ 14,999,169	$ 5,000,000
Unrealized Gains	699	699
Unrealized Losses	(268)	(268)
Fair Value	$ 19,999,600	$ 14,999,600	$ 5,000,000

Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments (USD $)	Sep. 30, 2014	Dec. 31, 2013
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	$ 19,999,600
Fair Value, Inputs, Level 1 [Member] \| US States and Political Subdivisions Debt Securities [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	14,999,600
Fair Value, Inputs, Level 1 [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	14,999,600
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Money market funds	49,285,168	34,266,501
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	5,000,000
Fair Value, Inputs, Level 2 [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	5,000,000
Money Market Funds [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Money market funds	49,285,168	34,266,501
US States and Political Subdivisions Debt Securities [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	14,999,600
Certificates of Deposit [Member]
Note 4 - Fair Value Measurements (Details) - Fair Value of Financial Instruments [Line Items]
Marketable securities	$ 5,000,000

Note 8 - Intangible Assets and Goodwill (Details) - Changes in Carrying Value of Goodwill (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Changes in Carrying Value of Goodwill [Abstract]
Balance, beginning	$ 9,360,884	$ 9,443,894
Effect of foreign currency adjustments	(658,589)	(741,599)
Balance, ending	$ 8,702,295	$ 8,702,295

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 71,772,194	$ 63,333,160
Marketable securities	19,999,600
Accounts receivable, net of reserves of $546,455 and $593,023 at September 30, 2014 and December 31, 2013, respectively	20,170,095	18,736,845
Inventories	13,582,456	10,996,785
Prepaid income taxes	1,343,576
Current portion deferred income taxes	659,040	659,040
Prepaid expenses and other	1,128,693	865,957
Total current assets	128,655,654	94,591,787
Property and equipment, at cost	53,379,965	52,413,423
Less: accumulated depreciation	(21,343,322)	(19,474,712)
	32,036,643	32,938,711
Long-term deposits and other	69,054	69,080
Intangible assets, net	16,033,944	18,998,409
Goodwill	8,702,295	9,443,894
Total assets	185,497,590	156,041,881
Current liabilities:
Accounts payable	1,167,545	2,793,911
Accrued expenses	5,253,693	5,537,881
Deferred revenue	12,885	180,433
Income taxes payable		770,276
Total current liabilities	6,434,123	9,282,501
Other long-term liabilities	948,858	1,133,544
Long-term deferred revenue	56,573	2,054,941
Deferred tax liability	8,353,531	7,936,864
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively
Common stock, $.01 par value; 30,000,000 shares authorized, 14,800,453 and 14,289,308 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	148,004	142,893
Additional paid-in-capital	76,064,383	70,606,031
Accumulated other comprehensive loss	(3,595,487)	(1,699,095)
Retained earnings	97,087,605	66,584,202
Total stockholders’ equity	169,704,505	135,634,031
Total Liabilities and Stockholders’ Equity	$ 185,497,590	$ 156,041,881

Note 13 - Segment and Geographic Information (Details)	9 Months Ended
Note 13 - Segment and Geographic Information (Details)	Sep. 30, 2014
Segment Reporting [Abstract]
Number of Reportable Segments	1

Note 6 - Earnings Per Share (Details)	3 Months Ended		9 Months Ended
Note 6 - Earnings Per Share (Details)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	122,967	0	118,725	88,278

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts receivable, net of reserves (in Dollars)	$ 546,455	$ 593,023
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,250,000	1,250,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	14,800,453	14,289,308
Common stock,shares outstanding	14,800,453	14,289,308

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Anika Therapeutics, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		14,504,014
Amendment Flag	false
Entity Central Index Key	0000898437
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity (USD $)	9 Months Ended
	Sep. 30, 2014
Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]
Balance	$ 24,638
Cash Proceeds (Disbursements)	(11,555)
Foreign Exchange Impact	(1,174)
Balance	11,909
Employee termination costs [Member]
Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]
Balance	21,709
Cash Proceeds (Disbursements)	(10,130)
Foreign Exchange Impact	(1,050)
Balance	10,529
Activity Termination and Facility Closure Costs [Member]
Note 14 - Restructuring Credits (Details) - Restructuring Accrual Activity [Line Items]
Balance	2,929
Cash Proceeds (Disbursements)	(1,425)
Foreign Exchange Impact	(124)
Balance	$ 1,380

Note 9 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accrued Expenses [Abstract]
Labor and related expenses	$ 2,842,234	$ 2,870,147
Clinical trial costs	962,031	882,651
Professional fees	382,423	383,231
Research grants	562,558	610,498
Restructuring costs	11,909	24,638
Other	492,538	766,716
Total	$ 5,253,693	$ 5,537,881

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net income	$ 30,503,403	$ 13,920,152
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,576,441	3,579,474
Stock-based compensation expense	1,196,361	1,156,929
Provision for doubtful accounts		24,098
Provision for inventory	220,207	165,803
Gain on sale of assets		(442,341)
Tax benefit from exercise of stock options	(9,236,708)	(764,181)
Changes in operating assets and liabilities:
Accounts receivable	(1,840,407)	4,667,839
Inventories	(2,923,628)	(3,430,655)
Prepaid expenses, other current and long-term assets	183,481	531,449
Long-term deposits and other		25,497
Accounts payable	(992,822)	124,679
Accrued expenses	(989,291)	(642,430)
Deferred revenue	(2,078,543)	(2,150,000)
Income taxes	7,771,001	766,598
Other long-term liabilities	(167,123)	(373,712)
Net cash provided by operating activities	25,222,372	17,159,199
Cash flows from investing activities:
Purchase of marketable securities	(19,999,169)	0
Proceeds from sale of assets		530,865
Purchase of property and equipment	(920,132)	(235,803)
Net cash provided by (used in) investing activities	(20,919,301)	295,062
Cash flows from financing activities:
Proceeds from exercise of stock options	1,379,294	2,932,649
Tax benefit from exercise of stock options	9,236,708	764,181
Minimum tax withholding on share based awards	(6,348,900)
Principal payments on debt		(1,200,000)
Net cash provided by financing activities	4,267,102	2,496,830
Exchange rate impact on cash	(131,139)	36,870
Increase in cash and cash equivalents	8,439,034	19,987,961
Cash and cash equivalents at beginning of period	63,333,160	44,067,477
Cash and cash equivalents at end of period	$ 71,772,194	$ 64,055,438